UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10

 

GENERAL FORM FOR REGISTRATION OF SECURITIES

Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934

 

THC THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

26-0164981

(State or other jurisdiction of incorporation)

 

(IRS Employer Identification No.)

 

11700 W Charleston Blvd #73

Las Vegas, Nevada

 

89135

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: ( 702) 602-8422

 

Securities to be registered pursuant to Section 12(b) of the Act:

 

Securities to be registered pursuant to Section 12(g) of the Act:

 

Common Stock, $0.001 par value

(Title of Class)

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer

¨

Non-accelerated filer

¨

Accelerated filer

¨

Smaller reporting company

x

(Do not check if a smaller reporting company)

 

 
 
 
 

  TABLE OF CONTENTS

 

 

Page

 

EXPLANATORY NOTE

 

3

 

FORWARD-LOOKING STATEMENTS

 

3

 

WHERE YOU CAN FIND MORE INFORMATION ABOUT US

 

3

 

Item 1.

Business.

 

4

 

Item 1A.

Risk Factors.

 

9

 

Item 2.

Financial Information.

 

14

 

Item 3.

Properties.

 

24

 

Item 4.

Security Ownership of Certain Beneficial Owners and Management.

 

24

 

Item 5.

Directors and Executive Officers.

 

25

 

Item 6.

Executive Compensation.

 

27

 

Item 7.

Certain Relationships and Related Transactions, and Director Independence.

 

28

 

Item 8.

Legal Proceedings.

 

29

 

Item 9.

Market Price of and Dividends on the Registrant’s Common Equity and Related Stockholder Matters.

 

30

 

Item 10.

Recent Sales of Unregistered Securities.

 

30

 

Item 11.

Description of Registrant’s Securities to be Registered.

 

32

 

Item 12.

Indemnification of Directors and Officers.

 

33

 

Item 13.

Financial Statements and Supplementary Data.  

 

34

 

Item 14.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

34

 

Item 15.

Financial Statements and Exhibits.

 

34

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

F-2

 

BALANCE SHEET

 

F-3

 

STATEMENT OF OPERATIONS

 

F-4

 

STATEMENT OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

 

F-5

 

STATEMENT OF CASH FLOWS

 

F-6

 

NOTES TO FINANCIAL STATEMENTS

 

F-7

 

SIGNATURES

 

35

 

EXHIBIT INDEX

 

36

 

 
2
 
Table of Contents

 

EXPLANATORY NOTE

 

THC Therapeutics, Inc. (formerly known as Millennium BlockChain Inc.) is filing this General Form for Registration of Securities on Form 10, which we refer to as the Registration Statement, to register its common stock, par value $0.001 per share, pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended. Unless otherwise mentioned or unless the context requires otherwise, when used in this Registration Statement, the terms “THC Therapeutics,” “Company,” “we,” “us,” and “our” refer to THC Therapeutics, Inc. (formerly known as Millennium BlockChain Inc.).

 

FORWARD-LOOKING STATEMENTS

 

This Registration Statement contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this Registration Statement, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

 

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important cautionary statements in this Registration Statement, particularly in the “Risk Factors” section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.

 

You should read this Registration Statement and the documents that we have filed as exhibits to this Registration Statement with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Registration Statement are made as of the date of this Registration Statement, and we do not assume any obligation to update any forward-looking statements except as required by applicable law.

 

WHERE YOU CAN FIND MORE INFORMATION ABOUT US

 

When this Registration Statement becomes effective, we will begin to file reports, proxy statements, information statements and other information with the United States Securities and Exchange Commission (the “SEC”). You may read and copy this information, for a copying fee, at the SEC’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information on its Public Reference Room. Our SEC filings will also be available to the public from commercial document retrieval services, and at the website maintained by the SEC at http://www.sec.gov.

 

Our Internet website address is http://www.thctherapeutics.com. Information contained on the website does not constitute part of this Registration Statement. We have included our website address in this Registration Statement solely as an inactive textual reference. When this Registration Statement is effective, we will make available, through a link to the SEC’s website, electronic copies of the materials we file with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, Section 16 reports filed by our executive officers, directors and 10% stockholders and amendments to those reports.

 

 
3
 
Table of Contents

  

Item 1. Business.

 

Overview

 

THC Therapeutics, Inc. (the “Company”), was incorporated in the State of Nevada on May 1, 2007, as Fairytale Ventures, Inc., and later changed its name to Aviation Surveillance Systems, Inc. and Harmonic Energy, Inc. On January 23, 2017, the Company changed its name to THC Therapeutics, Inc. On January 17, 2018, the Company changed its name to Millennium Blockchain Inc. On September 28, 2018, the Company changed its name back to THC Therapeutics, Inc. THC Therapeutics, Inc., together with its subsidiaries, is collectively referred to herein as the “Company,” and “THC Therapeutics.”

 

The Company is primarily focused on developing a sanitizing herb dryer, the dHydronator®, which has been specifically designed for drying and sanitizing freshly harvested cannabis, and other herbs, flowers, and tea leaves.

 

Corporate History

 

THC Therapeutics, Inc., was incorporated in the State of Nevada on May 1, 2007, as Fairytale Ventures, Inc., and later changed its name to Aviation Surveillance Systems, Inc. and Harmonic Energy, Inc. On January 23, 2017, the Company changed its name to THC Therapeutics, Inc. On May 30, 2017, the Company formed Genesis Float Spa LLC, a wholly-owned subsidiary, to market its float spa assets purchased for wellness centers. On January 17, 2018, the Company changed its name to Millennium BlockChain Inc. On September 28, 2018, the Company changed its name back to THC Therapeutics, Inc.

 

The Company’s fiscal year end is July 31 st , its telephone number is (702) 602-8422, and the address of its principal executive office is 11700 W Charleston Blvd #73, Las Vegas, Nevada, 89135.

 

Description of Business

 

The Company is primarily focused on operations in the wellness industry. The Company is developing a sanitizing herb dryer, the dHydronator®, with multiple design, function, and usage patents pending. This innovative, laboratory-proven product is specifically designed for drying and sanitizing freshly harvested cannabis, and other herbs, flowers, and tea leaves. The dHydronator® can reduce moisture content of cannabis to 10-15% in only 10-14 hours. Traditional herbal drying times can take up to two weeks. Additionally, after the Company has launched the dHydronator®, and depending on available funding, the Company intends to establish a float spa facility that will allow each guest to customize their wellness experience, at their own pace, based on their individual needs.

 

Previously, the Company had also been focused on seeking partnerships and investments in the blockchain technology industry, and making strategic investments in the equity of target companies and their tokens. In September of 2018, the Company assessed the current regulatory environment regarding companies focused on investing in cryptocurrencies and other digital assets, as well as the progress of the Company’s 20 separate patent claims for the Company’s sanitizing herb dryer, and the Company determined that it would refocus its efforts on developing the Company’s dHydronator sanitizing herb dryer.

 

Wellness Operations

 

THC Therapeutics is focused on the wellness industry, with plans to develop a patent-pending herb dryer as well as an innovative float spa facility in Las Vegas, Nevada, or southern California.

 

The Company is developing a sanitizing herb dryer, the dHydronator®, with multiple design, function, and usage patents pending. This innovative, laboratory-proven product is specifically designed for drying and sanitizing freshly harvested cannabis, and other herbs, flowers, and tea leaves. The dHydronator® can reduce moisture content of cannabis to 10-15% in only 10-14 hours. Traditional herbal drying times can take up to two weeks.

 

The Company has a functioning prototype of the dHydronator® similar in design to that shown below, and if the Company is issued a patent by the United States Patent and Trademark Office (see “Patent, Trademark, License & Franchise Restrictions and Contractual Obligations & Concessions” below), and if the Company has sufficient funds available, the Company plans to source parts for serial manufacturing and negotiate and secure serial manufacturing and assembly. The Company also plans to hire sales and marketing staff as funds are available.

 

 

 
4
 
Table of Contents

 

More specifically, once we have at least $2,000,000 in in available cash flow or funds from other operations and if we receive the patent, we intend to engage in further development efforts as follows: (i) finalizing case design, with an estimated tooling expense of approximately $300,000-$500,000; manufacturing pre-production units for field testing and presentation to potential partners and distributors, with an estimated expense of $250,000; (iii) hiring a subject-matter expert and consultants or employees in the home herb garden and legal cannabis marketplace to manage the development and sales of herb dryer, with an estimated expense of $400,000 for 12 months; (iv) engaging in further detailed laboratory of our herb drying with respect to cannabis plants and home herb garden plants, with an estimated expense of $50,000 to $100,000 for 12 months; (v) establishing a relationship with a market research and/or marketing company to explore creative strategies, advertising concepts, and consumer opinion, explore applications of our intellectual property in the existing wholesale and retail distribution channels for home herb, garden products and legal cannabis markets, and determine the best path for sales, distribution and licensing of our intellectual property, with an estimated expense of $1,000,000 for 12 months.

 

Additionally, on May 12, 2017, the Company entered into an asset purchase agreement with a third party under which it acquired four (4) float spa units and associated equipment. With the acquisition of these assets, the Company intends to establish a float spa facility that will allow each guest to customize their wellness experience, at their own pace, based on their individual needs. Once we have approximately $500,000-$1,000,000 in available cash flow or funds from other operations, and after the launch of our dHydronator® sanitizing herb dryer, we plan to capitalize on our spa assets purchased in 2017 by (i) leasing a 2,500 to 5,000 square foot facility in Nevada or California, to be built out as needed (and with the size of the facility dependent on available capital); (ii) obtaining necessary licenses and permits, (iii) purchasing inventory, equipment, furnishings and supplies, including inventory, fixtures, furnishings and equipment for an oxygen bar and a Kampuchea, juice and tea Bar, refrigeration and storage equipment, point of sale computers and tablets, digital monitors, signage and display materials, and other suppliers; (iv) hiring spa management personnel including a manager, assistant manager and two spa attendants; (v) hiring marketing and sales consultants, and (vi) launching a marketing campaign to include internet lead services, Groupon and social networking.

 

Legacy Crypto-Related Assets

 

The Company had previously focused some of its efforts on seeking partnerships with blockchain technology companies (each a “Target Company”). During calendar 2018, the Company issued shares of its common stock and preferred stock to two Target Companies (see “ BurstIQ ” and “ ImpactPPA ” below) in exchange for rights to tokens and equity purchase rights in the Target Companies.

 

BurstIQ

 

BurstIQ Analytics Corporation (“BurstIQ”) is a healthcare blockchain data company serving major healthcare institutions, OEM data partners, unions, government agencies and sovereign nations. Healthcare data lives in siloed IT environments to comply with and HIPAA regulations, while valuable and necessary, the segregation of data makes it extremely hard to combine and share data sources. Data is becoming increasingly critical to the healthcare industry and to the ecosystem of companies that rely on accurate date. BurstIQ is seeking to solve this market problem. The BurstIQ platform leverages blockchain and machine intelligence to enable data from disparate sources to be brought together to create a single, unified data repository, and to be shared quickly and easily while still maintaining strict security standards and HIPAA compliance.

 

On or about April 19, 2018, the Company acquired (i) the right to a number of BurstIQ’s BIQ tokens equal to $2.5 million divided by a 35% discount to the maximum price per token sold by BurstIQ during its network launch, and (ii) the right to a number of shares of BurstIQ’s preferred stock which will be sold in a subsequent equity financing equal to $2.5 million divided by a $6.50 price per share, or approximately 384,615 shares of preferred stock, in consideration of the issuance of 5,000,000 shares of the Company’s common stock to BurstIQ. Based upon the investment criteria, we expect to own a 2.96% equity stake in BurstIQ along with the BIQ tokens.

 

 
5
 
Table of Contents

  

ImpactPPA

 

ImpactPPA Limited (“ImpactPPA”) has designed an Ethereum-based decentralized energy platform to potentially transform the global energy finance industry. ImpactPPA uses the power of the blockchain to bring together capital and consumers in a way that is direct, responsive, and expedient. ImpactPPA seeks to solve the problems created by legacy financial institutions which are hindered by bureaucracy, cost and inflated infrastructure to effectively and efficiently provide solutions to the market.

 

ImpactPPA uses a token model for financing projects, which provides the token-holding community a voice in deciding which projects should be funded. The goal of the Company is to achieve “Impact Equilibrium,” a financial state at which revenues from implemented PPAs flow back into the system, creating a pool of capital that is used to fund future projects. The SmartPPA (Power Purchase Agreement) is the core of the platform allowing anyone, anywhere to create a proposal for a project of any size or technology. Using the SmartPPA platform, a user specifies the requirements for a project and submits it to the ImpactPPA community, whether it is an individual business who wants reliable energy to keep a factory running or a nation seeking to provide power to its people. By using blockchain and smart contract technology, ImpactPPA’s goal is to open the bottleneck to energy financing created by NGOs and government agencies.

 

On or about June 14, 2018, the Company acquired the rights to $4,500,000 of ImpactPPA’s MPQ tokens in consideration of the Company’s issuance of 60,000 shares of the Company’s Series A Preferred Stock to ImpactPPA (with each share of Series A Preferred Stock convertible into 100 shares of the Company’s common stock at the holder’s election). At the time of ImpactPPA’s network launch, the Company will receive $3,000,000 of MPQ tokens, three months after the launch, the Company will be issued an additional $750,000 in tokens, and six months after the launch, the Company will receive the other $750,000 in tokens.

 

Robot Cache

 

Robot Cache, S.L. (“Robot Cache”) has is the first decentralized PC video game distribution platform with a revolutionary digital resale model utilizing the blockchain. Robot Cache allows publishers to keep significantly more revenues than other distribution platforms and gives gamers, for the first time ever, the ability to re-sell their digital games. Founded by video game legend Brian Fargo, Robot Cache is led by video game luminaries such as Lee Jacobson (CEO), Mark Caldwell (CTO), Laura Naviaux Sturr (CMO) and Philippe Erwin (GC & VP of Business Development).

 

Utilizing Blockchain technology, Robot Cache plans to reduce the fees publishers and developers pay by 80% and allow gamers to resell their digital PC video games. Developers and publishers should benefit from the lowest transaction fees of any digital PC video game distribution platform. Gamers should benefit from Robot Cache's distribution approach. Currently, gamers can only resell physical retail copies of a video game, but once the Robot Cache platform launches, gamers will have the option to resell their digital games purchased on the Robot Cache platform and retain 25% of the proceeds in IRON, which is Robot Cache's digital token. In addition, it is anticipated that gamers will be able to opt-in to mine and exchange IRON. IRON can be used toward the purchase of games on the platform.

 

 
6
 
Table of Contents

 

On July 31, 2018, the Company (i) acquired the rights to 10,536,315 IRON cryptographic tokens from Robot Cache, and (ii) a right of first refusal to purchase up to 3% of the capital stock of Robot Cache in a subsequent equity financing, in consideration of the Company’s issuance of 6,000,000 shares of the Company’s common stock to Robot Cache, and non-cashless warrants to purchase 3,000,000 shares of the Company’s common stock on the below-described terms (the “Warrants”). The Warrants are exercisable through the earlier of July 31, 2021, and the date that is 30 days after the date that the 5-day volume-weighted average price of the Company’s common stock exceeds the exercise price for the Warrants by 25%. The exercise price for the Warrants is staggered as follows: 500,000 shares at $0.75/share, 500,000 shares at $1.00/share, 500,000 shares at $1.50/share, 500,000 shares at $2.00/share, and 1,000,000 shares at $5.00/share.

 

Competition

 

There are a number of commercial herb dryers sold by competitors, including Yofumo Technologies, which are already commercially available, and which have significant market share. As to our float spa plans, we believe True Rest Float Spa, which has over 20 spa locations across the country, is our primary national competitor, and there are numerous locally owned float spas throughout the country that would considered competitors with our spa operations. There is no assurance that we will be able to compete effectively with any of these competitors.

 

Market Opportunity

 

The Company’s herb dryer, the dHydronator®, safely lowers moisture content and sanitizes without harm to the integrity of the plant. Our test results have been proven to dry cannabis in less than 14 hours verses up to 14 days using traditional drying methods. Test results indicate the removal of many surface germs and bacteria including powder mold, dust mites and spider mites from herbs, plants, the surface of glass or ceramic herbal tea accessories, and any other object that fits safely in the drying chamber. Therefore, we believe that our product will be attractive to the cannabis and home herb and garden product markets.

 

With regard to floatation therapy, the sensory deprivation consumer typically ranges in age from eighteen to eighty. Floatation therapy is a service that is unisex in its appeal and attracts many. As many consumers seek natural alternative therapies for the relief from pain, stress and sleep disorders that affect a significant percentage of the population, we believe that our planned floatation therapy spa facilities will be attractive to these consumers.

 

 
7
 
Table of Contents

  

Marketing Strategy

 

We plan to attend regional cannabis-related trade shows and offer field testing to legal cannabis growers and suppliers in the United States and Canada initially, and throughout the world once the technology has been adopted in the regional market. We also plan to establish a relationship with a market research and marketing company to explore creative strategies, advertising concepts, consumer opinion, existing distribution and sales channels and potential licensing of our intellectual property, to determine the best path for sales and distribution. We also intend to hire subject matter expert consultants or employees in the legal cannabis and home herb marketplace to manage the development and sales of our products. Once our marketing experts identify an herbal or commercial agriculture niche or venue to enter or solicit, we will market to distributors and retailers via trade shows and direct contact.

 

With regard to our spa plans, we intend to launch internet, Groupon and social networking campaigns offering coupons and membership plans for floatation therapy, and our planned oxygen bar and Kampuchea, juice and tea bar. We plan to invite local TV and Radio personalities to tour our facilities, and we plan to offer local healthcare and rehabilitation service providers and non-competitive spa owners and managers a private tour of our spa facilities.

 

Customers

 

Due to the nature of its business, the Company does not currently have any customers. 

 

Patent, Trademark, License & Franchise Restrictions and Contractual Obligations & Concessions

 

The Company has acquired the exclusive intellectual property rights to the dHydronator® sanitizing plant dryer with improved convection flow from the Company’s CEO and Director, Brandon Romanek. A trademark application for the mark “dHyrdonator” has been filed (serial no. 86874611), and a patent application has been filed with the United States Patent and Trademark Office (“USPTO”), docket number 5503.101 (application nos. 15/467,722 and 62/312,327), for 20 separate herb dryer design, function, and usage patents. On or about July 20, 2018, the Company’s patent counsel received a Notification of Allowance from the USPTO, notifying the Company that the USPTO would be allowing all 20 claims.

 

Governmental Regulations

 

We will be governed by government laws and regulations governing spas. We believe that we are currently in compliance with all laws which govern our operations and have no current liabilities thereunder. Our intent is to maintain strict compliance with all relevant laws, rules and regulations.

 

Employees

 

The Company currently has only one full-time management employee, our founder, CEO and director, Brandon Romanek, and no other full-time employees.

 

 
8
 
Table of Contents

  

Item 1A. Risk Factors.

 

There is substantial doubt about our ability to continue as a going concern

 

We have not generated any revenues or profit during the years ended July 31, 2017 and 2016, or the interim periods since July 31, 2017. We expect that our operating expenses will increase over the next twelve months to continue our development activities. Based on our average monthly expenses and current burn rate, we estimate that our cash on hand will not sufficiently support our operation for the next twelve months. If we cannot raise the money that we need in order to continue to operate our business, we will be forced to delay, scale back or eliminate some or all of our proposed operations. If any of these were to occur, there is a substantial risk that our business would fail. If we are unsuccessful in raising additional financing, we may need to curtail, discontinue or cease operations.

 

We have had a history of losses and may incur future losses, which may prevent us from attaining profitability.

 

We have had a history of operating losses since our inception and, as of April 30, 2018, we had an accumulated deficit of approximately $3.9 million. We may incur operating losses in the future, and these losses could be substantial and impact our ability to attain profitability. We expect to significantly increase expenditures for product development, general and administrative expenses, and sales and marketing expenses, and there is no guarantee that we will ever generate revenues, or that we ever achieve or sustain profitability or positive operating cash flows. Even if we achieve profitability and positive operating cash flows, we may not be able to sustain or increase profitability or positive operating cash flows on a quarterly or annual basis.

 

Federal drug regulation and enforcement may adversely impact our operations.

 

Currently, there are approximately 30 states plus the District of Columbia that have laws and/or regulation that recognize in one form or another legitimate medical uses for cannabis and consumer use of cannabis in connection with medical treatment, and there are approximately 8 states and the District of Columbia that have more expansive laws legalizing marijuana for recreational use. Conversely, under the Controlled Substances Act (the “CSA”), the policy and regulations of the Federal government and its agencies is that cannabis has no medical benefit and a range of activities including cultivation and use of cannabis for personal use is prohibited. Until Congress amends the CSA with respect to medical marijuana, there is a risk that federal authorities may enforce current federal law.

 

As we plan on marketing our herb dryer to the cannabis industry, federal enforcement of federal law would adversely affect the cannabis industry and would therefore adversely affect the Company’s planned operations and sales. Active enforcement of the current federal regulatory position on cannabis may thus indirectly and adversely affect revenues and profits of the Company.

 

We may not be able to achieve our strategic initiatives and grow our business as anticipated.

 

Beginning in early 2018, based on the historical experience of our sole officer and director trading commodities, we made a strategic decision to focus on acquiring crypto-related assets. In September 2018, we determined to focus on our sanitizing herb dryer and floatation spa plans. Our strategic initiatives have required us to devote financial and operational assets to these activities. Our success depends on our ability to appropriately manage our expenses as we execute on our planned initiatives. If we are not able to execute on this strategy successfully, our business may not grow as we anticipate, which could adversely affect our operating results.

 

We plan to hold investments in various entities and in cryptocurrency or digital tokens, but we may never actually acquire those investments.

 

We currently have the rights to acquire equity and digital tokens of BurstIQ and ImpactPPA. However, there is no guarantee that we will ever actually receive the equity and digital tokens of either company. If we are not able to do so, the rights that we have acquired would essentially be worthless, and our business would be harmed.

 

 
9
 
Table of Contents

 

We plan to hold investments in various entities and in cryptocurrency or digital tokens, which we may never be able to sell, and which are subject to impairment.

 

Even if we acquire the equity and digital tokens of BurstIQ and ImpactPPA described above, there is no guarantee that these assets will maintain and/or increase in value, or that we will be able to liquidate these assets for a profit or at all. Our inability or failure to liquidate any such assets could have a material adverse impact on our business and financial position. Our assets could become impaired in the future. Cryptocurrencies and digital tokens are an emerging technology, are currently unregulated, have no investor protections, and their value may become extremely volatile or even worthless. Future impairment of our anticipated equity and token holdings could have an adverse impact on our balance sheet as it relates to the value of these assets.

 

If we fail to protect our intellectual property, then our ability to compete could be negatively affected, which would harm our financial condition and operating results.

 

We have acquired the rights to our sanitizing herb dryer, the dHydronator®, from our CEO, Mr. Romanek, and a patent application has been filed with the United States Patent and Trademark Office (“USPTO”), docket number 5503.101, for 20 separate design, function, and usage patents. On or about July 20, 2018, the Company’s patent counsel received a Notification of Allowance from the USPTO, notifying the Company that the USPTO would be allowing all 20 claims. There is no guarantee that the USPTO will issue the patent, or that if we are issued the patent, that we will be able to maintain the patent in the future.

 

We believe that the market for the dHydronator® depend to a significant extent upon the goodwill and patent protection afforded by any patent that is ultimately issued. In addition, the laws of certain foreign countries may not protect our intellectual property rights to the same extent as the laws of the United States. The failure to secure a patent, the failure to maintain any patent we are ultimately issued, or the loss or infringement of any patent we are issued would impair the goodwill associated with the dHydronator® and harm our reputation, which would harm our financial condition and operating results.

 

If our intellectual property is not adequate to provide us with a competitive advantage or to prevent competitors from replicating our products, or if we infringe the intellectual property rights of others, then our financial condition and operating results would be harmed.

 

Our future success and ability to compete in the herb drying market depends upon our ability to produce a sanitizing herb dryer, which we attempt to protect under a combination of patent and trade secret laws, confidentiality procedures and contractual provisions. However, we have not yet been issued a patent, and even if we are, the legal protections afforded by patent law and contractual proprietary rights in our products provide only limited protection and may be time-consuming and expensive to enforce or maintain. Further, despite our efforts, we may be unable to prevent third parties from infringing upon or misappropriating our proprietary rights or from independently developing non-infringing products that are competitive with, equivalent to or superior to our herb dryer.

 

Monitoring infringement or misappropriation of intellectual property can be difficult and expensive, and we may not be able to detect every infringement or misappropriation of intellectual property rights. Even if we do detect infringement or misappropriation of our proprietary rights, litigation to enforce these rights could cause us to divert financial and other resources away from our business operations. Further, the laws of some foreign countries do not protect our proprietary rights to the same extent as do the laws of the United States.

 

Additionally, third parties may claim that our herb dryer infringes upon their intellectual property rights, and there can be no assurance that one or more of our products will not be found to infringe upon third-party intellectual property rights in the future.

 

 
10
 
Table of Contents

  

Our products may be subject to recalls.

 

Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labeling disclosure. If our sanitizing herb dryer, the dHydronator®, is recalled due to an alleged product defect or for any other reason, we could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. We may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin, or at all. In addition, a product recall may require significant management attention and adversely affect our other operations.

 

Additionally, if our herb dryer were subject to recall, the goodwill associated with that product and with us could be harmed. A recall would likely lead to decreased demand for our herb dryer, but it could also materially and adversely effect our spa as well and the perception of our company as a whole. Additionally, product recalls may lead to increased scrutiny of our operations by regulatory agencies, requiring further management attention and potential legal fees and other expenses. Furthermore, any product recall affecting the cannabis industry more broadly could lead consumers to lose confidence in the safety and security of products sold by other participants in the industry, which could have a material adverse effect on our business, financial condition and results of operations.

 

Our future success depends on our ability to retain our chief executive officer and other key executives and to attract, retain and motivate qualified personnel.

 

We are highly dependent on Brandon Romanek, our Chief Executive Officer. Although we have entered into an employment agreement with Mr. Romanek providing for certain benefits, including severance in the event of a termination without cause, this agreement does not prevent him from terminating his employment with us at any time. We do not maintain “key person” insurance for any personnel. The loss of the services of Mr. Romanek could impede the achievement of our herb dryer and spa research, development, commercialization and acquisition objectives.

 

In addition, we rely on consultants and advisors, to assist us in formulating our development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.

 

We will need additional funding if we intend on executing our operational plans and making future acquisitions. If we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our planned development.

 

We expect our expenses to increase in connection with our ongoing activities. Furthermore, upon the effectiveness of this Registration Statement, we expect to incur additional costs associated with operating as a mandatory filer under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate some or all of our herb dryer and spa development plans.

 

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or other assets.

 

Until the time, if ever, that we can generate substantial product revenues, we plan to finance our cash needs through some combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

 

 
11
 
Table of Contents

  

Because we will become a reporting company under the Exchange Act by means other than a traditional underwritten initial public offering, we may not be able to attract the attention of research analysts at major brokerage firms.

 

Because we will not become a reporting company by conducting an underwritten initial public offering, or IPO, of our common stock, and because we will not be listed on a national securities exchange, security analysts of brokerage firms may not provide coverage of our company. In addition, investment banks may be less likely to agree to underwrite secondary offerings on our behalf than they might if we were to become a public reporting company by means of an IPO because they may be less familiar with our company as a result of more limited coverage by analysts and the media, and because we became public at an early stage in our development.

 

Our common stock is subject to the SEC’s penny stock rules, which may make it difficult for broker-dealers to complete customer transactions and could adversely affect trading activity in our securities.

 

The SEC has adopted regulations which generally define “penny stock” to be an equity security that has a market price of less than $5.00 per share, subject to specific exemptions. The market price of our common stock is currently less than $5.00 per share and therefore our stock is considered a “penny stock” according to SEC rules, unless we are listed on a national securities exchange. Under these rules, broker-dealers who recommend such securities to persons other than institutional accredited investors must:

 

 

·

make a special written suitability determination for the purchaser;

 

·

receive the purchaser’s prior written agreement to the transaction;

 

·

provide the purchaser with risk disclosure documents which identify certain risks associated with investing in “penny stocks” and which describe the market for these “penny stocks” as well as a purchaser’s legal remedies; and

 

·

obtain a signed and dated acknowledgment from the purchaser demonstrating that the purchaser has actually received the required risk disclosure document before a transaction in a “penny stock” can be completed.

 

If required to comply with these rules, broker-dealers may find it difficult to effectuate customer transactions and trading activity in our securities may be adversely affected.

 

The market price of our common stock may be volatile and may fluctuate in a way that is disproportionate to our operating performance.

 

Our stock price may experience substantial volatility as a result of a number of factors, including:

 

 

·

sales or potential sales of substantial amounts of our common stock;

 

·

the success of competitive products or technologies;

 

·

announcements about us or about our competitors, including new product introductions and commercial results;

 

·

the recruitment or departure of key personnel;

 

·

developments concerning our licensors or manufacturers;

 

·

litigation and other developments;

 

·

actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

 

·

variations in our financial results or those of companies that are perceived to be similar to us; and

 

·

general economic, industry and market conditions.

 

Many of these factors are beyond our control. The stock markets in general, and the market for companies related to the cannabis and blockchain markets in any way in particular, have historically experienced extreme price and volume fluctuations. These fluctuations often have been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors could reduce the market price of our common stock, regardless of our actual operating performance.

 

 
12
 
Table of Contents

  

We currently have outstanding shares of preferred stock that have special rights that could limit our ability to undertake corporate transactions, inhibit potential changes of control and reduce the proceeds available to our common stockholders in the event of a change in control. Additionally, even after our preferred stock converts to common stock, certain of our stockholders will have rights that could limit our ability to undertake corporation transactions and inhibit changes of control.

 

We currently have outstanding two classes of stock, common stock and preferred stock, and there are two series of preferred stock, Series A Preferred Stock and Series B Preferred Stock. The holders of our Series A Preferred Stock are entitled to super voting and super converting rights.

 

As a result of the rights the holder of our Series A Preferred Stock has, we may not be able to undertake certain corporate transactions, including equity or debt offerings necessary to raise sufficient capital to run our business, change of control transactions or other transactions that may otherwise be beneficial to our businesses. These provisions may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our common stockholders might otherwise receive a premium price for their shares. The market price of our common stock could be adversely affected by the rights of our preferred stockholders.

 

We have never paid and do not intend to pay cash dividends.

 

We have never paid cash dividends on any of our capital stock and we currently intend to retain future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be our common stockholders’ sole source of gain for the foreseeable future. Under the terms of our existing Articles of Incorporation, we cannot declare, pay or set aside any dividends on shares of any class or series of our capital stock, other than dividends on shares of common stock payable in shares of common stock, unless we pay dividends to the holders of our preferred stock. Additionally, without special stockholder and board approvals, we cannot currently pay or declare dividends and will be limited in our ability to do so until such time, if ever, that we are listed on a stock exchange.

 

Our executive officer and director have the ability to control all matters submitted to stockholders for approval.

 

Our executive officer and director, Brandon Romanek, holds 2,000,000 shares of our Series A Preferred Stock (each share votes as the equivalent of 100 shares of common stock on all matters submitted for a vote by the common stockholders), and as such, he would be able to control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, Mr. Romanek would control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire.

 

Provisions in our articles of incorporation and by-laws and under Nevada law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

 

Provisions in our articles of incorporation and by-laws, respectively, may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our common stockholders might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors.

 

We will incur increased costs as a result of operating as a public reporting company, and our management will be required to devote substantial time to new compliance initiatives.

 

As a public reporting company, we will incur significant legal, accounting and other expenses that we did not incur as a non-reporting company. In addition, the Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC, have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.

 

 
13
 
Table of Contents

  

We currently have outstanding, and we may, in the future issue instruments which are convertible into shares of common stock, which will result in additional dilution to you.

 

We currently have outstanding debt and equity instruments which are convertible into shares of common stock, and we may need to issue similar instruments in the future. In the event that these convertible instruments are converted into shares of common stock, or that we make additional issuances of other convertible or exchangeable securities, you could experience additional dilution. Furthermore, we cannot assure you that we will be able to issue shares or other securities in any offering at a price per share that is equal to or greater than the price per share paid by investors or the then-current market price.

 

We cannot predict every event and circumstance that may impact our business and, therefore, the risks discussed herein may not be the only ones you should consider.

 

As we continue to grow our business, we may encounter other risks of which we are not aware as of the date of this Registration Statement. These additional risks may cause serious damage to our business in the future, the impact of which we cannot estimate at this time.

 

Item 2. Financial Information.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing at the end of this Registration Statement. Some of the information contained in this discussion and analysis or set forth elsewhere in this Registration Statement, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read the “Risk Factors” section of this Registration Statement for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

 

Plan of Operation

 

THC Therapeutics is focused on the wellness and nutraceutical industry. The Company is developing a sanitizing herb dryer, the dHydronator®, with multiple design, function, and usage patents pending. This innovative, laboratory-proven product is specifically designed for drying and sanitizing freshly harvested cannabis, and other herbs, flowers, and tea leaves. The dHydronator® can reduce moisture content of cannabis to 10-15% in only 10-14 hours. Traditional herbal drying times can take up to two weeks. The Company also intends to establish a float spa facility that will allow each guest to customize their wellness experience, at their own pace, based on their individual needs.

 

 
14
 
Table of Contents

  

Results of Operations

 

The following summary of our results of operations should be read in conjunction with our unaudited consolidated financial statements for the three and nine months ended April 30, 2018 and 2017, which are included herein.

 

Three Months Ended April 30, 2018 and 2017

 

Our operating results for the three months ended April 30, 2018 and 2017, and the changes between those periods for the respective items are summarized as follows:

 

 

 

Three months ended

 

 

 

 

 

 

 

 

 

April 30,

 

 

Change

 

 

 

2018

 

 

2017

 

 

Amount

 

 

Percentage

 

Operating income (loss)

 

$ (226,602 )

 

$ (47,064 )

 

$ (179,538 )

 

 

(381 %)

Other income (expense)

 

$ (17,456 )

 

$ 14,562

 

 

$ (32,018 )

 

 

(220 %)

Net income (loss)

 

$ (244,058 )

 

$ (32,502 )

 

$ (211,556 )

 

 

(651 %)

 

Revenues

 

We did not earn any revenues during the three months ended April 30, 2018 and 2017, respectively. We do not anticipate earning significant revenues until such time that we have fully developed our investment strategy.

 

Operating Income (Loss)

 

Our loss from operations increased to $226,602 during the three months ended April 30, 2018, from an operating loss of $47,064 in the same period in 2017. The following table presents operating expenses for the quarterly periods in 2018 and 2017:

 

 

 

Three months ended 

 

 

 

 

 

 

April 30, 

 

 

Change

 

 

 

2018

 

 

2017

 

 

Amount 

 

 

Percentage

 

Professional fees

 

$ 23,192

 

 

$ 17,115

 

 

$ 6,077

 

 

 

36 %

Consulting fees

 

 

135,486

 

 

 

4,100

 

 

 

131,386

 

 

 

3205 %

Payroll expense

 

 

20,569

 

 

 

-

 

 

 

20,569

 

 

 

100 %

General and administrative expenses

 

 

41,142

 

 

 

22,680

 

 

 

18,462

 

 

 

81 %

Depreciation and amortization

 

 

6,213

 

 

 

3,169

 

 

 

3,044

 

 

 

96 %

Total operating expenses

 

$ 226,602

 

 

$ 47,064

 

 

$ 179,538

 

 

 

381 %

 

We realized an increase of $6,077 in professional fees during the three months ended April 30, 2018, as compared to the same period in 2017, primarily due to increased accounting and audit fees associated with our reporting obligations. We realized an increase of $131,386 in consulting fees during the three months ended April 30, 2018, as compared to the same period in 2017, primarily due to increased stock-based compensation expense. We realized an increase of $18,462 in general and administrative expenses during the three months ended April 30, 2018, as compared to the same period in 2017, primarily due to an increase in office expenses related to our increased operations in 2018. We realized an increase of $20,569 in payroll expenses during the three months ended April 30, 2018, as compared to the same period in 2017, primarily due to the employment agreement entered into with to our Chief Executive Officer in November of 2017. We realized an increase of $3,044 in depreciation expenses during the three months ended April 30, 2018, as compared to the same period in 2017, primarily due to increase in assets related to the acquisition of the assets of the float spa.

 

 
15
 
Table of Contents

  

Other Income (Expense)

 

The following table presents other income and expenses for the three months ended April 30, 2017 and 2016:

 

 

 

Three months ended

 

 

 

 

 

 

 

 

April30,

 

 

Change

 

 

 

2018

 

 

2017

 

 

Amount

 

 

Percentage

 

Gain/(loss) on change in derivative liability

 

$ 11,273

 

 

$ (162 )

 

$ 11,435

 

 

 

7,059 %

Gain on settlement of debts

 

 

-

 

 

 

122,839

 

 

 

(122,839 )

 

 

(100 )%

Gain on conveyance of liabilities to a related party

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Interest Expense

 

 

(28,729 )

 

 

(108,115 )

 

 

79,386

 

 

 

73 %

Total other income (expense)

 

$ (17,456 )

 

$ 14,562

 

 

$ (32,018 )

 

 

(220 )%

 

Gain/(loss) on change in derivative liability increased by $11,435 during the three months ended April 30, 2018, as compared to the same period in 2017, due to change in derivative liabilities caused by fluctuations in the price of our common stock between reporting periods. Gain on settlement of debts decreased by $122,839 during the three months ended April 30, 2018, as compared to the same period in 2017, because the company didn’t settle any debts in the current period. Interest expense decreased by $79,386 during the three months ended April 30, 2018, as compared to the same period in 2017, due to decrease in outstanding loans, and convertible notes during the same period.

 

Net Income (loss)

 

Net loss increased to $(244,058) during the three months ended April 30, 2018, from a net loss of $(32,502) in the same period 2017.

 

Nine Months Ended April 30, 2018 and 2017

 

Our operating results for the nine months ended April 30, 2018 and 2017, and the changes between those periods for the respective items are summarized as follows:

 

 

 

Nine months ended

 

 

 

 

 

 

 

 

 

April 30,

 

 

Change

 

 

 

2018

 

 

2017

 

 

Amount

 

 

Percentage

 

Operating income (loss)

 

$ (472,317 )

 

$ (83,306 )

 

$ (389,011 )

 

 

(467 )%

Other income (expense)

 

$ (181,582 )

 

$ 147,385

 

 

$ (328,967 )

 

 

(223 )%

Net income (loss)

 

$ (653,899 )

 

$ 64,079

 

 

$ (717,978 )

 

 

(1120 )%

 

Revenues

 

We did not earn any revenues during the nine months April 30, 2018 and 2017, respectively. We do not anticipate earning significant revenues until such time that we have fully developed our business and investment strategy.

 

Operating Income (Loss)

 

Our loss from operations increased to $472,317 during the nine months ended April 30, 2018, from an operating loss of $83,306 in the same period in 2017. The following table presents operating expenses for the quarterly periods in 2018 and 2017:

 

 

 

Nine months ended

 

 

 

 

 

 

April 30, 

 

 

Change

 

 

 

2018

 

 

2017 

 

 

Amount 

 

 

Percentage

 

Professional fees

 

$ 46,336

 

 

$ 24,126

 

 

$ 22,210

 

 

 

92 %

Consulting fees

 

 

257,641

 

 

 

22,162

 

 

 

235,479

 

 

 

1063 %

Payroll expense

 

 

41,137

 

 

 

-

 

 

 

41,137

 

 

 

100 %

General and administrative expenses

 

 

108,191

 

 

 

32,594

 

 

 

75,597

 

 

 

232 %

Depreciation and amortization

 

 

19,012

 

 

 

4,424

 

 

 

14,588

 

 

 

330 %

Total operating expenses

 

$ 472,317

 

 

$ 83,306

 

 

$ 389,011

 

 

 

467 %

 

 
16
 
Table of Contents

  

We realized an increase of $22,210 in professional fees during the nine months ended April 30, 2018, as compared to the same period in 2017, primarily due to increased accounting and audit fees associated with our reporting obligations. We realized an increase of $235,479 in consulting fees during the nine months ended April 30, 2018, as compared to the same period in 2017, primarily due to increased stock-based consulting. We realized an increase of $75,597 in general and administrative expenses during the nine months ended April 30, 2018, as compared to the same period in 2017, primarily due to an increase in office expenses related to our increased operational activities. We realized an increase of $41,137 in payroll expenses during the nine months ended April 30, 2018, as compared to the same period in 2017, primarily due to the employment agreement issued to our Chief Executive Officer in November of 2017. We realized an increase of $14,588 in depreciation expenses during the nine months ended April 30, 2018, as compared to the same period in 2017, primarily due to increase in assets related to the acquisition of the assets of THC therapeutics and the float spa assets.

 

Other Income (Expense)

 

The following table presents other income and expenses for the nine months ended April 30, 2018 and 2017:

 

 

 

Nine months ended

 

 

 

 

 

 

 

April 30,

 

 

Change

 

 

 

2018

 

 

2017

 

 

Amount

 

 

Percentage

 

Gain on change in derivative liability

 

$ 39,274

 

 

$ 4,701

 

 

$ 34,573

 

 

 

735 %

Gain on settlement of debts

 

 

(132,234 )

 

 

202,621

 

 

 

(334,855 )

 

 

(165 )%

Gain on conveyance of liabilities to a related party

 

 

-

 

 

 

79,110

 

 

 

(79,110 )

 

 

(100 )%

Interest Expense

 

 

(88,622 )

 

 

(139,047 )

 

 

50,425

 

 

 

36 %

Total other income (expense)

 

$ (181,582 )

 

$ 147,385

 

 

$ (328,967 )

 

 

(223 )%

 

Gain on change in derivative liability increased by $34,573 during the nine months ended April 30, 2018, as compared to the same period in 2017, due to change in derivative liabilities caused by fluctuations in the price of our common stock between reporting periods. Gain on settlement of debts decreased by $334,855 during the nine months ended April 30, 2018, as compared to the same period in 2017, because the company recognized losses on debt settlements in the current period as opposed to gains in the same period in 2017. Gain on conveyance of liabilities to a related party decreased by $79,110 during the nine months ended April 30, 2018, as compared to the same period in 2017, because the company didn’t convey any asset or liabilities to officers in the current period. Interest expense decreased by $50,425 during the nine months ended April 30, 2018, as compared to the same period in 2017, due to decreases in total loans, and convertible notes outstanding in the current period.

 

Net Income (loss)

 

Net loss increased to $(653,899) during the nine months ended April 30, 2018, from a net income of $64,079 in the same period 2017.

 

Liquidity and Capital Resources

 

Working Capital

 

The following table presents our working capital position as of April 30, 2018, and July 31, 2017:

 

 

 

April 30,

 

 

July 31,

 

 

Change

 

 

 

2018

 

 

2017

 

 

Amount

 

 

Percentage

 

Cash and cash equivalents

 

$ 2,237

 

 

$ 187

 

 

$ 2,050

 

 

 

1,096 %

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

$ 12,449

 

 

$ 78,952

 

 

$ (66,503 )

 

 

(84 %)

Current liabilities

 

 

548,829

 

 

 

389,515

 

 

 

159,314

 

 

 

40 %

Working capital

 

$ (536,380 )

 

$ (310,563 )

 

$ (225,817 )

 

 

(73 %)

 

 
17
 
Table of Contents

 

The change in working capital during the nine months ended April 30, 2018, was primarily due to an increase in current liabilities of $159,314. Current assets decreased due to a decrease in prepaid expenses during the nine months ended April 30, 2018. Current liabilities increased due to an increase in borrowing and accrued expenses, which resulted in accounts payable of $103,345, accrued liabilities due to related parties of $46,004, convertible notes payable, net of $97,534, advances from related parties of $146,791, notes payable of $48,200 and derivative liability of $106,955, as compared to $389,515 in current liabilities as of July 31, 2017, which consisted mainly of accounts payable of $82,140, accrued liabilities due to related parties of $1,120, convertible notes payable, net of $22,739, advances from related parties of $77,287, notes payable of $60,000 and derivative liability of $146,229.

 

Cash increased as of April 30, 2018, by $2,050 to $2,237, primarily from increased borrowing.

 

Cash Flow

 

We fund our operations with cash received from advances from officer’s parties, debt, and issuances of equity.

 

The following tables presents our cash flow for the nine months ended April 30, 2018 and 2017:

 

 

 

Nine months ended

 

 

 

 

 

 

April 30,

 

 

Change 2018

 

 

 

2018

 

 

2017

 

 

Versus 2017

 

Cash Flows Used in Operating Activities

 

$ (150,122 )

 

$ (109,224 )

 

$ (40,898 )

Cash Flows Used in Investing Activities

 

 

(532 )

 

 

-

 

 

 

(532 )

Cash Flows Provided by Financing Activities

 

 

152,704

 

 

 

108,986

 

 

 

43,718

 

Net increase (decrease) in Cash During Period

 

$ 2,050

 

 

$ (238 )

 

$ 2,288

 

 

Cash Flows from Operating Activities

 

We did not generate positive cash flows from operating activities for the nine months ended April 30, 2017.

 

For the nine months ended April 30, 2018, net cash flows used in operating activities consisted of a net loss of $653,899, reduced by depreciation of $19,012, stock-based compensation of $242,119, amortization of debt discount of $69,185, amortization of original issue discount of $5,610, offset by a loss on change in derivative liabilities of $39,274 and increased by a net increase in change of operating assets and liabilities of $72,770. For the nine months ended April 30, 2017, net cash flows provided by operating activities consisted of a net income of $64,079, increased by depreciation of $4,424, amortization of debt discount of $132,221, offset by a loss on change in derivative liabilities of $4,701, settlement of debts of $202,621, settlement of related party debts of $79,110 and by a net decrease in change of operating assets and liabilities of $23,516.

 

Cash Flows from Investing Activities

 

For the nine months ended April 30, 2018, net cash flows used in investing activities consisted of $532 investment in intangible assets as compared to the nine months ending April 30, 2017, during which we had no investing activities.

 

Cash Flows from Financing Activities

 

For the nine months ended April 30, 2018, we received $142,344 from loans from a related party, $30,000 from non-related party loans, $65,000 from the sale of common stock and warrants and used $72,840 for net repayments on related party debts and $11,800 on net repayments on loans. For the nine months ended April 30, 2017, we received $75,371 from loans from a related party, $112,400 from convertible loans, and used $28,785 for net repayments on related party debts and $50,000 on net repayments on loans

 

 
18
 
Table of Contents

  

Year Ended July 31, 2017 and 2016

 

The following summary of our results of operations should be read in conjunction with our consolidated financial statements for the years ended July 31, 2017 and 2016, which are included herein.

 

Our operating results for the year ended July 31, 2017 and 2016, and the changes between those periods for the respective items are summarized as follows:

 

 

 

Years ended

 

 

 

 

 

 

 

 

 

July 31,

 

 

Change

 

 

 

2017

 

 

2016

 

 

Amount

 

 

Percentage

 

Operating income (loss)

 

$ (223,605 )

 

$ (103,533 )

 

$ (120,072 )

 

 

(116 )%

Other income (expense)

 

$ (162,103 )

 

$ (191,464 )

 

$ 29,361

 

 

 

15 %

Net income (loss)

 

$ (385,708 )

 

$ (294,997 )

 

$ (90,711 )

 

 

(31 )%

 

Revenues

 

We did not earn any revenues during the years ending July 31, 2017 and 2016, respectively. We do not anticipate earning significant revenues until such time that we have fully developed our investment strategy.

 

Operating Income (Loss)

 

Our loss from operations increased by $120,072 during the year ended July 31, 2017, from an operating loss of $103,533 in the same period in 2016. The following table presents operating expenses for the annual periods in 2017 and 2016:

 

 

 

Years ended 

 

 

 

 

 

 

 

 

 

July 31, 

 

 

Change

 

 

 

2017

 

 

2016

 

 

Amount

 

 

Percentage

 

Professional fees

 

$ 90,168

 

 

$ 20,526

 

 

$ 69,642

 

 

 

339 %

Compensation

 

 

5,490

 

 

 

-

 

 

 

5,490

 

 

 

100 %

Consulting fees

 

 

39,173

 

 

 

67,925

 

 

 

(28,752 )

 

 

(42 )%

General and administrative expenses

 

 

78,283

 

 

 

15,082

 

 

 

63,201

 

 

 

419 %

Depreciation and amortization

 

 

10,491

 

 

 

-

 

 

 

10,491

 

 

 

100 %

Total operating expenses

 

$ 223,605

 

 

$ 103,533

 

 

$ 120,072

 

 

 

116 %

 

We realized an increase of $69,642 in professional fees during the year ended July 31, 2017, as compared to the same period in 2016, primarily due to increased accounting and audit fees associated with our reporting obligations. We realized a decrease of $28,752 in consulting fees during the year ended July 31, 2017, as compared to the same period in 2016, primarily due to a decrease in stock-based compensation. We realized an increase of $63,201 in general and administrative expenses during the year ended July 31, 2017, as compared to the same period in 2018, primarily due to an increase in travel expenses related to trade show attendance. We realized an increase of $10,491 in depreciation expenses during year ended July 31, 2017, as compared to the same period in 2016, primarily due to increase in assets related to the acquisition of the assets of THC Therapeutics.

 

Other Income (Expense)

 

The following table presents other income and expenses for the years ended July 31, 2017 and 2016:

 

 

 

Years ended

July 31,

 

 

Change

 

 

 

 2017

 

 

2016

 

 

Amount

 

 

Percentage

 

Gain/(loss) on change in derivative liability

 

$ (81,145 )

 

$ 2,454

 

 

$ (83,599 )

 

(3,407)

Gain/(loss) on settlement of debts

 

 

202,621

 

 

 

(162,235 )

 

 

364,856

 

 

 

225 %

Impairment expense

 

 

(197,761 )

 

 

-

 

 

 

(197,761 )

 

 

100 %

Gain on conveyance of liabilities to a related party

 

 

79,110

 

 

 

-

 

 

 

79,110

 

 

 

100 %

Interest Expense

 

 

(164,928 )

 

 

(31,683 )

 

 

(133,245 )

 

 

(421 )%

Total other income (expense)

 

$ (162,103 )

 

$ (191,464 )

 

$ 29,361

 

 

 

15 %

 

 
19
 
Table of Contents

  

Loss on change in derivative liability increased by $83,599 during the years ended July 31, 2017, as compared to the same period in 2016, due to change in derivative liabilities caused by fluctuations in the price of our common stock between reporting periods. Gain on settlement of debts increased by $364,856 during the year ended July 31, 2017, as compared to the same period in 2016, because the company settled a significant amount of debts as part of its restructuring efforts. Gain on conveyance of liabilities to a related party increased by $79,110 during the year ended July 31, 2017, as compared to the same period in 2016, because the company conveyed certain liabilities to a former officer. Interest expense increased by $133,245 during the year ended July 31, 2017, as compared to the same period in 2016, due to increases in loans, and convertible notes. The Company also recorded an impairment expense of $197,761 due to the impairment of intangible assets related to the THC business segment.

 

Net Income (loss)

 

Net loss increased to $(385,708) during the year ended July 31, 2017, from a net loss of $(294,997) in the same period 2016.

 

Liquidity and Capital Resources

 

Working Capital

 

The following table presents our working capital position as of July 31, 2017, and July 31, 2016:

 

 

 

July 31,

 

 

July 31,

 

 

Change

 

 

 

2017

 

 

2016

 

 

Amount

 

 

Percentage

 

Cash and cash equivalents

 

$ 187

 

 

$ 245

 

 

$ (58 )

 

 

(24 )%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets

 

$ 78,952

 

 

$ 245

 

 

$ 78,707

 

 

 

32,125 %

Current liabilities

 

 

389,515

 

 

 

377,952

 

 

 

11,563

 

 

 

3 %

Working capital

 

$ (310,563 )

 

$ (377,707 )

 

$ 67,144

 

 

 

18 %

 

The change in working capital during the year ended July 31, 2017, was primarily due to an increase in current assets of $78,707 and an increase in current liabilities of $11,563. Current assets increased due to an increase in prepaid expenses as of July 31, 2017. Current liabilities increased due to an increase in borrowing, which resulted in convertible notes payable, advances from related parties, notes payable, derivative liability of $389,515, as compared to $377,952 as of July 31, 2017. Cash decreased as of July 31, 2017, by $(58) to $187, primarily caused by from increased expenses for the year ending July 31, 2017.

 

Cash Flow

 

We fund our operations with cash received from advances from officer’s and related parties, debt, and issuances of equity.

 

The following tables presents our cash flow for the years ended July 31, 2017 and 2016:

 

 

 

Years ended

 

 

 

 

 

 

July 31,

 

 

Change 2017

 

 

 

2017

 

 

2016

 

 

Versus 2016

 

Cash Flows Provided from (Used in) Operating Activities

 

$ (151,671 )

 

$ (17,367 )

 

$ (134,304 )

Cash Flows Used in Investing Activities

 

 

(25,062 )

 

 

-

 

 

 

(25,062 )

Cash Flows Provided by Financing Activities

 

 

176,675

 

 

 

11,144

 

 

 

165,531

 

Net increase (decrease) in Cash During Period

 

$ (58 )

 

$ (6,223 )

 

$ 6,165

 

 

 
20
 
Table of Contents

 

Cash Flows from Operating Activities

 

We did not generate positive cash flows from operating activities for the year ended July 31, 2017.

 

For the years ended July 31, 2017, net cash flows used in operating activities consisted of a net loss of $385,708, reduced by depreciation of $10,491, stock-based compensation of $46,377, amortization of debt discount of $155,820, offset by a loss on change in derivative liabilities of $81,145, gain on settlement of debts of $197,761, loss on impairment of assets of $197,761, gain on conveyance of liabilities or $(79,110) and increased by a net increase in change of operating assets and liabilities of $18,656. For the year ended July 31, 2016, net cash flows provided by operating activities consisted of a net loss of $294,997, reduced by amortization of debt discount of $19,221, offset by a loss on change in derivative liabilities of $2,488, settlement of debts of $162,269, and by a net increase on change of operating assets and liabilities of $98,628.

 

Cash Flows from Investing Activities

 

For the year ended July 31, 2017, net cashflows used in investing activities consisted of purchases of intangible assets of $5,062 and purchase of fixed assets of $20,000. For the year ending in July 31, 2016, we had no investing activities.

 

Cash Flows from Financing Activities

 

For the year ended July 31, 2017, we received $134,113 from loans from related party, $92,500 from convertible notes and used $49,938 for net repayments on related party debts. For the year ended July 31, 2016, we received $11,144 from loans from related party.

 

Anticipated Cash Requirements

 

We estimate that our expenses to further implement our plan of operations over the next 12 months, will be approximately $3,810,000 as described in the table below. These estimates may change significantly depending on the nature of our future business activities and our ability to raise capital from shareholders or other sources. We further anticipate incurring additional costs and expenses for accounting, legal, and other miscellaneous fees relating to compliance with SEC requirements and the filing of the registration statement of which this prospectus forms a part.

 

Description

 

Estimated

Expenses

 

Legal, Accounting & Other Registration Expenses

 

$ 200,000

 

Costs Associated with Being a Public Company

 

 

200,000

 

Trade Shows and Travel

 

 

400,000

 

Website Development

 

 

120,000

 

Rent

 

 

70,000

 

Advertising and Marketing

 

 

750,000

 

Staffing

 

 

770,000

 

General Working Capital

 

 

800,000

 

Cash Reserves

 

 

500,000

 

Total

 

$

3,810,000

 

 

Given that our cash needs are strongly driven by our growth requirements, we also intend to maintain a reserve sum for other risk contingencies that may arise.

 

We intend to meet our cash requirements for the next 12 months through the use of the cash we have on hand and through business operations, future equity financing, debt financing, or other sources, which may result in further dilution in the equity ownership of our shares. We currently do not have any other arrangements in place to complete any private placement financings and there is no assurance that we will be successful in completing any such financings on terms that will be acceptable to us.

 

 
21
 
Table of Contents

 

Off-Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

Critical Accounting Policies and Estimates

 

The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (“GAAP”) and the Company’s discussion and analysis of its financial condition and operating results require the Company’s management to make judgments, assumptions and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Note 3, “Summary of Significant Accounting Policies,” of the Notes to Consolidated Financial Statements included in this Form 10, describes the significant accounting policies and methods used in the preparation of the Company’s consolidated financial statements. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material.

 

Management believes the Company’s critical accounting policies and estimates are those related to revenue recognition. Management considers these policies critical because they are both important to the portrayal of the Company’s financial condition and operating results, and they require management to make judgments and estimates about inherently uncertain matters. The Company’s management has reviewed these critical accounting policies and related disclosures.

 

Principles of Consolidation – The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated.

 

Use of Estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s goodwill, impairments and estimations of long-lived assets, revenue recognition on percentage of completion type contracts, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

Cash and Cash Equivalents – For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents.

 

Fair Value of Financial Instruments – The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.

 

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

 
22
 
Table of Contents

 

The three levels of the fair value hierarchy are described below:

 

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

 

Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

 

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

 

Revenue Recognition :

 

Product Sales – Revenues from the sale of products are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

 

Costs of Revenue – Costs of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

 

Goodwill and Intangible Assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “ Intangibles – Goodwill and Other. ” According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

 

Long-Lived Assets  – In accordance with the Financial Accounting Standards Board ("FASB") Accounts Standard Codification (ASC) ASC 360-10, "Property, Plant and Equipment," the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.

 

Segment Reporting  – Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding the method to allocate resources and assess performance. The Company currently has one reportable segment for financial reporting purposes, which represents the Company's core business.

 

Income Taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “ Income Taxes ”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

Stock-Based Compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “ Compensation-Stock Compensation ”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values.

 

Earnings (Loss) Per Share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “ Earnings Per Share .” Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

 

 
23
 
Table of Contents

 

Emerging Growth Company

 

We are an “emerging growth company” under the federal securities laws and will be subject to reduced public company reporting requirements. In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are choosing to take advantage of the extended transition period for complying with new or revised accounting standards. As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates.

 

Recently Issued Accounting Pronouncements

 

We do not expect the adoption of any recently issued accounting pronouncements to have a significant impact on our net results of operations, financial position, or cash flows.

 

Seasonality

 

We do not expect our sales to be impacted by seasonal demands for our products and services.

 

Item 3. Properties.

 

Currently the Company leases approximately 1,300 square feet of office space in San Diego, California, at a monthly rent of $3,300, on a month-to-month basis and including all utilities. There is no obligation for the landlord to continue to lease the Company the office space on the same terms.

 

Item 4. Security Ownership of Certain Beneficial Owners and Management.

 

The following tables set forth, as of April 30, 2018, certain information concerning the beneficial ownership of our capital stock, including our common stock, and Series A Preferred Stock, and Series B Preferred Stock, by:

 

 

·

each stockholder known by us to own beneficially 5% or more of any class of our outstanding stock;

 

·

each director;

 

·

each named executive officer;

 

·

all of our executive officers and directors as a group; and

 

·

each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of any class of our outstanding stock.

 

As of April 30, 2018, the Company had authorized 500,000,000 shares of common stock and 10,000,000 shares of preferred stock, with 3,000,000 shares of preferred stock designated as Series A Preferred Stock, and 165,000 shares of preferred stock designated as Series B Preferred Stock. There were 123,985,891 shares of common stock, 2,000,000 shares of Series A Preferred Stock, and 165,000 shares of Series B Preferred Stock outstanding as of April 30, 2018. Each share of Series A Preferred Stock is convertible into 100 shares of common stock, and each share entitles the holder thereof to 100 votes per share. Each share of Series B Preferred Stock is convertible one year following issuance at a variable conversion rate equal to the stated price of $1.00 divided by the prior day’s closing price of the Company’s common stock as quoted on the OTC Link, LLC operated by OTC Markets Group, Inc.

 

Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to our common stock. Shares of our common stock subject to options that are currently exercisable or exercisable within 60 days of April 30, 2018, are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Except as otherwise noted, we believe the persons and entities included in the below table have sole voting and investing power with respect to all of the shares of our common stock beneficially owned by them, subject to community property laws, where applicable, and their address is c/o the Company at 11700 W Charleston Blvd #73, Las Vegas, NV 89135.

 

 
24
 
Table of Contents

 

Security Ownership of Certain Beneficial Owners & Management

 

Title of Class

 

Name and Address of Beneficial Owner

 

Amount and nature of beneficial ownership

 

 

Percent of Class

 

Common Stock

 

Brandon Romanek

 

 

105,316,322

 

 

 

84.9 %

Series A Preferred Stock

 

Brandon Romanek

 

 

2,000,000

 

 

 

100 %

Series B Preferred Stock

 

Carlos Escamilla & Daniel Jones

 

 

165,000

 

 

 

100 %

___________ 

 

Item 5. Directors and Executive Officers.

 

The names, ages, positions, periods served of the Company’s present directors are set forth in the following table:

 

Name

 

Age

 

Positions

 

Period of Service Began

Brandon Romanek

 

44

 

CEO, President, CFO, Secretary, Director (1)

 

January 12, 2017

 

______ 

(1) All directors hold office until the next annual meeting of stockholders and until their successors have been duly elected and qualified.

 

There are no agreements with respect to electing directors. The Board of Directors appoints officers annually and each executive officer serves at the discretion of the Board of Directors. The Company does not have any standing committees at this time, and due to its small size does not believe that committees are necessary at this time. As of the date of this Registration Statement, the Company’s Board fulfills the duties of an audit committee. None of the directors held any directorships during the past five years in any company with a class of securities registered pursuant to Section 12 of the Exchange Act or subject to the requirements of Section 15(d) of such act, or of any company registered as an investment company under the Investment Company Act of 1940.

 

Director and Officer Biographical Information

 

Brandon Romanek

 

Brandon’s background in brokerage firms, hedge funds, institutions, money management, and trading prepared him for the task of building THC Therapeutics. Beginning in 1999, Brandon traded with Wedbush, Merrill Lynch other brokerage firms using portfolio margin. Brandon has traded on many platforms including Real Tick, Sterling, LightSpeed, and Firetip. From 2002-2006, Brandon traded CFD’s with the CMC Markets in Toronto. From 2008, Brandon was a commodities trader in the precious metals markets. He was a broker dealer in physical metals from 2009-2011, mostly doing business with Amark, a publicly traded metals dealer. Brandon is also founder and CEO of SBR Asset Management. Brandon became the CEO and director of the Company in January of 2017, and he has not been the director of any other public company during the past five years. We believe that Brandon’s financial markets background makes him a valuable member of our Board of Directors.

 

Involvement in Certain Legal Proceedings

 

To the best of our knowledge, none of our directors or executive officers has, during the past ten years:

 

(1) had a petition under the Federal bankruptcy laws or any state insolvency law filed by or against, or a receiver, fiscal agent or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing;

 

 
25
 
Table of Contents

 

(2) has been convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);

 

(3) has been the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:

 

(i) Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity;

 

(ii) Engaging in any type of business practice; or

 

(iii) Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws;

 

(4) has been the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in (3)(i) above, or to be associated with persons engaged in any such activity;

 

(5) has been found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;

 

(6) has been found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;

 

(7) has been the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:

 

(i) Any Federal or State securities or commodities law or regulation; or

 

(ii) Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or

 

(iii) Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

 

(8) has been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 

 
26
 
Table of Contents

  

Item 6. Executive Compensation.

 

Summary Compensation Table

 

The following table sets forth, for the fiscal years ended July 31, 2017 and July 31, 2016, certain information regarding the compensation earned by the Company’s named executive officers.

 

Summary Compensation Table

 

Name and Principal Position

 

Fiscal Year

Ended

July 31,

 

Salary($)

 

 

Total ($)

 

Brandon Romanek, CEO/CFO (1)

 

2017

 

$ -

 

 

$ -

 

 

 

2016

 

 

-

 

 

 

-

 

Jamie Mann, CEO/CFO (2)

 

2017

 

$ 17,712

 

 

$ 17,712

 

 

 

2016

 

 

67,925

 

 

 

67,925

 

___________  

(1) Mr. Romanek was appointed as CEO of the Company on January 12, 2017.
(2) Mr. Mann was the former CEO and CFO of the Company until January 12, 2017, when he resigned and Mr. Romanek was appointed as the sole officer and director of the Company.

 

Director Compensation

 

Directors do not receive compensation for serving as a Director of the Company.

 

Employment Agreements

 

Except for the following agreements, the Company does not have any written agreements with any of its executive officers.

 

On November 1, 2017, we entered into an employment agreement with Brandon Romanek, our Chief Executive Officer. In accordance with this agreement, Mr. Romanek provided services to the Company in exchange for $78,000 per year plus vacation and bonuses as approved annually by the board of directors and reimbursable expenses incurred. During the nine months ending April 30, 2018, the Company accrued $41,137 related to this agreement. As of April 30, 2018, Mr. Romanek allowed the Company to defer all compensation related to his employment totaling $41,137.

 

Stock Option Plan and other Employee Benefits Plans

 

The Company does not maintain a Stock Option Plan or other Employee Benefit Plans.

 

Overview of Compensation Program

 

We currently do not maintain a Compensation Committee of the Board of Directors. Until a formal committee is established, our entire Board of Directors has responsibility for establishing, implementing and continually monitoring adherence with the Company’s compensation philosophy. The Board of Directors ensures that the total compensation paid to the executives is fair, reasonable, and competitive.

 

Compensation Philosophy and Objectives

 

The Board of Directors believes that the most effective executive compensation program is one that is designed to reward the achievement of specific annual, long-term and strategic goals by the Company and that aligns executives’ interests with those of the stockholders by rewarding performance above established goals, with the ultimate objective of improving stockholder value. As a result of the size of the Company, the Board evaluates both performance and compensation on an informal basis. Upon hiring additional executives, the Board intends to establish a Compensation Committee to evaluate both performance and compensation to ensure that the Company maintains its ability to attract and retain superior employees in key positions and that compensation provided to key employees remains competitive relative.

 

 
27
 
Table of Contents

  

Role of Executive Officers In Compensation Decisions

 

The Board of Directors makes all compensation decisions for, and approves recommendations regarding equity awards to, the executive officers and directors of the Company.

 

Item 7. Certain Relationships and Related Transactions, and Director Independence.

 

Transactions with Related Persons

 

Advances from related parties for the years ending July 31, 2017 and 2016  

 

Our Chief Executive Officer and a shareholder, a relative of our Chief Executive Officer, have agreed to advance funds to the Company from time to time to support the ongoing operations of the Company. The advances are due within ten (10) days of demand and bear interest at 5% annually.

 

Advances from related parties consist of the following as of July 31, 2017:

 

 

 

Year ending July 31, 2017

 

 

Principal as of

 

 

Accrued interest balance

As of

 

 

 

Funds advanced

 

 

Funds repaid

 

 

July 31, 2017

 

 

July 31, 2017

 

B. Romanek, President and CEO

 

$ 121,200

 

 

$ 49,938

 

 

$ 71,262

 

 

$ 1,040

 

Shareholder Relative of our President and CEO

 

 

6,025

 

 

 

-

 

 

 

6,025

 

 

 

79

 

TOTAL

 

$ 127,225

 

 

$ 49,938

 

 

$ 77,287

 

 

$ 1,120

 

 

The former sole officer and director of the Company advanced the Company $6,888 and $11,144 during the years ending July 31, 2017 and 2016, respectively.

 

On January 4, 2017, the former sole officer and director forgave all advances in relation to his acquisition of the assets under the Kouei International license agreement and related business.

 

Advances from related parties for the nine months ending April 30, 2018

 

Our Chief Executive Officer and a shareholder, a relative of our Chief Executive Officer, have agreed to advance funds to the Company from time to time to support the ongoing operations of the Company. The advances are due within ten (10) days of demand and bear interest at 5% annually.

 

Advances from related parties consist of the following as of April 30, 2018:

 

 

 

Principal as of

 

 

Nine months ending April 30, 2018

 

 

Principal as of

 

 

Accrued interest balance

 

 

 

July 31,

2017

 

 

Funds

advanced

 

 

Funds

repaid

 

 

April 30,

2018

 

 

As of April 30, 2018

 

B. Romanek, President and CEO

 

$ 71,262

 

 

$ 105,256

 

 

$ 62,916

 

 

$ 113,602

 

 

$ 4,342

 

Shareholder Relative of our President and CEO

 

$ 6,025

 

 

 

37,088

 

 

 

9,924

 

 

 

33,189

 

 

 

524

 

TOTAL

 

$ 77,287

 

 

$ 142,344

 

 

$ 72,840

 

 

$ 146,791

 

 

$ 4,866

 

 

 
28
 
Table of Contents

  

Asset purchase agreement with related parties

 

On January 20, 2017, the Company entered into an asset purchase agreement with its current officer and director, Brandon Romanek, under which it acquired certain patent and trademark applications and other intellectual property in exchange for 100,000,000 shares of common stock and 2,000,000 shares of Series A Preferred Stock.

 

Due to the common control nature of the transaction the Company recorded the assets at their historical carrying amounts in accordance with ASC 805-50-30. The shares issued as consideration were fair valued at $20,100,000, as a result the difference between the value of the proceeds transferred and the carrying amounts of the net assets received was recognized in additional paid-in capital.

 

The purchase price was allocated as follows:

 

Amount

 

Patents and patents pending

 

$ 13,717

 

Trademarks

 

 

1,000

 

Website and domain names

 

 

15,098

 

dHydronator® Prototype

 

 

27,100

 

Total historical costs of assets acquired

 

$ 56,915

 

 

Stock issuances to related parties

 

Issuances of Common and Preferred Stock for the year ended July 31, 2016

 

On July 20, 2016, the Company issued 3,200,569 shares of common stock of the Company to a former officer of the Company in exchange for $225,000 of accrued consulting fees due to our sole officer and director. The shares were fair valued at $384,067, and a loss on settlement of debt of $162,269 was recorded as a result of the transaction.

 

Issuances of Common and Preferred Stock for the year ended July 31, 2017

 

On January 23, 2017, the Company issued 100,000,000 shares of common stock and 2,000,000 shares of Series A Preferred Stock to our current officer and director, Brandon Romanek, as consideration under an asset purchase agreement with him. (See Note 12 for additional details.)

 

Promoters and Certain Control Persons

 

None.

 

List of Parents

 

None.

 

Director Independence

 

The Company has one independent director. All current directors are shareholders of the Company.

 

Item 8. Legal Proceedings.

 

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are not presently a party to any material litigation, nor to the knowledge of management is any litigation threatened against us, which may materially affect us.

 

 
29
 
Table of Contents

 

Item 9. Market Price of and Dividends on the Registrant’s Common Equity and Related Stockholder Matters.

 

Market Information

 

The Common Stock of the Company is currently trading on the OTC Link, LLC quotation board operated by OTC Markets Group, Inc., under the symbol “MBLC.” The following information reflects the high and low bid prices of the Company’s common stock on the OTC Link found on OTCMarkets.com.

 

Quarterly period

 

High

 

 

Low

 

Fiscal year ended July 31, 2016:

 

 

 

 

 

 

First Quarter

 

$ 0.21

 

 

$ 0.056

 

Second Quarter

 

$ 0.14

 

 

$ 0.056

 

Third Quarter

 

$ 1.33

 

 

$ 0.0336

 

Fourth Quarter

 

$ 2.77

 

 

$ 0.07

 

 

 

 

 

 

 

 

 

 

Fiscal year ended July 31, 2017:

 

 

 

 

 

 

 

 

First Quarter

 

$ 0.0885

 

 

$ 0.02

 

Second Quarter

 

$ 0.3161

 

 

$ 0.0201

 

Third Quarter

 

$

0.1.30

 

 

$ 0.112

 

Fourth Quarter

 

$ 0.5746

 

 

$ 0.3002

 

 

Fiscal year ended July 31, 2018:

 

 

 

 

 

 

First Quarter

 

$ 0.4149

 

 

$ 0.2151

 

Second Quarter

 

$ 1.94

 

 

$ 0.1965

 

Third Quarter

 

$ 0.9875

 

 

$ 0.301

 

 

Holders

 

As of April 30, 2018, there were 123,985,891 shares of common stock outstanding, which were held by approximately nine shareholders of record. In addition, there were 2,000,000 shares of our Series A Preferred Stock outstanding, which shares were held by one shareholder of record, and there were 165,000 shares of our Series B Preferred Stock outstanding, which shares were held by two shareholders of record.

 

Dividends

 

We have never paid cash dividends on any of our capital stock and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. We do not intend to pay cash dividends to holders of our common stock in the foreseeable future.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

The Company does not currently maintain any Equity Compensation Plans.

 

Item 10. Recent Sales of Unregistered Securities.

 

On July 20, 2016, the Company issued 3,200,569 shares of common stock of the Company to a former officer of the Company in exchange for $225,000 of accrued consulting fees due to that former officer.

 

On January 13, 2017, we entered into a convertible promissory note with a note holder who assumed two outstanding notes totaling $112,400. Interest under the convertible promissory note is 5% per annum, and the principal and all accrued but unpaid interest is due on January 13, 2018. The note is convertible at any time following the issuance date at noteholder’s option into shares of our common stock at a fixed conversion price of $0.001. On February 6, 2017, the holder of the note converted $10,000 of the principal of the note into 10,000,000 common shares of the Company at a conversion price of $0.001. On April 28, 2017, the note holder forgave the remaining balance principal of $102,400 and accrued interest of 1,507.

 

 
30
 
Table of Contents

  

On January 23, 2017, the Company issued 100,000,000 shares of common stock and 2,000,000 shares of Series A Preferred Stock to our officer and director, Brandon Romanek, as consideration under an asset purchase agreement with him.

 

On May 9, 2017, the Company entered into a convertible promissory note pursuant to which we borrowed $92,500 from a third-party lender. The note carries an original issue discount of 7.5% ($7,500). Interest under the convertible promissory note is 6% per annum, and the principal and all accrued but unpaid interest is due on May 9, 2018. The note is convertible at any date after the issuance date at noteholder’s option into shares of our common stock at a variable conversion price of 65% of the lowest closing market price of our common stock during the previous 20 days to the date of the notice of conversion.

 

Also on May 9, 2017, the Company issued stock warrants to purchase 100,000 shares of its common stock to a third-party lender as part of a financing agreement. The warrants have a strike price of $0.75. The stock warrants were exercisable six-months from grant and have a life of 3 years.

 

On May 12, 2017, the Company issued 120,000 shares of Series A Preferred Stock as consideration to the seller under an asset purchase agreement.

 

On June 6, 2017, the Company issued 45,000 shares of Series A Preferred Stock as consideration to a lender to settle a lien on assets acquired under the May 12, 2017, asset purchase agreement.

 

On June 12, 2017, the Company issued 200,000 shares of common stock to a consultant for services to be rendered between June 15, 2017 and September 15, 2017.

 

On June 26, 2017, the Company issued 88,000 shares of common stock to a consultant for services to be rendered between July 1, 2017, and June 30, 2018.

 

On August 10, 2017, the Company issued 5,000 shares of common stock to a consultant for services rendered. The shares were fair valued at $1,740 at the date of grant.

 

On August 28, 2017, the Company issued 2,500 shares of common stock to a consultant for services rendered. The shares were fair valued at $973 at the date of grant.

 

On October 13, 2017, the Company issued stock warrants to purchase 30,000 shares of its common stock to a third-party lender as part of a financing agreement. The warrants have a strike price of $2.00. The stock warrants were exercisable immediately upon grant and have a life of 3 years.

 

On February 15, 2018, the Company agreed to issue 150,000 shares of common stock to a consultant for services rendered. The shares were fair valued at $102,000 ($0.68 per share) and deemed fully earned at the date of grant.

 

On March 5, 2018, the Company received $25,000 from an investor pursuant to a private placement agreement with the investor to purchase 62,500 shares of the Company’s common stock and 62,500 warrants to purchase shares of the Company’s common stock at $2.00 per share for a period of three years. If the Company’s common stock has closed for 20 consecutive trading days above $3.00 per share, the investor must exercise the warrant within 30 days.

 

On March 31, 2018, the Company entered into two agreements with BurstIQ Analytics Corporation, a Colorado corporation (“BurstIQ”), a Simple Agreement for Future Tokens (the “SAFT”) and Simple Agreement for Future Equity (the “SAFE”). Pursuant to the SAFT and the SAFE, the Company purchased (i) the right to a number of BIQ tokens equal to $2,500,000 divided by a 35% discount to the maximum price per token sold by BurstIQ to the public during a network launch, and (ii) the right to a number shares of BurstIQ’s preferred stock sold in a subsequent equity financing equal to $2,500,000 divided by a deemed $6.50 price per share, in consideration of the issuance of an aggregate of 5,000,000 shares of the Company’s common stock to BurstIQ.

 

 
31
 
Table of Contents

 

On March 31, 2018, the Company and a lender agreed to settle a $30,000 promissory note and associated accrued interest of $3,473. The Company agreed to issue 95,000 shares of the Company’s common stock and warrants to purchase 195,000 shares of the Company’s common stock at $2.00 for a three-year term. In return for the consideration, the Lender agreed to release the Company from all amounts owed.

 

On April 6, 2018, the Company received $40,000 from an investor pursuant to a private placement agreement with the investor to purchase 100,000 shares of the Company’s common stock and 250,000 warrants to purchase shares of the Company’s common stock at $2.00 per share for a period of five years.

 

The issuance described above for conversion of debt on February 6, 2017, was made in reliance on the exemptions from registration provided by Sections 3(a)(9) and 4(a)(1) of the Securities Act, as the common stock was issued in exchange for debt securities of the Company held by the shareholder for the requisite holding period, there was no additional consideration for the exchange, there was no remuneration for the solicitation of the exchange, there was no general solicitation, and the transactions did not involve a public offering. The other securities identified in this section were issued or will be issued with restrictive legends (stating that the shares have not been registered and cannot be transferred unless registered under the Securities Act of 1933 or unless an exemption from registration is available) pursuant to exemptions from registration requirements relying on Section 4(a)(2) of the Securities Act of 1933 and/or upon Rule 506(b) of Regulation D of the Securities Act of 1933 as there was no general solicitation, and the transactions did not involve a public offering.

 

Item 11. Description of Registrant’s Securities to be Registered.

 

We are registering on this Registration Statement only our common stock, the terms of which are described below. However, because our preferred stock will remain outstanding following the effectiveness of this Registration Statement, we also describe below the terms of our preferred stock to the extent such terms qualify the rights of our common stock.

 

As of April 30, 2018, the Company had authorized 500,000,000 shares of common stock and 10,000,000 shares of preferred stock, with 3,000,000 shares of preferred stock designated as Series A Preferred Stock, and 165,000 shares of preferred stock designated as Series B Preferred Stock.

 

Common Stock

 

Subject to the voting rights of the Company’s preferred stock, at any meeting of the shareholders, every shareholder of common stock is entitled to vote and may vote in person or by proxy authorized by an instrument in writing filed in accordance with the procedure established for the meeting.

 

Each shareholder shall have one vote for every share of stock entitled to vote, which is registered in his name on the record date for the meeting, except as otherwise required by law or the Articles of Incorporation.

 

All elections of directors shall be determined by a plurality of the votes cast by the holders of shares entitled to vote in the election of directors at a meeting of shareholders at which a quorum is present. Except as otherwise required by law or the Articles of Incorporation, all matters other than the election of directors shall be determined by the affirmative vote of the holders of a majority of the shares entitled to vote on that matter and represented in person or by proxy at a meeting of shareholders at which a quorum is present.

 

The Company’s Articles of Incorporation do not provide for cumulative voting or preemptive rights.

 

Preferred Stock

 

Holders of the Series A Preferred Stock are entitled at their option to convert their preferred shares into common stock at a conversion rate of one hundred (100) shares of common stock for every one (1) share of Series A Preferred Stock. The holders are further entitled to vote together with the holders of the Company’s common stock on all matters submitted to shareholders at a rate of one hundred (100) votes for each share held. The holders are entitled to equal rights with our common stockholders as it relates to liquidation preference.

 

 
32
 
Table of Contents

 

Holders of Series B Preferred Stock are entitled to a liquidation preference on the stated value of $1.00 per share. The shares carry a mandatory conversion provision, with all shares of Series B Preferred Stock convertible by the Company one year from issuance, at a variable conversion rate equal to the stated price of $1.00 divided by the prior day’s closing price as quoted on OTC Markets. Holders of Series B Preferred Stock are not entitled to any voting or dividend rights.

 

Convertible Instruments

 

The following is a description of the material terms of our convertible instruments which remain outstanding as of April 30, 2018):

 

On May 9, 2017, the Company entered into a convertible promissory note pursuant to which we borrowed $92,500 from a third-party lender. The note carries an original issue discount of 7.5% ($7,500). Interest under the convertible promissory note is 6% per annum, and the principal and all accrued but unpaid interest is due on May 9, 2018. The note is convertible at any date after the issuance date at noteholder’s option into shares of our common stock at a variable conversion price of 65% of the lowest closing market price of our common stock during the previous 20 days to the date of the notice of conversion.

 

Warrants

 

On May 9, 2017, the Company issued to the convertible note lender described in the preceding paragraph, warrants to purchase 100,000 shares of the Company’s common stock. The warrants have a strike price of $0.75. The stock warrants were exercisable six-months from grant and have a life of 3 years.

 

On October 13, 2017, the Company issued warrants to purchase 30,000 shares of Company’s common stock to a third-party lender. The warrants have a strike price of $2.00. The warrants were exercisable immediately upon grant and have a life of 3 years.

 

On March 5, 2018, the Company issued to an investor warrants to purchase 62,500 shares the Company’s common stock at $2.00 per share for a period of three years. If the Company’s common stock has closed for 20 consecutive trading days above $3.00 per share, the investor must exercise the warrant within 30 days.

 

On March 31, 2018, the Company agreed to issue to a lender warrants to purchase 195,000 shares of the Company’s common stock at $2.00 for a three-year term.

 

On April 6, 2018, the Company issued to an investor warrants to purchase 250,000 shares of the Company’s common stock at $2.00 per share for a period of five years.

 

Item 12. Indemnification of Directors and Officers.

 

Our Articles of Incorporation and bylaws both provide for the indemnification of our officers and directors to the fullest extent permitted by the Nevada Revised Statutes. These provisions state that certain persons (hereinafter called “lndemnitees”) may be indemnified by a Nevada corporation pursuant to the provisions of applicable law, namely, any person (or the heirs, executors or administrators of such person) who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise. The Company will indemnify the Indemnitees in each and every situation where the Company is obligated to make such indemnification pursuant to the aforesaid statutory provisions. The Company will also indemnify the Indemnitees in each and every situation where, under the aforesaid statutory provisions, the Company is not obligated, but is nevertheless permitted or empowered, to make such indemnification. Before making such indemnification with respect to any situation covered under the foregoing sentence, the Company will make a determination as to whether each Indemnitee acted in good faith and in a manner such Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and, in the case of any criminal action or proceeding, had no reasonable cause to believe that such Indemnitee’s conduct was unlawful. No such indemnification shall be made (where not required by statute) unless it is determined that such Indemnitee acted in good faith and in a manner such Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and, in the case of any criminal action or proceeding, had no reasonable cause to believe that such Indemnitee’s conduct was unlawful.

 

 
33
 
Table of Contents

 

Item 13. Financial Statements and Supplementary Data.

 

The information required by this item may be found beginning on page F-1 of this Registration Statement and are incorporated herein by reference.

 

Item 14. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

We have had no disagreements with our independent auditors on accounting or financial disclosures.

 

Item 15. Financial Statements and Exhibits.

 

(a) Financial Statements

 

Financial Statements:

 

For the Years Ended July 31, 2017 and 2016

 

Report of Independent Registered Public Accounting Firm

 

Consolidated Balance Sheets as of July 31, 2017 and 2016

 

Consolidated Statements of Operations for the years ended July 31, 2017 and 2016

 

Consolidated Statements of Changes in Stockholders’ Deficit for the years ended July 31, 2017 and 2016

 

Consolidated Statement of Cash Flows for the years ended July 31, 2017 and 2016

 

Notes to Consolidated Financial Statements

 

For the Three and Nine Months Ended April 30, 2018 (Unaudited)

 

Consolidated Balance Sheets as of April 30, 2018 and July 31, 2017

 

Consolidated Statements of Operations for the three and nine months ended April 30, 2018 and 2017

 

Consolidated Statement of Cash Flows for the nine months ended April 30, 2018 and 2017

 

Notes to Consolidated Financial Statements

 

(b) Exhibits.

 

See the Exhibit Index attached hereto which is incorporated by reference.

 

 
34
 
Table of Contents

 

THC THERAPEUTICS, INC

 

(formerly MILLENNIUM BLOCKCHAIN, INC.)

 

NOTES TO THE FINANCIAL STATEMENTS

 

JULY 31, 2017

 

 
F-1
 
Table of Contents

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of

Millennium Blockchain, Inc.

 

We have audited the accompanying balance sheets of Millennium Blockchain, Inc. as of July 31, 2017 and July 31, 2016 and the related statements of operations, stockholders' (deficit), and cash flows for each of the years in the two-year period ended July 31, 2017 and July 31, 2016. Millennium Blockchain, Inc.'s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Millennium Blockchain, Inc. as of July 31, 2017 and July 31, 2016, and the results of its operations and its cash flows for each of the years in the two-year period ended July 31, 2017 and July 31, 2016 in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has no revenues, has negative working capital at July 31, 2017 and July 31, 2016, has incurred recurring losses and recurring negative cash flow from operating activities, and has an accumulated deficit which raises substantial doubt about its ability to continue as a going concern. Management's plans concerning these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

/s/ AMC Auditimg

 

AMC Auditing

Las Vegas, Nevada

February 28, 2018

 

 
F-2
 
Table of Contents

 

THC THERAPEUTICS INC.

(formerly MILLENNIUM BLOCKCHAIN, INC.)

CONSOLIDATED BALANCE SHEETS

(AUDITED)

 

ASSETS

 

July 31,

2017

 

 

July 31,

2016

 

Current assets

 

 

 

 

 

 

Cash

 

$ 187

 

 

$ 245

 

Prepaid

 

 

78,765

 

 

 

-

 

Total current assets

 

 

78,952

 

 

 

245

 

 

 

 

 

 

 

 

 

 

Deposits

 

 

3,208

 

 

 

-

 

Fixed Assets

 

 

78,874

 

 

 

-

 

Intangible Assets

 

 

32,612

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Total assets

 

 

193,646

 

 

 

245

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$ 82,140

 

 

$ 128,255

 

Accrued liabilities due to related parties

 

 

1,120

 

 

 

20,841

 

Advances from related parties

 

 

77,287

 

 

 

11,482

 

Notes payable

 

 

60,000

 

 

 

50,000

 

Convertible Notes payable, net

 

 

22,739

 

 

 

99,998

 

Derivative liability

 

 

146,229

 

 

 

67,376

 

Total current liabilities

 

 

389,515

 

 

 

377,952

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

389,515

 

 

 

377,952

 

 

 

 

 

 

 

 

 

 

Stockholders' equity (deficit)

 

 

 

 

 

 

 

 

Common stock; $0.001 par value; 500,000,000 shares authorized;

 

 

 

 

 

 

 

 

118,778,391 and 8,490,391 shares issued and outstanding

 

 

 

 

 

 

 

 

as of July 31, 2017 and July 31, 2016, respectively

 

 

118,778

 

 

 

8,490

 

Preferred stock; $0.001 par value; 10,000,000 shares authorized;

 

 

 

 

 

 

 

 

2,165,000 and 0 series A and B shares issued and outstanding as of

 

 

 

 

 

 

 

 

July 31, 2017 and July 31, 2016, respectively

 

 

 

 

 

 

 

 

Preferred A stock; $0.001 par value; 3,000,000 shares authorized;

 

 

 

 

 

 

 

 

2,000,000 and 0 shares issued and outstanding as of

 

 

 

 

 

 

 

 

July 31, 2017 and July 31, 2016, respectively

 

 

2,000

 

 

 

-

 

Preferred B stock; $0.001 par value; 165,000 shares authorized;

 

 

 

 

 

 

 

 

165,000 and 0 shares issued and outstanding as of

 

 

 

 

 

 

 

 

July 31, 2017 and July 31, 2016, respectively

 

 

165

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Additional paid-in capital

 

 

2,937,860

 

 

 

2,482,767

 

Accumulated deficit

 

 

(3,254,672 )

 

 

(2,868,964 )

Total stockholders' deficit

 

 

(195,869 )

 

 

(377,707 )

 

 

 

 

 

 

 

 

 

Total liabilities and stockholders' equity (deficit)

 

$ 193,646

 

 

$ 245

 

 

The accompanying notes are an integral part of these financial statements.

 

 
F-3
 
Table of Contents

 

THC THERAPEUTICS INC.

(formerly MILLENNIUM BLOCKCHAIN, INC.)

CONSOLIDATED STATEMENT OF OPERATIONS

(AUDITED)

 

 

 

For the Years Ended

 

 

 

July 31,

2017

 

 

July 31,

2016

 

 

 

 

 

 

 

 

Revenues

 

$ -

 

 

$ -

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

Professional fees

 

 

90,168

 

 

 

20,526

 

Compensation

 

 

5,490

 

 

 

-

 

Consulting fees

 

 

39,173

 

 

 

67,925

 

General and administrative expenses

 

 

78,283

 

 

 

15,082

 

Depreciation and amortization

 

 

10,491

 

 

 

-

 

Total operating expenses

 

 

223,605

 

 

 

103,533

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(223,605 )

 

 

(103,533 )

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

Gain/(loss) on change in derivative liability

 

 

(81,145 )

 

 

2,454

 

Gain/(loss) on settlement of debts

 

 

202,621

 

 

 

(162,235 )

Impairment expense

 

 

(197,761 )

 

 

-

 

Interest Expense

 

 

(164,928 )

 

 

(31,683 )

Gain on conveyance of assets and liabilities to a related party

 

 

79,110

 

 

 

-

 

Total other income (expense)

 

 

(162,103 )

 

 

(191,464 )

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$ (385,708 )

 

$ (294,997 )

 

 

 

 

 

 

 

 

 

Basic income (loss) per common share

 

$ (0.01 )

 

$ (0.05 )

 

 

 

 

 

 

 

 

 

Basic weighted average common shares outstanding

 

 

65,922,939

 

 

 

5,399,477

 

 

The accompanying notes are an integral part of these financial statements.

 

 
F-4
 
Table of Contents

 

THC THERAPEUTICS INC.

(formerly MILLENNIUM BLOCKCHAIN, INC.)

CONSOLIDATED STATEMENT OF STOCKHOLDERS DEFICIT

(AUDITED)

 

 

 

Preferred A Stock

 

 

Preferred B Stock

 

 

Common Stock

 

 

Additional

Paid-in

 

 

Accumulated

 

 

Total Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Deficit

 

Balance, July 31, 2015

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

5,288,376

 

 

 

5,288

 

 

 

2,098,700

 

 

 

(2,573,967 )

 

 

(469,979 )

Shares issued to an officer in settlement of liabilities

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

3,200,569

 

 

 

3,200

 

 

 

384,069

 

 

 

-

 

 

 

387,269

 

Shares issued for fractional shares on reverse-split

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,446

 

 

 

2

 

 

 

(2 )

 

 

-

 

 

 

-

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(294,997 )

 

 

(294,997 )

Balance, July 31, 2016

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

8,490,391

 

 

 

8,490

 

 

 

2,482,767

 

 

 

(2,868,964 )

 

 

(377,707 )

Settlement of derivative liabilities

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

62,513

 

 

 

-

 

 

 

62,513

 

Beneficial conversion feature on convertible debt

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

134,557

 

 

 

-

 

 

 

134,557

 

Shares and warrants issued to acquire assets

 

 

2,000,000

 

 

 

2,000

 

 

 

120,000

 

 

 

120

 

 

 

100,000,000

 

 

 

100,000

 

 

 

87,556

 

 

 

-

 

 

 

189,676

 

Warrants issued as financing fee

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Shares issued on conversion of debts

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

10,000,000

 

 

 

10,000

 

 

 

-

 

 

 

-

 

 

 

10,000

 

Preferred shares issued for settlement of debts

 

 

-

 

 

 

-

 

 

 

45,000

 

 

 

45

 

 

 

-

 

 

 

-

 

 

 

44,955

 

 

 

-

 

 

 

45,000

 

Imputed interest

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

658

 

 

 

-

 

 

 

658

 

Shares issued for services

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

288,000

 

 

 

288

 

 

 

124,854

 

 

 

-

 

 

 

125,142

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(385,708 )

 

 

(385,708 )

Balance, July 31, 2017

 

 

2,000,000

 

 

 

2,000

 

 

 

165,000

 

 

 

165

 

 

 

118,778,391

 

 

 

118,778

 

 

 

2,937,860

 

 

 

(3,254,672 )

 

 

(195,869 )

 

The accompanying notes are an integral part of these financial statements.

 

 
F-5
 
Table of Contents

 

THC THERAPEUTICS INC.

(formerly MILLENNIUM BLOCKCHAIN, INC.)

CONSOLIDATED STATEMENT OF CASHFLOWS

(AUDITED)

 

 

 

For the Years Ended

 

 

 

July 31,

2017

 

 

July 31,

2016

 

Cash Flows from Operating Activities

 

 

 

 

 

 

Net loss

 

$ (385,708 )

 

$ (294,997 )

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Gain on conveyance of assets and liabilities to a related party

 

 

(79,110 )

 

 

-

 

Loss on impairment of assets

 

 

197,761

 

 

 

-

 

Loss on change in derivative liabilities

 

 

81,145

 

 

 

(2,488 )

Impairment expense

 

 

658

 

 

 

 

 

Loss on acquisition of assets from a related party

 

 

-

 

 

 

-

 

Amortization of debt discount

 

 

155,820

 

 

 

19,221

 

Stock based compensation

 

 

46,377

 

 

 

-

 

Depreciation and amortization

 

 

10,491

 

 

 

-

 

Loss (gain) on settlement of debts

 

 

(197,761 )

 

 

162,269

 

Changes in assets and liabilities

 

 

 

 

 

 

 

 

(Increase) decrease in deposits

 

 

(3,208 )

 

 

-

 

Increase (decrease) in accounts payable

 

 

3,032

 

 

 

30,704

 

Increase (decrease) in accounts payable related party

 

 

18,832

 

 

 

67,924

 

Net cash from operating activities

 

 

(151,671 )

 

 

(17,367 )

 

 

 

 

 

 

 

 

 

Cash Flows from investing

 

 

 

 

 

 

 

 

Purchase of intangible assets

 

 

(5,062 )

 

 

-

 

Purchase of fixed assets

 

 

(20,000 )

 

 

-

 

Net cash used in investing activities

 

 

(25,062 )

 

 

-

 

 

 

 

 

 

 

 

 

 

Cash Flows from Financing Activities

 

 

 

 

 

 

 

 

Proceeds from related party debts

 

 

134,113

 

 

 

11,144

 

Payments on related party debts

 

 

(49,938 )

 

 

-

 

Proceeds from convertible debts

 

 

92,500

 

 

 

-

 

Net cash from financing activities

 

 

176,675

 

 

 

11,144

 

 

 

 

 

 

 

 

 

 

Net increase (decrease) in Cash

 

 

(58 )

 

 

(6,223 )

 

 

 

 

 

 

 

 

 

Beginning cash balance

 

 

245

 

 

 

6,468

 

 

 

 

 

 

 

 

 

 

Ending cash balance

 

$ 187

 

 

$ 245

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information

 

 

 

 

 

 

 

 

Cash paid for interest

 

$ -

 

 

$ -

 

Cash paid for tax

 

$ -

 

 

$ -

 

 

 

 

 

 

 

 

 

 

Non-Cash investing and financing transactions

 

 

 

 

 

 

 

 

Beneficial conversion feature

 

$ 134,557

 

 

$ -

 

Shares issued to settle debt

 

$ 10,000

 

 

$ 387,269

 

 

The accompanying notes are an integral part of these financial statements.

 

 
F-6
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(AUDITED)

 

1. DESCRIPTION OF BUSINESS AND HISTORY

 

Description of business – THC Theraputics, Inc., (referred to as the “Company”) is focused developing their patent-pending product, the dHydronator®, a sanitizing herb dryer. The main function of the dHydronator is to greatly accelerate the drying time of a herb while sanitizing it.  The dHydronator can be used to dry a variety of herbs, and it has been specifically tested for use with cannabis, and it will reduce the drying time for cannabis from 10-14 days to less than 14 hours.

 

The Company is also focusing some of its operations on participation in testing facilities and developing personal wellness centers, as well as investigating other potentially disruptive technologies including blockchain technologies and crypto-assets focused on financial markets, healthcare, crypto-mining and high-technology.

 

History – The Company was incorporated in the State of Nevada on May 1, 2007, as Fairytale Ventures, Inc., and later changed its name to Aviation Surveillance Systems, Inc. and Harmonic Energy, Inc. On January 23, 2017, the Company changed its name to THC Therapeutics, Inc.

 

On May 30, 2017, the Company formed Genesis Float Spa LLC, a wholly-owned subsidiary, to market its float spa assets purchased for wellness centers. The Company’s health spa plans are part of the Company’s strategic focus on revenue generation and creating shareholder value.

 

On January 17, 2018, the Company changed its name to Millennium Blockchain, Inc.

 

On September 28, 2018, the Company changed its name back to THC Therapeutics, Inc.

 

THC Therapeutics, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”

 

2. BASIS OF PRESENTATION AND GOING CONCERN

 

Basis of Presentation – The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the period presented have been reflected herein.

 

Going Concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $3,254,672 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

3. SUMMARY OF SIGNIFICANT POLICIES

 

This summary of significant accounting policies of THC Therapeutics, Inc. is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America, and have been consistently applied in the preparation of the consolidated financial statements.

 

Principles of Consolidation – The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated.

 

Use of Estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s goodwill, impairments and estimations of long-lived assets, revenue recognition on percentage of completion type contracts, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

 
F-7
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(AUDITED)

 

Cash and Cash Equivalents – For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents. There are $187 and $245 in cash and cash equivalents as of July 31, 2017, and July 31, 2016, respectively.

 

Concentration Risk – At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of FDIC limits. As of July 31, 2017, the cash balance in excess of the FDIC limits was $0. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts.

 

Fair Value of Financial Instruments – The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.

 

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

The three levels of the fair value hierarchy are described below:

 

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

 

Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

 

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

 

Revenue Recognition :

 

Product Sales – Revenues from the sale of products are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

 

Costs of Revenue – Costs of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

 

Goodwill and Intangible Assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “ Intangibles – Goodwill and Other. ” According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

 

Long-Lived Assets – In accordance with the Financial Accounting Standards Board (“FASB”) Accounts Standard Codification (ASC) ASC 360-10, “Property, Plant and Equipment,” the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.

 

Segment Reporting – Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding the method to allocate resources and assess performance. The Company currently has one reportable segment for financial reporting purposes, which represents the Company’s core business.

 

Income Taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “ Income Taxes ”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

 
F-8
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(AUDITED)

 

Stock-Based Compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “ Compensation-Stock Compensation ”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values.

 

Stock based compensation expense recognized under ASC 718-10 for the years ended July 31, 2017 and 2016, totaled $46,377 and $0, respectively.

 

Earnings (Loss) Per Share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “ Earnings Per Share .” Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

 

Advertising Costs – The Company’s policy regarding advertising is to expense advertising when incurred. The Company incurred advertising expenses of $13,726 and $0 as of July 31, 2017 and July 31, 2016, respectively.

 

Recently Issued Accounting Pronouncements – The Company has evaluated the all recent accounting pronouncements through ASU 2018-01, and believes that none of them will have a material effect on the Company’s financial position, results of operations or cash flows.

 

4. FIXED ASSETS

 

Fixed assets consist of the following as of July 31, 2017, and July 31, 2016:

 

 

 

July 31,

2017

 

 

July 31,

2016

 

dHydronator prototype

 

 

27,100

 

 

 

 

Float Spa and associated equipment

 

$ 60,000

 

 

$ -

 

Less: accumulated depreciation

 

 

(8,226 )

 

 

-

 

Fixed assets, net

 

$ 78,874

 

 

$ -

 

 

Depreciation expense for the years ended July 31, 2017, and July 31, 2016, was $8,226 and $0, respectively.

 

5. INTANGIBLE ASSETS

 

Intangible assets consist of the following as of July 31, 2017, and July 31, 2016:

 

 

 

July 31,

2017

 

 

July 31,

2016

 

Patents and patents pending

 

 

18,505

 

 

 

 

Trademarks

 

 

1,275

 

 

 

 

Website and domain names

 

 

15,098

 

 

 

 

Less: accumulated depreciation

 

 

(2,265 )

 

 

-

 

Intangible assets, net

 

$ 32,612

 

 

$ -

 

 

Amortization expense for the years ended July 31, 2017, and July 31, 2016, was $2,265 and $0, respectively.

 

7. ADVANCES FROM RELATED PARTIES

 

Our Chief Executive Officer and a shareholder, a relative of our Chief Executive Officer, have agreed to advance funds to the Company from time to time to support the ongoing operations of the Company. The advances are due within ten (10) days of demand and bear interest at 5% annually.

 

Advances from related parties consist of the following as of July 31, 2017:

 

 

 

Year ending July 31,

2017

 

 

Principal as of

 

 

Accrued interest balance As of

 

 

 

Funds

advanced

 

 

Funds

repaid

 

 

July 31,

2017

 

 

July 31,

2017

 

B. Romanek, President and CEO

 

$ 121,200

 

 

$ 49,938

 

 

$ 71,262

 

 

$ 1,040

 

Shareholder Relative of our President and CEO

 

 

6,025

 

 

 

-

 

 

 

6,025

 

 

 

79

 

TOTAL

 

$ 127,225

 

 

$ 49,938

 

 

$ 77,287

 

 

$ 1,120

 

 

 
F-9
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(AUDITED)

 

The former sole officer and director of the Company advanced the Company $6,888 and $11,144 during the years ending July 31, 2017 and 2016, respectively.

 

On January 4, 2017, the former sole officer and director forgave all advances in relation to his acquisition of the assets under the Kouei International license agreement and related business. (See Note 4 for additional details.)

 

8. NOTES PAYABLE

 

Notes Payable at consists of the following:

 

July 31,

 

 

July 31,

 

 

 

2017

 

 

2016

 

On January 9, 2013, the Company signed an unsecured promissory note for $50,000. The loan was originally due on January 9, 2014, and carried an interest at 8%. On January 9, 2014, the promissory note was acquired by a non-related lender, and the maturity date was extended to January 9, 2015. All other loan terms remained the same.

 

On January 13, 2017, the note was purchased by an investor in exchange for a convertible promissory note, and the original lender released all future claims related to the debt.

 

$ -

 

 

$ 50,000

 

On May 12, 2017, the Company issued a $60,000 promissory note; the note carries no interest rate and is payable in monthly installments of $5,000. As of July 31, 2017, no principal installments had been paid.

 

 

60,000

 

 

 

-

 

Total

 

 

60,000

 

 

 

50,000

 

 

9. CONVERTIBLE NOTES PAYABLE

 

Convertible Notes Payable at consists of the following:

 

July 31,

 

 

July 31,

 

 

 

2017

 

 

2016

 

On May 22, 2013, we entered into a convertible promissory note pursuant to which we borrowed $62,440. Interest under the convertible promissory note is 7% per annum, and the principal and all accrued but unpaid interest is due on May 22, 2014. The note is convertible at any time following the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 90% of the market price of our common stock at the date of notice of conversion. The Company recorded a debt discount in the amount of $50,041 in connection with the initial valuation of the derivative liability of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. Further, the Company recognized a derivative liability of $50,041 and an initial loss of $0 based on the Black-Scholes pricing model.

 

The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $0 and $0 during the years ended July 31, 2017 and 2016, respectively.

 

On January 13, 2017, the note was purchased by an investor and the original lender released all future claims related to the convertible debts.

 

$ -

 

 

$ 62,440

 

Unamortized debt discount

 

 

-

 

 

 

-

 

Total, net of unamortized discount

 

 

-

 

 

 

62,440

 

 

 
F-10
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(AUDITED)

 

On June 26, 2014, we entered into a convertible promissory note pursuant to which we borrowed $35,000. Interest under the convertible promissory note is 7% per annum, and the principal and all accrued but unpaid interest is due on June 26, 2017. The note is convertible at any time following the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 90% of the market price of our common stock at the date of notice of conversion. The Company recorded a debt discount in the amount of $35,000 in connection with the initial valuation of the derivative liability of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. Further, the Company recognized a derivative liability of $36,464 and an initial loss of $1,454 based on the Black-Scholes pricing model.

 

The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $11,699 and $9,461 during the years ended July 31, 2017 and 2016, respectively.

 

On December 16, 2016, the lender released all claims related to the convertible debts.

 

 

-

 

 

 

35,000

 

Unamortized debt discount

 

 

-

 

 

 

(9,461 )

Total, net of unamortized discount

 

 

-

 

 

 

1,111,110

 

 

 

 

 

 

 

 

 

 

On July 31, 2014, we entered into a convertible promissory note pursuant to which we borrowed $10,000. Interest under the convertible promissory note is 7% per annum, and the principal and all accrued but unpaid interest is due on July 31, 2017. The note is convertible at any time following the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 90% of the market price of our common stock at the date of notice of conversion. The Company recorded a debt discount in the amount of $10,000 in connection with the initial valuation of the derivative liability of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. Further, the Company recognized a derivative liability of $10,804 and an initial loss of $804 based on the Black-Scholes pricing model.

 

The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $3,342 and $3,333 during the years ended July 31, 2017 and 2016, respectively.

 

On December 16, 2016, the lender released all claims related to the convertible debts.

 

 

-

 

 

 

10,000

 

Unamortized debt discount

 

 

-

 

 

 

(3,333 )

Total, net of unamortized discount

 

 

-

 

 

 

6,667

 

 

 

 

 

 

 

 

 

 

On February 2, 2015, we entered into a convertible promissory note pursuant to which we borrowed $2,500. Interest under the convertible promissory note is 7% per annum, and the principal and all accrued but unpaid interest is due on May 2, 2018. The note is convertible at any time following the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 90% of the market price of our common stock at the date of notice of conversion. The Company recorded a debt discount in the amount of $2,500 in connection with the initial valuation of the derivative liability of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. Further, the Company recognized a derivative liability of $2,714 and an initial loss of $214 based on the Black-Scholes pricing model.

 

The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $836 and $1,258 during the years ended July 31, 2017 and 2016, respectively.

 

On December 16, 2016, the lender released all claims related to the convertible debts.

 

 

-

 

 

 

2,500

 

Unamortized debt discount

 

 

-

 

 

 

(1,258 )

Total, net of unamortized discount

 

 

-

 

 

 

1,242

 

 
 
F-11
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(AUDITED)

 

On May 7, 2015, we entered into a convertible promissory note pursuant to which we borrowed $10,000. Interest under the convertible promissory note is 7% per annum, and the principal and all accrued but unpaid interest is due on May 7, 2018. The note is convertible at any time following the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 90% of the market price of our common stock at the date of notice of conversion. The Company recorded a debt discount in the amount of $10,000 in connection with the initial valuation of the derivative liability of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. Further, the Company recognized a derivative liability of $10,880 and an initial loss of $880 based on the Black-Scholes pricing model.

 

The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $3,342 and $5,890 during the years ended July 31, 2017 and 2016, respectively.

 

On December 16, 2016, the lender released all claims related to the convertible debts.

 

 

-

 

 

 

10,000

 

Unamortized debt discount

 

 

-

 

 

 

(5,890 )

Total, net of unamortized discount

 

 

-

 

 

 

4,110

 

 

 

 

 

 

 

 

 

 

On January 13, 2017, we entered into a convertible promissory note with a note holder who assumed two outstanding notes totaling $112,400. Interest under the convertible promissory note is 5% per annum, and the principal and all accrued but unpaid interest is due on January 13, 2018. The note is convertible at any time following the issuance date at the noteholder’s option into shares of our common stock at a fixed conversion price of $0.001. The Company has determined the value associated with the beneficial conversion feature in connection with the notes and interest to be $112,400.

 

The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $112,400 and $0 during the years ended July 31, 2017 and 2016, respectively.

 

On February 6, 2017, the holder of the note converted $10,000 of the principal of the note into 10,000,000 common shares of the Company at a conversion price of $.001.

 

On April 28, 2017, the note holder forgave the remaining balance principal of $102,400 and accrued interest of 1,507. A gain on settlement of debt of $103,947 was recorded on the settlement of the note payable.

 

 

-

 

 

 

-

 

Unamortized debt discount

 

 

-

 

 

 

-

 

Total, net of unamortized discount

 

 

-

 

 

 

-

 

 

 
F-12
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(AUDITED)

 

On May 9, 2017, we entered into a convertible promissory note pursuant to which we borrowed $92,500. The note carries an original issue discount of 7.5% ($7,500). Interest under the convertible promissory note is 6% per annum, and the principal and all accrued but unpaid interest is due on May 9, 2018. The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 65% of the lowest closing market price of our common stock during the previous 20 days to the date of the notice of conversion. The Company recorded a debt discount in the amount of $92,500 in connection with the initial valuation of the derivative liability of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. Further, the Company recognized a derivative liability of $150,122 and an initial loss of $89,739 based on the Black-Scholes pricing model.

 

The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $21,034 and $0 during the years ended July 31, 2017 and 2016, respectively.

 

 

92,500

 

 

 

-

 

Original issue discount

 

 

7,500

 

 

 

-

 

Unamortized debt discount

 

 

(77,261 )

 

 

 

 

Total, net of unamortized discount

 

 

22,739

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Total

 

$ 22,739

 

 

 

99,998

 

 

Derivative liability

The Company accounts for the fair value of the conversion features of its convertible debt in accordance with ASC Topic No. 815-15 “Derivatives and Hedging; Embedded Derivatives” (“Topic No. 815-15”). Topic No. 815-15 requires the Company to bifurcate and separately account for the conversion features as an embedded derivative contained in the Company’s convertible debt. The Company is required to carry the embedded derivative on its balance sheet at fair value and account for any unrealized change in fair value as a component of results of operations. The Company values the embedded derivatives using the Black-Scholes pricing model.

 

The following table presents a summary of the Company’s derivative liabilities associated with its convertible notes as of July 31, 2017, and July 31, 2016:

 

 

 

Amount

 

Balance July 31, 2015

 

$ 69,864

 

Debt discount originated from derivative liabilities

 

 

-

 

Initial loss recorded

 

 

-

 

Adjustment to derivative liability due to debt conversion

 

 

-

 

Change in fair market value of derivative liabilities

 

 

(2,488 )

Balance July 31, 2016

 

$ 67,376

 

Debt discount originated from derivative liabilities

 

 

50,383

 

Initial loss recorded

 

 

89,739

 

Adjustment to derivative liability due to debt settlement

 

 

(62,513 )

Change in fair market value of derivative liabilities

 

 

1,244

 

Balance July 31, 2017

 

$ 146,229

 

 

The Black-Scholes model utilized the following inputs to value the derivative liabilities at the date of issuance of the convertible note and at July 31, 2017:

 

Fair value assumptions – derivative notes:

 

July 31,

2017

 

Risk free interest rate

 

0.11-1.23

%

Expected term (years)

 

0.01-3

 

Expected volatility

 

210-378

%

Expected dividends

 

 

0 %

 

 
F-13
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(AUDITED)

 

10. STOCK WARRANTS

 

The following is a summary of warrant activity during years ended July 31, 2017 and 2016:

 

 

 

Number of

Shares

 

 

Weighted Average Exercise

Price

 

Balance, July 31, 2015

 

 

47,619

 

 

$ 0.05

 

 

 

 

 

 

 

 

 

 

Warrants granted and assumed

 

 

-

 

 

 

-

 

Warrants expired

 

 

47,619

 

 

$ 0.05

 

Warrants canceled

 

 

-

 

 

 

-

 

Warrants exercised

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Balance, July 31, 2016

 

 

-

 

 

$ -

 

 

 

 

 

 

 

 

 

 

Warrants granted and assumed

 

 

125,000

 

 

$ 1.00

 

Warrants expired

 

 

-

 

 

 

-

 

Warrants canceled

 

 

-

 

 

 

-

 

Warrants exercised

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Balance, July 31, 2017

 

 

125,000

 

 

$ 1.00

 

 

None of the warrants outstanding as of July 31, 2017 were exercisable.

 

On May 9, 2017, the Company issued stock warrants to purchase 100,000 shares of its common stock to a lender as part of a financing agreement with Bellridge Capital. The warrants have a strike price of $0.75. The stock warrants were exercisable six-months from grant and have a life of 3 years.

 

On May 12, 2017, the Company issued stock warrants to purchase 25,000 shares of its common stock as part of an asset purchase agreement. The warrants have a strike price of $2.00. The stock warrants were exercisable six-months from grant and have a life of 3 years. The stock warrants were valued at $12,761 using the Black-Scholes option pricing model. The valuation was made using the following assumptions: stock price at grant: $0.51; exercise price: $2.00; term: 3 years; risk-free interest rate: 1.49%; volatility: 434%.

 

11. SHAREHOLDERS’ DEFICIT

 

Overview

 

The Company’s authorized capital stock consists of 500,000,000 shares of $0.001 par value common stock and 10,000,000 shares of $0.001 par value preferred stock.

 

As of July 31, 2017, and July 31, 2016, the Company had 118,778,391 and 8,490,391 shares of common stock issued and outstanding, respectively.

 

As of July 31, 2017, and July 31, 2016, the Company had 2,000,000 and 0 shares of Series A Preferred Stock issued and outstanding, respectively.

 

As of July 31, 2017, and July 31, 2016, the Company had 165,000 and 0 shares of Series B Preferred Stock issued and outstanding, respectively.

 

On June 10, 2016, the Company effected a 14:1 reverse stock split. All share and per share data in the accompanying financial statements and footnotes has been adjusted retrospectively for the effects of the stock split.

 

On January 23, 2017, the Company increased its number of authorized shares of common stock from 100,000,000 to 500,000,000, and authorized 10,000,000 shares of preferred stock, with the Company’s board of directors having authority to designate the rights and preferences of each series of preferred stock.

 

 
F-14
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(AUDITED)

 

Description of Common Stock

 

Our common stock is entitled to one vote per share on all matters submitted to a vote of the stockholders, including the election of directors. Except as otherwise required by law or provided in any resolution adopted by our board of directors with respect to any series of preferred stock, the holders of our common stock will possess all voting power. Generally, all matters to be voted on by stockholders must be approved by a majority (or, in the case of election of directors, by a plurality) of the votes entitled to be cast by all shares of our common stock that are present in person or represented by proxy, subject to any voting rights granted to holders of any preferred stock. Holders of our capital stock representing fifty percent (50%) of the votes associated with our capital stock issued, outstanding and entitled to vote, represented in person or by proxy, are necessary to constitute a quorum at any meeting of our stockholders. A vote by the holders of a majority of our outstanding shares is required to effectuate certain fundamental corporate changes such as a liquidation, merger or an amendment to our articles of incorporation.

 

Subject to any preferential rights of any outstanding series of preferred stock created by our board of directors from time to time, the holders of shares of our common stock will be entitled to such cash dividends as may be declared from time to time by our board of directors from funds available therefor.

 

Subject to any preferential rights of any outstanding series of preferred stock created from time to time by our board of directors, upon liquidation, dissolution or winding up, the holders of shares of our common stock will be entitled to receive pro rata all assets available for distribution to such holders.

 

In the event of any merger or consolidation of our company with or into another company in connection with which shares of our common stock are converted into or exchangeable for shares of stock, other securities or property (including cash), all holders of our common stock will be entitled to receive the same kind and amount of shares of stock and other securities and property (including cash). Holders of our common stock have no pre-emptive rights, no conversion rights and there are no redemption provisions applicable to our common stock.

 

Description of Preferred Stock

 

Our board of directors is authorized to divide the authorized shares of our preferred stock into one or more series, each of which must be so designated as to distinguish the shares of each series of preferred stock from the shares of all other series and classes. Our board of directors is authorized, within any limitations prescribed by law and our articles of incorporation, to fix and determine the designations, rights, qualifications, preferences, limitations and terms of the shares of any series of preferred stock, including, but not limited to, the following:

 

·

the rate of dividend, the time of payment of dividends, whether dividends are cumulative, and the date from which any dividends accrue;

 

·

whether shares may be redeemed, and, if so, the redemption price and the terms and conditions of redemption;

 

·

the amount payable upon shares in the event of voluntary or involuntary liquidation;

 

·

sinking fund or other provisions, if any, for the redemption or purchase of shares;

 

·

the terms and conditions on which shares may be converted, if the shares of any series are issued with the privilege of conversion;

 

·

voting powers, if any, provided that if any of the preferred stock or series thereof have voting rights, such preferred stock or series shall vote only on a share for share basis with the common stock on any matter, including, but not limited to, the election of directors, for which such preferred stock or series has such rights; and,

 

·

subject to the foregoing, such other terms, qualifications, privileges, limitations, options, restrictions, and special or relative rights and preferences, if any, of shares or such series as the board of directors may, at the time so acting, lawfully fix and determine under the laws of the State of Nevada.

 

Series A Preferred Stock

 

On January 24, 2017, pursuant to Article III of our Articles of Incorporation, the Company designated a class of preferred stock, the “Series A Preferred Stock,” consisting of three million (3,000,000) shares, par value $0.001.

 

Under the Certificate of Designation, holders of the Series A Preferred Stock are entitled at their option to convert their preferred shares into common stock at a conversion rate of one hundred (100) shares of common stock for every one (1) share of Series A Preferred Stock. The holders are further entitled to vote together with the holders of the Company’s common stock on all matters submitted to shareholders at a rate of one hundred (100) votes for each share held. The holders are entitled to equal rights with our common stockholders as it relates to liquidation preference.

 

 
F-15
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(AUDITED)

 

Series B Preferred Stock

 

On May 12, 2017, pursuant to Article III of our Articles of Incorporation, the Company designated a class of preferred stock, the “Series B Preferred Stock,” consisting of up to one hundred twenty thousand (120,000) shares, par value $0.001.

 

On June 5, 2017, the Company amended the designation to increase the number of shares of Series B Preferred Stock to one hundred sixty-five thousand (165,000) shares, par value $0.001.

 

Under the Certificate of Designation, as amended, holders of Series B Preferred Stock are entitled to a liquidation preference on the stated value of $1.00 per share. The shares carry a mandatory conversion provision, and all shares of Series B Preferred Stock will be redeemed by the Company one year from issuance, at a variable conversion rate equal to the stated price of $1.00 divided by the prior day’s closing price as quoted on OTC Markets. Holders of Series B Preferred Stock are not entitled to any voting or dividend rights.

 

Issuances of Common and Preferred Stock for the year ended July 31, 2016

 

On July 20, 2016, the Company issued 3,200,569 shares of common stock of the Company to a former officer of the Company in exchange for $225,000 of accrued consulting fees due to our sole officer and director. The shares were fair valued at $384,067, and a loss on settlement of debt of $162,269 was recorded as a result of the transaction.

 

Issuances of Common and Preferred Stock for the year ended July 31, 2017

 

On January 23, 2017, the Company issued 100,000,000 shares of common stock and 2,000,000 shares of Series A Preferred Stock to our current officer and director, Brandon Romanek, as consideration under an asset purchase agreement with him. (See Note 12 for additional details.)

 

On February 6, 2017, the Company issued 10,000,000 shares of common stock in settlement of $10,000 of debt. (See Note 9 for additional details.)

 

On May 12, 2017, the Company issued 120,000 shares of Series B Preferred Stock as consideration under the asset purchase agreement described in Note 13. (See Note 13 for additional details.)

 

On June 6, 2017, the Company issued 45,000 shares of Series B Preferred Stock as consideration under the asset purchase agreement described in Note 13. (See Note 13 for additional details.)

 

On June 26, 2017, the Company issued 88,000 shares of common stock to a consultant for services to be rendered between July 1, 2017, and June 30, 2018. The shares were fair valued at $38,782 at the date of grant. $3,196 was reported as stock compensation, and $35,586 was capitalized as prepaid expense as of July 31, 2017.

 

On June 12, 2017, the Company issued 200,000 shares of common stock to a consultant for services to be rendered between June 15, 2017 and September 15, 2017. The shares were fair valued at $86,360 at the date of grant. $43,181 was reported as stock compensation, and $43,179 was capitalized as prepaid expense as of July 31, 2017.

 

12. ASSET PURCHASE AGREEMENT

 

On January 20, 2017, the Company entered into an asset purchase agreement with its current officer and director, Brandon Romanek, under which it acquired certain patent and trademark applications and other intellectual property in exchange for 100,000,000 shares of common stock and 2,000,000 shares of Series A Preferred Stock.

 

Due to the common control nature of the transaction the Company recorded the assets at their historical carrying amounts in accordance with ASC 805-50-30. The shares issued as consideration were fair valued at $20,100,000, as a result the difference between the value of the proceeds transferred and the carrying amounts of the net assets received was recognized in additional paid-in capital.

 

The purchase price was allocated as follows:

 

Amount

 

Patents and patents pending

 

$ 13,717

 

Trademarks

 

 

1,000

 

Website and domain names

 

 

15,098

 

dHydronator Prototype

 

 

27,100

 

Total historical costs of assets acquired

 

$ 56,915

 

 

 
F-16
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(AUDITED)

 

13. ASSET PURCHASE AGREEMENT - HEALTH SPA

 

On May 12, 2017, the Company entered into an asset purchase agreement with a third party under which it acquired four (4) float spa units and the associated equipment, subject to an existing lien, along with a client list, in exchange for an initial payment of $20,000 cash, 120,000 shares of Series B Preferred Stock valued at $120,000, a $60,000 promissory note and warrants to purchase 25,000 shares of common stock. The Company also agreed to settled a lien on certain assets acquired through the issuance of 45,000 shares of Series B Preferred Stock.

 

The warrants have a strike price of $2.00. The stock warrants were exercisable six-months from grant and have a life of 3 years. The stock warrants were valued at $12,761 using the Black-Scholes option pricing model. The valuation was made using the following assumptions: stock price at grant: $0.51; exercise price: $2.00; term: 3 years; risk-free interest rate: 1.49%; volatility: 434%.

 

The total consideration for the transaction carried a fair value of $257,761, and the fair value of the assets was deemed by the Company to be $60,000. An initial impairment loss of $197,761 was reported as a result of the transaction.

 

The purchase price was allocated as follows:

 

Amount

 

Float Spa units and related equipment

 

$ 60,000

 

Client lists

 

 

-

 

Balance July 31, 2017

 

$ 60,000

 

 

14. COMMITMENTS AND CONTINGENCIES

 

The Company does not own any real property. It does own personal property, and it leases office space on a month-to-month basis. There is no obligation for this arrangement to continue.

 

15. SUBSEQUENT EVENTS

 

In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to July 31, 2017 to the date these financial statements were available to be issued, and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described below.

 

On August 10, 2017, the Company issued 5,000 shares of common stock to a consultant for services rendered. The shares were fair valued at $1,740 at the date of grant.

 

On August 28, 2017, the Company issued 2,500 shares of common stock to a consultant for services rendered. The shares were fair valued at $778 at the date of grant.

 

On October 13, 2017, we entered into a promissory note pursuant to which we borrowed $30,000. Interest under the convertible promissory note is 25% per annum, and the principal and all accrued but unpaid interest is due in four equal quarterly payments of $9,375.

 

On October 13, 2017, the Company issued stock warrants to purchase 30,000 shares of its common stock to a lender as part of a financing agreement. The warrants have a strike price of $2.00. The stock warrants were exercisable immediately upon grant and have a life of 3 years. The stock warrants were valued at $8,497 using the Black-Scholes option pricing model. The valuation was made using the following assumptions: stock price at grant: $0.34; exercise price: $2.00; term: 3 years; risk-free interest rate: 1.64%; volatility: 434%.

 

Effective November 20, 2017, the Company entered into a Joint Venture Agreement with ADVFN plc of the United Kingdom (“ADVFN”) to create a joint venture entity, MJAC InvestorsHub International Conferences Limited, to be owned 50/50 by the Company and ADVFN. A copy of the agreement can be viewed on the Company’s website at http://thctherapeutics.com/wp-content/uploads/2017/03/MJAC%20JV%20agreement%2020-11-17%20opt2.pdf.

 

 
F-17
 
Table of Contents

 

THC THERAPEUTICS, INC

 

(formerly MILLENNIUM BLOCKCHAIN, INC.)

 

NOTES TO THE FINANCIAL STATEMENTS

 

(UNAUDITED)

 

April 30, 2018

 

 
F-18
 
Table of Contents

 

THC THERAPEUTICS INC.

(formerly MILLENNIUM BLOCKCHAIN, INC.)

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

 

 

April 30,

2018

 

 

July 31,

2017

 

ASSETS

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Cash

 

$ 2,237

 

 

$ 187

 

Prepaid

 

 

10,212

 

 

 

78,765

 

Total current assets

 

 

12,449

 

 

 

78,952

 

 

 

 

 

 

 

 

 

 

Deposits

 

 

-

 

 

 

3,208

 

Fixed Assets

 

 

63,629

 

 

 

78,874

 

Intangible Assets

 

 

29,377

 

 

 

32,612

 

Rights to Burst IQ Coins

 

 

1,564,000

 

 

 

-

 

Investment in Burst IQ

 

 

1,564,000

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Total assets

 

 

3,233,455

 

 

 

193,646

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$ 103,345

 

 

$ 82,140

 

Accrued liabilities due to related parties

 

 

46,004

 

 

 

1,120

 

Advances from related parties

 

 

146,791

 

 

 

77,287

 

Notes payable

 

 

48,200

 

 

 

60,000

 

Convertible Notes payable, net

 

 

97,534

 

 

 

22,739

 

Derivative liability

 

 

106,955

 

 

 

146,229

 

Total current liabilities

 

 

548,829

 

 

 

389,515

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

548,829

 

 

 

389,515

 

 

 

 

 

 

 

 

 

 

Stockholders' equity (deficit)

 

 

 

 

 

 

 

 

Common stock; $0.001 par value; 500,000,000 shares authorized;

 

 

 

 

 

 

 

 

123,985,891 and 118,778,391 shares issued and outstanding

 

 

 

 

 

 

 

 

as of April 30, 2018 and July 31, 2017, respectively

 

 

123,986

 

 

 

118,778

 

Preferred stock; $0.001 par value; 10,000,000 shares authorized;

 

 

 

 

 

 

 

 

2,165,000 and 2,165,000 series A and B shares issued and outstanding as of

 

 

 

 

 

 

 

 

April 30, 2018 and July 31, 2017, respectively

 

 

 

 

 

 

 

 

Preferred A stock; $0.001 par value; 3,000,000 shares authorized;

 

 

 

 

 

 

 

 

2,000,000 and 2,000,000 shares issued and outstanding as of

 

 

 

 

 

 

 

 

April 30, 2018 and July 31, 2017, respectively

 

 

2,000

 

 

 

2,000

 

Preferred B stock; $0.001 par value; 165,000 shares authorized;

 

 

 

 

 

 

 

 

165,000 and 165,000 shares issued and outstanding as of

 

 

 

 

 

 

 

 

April 30, 2018 and July 31, 2017, respectively

 

 

165

 

 

 

165

 

Stock payable

 

 

172,695

 

 

 

-

 

Additional paid-in capital

 

 

6,294,351

 

 

 

2,937,860

 

Accumulated deficit

 

 

(3,908,571 )

 

 

(3,254,672 )

Total stockholders' deficit

 

 

2,684,626

 

 

 

(195,869 )

 

 

 

 

 

 

 

 

 

Total liabilities and stockholders' equity (deficit)

 

$ 3,233,455

 

 

$ 193,646

 

 

The accompanying notes are an integral part of these financial statements.

 

 
F-19
 
Table of Contents

 

THC THERAPEUTICS INC.

(formerly MILLENNIUM BLOCKCHAIN, INC.)

CONSOLIDATED STATEMENT OF OPERATIONS

(UNAUDITED)

 

 

 

For the Three Months Ended

 

 

For the Nine Months Ended

 

 

 

April 30,

2018

 

 

April 30,

2017

 

 

April 30,

2018

 

 

April 30,

2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$ -

 

 

$ -

 

 

$ -

 

 

$ -

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Professional fees

 

 

23,192

 

 

 

17,115

 

 

 

46,336

 

 

 

24,126

 

Compensation

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Consulting fees

 

 

135,486

 

 

 

4,100

 

 

 

257,641

 

 

 

22,162

 

Payroll expense

 

 

20,569

 

 

 

-

 

 

 

41,137

 

 

 

-

 

General and administrative expenses

 

 

41,142

 

 

 

22,680

 

 

 

108,191

 

 

 

32,594

 

Depreciation and amortization

 

 

6,213

 

 

 

3,169

 

 

 

19,012

 

 

 

4,424

 

Total operating expenses

 

 

226,602

 

 

 

47,064

 

 

 

472,317

 

 

 

83,306

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(226,602 )

 

 

(47,064 )

 

 

(472,317 )

 

 

(83,306 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gain/(loss) on change in derivative liability

 

 

11,273

 

 

 

(162 )

 

 

39,274

 

 

 

4,701

 

Gain/(loss) on settlement of debts

 

 

-

 

 

 

122,839

 

 

 

(132,234 )

 

 

202,621

 

Gain on conveyance of liabilities to a related party

 

 

-

 

 

 

-

 

 

 

-

 

 

 

79,110

 

Interest Expense

 

 

(28,729 )

 

 

(108,115 )

 

 

(88,622 )

 

 

(139,047 )

Total other income (expense)

 

 

(17,456 )

 

 

14,562

 

 

 

(181,582 )

 

 

147,385

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$ (244,058 )

 

$ (32,502 )

 

$ (653,899 )

 

$ 64,079

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic income (loss) per common share

 

$ (0.00 )

 

$ (0.00 )

 

$ (0.01 )

 

$ 0.00

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic weighted average common shares outstanding

 

 

120,637,576

 

 

 

117,816,224

 

 

 

119,389,144

 

 

 

48,160,721

 

 

The accompanying notes are an integral part of these financial statements.

 

 
F-20
 
Table of Contents

 

THC THERAPEUTICS INC.

(formerly MILLENNIUM BLOCKCHAIN, INC.)

CONSOLIDATED STATEMENT OF CASHFLOWS

(UNAUDITED)

 

 

 

For the Nine Months Ended

 

 

 

April 30,

2018

 

 

April 30,

2017

 

Cash Flows from Operating Activities

 

 

 

 

 

 

Net loss

 

$ (653,899 )

 

$ 64,079

 

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Loss on change in derivative liabilities

 

 

(39,274 )

 

 

(4,701 )

Amortization of original issue discount

 

 

5,610

 

 

 

-

 

Amortization of debt discount

 

 

69,185

 

 

 

132,221

 

Settlement of related party debts

 

 

-

 

 

 

(79,110 )

Settlement of debts

 

 

-

 

 

 

(202,621 )

Stock based compensation

 

 

242,119

 

 

 

-

 

Depreciation and amortization

 

 

19,012

 

 

 

4,424

 

Inputed interest

 

 

2,121

 

 

 

-

 

Loss (gain) on settlement of debts

 

 

132,234

 

 

 

-

 

Changes in assets and liabilities

 

 

 

 

 

 

 

 

(Increase) decrease in deposits

 

 

3,208

 

 

 

-

 

(Increase) decrease in prepaids

 

 

-

 

 

 

-

 

Increase (decrease) in accounts payable

 

 

24,678

 

 

 

(23,516 )

Increase (decrease) in accounts payable related party

 

 

44,884

 

 

 

-

 

Net cash from operating activities

 

 

(150,122 )

 

 

(109,224 )

 

 

 

 

 

 

 

 

 

Cash Flows from investing

 

 

 

 

 

 

 

 

Purchase of intangible assets

 

 

(532 )

 

 

-

 

Net cash used in investing activities

 

 

(532 )

 

 

-

 

 

 

 

 

 

 

 

 

 

Cash Flows from Financing Activities

 

 

 

 

 

 

 

 

Proceeds from sale of common stock and warrants

 

 

65,000

 

 

 

-

 

Proceeds from related party debts

 

 

142,344

 

 

 

75,371

 

Payments on related party debts

 

 

(72,840 )

 

 

(28,785 )

Proceeds from loans

 

 

30,000

 

 

 

-

 

Payments on loans

 

 

(11,800 )

 

 

(50,000 )

Proceeds from convertible debts

 

 

-

 

 

 

112,400

 

Net cash from financing activities

 

 

152,704

 

 

 

108,986

 

 

 

 

 

 

 

 

 

 

Net increase (decrease) in Cash

 

 

2,050

 

 

 

(238 )

 

 

 

 

 

 

 

 

 

Beginning cash balance

 

 

187

 

 

 

245

 

 

 

 

 

 

 

 

 

 

Ending cash balance

 

$ 2,237

 

 

$ 7

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information

 

 

 

 

 

 

 

 

Cash paid for interest

 

$ -

 

 

$ -

 

Cash paid for tax

 

$ -

 

 

$ -

 

 

 

 

 

 

 

 

 

 

Non-Cash investing and financing transactions

 

 

 

 

 

 

 

 

Beneficial conversion feature

 

$ -

 

 

$ -

 

Shares issued to settle debt

 

$ -

 

 

$ -

 

 

The accompanying notes are an integral part of these financial statements.

 

 
F-21
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

1. DESCRIPTION OF BUSINESS AND HISTORY

 

Description of business – THC Theraputics, Inc., (referred to as the “Company”) is focused developing their patent-pending product, the dHydronator®, a sanitizing herb dryer. The main function of the dHydronator is to greatly accelerate the drying time of a herb while sanitizing it.  The dHydronator can be used to dry a variety of herbs, and it has been specifically tested for use with cannabis, and it will reduce the drying time for cannabis from 10-14 days to less than 14 hours.

 

The Company is also focusing some of its operations on participation in testing facilities and developing personal wellness centers, as well as investigating other potentially disruptive technologies including blockchain technologies and crypto-assets focused on financial markets, healthcare, crypto-mining and high-technology.

 

History – The Company was incorporated in the State of Nevada on May 1, 2007, as Fairytale Ventures, Inc., and later changed its name to Aviation Surveillance Systems, Inc. and Harmonic Energy, Inc. On January 23, 2017, the Company changed its name to THC Therapeutics, Inc.

 

On May 30, 2017, the Company formed Genesis Float Spa LLC, a wholly-owned subsidiary, to market its float spa assets purchased for wellness centers. The Company’s health spa plans are part of the Company’s strategic focus on revenue generation and creating shareholder value.

 

On January 17, 2018, the Company changed its name to Millennium Blockchain Inc.

 

On September 28, 2018, the Company changed its name back to THC Therapeutics, Inc.

 

THC Therapeutics, Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”

 

2. BASIS OF PRESENTATION AND GOING CONCERN

 

Basis of Presentation – The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s most recent Annual Audited Financial Statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent Annual Audited Financial Statements have been omitted.

 

Going Concern – The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $3,908,571 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

3. SUMMARY OF SIGNIFICANT POLICIES

 

This summary of significant accounting policies of THC Therapeutics, Inc. is presented to assist in understanding the Company’s consolidated financial statements. The consolidated financial statements and notes are representations of the Company’s management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the consolidated financial statements.

 

Principles of Consolidation – The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated.

 

Use of Estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include estimates used to review the Company’s goodwill, impairments and estimations of long-lived assets, revenue recognition on percentage of completion type contracts, allowances for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

 

 
F-22
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

Cash and Cash Equivalents – For purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original maturities of three months or less to be cash equivalents. There are $2,237 and $187 in cash and cash equivalents as of April 30, 2018, and July 31, 2017, respectively.

 

Concentration Risk – At times throughout the year, the Company may maintain cash balances in certain bank accounts in excess of FDIC limits. As of April 30, 2018, the cash balance in excess of the FDIC limits was $0. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts.

 

Fair Value of Financial Instruments – The carrying amounts reflected in the balance sheets for cash, accounts payable and accrued expenses approximate the respective fair values due to the short maturities of these items.

 

As required by the Fair Value Measurements and Disclosures Topic of the FASB ASC, fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

 

The three levels of the fair value hierarchy are described below:

 

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

 

Level 2: Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

 

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

 

Revenue Recognition :

 

Product Sales – Revenues from the sale of products are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.

 

Costs of Revenue – Costs of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.

 

Goodwill and Intangible Assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “ Intangibles – Goodwill and Other. ” According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.

 

Long-Lived Assets – In accordance with the Financial Accounting Standards Board (“FASB”) Accounts Standard Codification (ASC) ASC 360-10, “Property, Plant and Equipment,” the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.

 

Segment Reporting – Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding the method to allocate resources and assess performance. The Company currently has one reportable segment for financial reporting purposes, which represents the Company’s core business.

 

Income Taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “ Income Taxes ”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

 
F-23
 
Table of Contents

  

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

Stock-Based Compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “ Compensation-Stock Compensation ”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase Plan based on the estimated fair values.

 

Stock based compensation expense recognized under ASC 718-10 for the nine months ended April 30, 2018 and 2017, totaled $242,119 and $0, respectively.

 

Earnings (Loss) Per Share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “ Earnings Per Share .” Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

 

Advertising Costs – The Company’s policy regarding advertising is to expense advertising when incurred. The Company incurred advertising expenses of $24,274 and $10,066 during the nine months ended of April 30, 2018 and 2017, respectively.

 

Recently Issued Accounting Pronouncements – The Company has evaluated the all recent accounting pronouncements through ASU 2018-08 and believes that none of them will have a material effect on the Company’s financial position, results of operations or cash flows.

 

4. FIXED ASSETS

 

Fixed assets consist of the following as of April 30, 2018, and July 31, 2017:

 

 

 

April 30,

2018

 

 

July 31,

2017

 

dHydronator prototype

 

$ 27,100

 

 

$ 27,100

 

Float Spa and associated equipment

 

 

60,000

 

 

 

60,000

 

Office furniture and equipment

 

 

532

 

 

 

-

 

Less: accumulated depreciation

 

 

(24,003 )

 

 

(8,226 )

Fixed assets, net

 

$ 63,629

 

 

$ 78,874

 

 

Depreciation expense for the nine months ended April 30, 2018 and 2017, was $15,777 and $3,332, respectively.

 

5. INTANGIBLE ASSETS

 

Intangible assets consist of the following as of April 30, 2018, and July 31, 2017:

 

 

 

April 30,

2018

 

 

July 31,

2017

 

Patents and patents pending

 

$ 18,505

 

 

$ 18,505

 

Trademarks

 

 

1,275

 

 

 

1,275

 

Website and domain names

 

 

15,098

 

 

 

15,098

 

Less: accumulated depreciation

 

 

(5,500 )

 

 

(2,265 )

Intangible assets, net

 

$ 29,377

 

 

$ 32,612

 

 

Amortization expense for the nine months ended April 30, 2018, and 2017, was $3,235 and $1,092, respectively.

 

6. RIGHTS TO BURST IQ COINS

 

On March 31, 2018, the Company entered into a Simple Agreement for Future Tokens (the “SAFT”) with BurstIQ Analytics Corporation, a Colorado corporation (“BurstIQ”). Pursuant to the SAFT, the Company purchased the right to a number of BIQ tokens equal to $2,500,000 divided by a 35% discount to the maximum price per token sold by BurstIQ to the public during a network launch, in consideration of the issuance of 2,500,000 shares of the Company’s common stock to BurstIQ at a deemed value of $2,500,000.

 

In accordance with ASC 820, the company valued its investment in rights to Burst IQ coins based upon the unadjusted quoted prices of its common stock issued as consideration on the execution date of the agreement and determined the value to be $0.6256 per share or $1,564,000. The investment will be carried on the books at cost basis, until the coins are issued. It is anticipated that when the coins are issued that there will be an active market for the coins. If the market exists as anticipated, the Company intends to strategically sell the coins at opportune times that will create value for its shareholders.

 

 
F-24
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

7. RIGHTS TO BURST IQ EQUITY

 

On March 31, 2018, the Company entered into a Simple Agreement for Future Equity (the “SAFE”). Pursuant to the SAFE, the Company purchased the right to a number shares of Burst IQ’s preferred stock sold in a subsequent equity financing equal to $2,500,000 divided by a deemed $6.50 price per share, in consideration of the issuance of 2,500,000 shares of the Company’s common stock to BurstIQ.

 

In accordance with ASC 820, the company valued its investment in rights to Burst IQ preferred stock based upon the unadjusted quoted prices of its common stock issued as consideration on the execution date of the agreement and determined the value to be $0.6256 per share or $1,564,000. When the equity in Burst IQ is issued the Company plans to hold the equity as a long-term investment. The Company will conduct an impairment analysis on assets on an annual basis or at any time there is evidence that the value has been impaired more than temporarily.

 

8. ADVANCES FROM RELATED PARTIES

 

Our Chief Executive Officer and a shareholder, a relative of our Chief Executive Officer, have agreed to advance funds to the Company from time to time to support the ongoing operations of the Company. The advances are due within ten (10) days of demand and bear interest at 5% annually.

 

Advances from related parties consist of the following as of April 30, 2018:

 

 

 

Principal as of

 

 

Nine months ending

April 30, 2018

 

 

Principal as of

 

 

Accrued interest balance As of

 

 

 

July 31,

2017

 

 

Funds

advanced

 

 

Funds

repaid

 

 

April 30,

2018

 

 

April 30,

2018

 

B. Romanek, President and CEO

 

$ 71,262

 

 

$ 105,256

 

 

$ 62,916

 

 

$ 113,602

 

 

$ 4,342

 

Shareholder Relative of our President and CEO

 

$ 6,025

 

 

 

37,088

 

 

 

9,924

 

 

 

33,189

 

 

 

524

 

TOTAL

 

$ 77,287

 

 

$ 142,344

 

 

$ 72,840

 

 

$ 146,791

 

 

$ 4,866

 

 

9. RELATED PARTY TRANSACTIONS

 

On November 1, 2017, we entered into an employment agreement with Brandon Romanek Huber, our Chief Executive Officer. In accordance with this agreement, Mr. Romanek provided services to the Company in exchange for $78,000 per year plus vacation and bonuses as approved annually by the board of directors and reimbursable expenses incurred. During the nine months ending April 30, 2018, the Company accrued $41,137 related to this agreement. As of April 30, 2018, Mr. Romanek allowed the Company to defer all compensation related to his employment totaling $41,137.

 

10. NOTES PAYABLE

 

Notes Payable at consists of the following:

 

April 30,

 

 

July 31,

 

 

 

2018

 

 

2017

 

On May 12, 2017, the Company issued a $60,000 promissory note; the note carries no interest rate and is payable in monthly installments of $5,000. As of April 30, 2018, $11,800 in principal payments had been paid. The Company imputed interest at a rate of 5%, during the nine months ending April 30, 2018 the Company recorded imputed interest of $2,121.

 

 

48,200

 

 

 

60,000

 

 

 

 

 

 

 

 

 

 

Total

 

 

48,200

 

 

 

60,000

 

 

On October 13, 2017, we entered into a promissory note pursuant to which we borrowed $30,000. Interest under the promissory note was 25% per annum, the principal and all accrued interest was due in four equal quarterly payments of $9,375. On March 31, 2018, the Company entered into an agreement to settle all outstanding principal and interest due under the promissory note totaling $33,473. Under the terms of the agreement the Company issued 95,000 shares and 195,000 3-year, warrants with a strike price of $2.00 and received an unconditional release of all liability under the promissory note. The shares and warrants were fair valued at $165,707 on the date of issuance and a loss on settlement of debt of $132,234 was recoded as a result of the settlement agreement.

 

 
F-25
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

11. CONVERTIBLE NOTES PAYABLE

 

Convertible Notes Payable at consists of the following:

 

April 30,

 

 

July 31,

 

 

 

2018

 

 

2017

 

 

 

 

 

 

 

 

On May 9, 2017, we entered into a convertible promissory note pursuant to which we borrowed $92,500. The note carries an original issue discount of 7.5% ($7,500). Interest under the convertible promissory note is 6% per annum, and the principal and all accrued but unpaid interest is due on May 9, 2018. The note is convertible at any date after the issuance date at the noteholder’s option into shares of our common stock at a variable conversion price of 65% of the lowest closing market price of our common stock during the previous 20 days to the date of the notice of conversion. The Company recorded a debt discount in the amount of $92,500 in connection with the initial valuation of the derivative liability of the Note to be amortized utilizing the effective interest method of accretion over the term of the Note. Further, the Company recognized a derivative liability of $170,560 and an initial loss of $78,060 based on the Black-Scholes pricing model.

 

The aggregate issue discount feature has been accreted and charged to interest expenses as a financing expense in the amount of $73,151 and $0 during the nine months ended April 30, 2018 and 2017, respectively.

 

 

92,500

 

 

 

92,500

 

Original issue discount

 

 

7,500

 

 

 

7,500

 

Unamortized debt discount

 

 

(2,466 )

 

 

(77,261 )

Total, net of unamortized discount

 

 

97,534

 

 

 

22,739

 

 

 

 

 

 

 

 

 

 

Total

 

$ 97,534

 

 

$ 22,739

 

 

Derivative liability

 

The Company accounts for the fair value of the conversion features of its convertible debt in accordance with ASC Topic No. 815-15 “Derivatives and Hedging; Embedded Derivatives” (“Topic No. 815-15”). Topic No. 815-15 requires the Company to bifurcate and separately account for the conversion features as an embedded derivative contained in the Company’s convertible debt. The Company is required to carry the embedded derivative on its balance sheet at fair value and account for any unrealized change in fair value as a component of results of operations. The Company values the embedded derivatives using the Black-Scholes pricing model.

 

The following table presents a summary of the Company’s derivative liabilities associated with its convertible notes as of July 31, 2017, and April 30, 2018:

 

 

 

Amount

 

Balance July 31, 2016

 

$ 67,376

 

Debt discount originated from derivative liabilities

 

 

50,383

 

Initial loss recorded

 

 

89,739

 

Adjustment to derivative liability due to debt settlement

 

 

(62,513 )

Change in fair market value of derivative liabilities

 

 

1,244

 

Balance July 31, 2017

 

$ 146,229

 

Debt discount originated from derivative liabilities

 

 

-

 

Initial loss recorded

 

 

-

 

Adjustment to derivative liability due to debt settlement

 

 

-

 

Change in fair market value of derivative liabilities

 

 

(39,274 )

Balance April 30, 2018

 

$ 106,955

 

 

 
F-26
 
Table of Contents

  

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

The Black-Scholes model utilized the following inputs to value the derivative liabilities at the date of issuance of the convertible note and at April 30, 2018:

 

Fair value assumptions – derivative notes:

 

April 30,

2018

 

Risk free interest rate

 

 

2.24 %

Expected term (years)

 

 

0.025

 

Expected volatility

 

 

214 %

Expected dividends

 

 

0 %

 

12. STOCK WARRANTS

 

The following is a summary of warrant activity during the year ended July 31, 2017, and the nine months ended April 30, 2018:

 

 

 

Number of

Shares

 

 

Weighted Average Exercise

Price

 

Balance, July 31, 2016

 

 

-

 

 

$ -

 

 

 

 

 

 

 

 

 

 

Warrants granted and assumed

 

 

125,000

 

 

$ 1.00

 

Warrants expired

 

 

-

 

 

 

-

 

Warrants canceled

 

 

-

 

 

 

-

 

Warrants exercised

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Balance, July 31, 2017

 

 

125,000

 

 

$ -

 

 

 

 

 

 

 

 

 

 

Warrants granted and assumed

 

 

342,500

 

 

$ 2.00

 

Warrants expired

 

 

-

 

 

 

-

 

Warrants canceled

 

 

-

 

 

 

-

 

Warrants exercised

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Balance, April 30, 2018

 

 

467,500

 

 

$ 1.73

 

 

467,500 of the warrants outstanding as of April 30, 2018 were exercisable.

 

On May 9, 2017, the Company issued stock warrants to purchase 100,000 shares of its common stock to a lender as part of a financing agreement. The warrants have a strike price of $0.75. The stock warrants were exercisable six-months from grant and have a life of 3 years. The stock warrants were valued at $51,050 using the Black-Scholes option pricing model. The Company recorded an expense of $50,050 for the year ended July 31, 2017. The valuation was made using the following assumptions: stock price at grant: $0.51; exercise price: $0.75; term: 3 years; risk-free interest rate: 1.57%; volatility: 434%.

 

On May 12, 2017, the Company issued stock warrants to purchase 25,000 shares of its common stock as part of an asset purchase agreement. The warrants have a strike price of $2.00. The stock warrants were exercisable six-months from grant and have a life of 3 years. The stock warrants were valued at $12,761 using the Black-Scholes option pricing model. The valuation was made using the following assumptions: stock price at grant: $0.51; exercise price: $2.00; term: 3 years; risk-free interest rate: 1.49%; volatility: 434%.

 

On October 13, 2017, the Company issued stock warrants to purchase 30,000 shares of its common stock to a lender in connection with a financing agreement. The warrants have a strike price of $2.00. The stock warrants were exercisable immediately upon grant and have a life of 3 years. The stock warrants were valued at $8,467 using the Black-Scholes option pricing model. The valuation was made using the following assumptions: stock price at grant: $0.34; exercise price: $2.00; term: 3 years; risk-free interest rate: 1.64%; volatility: 434%.

 

On March 5, 2018, the Company received $25,000 from an investor pursuant to a private placement agreement with the investor to purchase 62,500 shares of the Company’s common stock and 62,500 warrants to purchase shares of the Company’s common stock at $2.00 per shares for a period of three years. If the Company’s common stock has closed for 20 consecutive trading days above $3.00 per shares the investor must exercise the warrant within 30 days.

 

On March 31, 2018, the Company and a lender agreed to settle a $30,000 promissory note and associated accrued interest of $3,473. The Company agreed to issue 95,000 shares of the Company’s common stock and warrants to purchase 195,000 shares of the Company’s common stock at $2.00 for a three-year term. In return for the consideration the Lender agreed to release the Company from all amounts owed.

 

 
F-27
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

On April 6, 2018, the Company received $40,000 from an investor pursuant to a private placement agreement with the investor to purchase 100,000 shares of the Company’s common stock and 250,000 warrants to purchase shares of the Company’s common stock at $2.00 per shares for a period of five years.

 

13. SHAREHOLDERS’ DEFICIT

 

Overview

 

The Company’s authorized capital stock consists of 500,000,000 shares of $0.001 par value common stock and 10,000,000 shares of $0.001 par value preferred stock.

 

As of April 30, 2018, and July 31, 2017, the Company had 123,985,891 and 118,778,391 shares of common stock issued and outstanding, respectively.

 

As of April 30, 2018, and July 31, 2017, the Company had 2,000,000 and 2,000,000 shares of Series A Preferred Stock issued and outstanding, respectively.

 

As of April 30, 2018, and July 31, 2017, the Company had 165,000 and 165,000 shares of Series B Preferred Stock issued and outstanding, respectively.

 

On January 23, 2017, the Company increased its number of authorized shares of common stock from 100,000,000 to 500,000,000, and authorized 10,000,000 shares of preferred stock, with the Company’s board of directors having authority to designate the rights and preferences of each series of preferred stock.

 

Series A Preferred Stock

 

On January 24, 2017, pursuant to Article III of our Articles of Incorporation, the Company designated a class of preferred stock, the “Series A Preferred Stock,” consisting of three million (3,000,000) shares, par value $0.001.

 

Under the Certificate of Designation, holders of the Series A Preferred Stock are entitled at their option to convert their preferred shares into common stock at a conversion rate of one hundred (100) shares of common stock for every one (1) share of Series A Preferred Stock. The holders are further entitled to vote together with the holders of the Company’s common stock on all matters submitted to shareholders at a rate of one hundred (100) votes for each share held. The holders are entitled to equal rights with our common stockholders as it relates to liquidation preference.

 

Series B Preferred Stock

 

On May 12, 2017, pursuant to Article III of our Articles of Incorporation, the Company designated a class of preferred stock, the “Series B Preferred Stock,” consisting of up to one hundred twenty thousand (120,000) shares, par value $0.001. On June 5, 2017, the Company amended the designation to increase the number of shares of Series B Preferred Stock to one hundred sixty-five thousand (165,000) shares, par value $0.001.

 

Under the Certificate of Designation, as amended, holders of Series B Preferred Stock are entitled to a liquidation preference on the stated value of $1.00 per share. The shares carry a mandatory conversion provision, and all shares of Series B Preferred Stock will be redeemed by the Company one year from issuance, at a variable conversion rate equal to the stated price of $1.00 divided by the prior day’s closing price as quoted on OTC Markets. Holders of Series B Preferred Stock are not entitled to any voting or dividend rights.

 

Issuances of Common and Preferred Stock for the nine months ended April 30, 2018

 

On August 10, 2017, the Company issued 5,000 shares of common stock to a consultant for services rendered. The shares were fair valued at $1,740 at the date of grant.

 

On August 28, 2017, the Company issued 2,500 shares of common stock to a consultant for services rendered. The shares were fair valued at $973 at the date of grant.

 

On February 15, 2018, the Company agreed to issue 150,000 shares of common stock to a consultant for services rendered. The shares were fair valued at $102,000 ($0.68 per share) and deemed fully earned at the date of grant.

 

On November 27, 2017, the Company agreed to issue 50,000 shares of common stock to a consultant for services rendered. The shares were fair valued at $13,000 and deemed fully earned at the date of grant.

 

 
F-28
 
Table of Contents

 

THC THERAPEUTICS, INC

(formerly MILLENNIUM BLOCKCHAIN, INC.)

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

 

On March 31, 2018, the Company issued of 5,000,000 shares of the Company’s common stock to BurstIQ in accordance with a SAFE and SAFT agreement. (See Note 6 and Note 7 for additional details.)

 

Common Stock Payable for the nine months ended April 30, 2018

 

On December 16, 2017, the Company agreed to issue 165,000 shares of common stock to a consultant. The shares were fair valued at $48,263 at the date of grant. The shares vest as follows: 100,000 shares vest on January 1, 2018; 25,000 shares vest upon completion of the audit of the fiscal years ending July 31, 2017 and 2016; 12,500 shares vest upon completion of the review of the Company’s financial statements for the quarter ending October 31, 2017; 12,500 shares vest upon completion of the January 31, 2018 review; and 12,500 shares vest upon filing of the Company’s April 30, 2018 review. As of April 30, 2018, the shares had not yet been issued.

 

On March 5, 2018, the Company received $25,000 from an investor pursuant to a private placement agreement with the investor to purchase 62,500 shares of the Company’s common stock and 62,500 warrants to purchase shares of the Company’s common stock at $2.00 per shares for a period of three years. If the Company’s common stock has closed for 20 consecutive trading days above $3.00 per shares the investor must exercise the warrant within 30 days. As of April 30, 2018, the shares had not yet been issued.

 

On March 31, 2018, the Company and a lender agreed to settle a $30,000 promissory note and associated accrued interest of $3,473. The Company agreed to issue 95,000 shares of the Company’s common stock and warrants to purchase 195,000 shares of the Company’s common stock at $2.00 for a three-year term. In return for the consideration the Lender agreed to release the Company from all amounts owed. As of April 30, 2018, the shares had not yet been issued.

 

On April 6, 2018, the Company received $40,000 from an investor pursuant to a private placement agreement with the investor to purchase 100,000 shares of the Company’s common stock and 250,000 warrants to purchase shares of the Company’s common stock at $2.00 per shares for a period of five years. As of April 30, 2018, the shares had not yet been issued.

 

14. COMMITMENTS AND CONTINGENCIES

 

The Company does not own any real property. It does own personal property, and it leases office space on a month-to-month basis. There is no obligation for this arrangement to continue.

 

15. SUBSEQUENT EVENTS

 

In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to April 30, 2018 to the date these financial statements were available to be issued and has determined that it does not have any material subsequent events to disclose in these financial statements other than the events described below.

 

Impact PPA

On June 14, 2018 THC Therapeutics, Inc issued 60,000 shares of the Company's Series A Preferred Stock, with each share convertible into 100 shares of the Company's common stock, to ImpactPPA Limited, a Bahamian company (“ImpactPPA”). In exchange, the Company received the right to $4,500,000 of ImpactPPA’s MPQ tokens and the right to purchase a 3% equity stake in ImpactPPA within four months of the closing date of this transaction.

 

ImpactPPA is a blockchain platform built to disrupt renewable energy finance and accelerate global energy production. ImpactPPA’s platform and tokenized model allows communities to rapidly fund and deploy clean energy solutions by untethering traditionally expensive and inefficient structures for energy financing.

 

Consulting agreement

 

On June 30, 2018, the Company engaged a consultant for business advisory services. The Consultant was issued 2-year cashless warrants to purchase 500,000 shares of the company’s common stock for $0.01 per share.

 

Promissory note

 

On June 30, 2018, the Company entered into a promissory note with an investor pursuant to which we borrowed $28,000. Interest under the promissory note is 12% per annum, principal and accrued interest is due monthly in 24 equal payments of $1,307 beginning on November 1, 2018.

 

 

F-29

 
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

THC THERAPEUTICS, INC.

 

(Registrant)

 

Date: October 17, 2018

By:

/s/ Brandon Romanek

 

Brandon Romanek

 

President

 

 
35
 
Table of Contents

  

EXHIBIT INDEX

 

Exhibit

 

Description

 

3.1

 

Bylaws

 

3.2

 

Articles of Incorporation filed May 1, 2007

 

3.3

 

Articles of Amendment filed January 23, 2017

 

3.4

 

Articles of Amendment filed January 17, 2018

 

3.5

 

Certificate of Designation for Series A Preferred Stock filed January 24, 2017

 

3.6

 

Certificate of Designation for Series B Preferred Stock May 12, 2017*

 

3.7

 

Amended Certificate of Designation for Series B Preferred Stock filed June 5, 2017

 

3.8

 

Articles of Amendment filed September 28, 2018

 

 

 

10.1

 

Asset Purchase Agreement with Brandon Romanek dated January 20, 2017

 

10.2

 

Asset Purchase Agreement with Urban Oasis Float Center, LLC dated June 1, 2017

 

10.3

 

Simple Agreement for Future Equity with BurstIQ Analytics Corporation dated March 31, 2018

 

10.4

 

Simple Agreement for Future Tokens with BurstIQ Analytics Corporation dated March 31, 2018

 

10.5

 

MPQ Tokens Purchase Agreement with ImpactPPA Limited dated May 8, 2018

 

10.6

 

Employment Agreement with Brandon Romanek dated November 1, 2017

 

 

 

10.8

 

Common Stock Purchase Agreement with Robot Cache, S.L. dated July 31, 2018

 

21.

 

Subsidiaries

  

 

36

 

EXHIBIT 3.1


 
BY-LAWS
OF
FAIRYTALE VENTURES, INC.

(A NEVADA CORPORATION)


ARTICLE I
OFFICES

Section 1. Registered Office. The registered office of the corporation in the State of Nevada shall be at such place as the board shall resolve.

Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the Board of Directors, and may also have offices at such other places, both within and without the State of Nevada as the Board of Directors may from time to time determine or the business of the corporation may require.

ARTICLE II
CORPORATE SEAL

Section 3. Corporate Seal. The corporate seal shall consist of a die bearing the name of the corporation and the inscription, "Corporate Seal-Nevada." Said seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise.

ARTICLE III
STOCKHOLDERS' MEETINGS

Section 4. Place of Meetings. Meetings of the stockholders of the corporation shall be held at such place, either within or without the State of Nevada, as may be designated from time to time by the Board of Directors, or, if not so designated, then at the office of the corporation required to be maintained pursuant to Section 2 hereof.

Section 5. Annual Meeting.

(a)   The annual meeting of the stockholders of the corporation, for the purpose of election of directors and for such other business as may lawfully come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors.
 
 
 
 
 

  

(b)   At an annual meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual meeting, business must be: (A) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors, (B) otherwise properly brought before the meeting by or at the direction of the Board of Directors, or (C) otherwise properly brought before the meeting by a stockholder. For business to be properly brought before an annual meeting by a stockholder, the stockholder must have given timely notice thereof in writing to the Secretary of the corporation. To be timely, a stockholder's notice must be delivered to or mailed and received at the principal executive offices of the corporation not later than the close of business on the sixtieth (60th) day nor earlier than the close of business on the ninetieth (90th) day prior to the first anniversary of the preceding year's annual meeting; provided, however, that in the event that no annual meeting was held in the previous year or the date of the annual meeting has been changed by more than thirty (30) days from the date contemplated at the time of the previous year's proxy statement, notice by the stockholder to be timely must be so received not earlier than the close of business on the ninetieth (90th) day prior to such annual meeting and not later than the close of business on the later of the sixtieth (60th) day prior to such annual meeting or, in the event public announcement of the date of such annual meeting is first made by the corporation fewer than seventy (70) days prior to the date of such annual meeting, the close of business on the tenth (10th) day following the day on which public announcement of the date of such meeting is first made by the corporation. A stockholder's notice to the Secretary shall set forth as to each matter the stockholder proposes to bring before the annual meeting: (i) a brief description of the business desired to be brought before the annual meeting and the reasons for conducting such business at the annual meeting, (ii) the name and address, as they appear on the corporation's books, of the stockholder proposing such business, (iii) the class and number of shares of the corporation which are beneficially owned by the stockholder, (iv) any material interest of the stockholder in such business and (v) any other information that is required to be provided by the stockholder pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the "1934 Act"), in his capacity as a proponent to a stockholder proposal. Notwithstanding the foregoing, in order to include information with respect to a stockholder proposal in the proxy statement and form of proxy for a stockholder's meeting, stockholders must provide notice as required by the regulations promulgated under the 1934 Act. Notwithstanding anything in these Bylaws to the contrary, no business shall be conducted at any annual meeting except in accordance with the procedures set forth in this paragraph (b). The chairman of the annual meeting shall, if the facts warrant, determine and declare at the meeting that business was not properly brought before the meeting and in accordance with the provisions of this paragraph (b), and, if he should so determine, he shall so declare at the meeting that any such business not properly brought before the meeting shall not be transacted.
 
(c)   Only persons who are confirmed in accordance with the procedures set forth in this paragraph (c) shall be eligible for election as directors. Nominations of persons for election to the Board of Directors of the corporation may be made at a meeting of stockholders by or at the direction of the Board of Directors or by any stockholder of the corporation entitled to vote in the election of directors at the meeting who complies with the notice procedures set forth in this paragraph (c). Such nominations, other than those made by or at the direction of the Board of Directors, shall be made pursuant to timely notice in writing to the Secretary of the corporation in accordance with the provisions of paragraph (b) of this Section 5. Such stock¬holder's notice shall

 
2
 
 

 

set forth (i) as to each person, if any, whom the stockholder proposes to nominate for election or re-election as a director: (A) the name, age, business address and residence address of such person, (B) the principal occupation or employment of such person, (c) the class and number of shares of the corporation which are beneficially owned by such person, (D) a description of all arrangements or understandings between the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nominations are to be made by the stockholder, and (E) any other information relating to such person that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Regulation 14A under the 1934 Act (including without limitation such person's written consent to being named in the proxy statement, if any, as a nominee and to serving as a director if elected); and (ii) as to such stockholder giving notice, the information required to be provided pursuant to paragraph (b) of this Section 5. At the request of the Board of Directors, any person nominated by a stockholder for election as a director shall furnish to the Secretary of the corporation that information required to be set forth in the stockholder's notice of nomination which pertains to the nominee. No person shall be eligible for election as a director of the corporation unless nominated in accordance with the procedures set forth in this paragraph (c). The chairman of the meeting shall, if the facts warrant, determine and declare at the meeting that a nomination was not made in accordance with the procedures prescribed by these Bylaws, and if he should so determine, he shall so declare at the meeting, and the defective nomination shall be disregarded.

(d)   For purposes of this Section 5, "public announcement" shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.

Section 6. Special Meetings.

(a)   Special meetings of the stockholders of the corporation may be called, for any purpose or purposes, by (i) the Chairman of the Board of Directors, (ii) the Chief Executive Officer, or (iii) the Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors (whether or not there exist any vacancies in previously authorized directorships at the time any such resolution is presented to the Board of Directors for adoption), and shall be held at such place, on such date, and at such time, as the Board of Directors shall determine.
 
(b)   If a special meeting is called by any person or persons other than the Board of Directors, the request shall be in writing, specifying the general nature of the business proposed to be transacted, and shall be delivered personally or sent by registered mail or by tele-graphic or other facsimile transmission to the Chairman of the Board of Directors, the Chief Executive Officer, or the Secretary of the corporation. No business may be transacted at such special meeting otherwise than specified in such notice. The Board of Directors shall determine the time and place of such special meeting, which shall be held not less than thirty-five (35) nor more than one hundred twenty (120) days after the date of the receipt of the request. Upon determination of the time and place of the meeting, the officer receiving the request shall cause notice to be given to the stockholders entitled to vote, in accordance with the provisions of Section 7 of these Bylaws. If the notice is not given within sixty (60) days after the receipt of the request, the person or persons requesting the meeting may set the time and place of the meeting and give the notice. Nothing contained in this paragraph (b) shall be construed as limiting, fixing, or affecting the time when a meeting of stockholders called by action of the Board of Directors may be held.
   
 
3
 
 

 

Section 7. Notice of Meetings. Except as otherwise provided by law or the Articles of   Incorporation, written notice of each meeting of stockholders shall be given not less than ten (10) nor more than sixty (60) days before the date of the meeting to each stockholder entitled to vote at such meeting, such notice to specify the place, date and hour and purpose or purposes of the meeting. Notice of the time, place and purpose of any meeting of stockholders may be waived in writing, signed by the person entitled to notice thereof, either before or after such meeting, and will be waived by any stockholder by his attendance thereat in person or by proxy, except when the stockholder attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given.

Section 8. Quorum. At all meetings of stockholders, except where otherwise provided by statute or by the Articles of Incorporation, or by these Bylaws, the presence, in person or by proxy duly authorized, of the holder or holders of not less than fifty percent (50%) of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, either by the chairman of the meeting or by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. The stockholders present at a duly called or convened meeting, at which a quorum is present, may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Except as otherwise provided by law, the Articles of Incorporation or these Bylaws, all action taken by the holders of a majority of the votes cast, excluding abstentions, at any meeting at which a quorum is present shall be valid and binding upon the corporation; provided, however, that directors shall be elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the election of directors. Where a separate vote by a class or classes or series is required, except where otherwise provided by the statute or by the Articles of Incorporation or these Bylaws, a majority of the outstanding shares of such class or classes or series, present in person or represented by proxy, shall constitute a quorum entitled to take action with respect to that vote on that matter and, except where otherwise provided by the statute or by the Articles of Incorporation or these Bylaws, the affirmative vote of the majority (plurality, in the case of the election of directors) of the votes cast, including abstentions, by the holders of shares of such class or classes or series shall be the act of such class or classes or series.
 
Section 9. Adjournment and Notice of Adjourned Meetings. Any meeting of stockholders, whether annual or special, may be adjourned from time to time either by the chairman of the meeting or by the vote of a majority of the shares casting votes, excluding abstentions. When a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.
 
 
4
 
 

 

Section 10. Voting Rights. For the purpose of determining those stockholders entitled to vote at any meeting of the stockholders, except as otherwise provided by law, only persons in whose names shares stand on the stock records of the corporation on the record date, as provided in Section 12 of these Bylaws, shall be entitled to vote at any meeting of stockholders. Every person entitled to vote shall have the right to do so either in person or by an agent or agents authorized by a proxy granted in accordance with Nevada law. An agent so appointed need not be a stockholder. No proxy shall be voted after three (3) years from its date of creation unless the proxy provides for a longer period.

Section 11. Joint Owners of Stock. If shares or other securities having voting power stand of record in the names of two (2) or more persons, whether fiduciaries, members of a partnership, joint tenants, tenants in common, tenants by the entirety, or otherwise, or if two (2) or more persons have the same fiduciary relationship respecting the same shares, unless the Secretary is given written notice to the contrary and is furnished with a copy of the instrument or order appointing them or creating the relationship wherein it is so provided, their acts with respect to voting shall have the following effect: (a) if only one (1) votes, his act binds all; (b) if more than one (1) votes, the act of the majority so voting binds all; (c) if more than one (1) votes, but the vote is evenly split on any particular matter, each faction may vote the securities in question proportionally, or may apply to the Nevada Court of Chancery for relief as provided in the General Corporation Law of Nevada, Section 217(b). If the instrument filed with the Secretary shows that any such tenancy is held in unequal interests, a majority or even-split for the purpose of subsection (c) shall be a majority or even-split in interest.

Section 12. List of Stockholders. The Secretary shall prepare and make, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting, arranged in alphabetical order, showing the address of each stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10) days prior to the meeting, either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not specified, at the place where the meeting is to be held. The list shall be produced and kept at the time and place of meeting during the whole time thereof and may be inspected by any stockholder who is present.

Section 13. Action Without Meeting. No action shall be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with these Bylaws, or by the written consent of the stockholders.

Section 14. Organization.

(a)   At every meeting of stockholders, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the President, or, if the President is absent, a chairman of the meeting chosen by a majority in interest of the stockholders entitled to vote, present in person or by proxy, shall act as chairman. The Secretary, or, in his absence, an Assistant Secretary directed to do so by the President, shall act as secretary of the meeting.
 
 
5
 
 

 

(b)   The Board of Directors of the corporation shall be entitled to make such rules or regulations for the conduct of meetings of stockholders as it shall deem necessary, appropriate or convenient. Subject to such rules and regulations of the Board of Directors, if any, the chairman of the meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts as, in the judgment of such chairman, are necessary, appropriate or convenient for the proper conduct of the meeting, including, without limitation, establishing an agenda or order of business for the meeting, rules and procedures for maintaining order at the meeting and the safety of those present, limitations on participation in such meeting to stockholders of record of the corporation and their duly authorized and constituted proxies and such other persons as the chairman shall permit, restrictions on entry to the meeting after the time fixed for the commencement thereof, limitations on the time allotted to questions or comments by participants and regulation of the opening and closing of the polls for balloting on matters which are to be voted on by ballot. Unless and to the extent determined by the Board of Directors or the chairman of the meeting, meetings of stockholders shall not be required to be held in accordance with rules of parliamentary procedure.
 
ARTICLE IV
DIRECTORS

Section 15. Number and Qualification. The authorized number of directors of the corporation shall be not less than one (1) nor more than thirteen (13) as fixed from time to time by resolution of the Board of Directors; provided that no decrease in the number of directors shall shorten the term of any incumbent directors. Directors need not be stockholders unless so required by the Articles of Incorporation. If for any cause, the directors shall not have been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of the stockholders called for that purpose in the manner provided in these Bylaws.

Section 16. Powers. The powers of the corporation shall be exercised, its business conducted and its property controlled by the Board of Directors, except as may be otherwise provided by statute or by the Articles of Incorporation.

Section 17. Election and Term of Office of Directors. Members of the Board of Directors shall hold office for the terms specified in the Articles of Incorporation, as it may be amended from time to time, and until their successors have been elected as provided in the Articles of Incorporation.

Section 18. Vacancies. Unless otherwise provided in the Articles of Incorporation, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors, shall unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by stockholder vote, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director's successor shall have been elected and qualified. A vacancy in the Board of Directors shall be deemed to exist under this Bylaw in the case of the death, removal or resignation of any director.
 
 
6
 
 

 

Section 19. Resignation. Any director may resign at any time by delivering his written resignation to the Secretary, such resignation to specify whether it will be effective at a particular time, upon receipt by the Secretary or at the pleasure of the Board of Directors. If no such specification is made, it shall be deemed effective at the pleasure of the Board of Directors. When one or more directors shall resign from the Board of Directors, effective at a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office for the unexpired portion of the term of the director whose place shall be vacated and until his successor shall have been duly elected and qualified.

Section 20. Removal . Subject to the Articles of Incorporation, any director may be removed by the affirmative vote of the holders of a majority of the outstanding shares of the Corporation then entitled to vote, with or without cause.

Section 21. Meetings.

(a)   Annual Meetings. The annual meeting of the Board of Directors shall be held immediately after the annual meeting of stockholders and at the place where such meeting is held. No notice of an annual meeting of the Board of Directors shall be necessary and such meeting shall be held for the purpose of electing officers and transacting such other business as may lawfully come before it.

(b)   Regular Meetings. Except as hereinafter otherwise provided, regular meetings of the Board of Directors shall be held in the office of the corporation required to be maintained pursuant to Section 2 hereof. Unless otherwise restricted by the Articles of Incorporation, regular meetings of the Board of Directors may also be held at any place within or without the state of Nevada which has been designated by resolution of the Board of Directors or the written consent of all directors.
 
(c)   Special Meetings. Unless otherwise restricted by the Articles of Incorporation, special meetings of the Board of Directors may be held at any time and place within or without the State of Nevada whenever called by the Chairman of the Board, the President or any two of the directors.

(d)   Telephone Meetings. Any member of the Board of Directors, or of any committee thereof, may participate in a meeting by means of conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in person at such meeting.
 
 
7
 
 

 

(e)   Notice of Meetings. Notice of the time and place of all special meetings of the Board of Directors shall be orally or in writing, by telephone, facsimile, telegraph or telex, during normal business hours, at least twenty-four (24) hours before the date and time of the meeting, or sent in writing to each director by first class mail, charges prepaid, at least three (3) days before the date of the meeting. Notice of any meeting may be waived in writing at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened.

(f)   Waiver of Notice. The transaction of all business at any meeting of the Board of Directors, or any committee thereof, however called or noticed, or wherever held, shall be as valid as though had at a meeting duly held after regular call and notice, if a quorum be present and if, either before or after the meeting, each of the directors not present shall sign a written waiver of notice. All such waivers shall be filed with the corporate records or made a part of the minutes of the meeting.

Section 22. Quorum and Voting.

(a)   Unless the Articles of Incorporation requires a greater number and except with respect to indemnification questions arising under Section 43 hereof, for which a quorum shall be one-third of the exact number of directors fixed from time to time in accordance with the Articles of Incorporation, a quorum of the Board of Directors shall consist of a majority of the exact number of directors fixed from time to time by the Board of Directors in accordance with the Articles of Incorporation provided, however, at any meeting whether a quorum be present or otherwise, a majority of the directors present may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting.

(b)   At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by the affirmative vote of a majority of the directors present, unless a different vote be required by law, the Articles of Incorporation or these Bylaws.

Section 23. Action Without Meeting. Unless otherwise restricted by the Articles of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the Board of Directors or committee, as the case may be, consent thereto in writing, and such writing or writings are filed with the minutes of proceedings of the Board of Directors or committee.

Section 24. Fees and Compensation. Directors shall be entitled to such compensation for their services as may be approved by the Board of Directors, including, if so approved, by resolution of the Board of Directors, a fixed sum and expenses of attendance, if any, for attendance at each regular or special meeting of the Board of Directors and at any meeting of a committee of the Board of Directors. Nothing herein contained shall be construed to preclude any director from serving the corporation in any other capacity as an officer, agent, employee, or otherwise and receiving compensation therefor.
 
 
8
 
 

 

Section 25. Committees.

(a)   Executive Committee. The Board of Directors may by resolution passed by a majority of the whole Board of Directors appoint an Executive Committee to consist of one (1) or more members of the Board of Directors. The Executive Committee, to the extent permitted by law and provided in the resolution of the Board of Directors shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the corporation, including without limitation the power or authority to declare a dividend, to authorize the issuance of stock and to adopt a certificate of ownership and merger, and may authorize the seal of the corporation to be affixed to all papers which may require it; but no such committee shall have the power or authority in reference to amending the Articles of Incorporation (except that a committee may, to the extent authorized in the resolution or resolutions providing for the issuance of shares of stock adopted by the Board of Directors fix the designations and any of the preferences or rights of such shares relating to dividends, redemption, dissolution, any distribution of assets of the corporation or the conversion into, or the exchange of such shares for, shares of any other class or classes or any other series of the same or any other class or classes of stock of the corporation or fix the number of shares of any series of stock or authorize the increase or decrease of the shares of any series), adopting an agreement of merger or consolidation, recommending to the stockholders the sale, lease or exchange of all or substantially all of the corporation's property and assets, recommending to the stockholders a dissolution of the corporation or a revocation of a dissolution, or amending the bylaws of the corporation.

(b)   Other Committees. The Board of Directors may, by resolution passed by a majority of the whole Board of Directors, from time to time appoint such other committees as may be permitted by law. Such other committees appointed by the Board of Directors shall consist of one (1) or more members of the Board of Directors and shall have such powers and perform such duties as may be prescribed by the resolution or resolutions creating such committees, but in no event shall such committee have the powers denied to the Executive Committee in these Bylaws.
 
(c)   Term. Each member of a committee of the Board of Directors shall serve a term on the committee coexistent with such member's term on the Board of Directors. The Board of Directors, subject to the provisions of subsections (a) or (b) of this Bylaw may at any time increase or decrease the number of members of a committee or terminate the existence of a committee. The membership of a committee member shall terminate on the date of his death or voluntary resignation from the committee or from the Board of Directors. The Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors may fill any committee vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee, and, in addition, in the absence or disqualification of any member of a committee, the member or members thereof present at any meeting and not disqualified from voting, whether or not he or they constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in the place of any such absent or disqualified member.
 
 
9
 
 

 

(d)   Meetings. Unless the Board of Directors shall otherwise provide, regular meetings of the Executive Committee or any other committee appointed pursuant to this Section 25 shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter. Special meetings of any such committee may be held at any place which has been determined from time to time by such committee, and may be called by any director who is a member of such committee, upon written notice to the members of such committee of the time and place of such special meeting given in the manner provided for the giving of written notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. Notice of any special meeting of any committee may be waived in writing at any time before or after the meeting and will be waived by any director by attendance thereat, except when the director attends such special meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. A majority of the authorized number of members of any such committee shall constitute a quorum for the transaction of business, and the act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee.

Section 26. Organization. At every meeting of the directors, the Chairman of the Board of Directors, or, if a Chairman has not been appointed or is absent, the President, or if the President is absent, the most senior Vice President, or, in the absence of any such officer, a chairman of the meeting chosen by a majority of the directors present, shall preside over the meeting. The Secretary, or in his absence, an Assistant Secretary directed to do so by the President, shall act as secretary of the meeting.
 
ARTICLE V
OFFICERS

Section 27. Officers Designated. The officers of the corporation shall include, if and when designated by the Board of Directors, the Chairman of the Board of Directors, the Chief Executive Officer, the President, one or more Vice Presidents, the Secretary, the Chief Financial Officer, the Treasurer, the Controller, all of whom shall be elected at the annual organizational meeting of the Board of Directors. The Board of Directors may also appoint one or more Assistant Secretaries, Assistant Treasurers, Assistant Controllers and such other officers and agents with such powers and duties as it shall deem necessary. The Board of Directors may assign such additional titles to one or more of the officers as it shall deem appropriate. Any one person may hold any number of offices of the corporation at any one time unless specifically prohibited therefrom by law. The salaries and other compensation of the officers of the corporation shall be fixed by or in the manner designated by the Board of Directors.

Section 28. Tenure and Duties of Officers.

(a)   General. All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been duly elected and qualified, unless sooner removed. Any officer elected or appointed by the Board of Directors may be removed at any time by the Board of Directors. If the office of any officer becomes vacant for any reason, the vacancy may be filled by the Board of Directors.
 
 
10
 
 

 

(b)   Duties of Chairman of the Board of Directors. The Chairman of the Board of Directors, when present, shall preside at all meetings of the stockholders and the Board of Directors. The Chairman of the Board of Directors shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors shall designate from time to time. If there is no President, then the Chairman of the Board of Directors shall also serve as the Chief Executive Officer of the corporation and shall have the powers and duties prescribed in paragraph (c) of this Section 28.

(c)   Duties of President. The President shall preside at all meetings of the stockholders and at all meetings of the Board of Directors, unless the Chairman of the Board of Directors has been appointed and is present. Unless some other officer has been elected Chief Executive Officer of the corporation, the President shall be the chief executive officer of the corporation and shall, subject to the control of the Board of Directors, have general supervision, direction and control of the business and officers of the corporation. The President shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors shall designate from time to time.

(d)   Duties of Vice Presidents. The Vice Presidents may assume and perform the duties of the President in the absence or disability of the President or whenever the office of President is vacant. The Vice Presidents shall perform other duties commonly incident to their office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time.

(e)   Duties of Secretary. The Secretary shall attend all meetings of the stockholders and of the Board of Directors and shall record all acts and proceedings thereof in the minute book of the corporation. The Secretary shall give notice in conformity with these Bylaws of all meetings of the stockholders and of all meetings of the Board of Directors and any committee thereof requiring notice. The Secretary shall perform all other duties given him in these Bylaws and other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors shall designate from time to time. The President may direct any Assistant Secretary to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time.

(f)   Duties of Chief Financial Officer. The Chief Financial Officer shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the President. The Chief Financial Officer, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Chief Financial Officer shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. The President may direct the Treasurer or any Assistant Treasurer, or the Controller or any Assistant Controller to assume and perform the duties of the Chief Financial Officer in the absence or disability of the Chief Financial Officer, and each Treasurer and Assistant Treasurer and each Controller and Assistant Controller shall perform other duties commonly incident to his office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time.

 
 
11
 
 

 

Section 29. Delegation of Authority. The Board of Directors may from time to time delegate the powers or duties of any officer to any other officer or agent, notwithstanding any provision hereof.

Section 30. Resignations. Any officer may resign at any time by giving written notice to the Board of Directors or to the President or to the Secretary. Any such resignation shall be effective when received by the person or persons to whom such notice is given, unless a later time is specified therein, in which event the resignation shall become effective at such later time. Unless otherwise specified in such notice, the acceptance of any such resignation shall not be necessary to make it effective. Any resignation shall be without prejudice to the rights, if any, of the corporation under any contract with the resigning officer.

Section 31. Removal. Any officer may be removed from office at any time, either with or without cause, by the affirmative vote of a majority of the directors in office at the time, or by the unanimous written consent of the directors in office at the time, or by any committee or superior officers upon whom such power of removal may have been conferred by the Board of Directors.
 
ARTICLE VI
EXECUTION OF CORPORATE INSTRUMENTS AND VOTING
OF SECURITIES OWNED BY THE CORPORATION

Section 32. Execution of Corporate Instrument. The Board of Directors may, in its discretion, determine the method and designate the signatory officer or officers, or other person or persons, to execute on behalf of the corporation any corporate instrument or document, or to sign on behalf of the corporation the corporate name without limitation, or to enter into contracts on behalf of the corporation, except where otherwise provided by law or these Bylaws, and such execution or signature shall be binding upon the corporation.

Unless otherwise specifically determined by the Board of Directors or otherwise required by law, promissory notes, deeds of trust, mortgages and other evidences of indebtedness of the corporation, and other corporate instruments or documents requiring the corporate seal, and certificates of shares of stock owned by the corporation, shall be executed, signed or endorsed by the Chairman of the Board of Directors, or the President or any Vice President, and by the Secretary or Treasurer or any Assistant Secretary or Assistant Treasurer. All other instruments and documents requiting the corporate signature, but not requiring the corporate seal, may be executed as aforesaid or in such other manner as may be directed by the Board of Directors.
 
 
12
 
 

 

All checks and drafts drawn on banks or other depositaries on funds to the credit of the corporation or in special accounts of the corporation shall be signed by such person .or persons as the Board of Directors shall authorize so to do.

Unless authorized or ratified by the Board of Directors or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.
 
Section 33. Voting of Securities Owned by the Corporation. All stock and other securities of other corporations owned or held by the corporation for itself, or for other parties in any capacity, shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors, or, in the absence of such authorization, by the Chairman of the Board of Directors, the Chief Executive Officer, the President, or any Vice President.

ARTICLE VII
SHARES OF STOCK

Section 34. Form and Execution of Certificates. Certificates for the shares of stock of the corporation shall be in such form as is consistent with the Articles of Incorporation and applicable law. Every holder of stock in the corporation shall be entitled to have a certificate signed by or in the name of the corporation by the Chairman of the Board of Directors, or the President or any Vice President and by the Treasurer or Assistant Treasurer or the Secretary or Assistant Secretary, certifying the number of shares owned by him in the corporation. Any or all of the signatures on the certificate may be facsimiles. In case any officer, transfer agent, or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent, or registrar before such certificate is issued, it may be issued with the same effect as if he were such officer, transfer agent, or registrar at the date of issue. Each certificate shall state upon the face or back thereof, in full or in summary, all of the powers, designations, preferences, and rights, and the limitations or restrictions of the shares authorized to be issued or shall, except as otherwise required by law, set forth on the face or back a statement that the corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative, participating, optional, or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Within a reasonable time after the issuance or transfer of uncertificated stock, the corporation shall send to the registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to this section or otherwise required by law or with respect to this section a statement that the corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Except as otherwise expressly provided by law, the rights and obligations of the holders of certificates representing stock of the same class and series shall be identical.
 
 
13
 
 

 


Section 35. Lost Certificates. A new certificate or certificates shall be issued in place of any certificate or certificates theretofore issued by the corporation alleged to have been lost, stolen, or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen, or destroyed. The corporation may require, as a condition precedent to the issuance of a new certificate or certificates, the owner of such lost, stolen, or destroyed certificate or certificates, or his legal representative, to advertise the same in such manner as it shall require or to give the corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be made against the corporation with respect to the certificate alleged to have been lost, stolen, or destroyed.

Section 36. Transfers.

(a)   Transfers of record of shares of stock of the corporation shall be made only upon its books by the holders thereof, in person or by attorney duly authorized, and upon the surrender of a properly endorsed certificate or certificates for a like number of shares.

(b)   The corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the corporation to restrict the transfer of shares of stock of the corporation of any one or more classes owned by such stockholders in any manner not prohibited by the General Corporation Law of Nevada.

Section 37. Fixing Record Dates.
 
(a)   In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given, or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.

(b)   In order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix, in advance, a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than sixty (60) days prior to such action. If no record date is filed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.

Section 38. Registered Stockholders. The corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Nevada.
 
 
14
 
 

 

ARTICLE VIII

OTHER SECURITIES OF THE CORPORATION

Section 39. Execution of Other Securities. All bonds, debentures and other corporate securities of the corporation, other than stock certificates (covered in Section 34), may be signed by the Chairman of the Board of Directors, the President or any Vice President, or such other person as may be authorized by the Board of Directors, and the corporate seal impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an Assistant Secretary, or the Chief Financial Officer or Treasurer or an Assistant Treasurer; provided, however, that where any such bond, debenture or other corporate security shall be authenticated by the manual signature, or where permissible facsimile signature, of a trustee under an indenture pursuant to which such bond, debenture or other corporate security shall be issued, the signatures of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an Assistant Treasurer of the corporation or such other person as may be authorized by the Board of Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested any bond, debenture or other corporate security, or whose facsimile signature shall appear thereon or on any such interest coupon, shall have ceased to be such officer before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless may be adopted by the corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the corporation.
 
ARTICLE IX
DIVIDENDS

Section 40. Declaration of Dividends. Dividends upon the capital stock of the corporation, subject to the provisions of the Articles of Incorporation, if any, may be declared by the Board of Directors pursuant to law at any regular or special meeting. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the Articles of Incorporation.

Section 41. Dividend Reserve. Before payment of any dividend, there may be set aside out of any funds of the corporation available for dividends such sum or sums as the Board of Directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies, or for equalizing dividends, or for repairing or maintaining any property of the corporation, or for such other purpose as the Board of Directors shall think conducive to the interests of the corporation, and the Board of Directors may modify or abolish any such reserve in the manner in which it was created.
 
 
15
 
 

 

ARTICLE X
FISCAL YEAR

Section 42. Fiscal Year. The fiscal year of the corporation shall be fixed by resolution of the Board of Directors.

ARTICLE XI
INDEMNIFICATION

Section 43. Indemnification of Directors, Executive Officers, Other Officers, Employees and Other Agents.

(a)   Directors Officers. The corporation shall indemnify its directors and officers to the fullest extent not prohibited by the Nevada General Corporation Law; provided, however, that the corporation may modify the extent of such indemnification by individual contracts with its directors and officers; and, provided, further, that the corporation shall not be required to indemnify any director or officer in connection with any proceeding (or part thereof) initiated by such person unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding was authorized by the Board of Directors of the corporation, (iii) such indemnification is provided by the corporation, in its sole discretion, pursuant to the powers vested in the corporation under the Nevada General Corporation Law or (iv) such indemnification is required to be made under subsection (d).

(b)   Employees and Other Agents. The corporation shall have power to indemnify its employees and other agents as set forth in the Nevada General Corporation Law.

(c)   Expense. The corporation shall advance to any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that he is or was a director or officer, of the corporation, or is or was serving at the request of the corporation as a director or executive officer of another corporation, partnership, joint venture, trust or other enterprise, prior to the final disposition of the proceeding, promptly following request therefor, all expenses incurred by any director or officer in connection with such proceeding upon receipt of an undertaking by or on behalf of such person to repay said mounts if it should be determined ultimately that such person is not entitled to be indemnified under this Bylaw or otherwise.

Notwithstanding the foregoing, unless otherwise determined pursuant to paragraph (e) of this Bylaw, no advance shall be made by the corporation to an officer of the corporation (except by reason of the fact that such officer is or was a director of the corporation in which event this paragraph shall not apply) in any action, suit or proceeding, whether civil, criminal, administrative or investigative, if a determination is reasonably and promptly made (i) by the Board of Directors by a majority vote of a quorum consisting of directors who were not parties to the proceeding, or (ii) if such quorum is not obtainable, or, even if obtainable, a quorum of disinterested directors so directs, by independent legal counsel in a written opinion, that the facts known to the decision-making party at the time such determination is made demonstrate clearly and convincingly that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed to the best interests of the corporation.
 
 
16
 
 

 

(d) Enforcement. Without the necessity of entering into an express contract, all rights to indemnification and advances to directors and officers under this Bylaw shall be deemed to be contractual rights and be effective to the same extent and as if provided for in a contract between the corporation and the director or officer. Any right to indemnification or advances granted by this Bylaw to a director or officer shall be enforceable by or on behalf of the person holding such right in any court of competent jurisdiction if (i) the claim for indemnification or advances is denied, in whole or in part, or (ii) no disposition of such claim is made within ninety (90) days of request therefor. The claimant in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting his claim. In connection with any claim for indemnification, the corporation shall be entitled to raise as a defense to any such action that the claimant has not met the standard of conduct that make it permissible under the Nevada General Corporation Law for the corporation to indemnify the claimant for the amount claimed. In connection with any claim by an officer of the corporation (except in any action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that such officer is or was a director of the corporation) for advances, the corporation shall be entitled to raise a defense as to any such action clear and convincing evidence that such person acted in bad faith or in a manner that such person did not believe to be in or not opposed in the best interests of the corporation, or with respect to any criminal action or proceeding that such person acted without reasonable cause to believe that his conduct was lawful. Neither the failure of the corporation (including its Board of Directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he has met the applicable standard of conduct set forth in the Nevada General Corporation Law, nor an actual determination by the corporation (including its Board of Directors, independent legal counsel or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct. In any suit brought by a director or officer to enforce a right to indemnification or to an advancement of expenses hereunder, the burden of proving that the director or officer is not entitled to be indemnified, or to such advancement of expenses, under this Article XI or otherwise shall be on the corporation.

(e) Non-Exclusivity of Rights. The rights conferred on any person by this Bylaw shall not be exclusive of any other right which such person may have or hereafter acquire under any statute, provision of the Articles of Incorporation, Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in his official capacity and as to action in another capacity while holding office. The corporation is specifically authorized to enter into individual contracts with any or all of its directors, officers, employees or agents respecting indemnification and advances, to the fullest extent not prohibited by the Nevada General Corporation Law.
 
 
17
 
 

 

(f) Survival of Rights. The rights conferred on any person by this Bylaw shall continue as to a person who has ceased to be a director, officer, employee or other agent and shall inure to the benefit of the heirs, executors and administrators of such a person.
 
(g) Insurance. To the fullest extent permitted by the Nevada General Corporation Law, the corporation, upon approval by the Board of Directors, may purchase insurance on behalf of any person required or permitted to be indemnified pursuant to this Bylaw.
 
(h) Amendments. Any repeal or modification of this Bylaw shall only be prospective and shall not affect the rights under this Bylaw in effect at the time of the alleged occurrence of any action or omission to act that is the cause of any proceeding against any agent of the corporation.
 
(i) Saving Clause. If this Bylaw or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the corporation shall nevertheless indemnify each director and officer to the full extent not prohibited by any applicable portion of this Bylaw that shall not have been invalidated, or by any other applicable law.
 
(j) Certain Definitions. For the purposes of this Bylaw, the following definitions shall apply:
 
(i)   The term "proceeding" shall be broadly construed and shall include, without limitation, the investigation, preparation, prosecution, defense, settlement, arbitration and appeal of, and the giving of testimony in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative.
 
(ii)   The term "expenses" shall be broadly construed and shall include, without limitation, court costs, attorneys' fees, witness fees, fines, amounts paid in settlement or judgment and any other costs and expenses of any nature or kind incurred in connection with any proceeding.
 
(iii)   The term the "corporation" shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent or another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Bylaw with respect to the resulting or surviving corporation as he would have with respect to such constituent corporation if its separate existence had continued.
 
(iv)   References to a "director," "executive officer," "officer," "employee," or "agent" of the corporation shall include, without limitation, situations where such person is serving at the request of the corporation as, respectively, a director, executive officer, officer, employee, trustee or agent of another corporation, partnership, joint venture, trust or other enterprise.
 
 
18
 
 

 

(v)   References to "other enterprises" shall include employee benefit plans; references to "fines" shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to "serving at the request of the corporation" shall include any service as a director, officer, employee or agent of the corporation which imposes duties on, or involves services by, such director, officer, employee, or agent with respect to an employee benefit plan, its participants, or beneficiaries; and a person who acted in good faith and in a manner he reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner "not opposed to the best interests of the corporation" as referred to in this Bylaw.

ARTICLE XII
NOTICES

Section 44. Notices.

(a)   Notice to Stockholders. Whenever, under any provisions of these Bylaws, notice is required to be given to any stockholder, it shall be given in writing, timely and duly deposited in the United States mail, postage prepaid, and addressed to his last known post office address as shown by the stock record of the corporation or its transfer agent.
 
(b)   Notice to directors. Any notice required to be given to any director may be given by the method stated in subsection (a), or by facsimile, telex or telegram, except that such notice other than one which is delivered personally shall be sent to such address as such director shall have filed in writing with the Secretary, or, in the absence of such filing, to the last known post office address of such director.
 
(c)   Affidavit of Mailing. An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or its transfer agent appointed with respect to the class of stock affected, specifying the name and address or the names and addresses of the stockholder or stockholders, or director or directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall in the absence of fraud, be prima facie evidence of the facts therein contained.
 
(d)   Time Notices Deemed Given. All notices given by mail, as above provided, shall be deemed to have been given as at the time of mailing, and all notices given by facsimile, telex or telegram shall be deemed to have been given as of the sending time recorded at time of transmission.
 
(e)   Methods of Notice. It shall not be necessary that the same method of giving notice be employed in respect of all directors, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others.
 
 
19
 
 

 

(f)   Failure to Receive Notice. The period or limitation of time within which any stockholder may exercise any option or right, or enjoy any privilege or benefit, or be required to act, or within which any director may exercise any power or right, or enjoy any privilege, pursuant to any notice sent him ill the manner above provided, shall not be affected or extended in any manner by the failure of such stockholder or such director to receive such notice.
 
(g)   Notice to Person with Whom Communication Is Unlawful. Whenever notice is required to be given, under any provision of law or of the Articles of Incorporation or Bylaws of the corporation, to any person with whom communication is unlawful, the giving of such notice to such person shall not be require and there shall be no duty to apply to any governmental authority or agency for a license or permit to give such notice to such person. Any action or meeting which shall be taken or held without notice to any such person with whom communication is unlawful shall have the same force and effect as if such notice had been duly given. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the Nevada General Corporation Law, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful.
 
(h)   Notice to Person with Undeliverable Address. Whenever notice is required to be given, under any provision of law or the Articles of Incorporation or Bylaws of the corporation, to any stockholder to whom (i) notice of two consecutive annual meetings, and all notices of meetings or of the taking of action by written consent without a meeting to such person during the period between such two consecutive annual meetings, or (ii) all, and at least two, payments (if sent by first class mail) of dividends or interest on securities during a twelve-month period, have been mailed addressed to such person at his address as shown on the records of the corporation and have been returned undeliverable, the giving of such notice to such person shall not be required. Any action or meeting which shall be taken or held without notice to such person shall have the same force and effect as if such notice had been duly given. If any such person shall deliver to the corporation a written notice setting forth his then current address, the requirement that notice be given to such person shall be reinstated. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the Nevada General Corporation Law, the certificate need not state that notice was not given to persons to whom notice was not required to be given pursuant to this paragraph.

ARTICLE XII
AMENDMENTS

Section 45. Amendments.

The Board of Directors shall have the sole power to adopt, amend, or repeal Bylaws as set forth in the Articles of Incorporation.
 
 
20
 
 

 

ARTICLE XIV

LOANS TO OFFICERS


Section 46. Loans to Officers. The corporation may lend money to, or guarantee any obligation of, or otherwise assist any officer or other employee of the corporation or of its subsidiaries, including any officer or employee who is a Director of the corporation or its subsidiaries, whenever, in the judgment of the Board of Directors, such loan, guarantee or assistance may reasonably be expected to benefit the corporation. The loan, guarantee or other assistance may be with or without interest and may be unsecured, or secured in such manner as the Board of Directors shall approve, including, without limitation, a pledge of shares of stock of the corporation. Nothing in these Bylaws shall be deemed to deny, limit or restrict the powers of guaranty or warranty of the corporation at common law or under any statute.

ARTICLE XV
BOARD OF ADVISORS

Section 47.   Board of Advisors. The Board of Directors, in its discretion, may establish a Board of Advisors consisting of individuals who may or may not be stockholders or directors of the corporation. The purpose of the Board of Advisors would be to advise the officers and directors of the corporation with respect to such matters as such officers and directors shall choose, and any other such matters which the members of such Board of Advisors deem appropriate in furtherance of the best interest of the corporation. The Board of Advisors shall meet on such basis as the members thereof may determine. The Board of Directors may eliminate the Board of Advisors at any time. No member of the Board of Advisors, nor the Board of Advisors itself, shall have any authority within the corporation or any decision making power and shall be merely advisory in nature. Unless the Board of Directors determines another method of appointment, the President shall recommend possible members to the Board of Directors, who shall approve or reject such appointments.

Declared and certified as the Bylaws of Innovative Consumer Products, Inc. on April 30, 2007.
 
     
Signature of Officer: /s/ Anusha Kumar

Name of Officer:

Anusha Kumar  
Position of Officer:

President, Secretary-Treasurer, Chief Executive Officer, and Chief Financial Officer

 

 

 

 

 

EXHIBIT 3.2

 

Ross Miller

Secretary of State
206 North Carson Street
Carson City, Nevada 89701-4299
(775) 684 5708
Website: secretaryofstate.biz

 
Articles of Incorporation
 
(PURSUANT TO NRS 78)
 
   
ABOVE SPACE IS FOR OFFICE USE ONLY
1.
Name of Corporation:
FAIRYTALE VENTURES, INC.
     
2.
Resident Agent
Name and Street Address:
(must be a Nevada address where process may be served)
ANUSHA KUMAR
 
Name
     
  5155 WEST TROPICANA, #1094 LAS VEGAS NV 89103
 
Street Address
City
ST
Zip Code
       
 
Optional Mailing Address
City
ST
Zip Code
3.
Shares:
(number of shares corporation authorized to issue)
Number of shares
with par value: 100,000,000
 
Par value:$
0.001
Number of shares without par value:
 
               
4.
Names &
Addresses
of Board of
Directors/Trustees:
(attach additional page if there is more than 3 directors/trustees)
1. ANUSHA KUMAR
 
  Name
 
  5155 WEST TROPICANA, #1094 LAS VEGAS NV 89103
 
Street Address
City
ST
Zip Code
 
2.
 
    Name
 
           
   
Street Address
City
ST
Zip Code
   
3.
 
    Name
 
           
   
Street Address
City
ST
Zip Code
           
5.
Purpose:
(optional-see instructions)
The purpose of this Corporation shall be: ALL LEGAL PURPOSES
           
6.
Name, Address and Signature of Incorporator.
(attach additional page if there is more than 1 incorporator)
ANUSHA KUMAR /S/ ANUSHA KUMAR
 
Name
Signature
  5155 WEST TROPICANA, #1094 LAS VEGAS NV 89103
 
Street Address
City
ST
Zip Code
           
7.
Certificate of
Acceptance of
Appointment of
Resident Agent:
I hereby accept appointment as Resident Agent for the above named corporation.
  /S/ ANUSHA KUMAR APRIL 30, 2007
 
Authorized Signature of R.A. or On Behalf of R.A. Company
Date

This form must be accompanied by appropriate fees.
Nevada Secretary of State Form 78 Articles 2007
Revised on: 01/01/07
 
 
 
 

 

ARTICLES OF INCORPORATION
 
OF
 
FAIRYTALE VENTURES, INC.
 
ARTICLE I
NAME
 
 
The name of the corporation shall be Fairytale Ventures, Inc. (hereinafter, the “Corporation”).
 
ARTICLE II
REGISTERED OFFICE
 
The initial office of the Corporation shall be 5155 West Tropicana, #1094, Las Vegas, Nevada 89103. The initial registered agent of the Corporation shall be Anusha Kumar , 5155 West Tropicana, #1094, Las Vegas, Nevada 89103. The Corporation may, from time to time, in the manner provided by law, change the resident agent and the registered office within the State of Nevada. The Corporation may also maintain an office or offices for the conduct of its business, either within or without the State of Nevada.
 
ARTICLE III
CAPITAL STOCK
 
Section 1. Authorized Shares.     The aggregate number of shares which the Corporation shall have authority to issue is one hundred million (100,000,000) shares, consisting of two classes to be designated, respectively, "Common Stock" and "Preferred Stock," with all of such shares having a par value of $.001 per share. The total number of shares of Common Stock that the Corporation shall have authority to issue is ninety million (90,000,000) shares. The total number of shares of Preferred Stock that the Corporation shall have authority to issue is ten million (10,000,000) shares. The Preferred Stock may be issued in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issuance of any shares thereof. The voting powers, designations, preferences, limitations, restrictions, and relative, participating, optional and other rights, and the qualifications, limitations, or restrictions thereof, of the Preferred Stock shall hereinafter be prescribed by resolution of the board of directors pursuant to Section 3 of this Article III.
 
Section 2.  Common Stock.     
 
(a)  Dividend Rate.  Subject to the rights of holders of any Preferred Stock having preference as to dividends and except as otherwise provided by these Articles of Incorporation, as amended from time to time (hereinafter, the " Articles ") or the Nevada Revised Statues (hereinafter, the “ NRS ”), the holders of Common Stock shall be entitled to receive dividends when, as and if declared by the board of directors out of assets legally available therefor.
 
(b)  Voting Rights.  Except as otherwise provided by the NRS, the holders of the issued and outstanding shares of Common Stock shall be entitled to one vote for each share of Common Stock. No holder of shares of Common Stock shall have the right to cumulate votes.
 
(c)  Liquidation Rights.  In the event of liquidation, dissolution, or winding up of the affairs of the Corporation, whether voluntary or involuntary, subject to the prior rights of holders of Preferred Stock to share ratably in the Corporation's assets, the Common Stock and any shares of Preferred Stock which are not entitled to any preference in liquidation shall share equally and ratably in the Corporation's assets available for distribution after giving effect to any liquidation preference of any shares of Preferred Stock. A merger, conversion, exchange or consolidation of the Corporation with or into any other person or sale or transfer of all or any part of the assets of the Corporation (which shall not in fact result in the liquidation of the Corporation and the distribution of assets to stockholders) shall not be deemed to be a voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Corporation.
 
 
1
 
 

 

(d)  No Conversion, Redemption, or Preemptive Rights.  The holders of Common Stock shall not have any conversion, redemption, or preemptive rights.
 
(e)  Consideration for Shares.  The Common Stock authorized by this Article shall be issued for such consideration as shall be fixed, from time to time, by the board of directors.
 
Section 3.  Preferred Stock.     
 
(a)  Designation.  The board of directors is hereby vested with the authority from time to time to provide by resolution for the issuance of shares of Preferred Stock in one or more series not exceeding the aggregate number of shares of Preferred Stock authorized by these Articles, and to prescribe with respect to each such series the voting powers, if any, designations, preferences, and relative, participating, optional, or other special rights, and the qualifications, limitations, or restrictions relating thereto, including, without limiting the generality of the foregoing: the voting rights relating to the shares of Preferred Stock of any series (which voting rights, if any, may be full or limited, may vary over time, and may be applicable generally or only upon any stated fact or event); the rate of dividends (which may be cumulative or noncumulative), the condition or time for payment of dividends and the preference or relation of such dividends to dividends payable on any other class or series of capital stock; the rights of holders of Preferred Stock of any series in the event of liquidation, dissolution, or winding up of the affairs of the Corporation; the rights, if any, of holders of Preferred Stock of any series to convert or exchange such shares of Preferred Stock of such series for shares of any other class or series of capital stock or for any other securities, property, or assets of the Corporation or any subsidiary (including the determination of the price or prices or the rate or rates applicable to such rights to convert or exchange and the adjustment thereof, the time or times during which the right to convert or exchange shall be applicable, and the time or times during which a particular price or rate shall be applicable); whether the shares of any series of Preferred Stock shall be subject to redemption by the Corporation and if subject to redemption, the times, prices, rates, adjustments and other terms and conditions of such redemption. The powers, designations, preferences, limitations, restrictions and relative rights may be made dependent upon any fact or event which may be ascertained outside the Articles or the resolution if the manner in which the fact or event may operate on such series is stated in the Articles or resolution. As used in this section "fact or event" includes, without limitation, the existence of a fact or occurrence of an event, including, without limitation, a determination or action by a person, government, governmental agency or political subdivision of a government. The board of directors is further authorized to increase or decrease (but not below the number of such shares of such series then outstanding) the number of shares of any series subsequent to the issuance of shares of that series. Unless the board of directors provides to the contrary in the resolution which fixes the characteristics of a series of Preferred Stock, neither the consent by series, or otherwise, of the holders of any outstanding Preferred Stock nor the consent of the holders of any outstanding Common Stock shall be required for the issuance of any new series of Preferred Stock regardless of whether the rights and preferences of the new series of Preferred Stock are senior or superior, in any way, to the outstanding series of Preferred Stock or the Common Stock.
 
(b)  Certificate.  Before the Corporation shall issue any shares of Preferred Stock of any series, a certificate of designation setting forth a copy of the resolution or resolutions of the board of directors, and establishing the voting powers, designations, preferences, the relative, participating, optional, or other rights, if any, and the qualifications, limitations, and restrictions, if any, relating to the shares of Preferred Stock of such series, and the number of shares of Preferred Stock of such series authorized by the board of directors to be issued shall be made and signed by an officer of the corporation and filed in the manner prescribed by the NRS.
 
 
2
 
 

  

Section 4.  Non-Assessment of Stock.  The capital stock of the Corporation, after the amount of the subscription price has been fully paid, shall not be assessable for any purpose, and no stock issued as fully paid shall ever be assessable or assessed, and the Articles shall not be amended in this particular. No stockholder of the Corporation is individually liable for the debts or liabilities of the Corporation.
 
ARTICLE IV
DIRECTORS AND OFFICERS
 
Section 1.  Number of Directors.  The members of the governing board of the Corporation are styled as directors. The board of directors of the Corporation shall be elected in such manner as shall be provided in the bylaws of the Corporation. The board of directors shall consist of at least one (1) individual and not more than thirteen (13) individuals. The number of directors may be changed from time to time in such manner as shall be provided in the bylaws of the Corporation.        
 
Section 2.  Initial Directors.  The name and post office box or street address of the director(s) constituting the initial board of directors is:
 
Name   Address
Anusha Kumar   5155 West Tropicana, #1094, Las Vegas, Nevada 89103
 
Section 3.  Limitation of Liability.  The liability of directors and officers of the Corporation shall be eliminated or limited to the fullest extent permitted by the NRS. If the NRS is amended to further eliminate or limit or authorize corporate action to further eliminate or limit the liability of directors or officers, the liability of directors and officers of the Corporation shall be eliminated or limited to the fullest extent permitted by the NRS, as so amended from time to time.
 
Section 4.  Payment of Expenses.  In addition to any other rights of indemnification permitted by the laws of the State of Nevada or as may be provided for by the Corporation in its bylaws or by agreement, the expenses of officers and directors incurred in defending any threatened, pending, or completed action, suit or proceeding (including without limitation, an action, suit or proceeding by or in the right of the Corporation), whether civil, criminal, administrative or investigative, involving alleged acts or omissions of such officer or director in his or her capacity as an officer or director of the Corporation or member, manager, or managing member of a predecessor limited liability company or affiliate of such limited liability company or while serving in any capacity at the request of the Corporation as a director, officer, employee, agent, member, manager, managing member, partner, or fiduciary of, or in any other capacity for, another corporation or any partnership, joint venture, trust, or other enterprise, shall be paid by the Corporation or through insurance purchased and maintained by the Corporation or through other financial arrangements made by the Corporation, as they are incurred and in advance of the final disposition of the action, suit or proceeding, upon receipt of an undertaking by or on behalf of the officer or director to repay the amount if it is ultimately determined by a court of competent jurisdiction that he or she is not entitled to be indemnified by the Corporation. To the extent that an officer or director is successful on the merits in defense of any such action, suit or proceeding, or in the defense of any claim, issue or matter therein, the Corporation shall indemnify him or her against expenses, including attorneys' fees, actually and reasonably incurred by him or her in connection with the defense. Notwithstanding anything to the contrary contained herein or in the bylaws, no director or officer may be indemnified for expenses incurred in defending any threatened, pending, or completed action, suit or proceeding (including without limitation, an action, suit or proceeding by or in the right of the Corporation), whether civil, criminal, administrative or investigative, that such director or officer incurred in his or her capacity as a stockholder, including, but not limited to, in connection with such person being deemed an Unsuitable Person (as defined in Article VII hereof).
 
 
3
 
 

 

Section 5.  Repeal And Conflicts.  Any repeal or modification of Sections 3 or 4 above approved by the stockholders of the Corporation shall be prospective only, and shall not adversely affect any limitation on the liability of a director or officer of the Corporation existing as of the time of such repeal or modification. In the event of any conflict between Sections 3 or 4 above and any other Article of the Articles, the terms and provisions of Sections 3 or 4 above shall control.
 
ARTICLE V
COMBINATIONS WITH INTERESTED STOCKHOLDERS
 
At such time, if any, as the Corporation becomes a "resident domestic corporation", as that term is defined in NRS 78.427, the Corporation shall not be subject to, or governed by, any of the provisions in NRS 78.411 to 78.444, inclusive, as may be amended from time to time, or any successor statute.
 
ARTICLE VI
BYLAWS
 
The board of directors is expressly granted the exclusive power to make, amend, alter, or repeal the bylaws of the Corporation pursuant to NRS 78.120.
 
IN WITNESS WHEREOF, the Corporation has caused these articles of incorporation to be executed in its name by its Incorporator on April 30, 2007.
 
 
/s/ Anusha Kumar
Anusha Kumar
 

 

 

 

EXHIBIT 3.3

 

BARBARA K. CEGAVSKE

Secretary of State

202 North Carson Street

Carson City, Nevada 89701-4201

(775) 684-5708

Website: www.nvsos.gov

 

 

Certificate of Amendment

(PURSUANT TO NRS 78.385 AND 78.390)

 

 

 

 

USE BLACK INK ONLY - DO NOT HIGHLIGHT

ABOVE SPACE IS FOR OFFICE USE ONLY

 

Certificate of Amendment to Articles of Incorporation

For Nevada Profit Corporations

(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)

 

1. Name of corporation:

Harmonic Energy, Inc.

 

2. The articles have been amended as follows: (provide article numbers, if available)

 

Article I of the Corporation's Articles of Incorporation have been amended to change the name of the Corporation to "THC Therapeutics, Inc."

 

Article III, Section 1 of the Corporation’s Articles of Incorporation have been amended to read as follows:

 

SEE ATTACHED

 

 

3. The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted in favor of the amendment is:

62.616%

  

4. Effective date and time of filing: (optional)

Date:

 

 

 

Time:

 

 

 

(must not be later than 90 days after the certificate is filed)

 

5. Signature: (required)

 

 

X /s/ Brandon Romanek                                                                       

Signature of Officer

 

*If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.

 

IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

 

This form must be accompanied by appropriate fees.

 

 

Nevada Secretary of State Amend Profit-After

Revised: 1-5-15

 

 

Reset

 

 

 

 
 
 
 

 

“Section 1. Authorized Shares. The aggregate number of shares which the Corporation shall have authority to issue is five hundred ten million (510,000,000) shares, consisting of two classes to be designated, respectively, “Common Stock” and “Preferred Stock,” with all of such shares having a par value of $.001 per share. The total number of shares of Common Stock that the Corporation shall have authority to issue is five hundred million (500,000,000) shares. The total number of shares of Preferred Stock that the Corporation shall have authority to issue is ten million (10,000,000) shares. The Preferred Stock may be issued in one or more series, each series to be appropriately designated by a distinguishing letter or title, prior to the issuance of any shares thereof. The voting powers, designations, preferences, limitations, restrictions, and relative, participating, optional and other rights, and the qualifications, limitations, or restrictions thereof, of the Preferred Stock shall hereinafter be prescribed by resolution of the board of directors pursuant to Section 3 of this Article III.”

 

 

 

 

EXHIBIT 3.4

 

 

BARBARA K. CEGAVSKE

Secretary of State

202 North Carson Street

Carson City, Nevada 89701-4201

(775) 684-5708

Website: www.nvsos.gov

 

 

 

Certificate of Amendment

(PURSUANT TO NRS 78.385 AND 78.390)

 

 

 

 

USE BLACK INK ONLY - DO NOT HIGHLIGHT

 

ABOVE SPACE IS FOR OFFICE USE ONLY

 

Certificate of Amendment to Articles of Incorporation

For Nevada Profit Corporations

(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)

 

1.  Name of corporation:

THC Therapeutics, Inc.

 

2. The articles have been amended as follows: (provide article numbers, if available)

Article I of the corporation's Articles of Incorporation is hereby amended to change the name of the corporation to "Millennium BlockChain Inc."

 

 

 

3. The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted in favor of the amendment is:

 

95.8%

 

4. Effective date and time of filing: (optional)

Date:

 

 

 

Time:

 

 

(must not be later than 90 days after the certificate is filed)

  

5. Signature: (required)

  

X /s/ Brandon Romanek                                                            

Signature of Officer

 

*If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.

 

IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

 

This form must be accompanied by appropriate fees.

 

 

 

Nevada Secretary of State Amend Profit-After

Revised: 1-5-15

 

 

Reset

 

 

 

 
 
 
 

 

 

 

 

EXHIBIT 3.5

 

BARBARA K. CEGAVSKE

Secretary of State

202 North Carson Street

Carson City, Nevada 89701-4201

(775) 684-5708

Website: www.nvsos.gov

  

 

Certificate of Designation

(PURSUANT TO NRS 78.1955)

 

 

 

 

USE BLACK INK ONLY - DO NOT HIGHLIGHT

ABOVE SPACE IS FOR OFFICE USE ONLY

 

Certificate of Designation For

Nevada Profit Corporations

(Pursuant to NRS 78.1955)

 

1. Name of corporation:

THC Therapeutics, Inc.

 

 

2. By resolution of the board of directors pursuant to a provision in the articles of incorporation this certificate establishes the following regarding the voting powers, designations, preferences, limitations, restrictions and relative rights of the following class or series of stock.

 

SERIES A PREFERRED STOCK

 

RESOLVED, that pursuant to the authority granted to and vested in the Board by the provisions of the articles of incorporation of the Company (the "Articles of Incorporation"), there hereby is created, out of the ten million (10,000,000) shares of preferred stock, par value $.001 per share, of the Company authorized by the Articles of Incorporation (“Preferred Stock”), a series of Series A Preferred Stock, consisting of three million (3,000,000) shares, which series shall have the following powers, designations, preferences and relative participating, optional and other special rights, and the following qualifications, limitations and restrictions:

 

SEE ATTACHED

 

   
 

3. Effective date of filing: (optional)

 

 

(must not be later than 90 days after the certificate is filed)

 

4. Signature: (required)

 

X /s/ Brandon Romanek                                                                       

Signature of Officer

 

Filing Fee: $175.00

 

IMPORTANT: 
Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

 

This form must be accompanied by appropriate fees.

PRINT

Nevada Secretary of State Stock Designation

Revised: 1-5-15

    

 
 
 

______________________________________

 

CERTIFICATE OF DESIGNATION

 

OF

 

THC THERAPEUTICS, INC.

 

Pursuant to Section 78.1955 of the

 

Nevada Revised Statutes

______________________________________

 

SERIES A PREFERRED STOCK

 

On behalf of THC Therapeutics, Inc., a Nevada corporation (the “Company”), the undersigned hereby certifies that the following resolution has been duly adopted by the board of directors of the Company (the “Board”):

 

RESOLVED, that, pursuant to the authority granted to and vested in the Board by the provisions of the articles of incorporation of the Company (the “Articles of Incorporation”), there hereby is created, out of the ten million (10,000,000) shares of preferred stock, par value $.001 per share, of the Company authorized by the Articles of Incorporation (“Preferred Stock”), a series of Series A Preferred Stock, consisting of three million (3,000,000) shares, which series shall have the following powers, designations, preferences and relative participating, optional and other special rights, and the following qualifications, limitations and restrictions:

 

The specific powers, preferences, rights and limitations of the Series A Preferred Stock are as follows:

 

1. Designation; Rank. This series of Preferred Stock shall be designated and known as “Series A Preferred Stock.” The number of shares constituting the Series A Preferred Stock shall be three million (3,000,000) shares. Except as otherwise provided herein, the Series A Preferred Stock shall, with respect to rights on liquidation, winding up and dissolution, rank pari passu to the common stock, par value $0.001 per share (the “Common Stock”) and any previously issued classes of capital stock of the Company.

 

2. Dividends. The holders of shares of Series A Preferred Stock have no dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds legally available for that purpose.

 

3. Liquidation Preference.

 

(a) In the event of any dissolution, liquidation or winding up of the Company (a “Liquidation”), whether voluntary or involuntary, the Holders of Series Preferred Stock shall be entitled to participate in any distribution out of the assets of the Company on an equal basis per share with the holders of the Common Stock. For the purposes of such distribution, Holders of Series A Preferred Stock shall be treated as if all shares of Series A Preferred Stock had been converted to Common Stock immediately prior to the distribution.

 

(b) A sale of all or substantially all of the Company’s assets or an acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, a reorganization, consolidated or merger) that results in the transfer of fifty percent (50%) or more of the outstanding voting power of the Company (a “Change in Control Event”), shall not be deemed to be a Liquidation for purposes of this Designation.

 

 
1
 
 

 

4.  Optional Conversion of Series A Preferred Stock . The Holders of Series A Preferred Stock shall have conversion rights as follows:

 

(a)  Conversion Right . Each share of Series A Preferred Stock shall be convertible at the option of the Holder thereof and without the payment of additional consideration by the Holder thereof, at any time, into shares of Common Stock on the Optional Conversion Date (as hereinafter defined) at a conversion rate of one hundred (100) shares of Common Stock (the “ Conversion Rate ”) for every one (1) share of Series A Preferred Stock.

 

(b)  Mechanics of Optional Conversion . To effect the optional conversion of shares of Series A Preferred Stock in accordance with Section 4(a) of this Designation, any Holder of record shall make a written demand for such conversion (for purposes of this Designation, a “ Conversion Demand ”) upon the Company at its principal executive offices setting forth therein (i) the certificate or certificates representing such shares, and the proposed date of such conversion (for purposes of this Designation, the “ Optional Conversion Date ”). Upon receipt of the Conversion Demand, the Company shall give written notice (for purposes of this Designation, a “ Conversion Notice ”) to the Holder setting forth therein (i) the address of the place or places at which the certificate or certificates representing any shares not yet tendered are to be converted are to be surrendered; and (ii) whether the certificate or certificates to be surrendered are required to be endorsed for transfer or accompanied by a duly executed stock power or other appropriate instrument of assignment and, if so, the form of such endorsement or power or other instrument of assignment. The Conversion Notice shall be sent by first class mail, postage prepaid, to such Holder at such Holder’s address as may be set forth in the Conversion Demand or, if not set forth therein, as it appears on the records of the stock transfer agent for the Series A Preferred Stock, if any, or, if none, of the Company. On or before the Optional Conversion Date, each Holder of the Series A Preferred Stock so to be converted shall surrender the certificate or certificates representing such shares, duly endorsed for transfer or accompanied by a duly executed stock power or other instrument of assignment, if the Conversion Notice so provides, to the Company at any place set forth in such notice or, if no such place is so set forth, at the principal executive offices of the Company. As soon as practicable after the Optional Conversion Date and the surrender of the certificate or certificates representing such shares, the Company shall issue and deliver to such Holder, or its nominee, at such Holder’s address as it appears on the records of the stock transfer agent for the Series A Preferred Stock, if any, or, if none, of the Company, a certificate or certificates for the number of whole shares of Common Stock issuable upon such conversion in accordance with the provisions hereof.

 

(c)  No Fractional Shares . No fractional shares of Common Stock or scrip shall be issued upon conversion of shares of Series A Preferred Stock. In lieu of any fractional share to which the Holder would be entitled but for the provisions of this Section 4(c) based on the number of shares of Series A Preferred Stock held by such Holder, the Company shall issue a number of shares to such Holder rounded up to the nearest whole number of shares of Common Stock. No cash shall be paid to any Holder of Series A Preferred Stock by the Company upon conversion of Series A Preferred Stock by such Holder.

 

(d)  Reservation of Stock . The Company shall at all times when any shares of Series A Preferred Stock shall be outstanding, reserve and keep available out of its authorized but unissued Common Stock, such number of shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding shares of Series A Preferred Stock. If at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all outstanding shares of the Series A Preferred Stock, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purpose.

 

(d)  Issue Taxes . The converting Holder shall pay any and all issue and other non-income taxes that may be payable in respect of any issue or delivery of shares of Common Stock on conversion of shares of Series A Preferred Stock.

 

5. Voting . The holders of Series A Preferred Stock shall have the right to cast one hundred (100) votes for every one (1) share of Series A Preferred Stock held on all matters submitted to a vote of holders of the Company’s common stock, including the election of directors, and all other matters as required by law. There is no right to cumulative voting in the election of directors. The holders of Series A Preferred Stock shall vote together with all other classes and series of common stock of the Company as a single class on all actions to be taken by the common stock holders of the Company except to the extent that voting as a separate class or series is required by law.

 

 
2
 
 

  

IN WITNESS WHEREOF the undersigned has signed this Designation this 20 th day of January, 2017.

 

 

 

THC Therapeutics, Inc.

 

 

 

By:  

/s/ Brandon Romanek

 

Name: 

Brandon Romanek

 

 

Title:

CEO

 

 

 

 

3

 

EXHIBIT 3.6

  

BARBARA K. CEGAVSKE

Secretary of State

202 North Carson Street

Carson City, Nevada 89701-4201

(775) 684-5708

Website: www.nvsos.gov

*150103*

 

 

 

 

 

 

Certificate of Designation

(PURSUANT TO NRS 78.1955)

 

 

 

 

USE BLACK INK ONLY - DO NOT HIGHLIGHT

ABOVE SPACE IS FOR OFFICE USE ONLY

 

Certificate of Designation For

Nevada Profit Corporations

(Pursuant to NRS 78.1955)

 

1. Name of corporation:

THC Therapeutics, Inc.

 

 

2. By resolution of the board of directors pursuant to a provision in the articles of incorporation this certificate establishes the following regarding the voting powers, designations, preferences, limitations, restrictions and relative rights of the following class or series of stock.

 

SERIES B PREFERRED STOCK

 

RESOLVED, that pursuant to the authority granted to and vested in the Board by the provisions of the articles of incorporation of the Company (the "Articles of Incorporation"), there hereby is created, out of the ten million (10,000,000) shares of preferred stock, par value $.001 per share, of the Company authorized by the Articles of Incorporation (“Preferred Stock”), a series of Series B Preferred Stock, consisting of one hundred twenty thousand (120,000) shares, which series shall have the following powers, designations, preferences and relative participating, optional and other special rights, and the following qualifications, limitations and restrictions:

 

SEE ATTACHED

 

  

3. Effective date of filing: (optional)

 

 

(must not be later than 90 days after the certificate is filed)

 

4. Signature: (required)

 

X /s/ Brandon Romanek                                                                       

Signature of Officer

 

Filing Fee: $175.00

 

IMPORTANT: 
Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

 

This form must be accompanied by appropriate fees.

PRINT

Nevada Secretary of State Stock Designation

Revised: 1-5-15

   
 
 
 
 

 

______________________________________

 

CERTIFICATE OF DESIGNATION

 

OF

 

THC THERAPEUTICS, INC.

 

Pursuant to Section 78.1955 of the

 

Nevada Revised Statutes

______________________________________

 

SERIES B PREFERRED STOCK

 

On behalf of THC Therapeutics, Inc., a Nevada corporation (the “ Company ”), the undersigned hereby certifies that the following resolution has been duly adopted by the board of directors of the Company (the “ Board ”):

 

RESOLVED, that, pursuant to the authority granted to and vested in the Board by the provisions of the articles of incorporation of the Company (the “ Articles of Incorporation ”), there hereby is created, out of the ten million (10,000,000) shares of preferred stock, par value $.001 per share, of the Company authorized by the Articles of Incorporation (“ Preferred Stock ”), a series of Series B Preferred Stock, consisting of one hundred twenty thousand (120,000) shares, which series shall have the following powers, designations, preferences and relative participating, optional and other special rights, and the following qualifications, limitations and restrictions:

 

The specific powers, preferences, rights and limitations of the Series B Preferred Stock are as follows:

 

1.  Designation; Rank . This series of Preferred Stock shall be designated and known as “Series B Preferred Stock.” The number of shares constituting the Series B Preferred Stock shall be 120,000 shares. Except as otherwise provided herein, the Series B Preferred Stock shall, with respect to rights on liquidation, winding up and dissolution, rank senior to the common stock, par value $0.001 per share (the “ Common Stock ”) and any previously issued classes of capital stock of the Company (the “ Junior Securities ”).

 

2.  Dividends . The holders of shares of Series B Preferred Stock have no dividend rights except as may be declared by the Board in its sole and absolute discretion, out of funds legally available for that purpose.

 

3.  Liquidation Preference .

 

(a) In the event of any dissolution, liquidation or winding up of the Company (a “ Liquidation ”), whether voluntary or involuntary, the Holders of Series Preferred Stock shall be entitled to receive out of the assets of the Company, before any payment or distribution shall be made in respect of any Junior Securities, cash in an amount equal to $1.00 (the " Stated Value ") for each one (1) share of Series B Convertible Preferred Stock plus an amount equal to all accrued but unpaid dividends thereon to the date of such payment. If upon the Liquidation, the assets to be distributed among the Holders of the Series B Convertible Preferred Stock are insufficient to permit the payment to such Holders of the full liquidation preference for their shares, then the entire assets of the Company legally available for distribution shall be distributed pro rata among the Holders of the Series B Convertible Preferred Stock.

 

 

1

 
 

  

(b) A sale of all or substantially all of the Company’s assets or an acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, a reorganization, consolidated or merger) that results in the transfer of fifty percent (50%) or more of the outstanding voting power of the Company (a “ Change in Control Event ”), shall not be deemed to be a Liquidation for purposes of this Designation.

 

(c) If upon any Liquidation, whether voluntary or involuntary, payment shall have been made to the Holders of Series B Convertible Preferred Stock of the full preferential amount to which they shall be entitled pursuant to Section 3(a) of this Designation, the entire remaining assets, if any, of the Company available for distribution to stockholders shall be distributed to the holders of Junior Securities or Common Stock, as the case may be.

 

(d) The Company shall give each Holder of Series B Preferred Convertible Stock written notice of any Liquidation not later than thirty (30) days prior to any meeting of stockholders to approve such Liquidation or, if no meeting is to be held, not later than forty-five (45) days prior to the date of such Liquidation.

 

4.  Mandatory Conversion of Series B Preferred Stock .

 

(a)  Mandatory Conversion: Conversion Rate . All shares of Series B Convertible Preferred Stock shall, on that date which is one ()) year from the date of issuance (the " Conversion Date "), be automatically converted to Common Stock of the Company at the Conversion Rate. The Conversion Rate, for each share of Series B Preferred Stock, shall be the Stated Value of $1.00 per share divided by the Market Price for the Company's Common Stock. " Market Price " means the Trading Price for the Company's common stock on the last Trading Day prior to the Conversion Date. " Trading Price " means the closing bid price reported on the electronic marketplace operated by OTC Markets, Inc., or, if the electronic marketplace operated by OTC Markets, Inc. is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Holder. " Trading Day " shall mean any day on which the Company's common stock is tradable for any period on the electronic marketplace operated by OTC Markets, Inc., or on the principal securities exchange or other securities market on which the Company's common stock is then being traded.

 

(b)  No Fractional Shares . No fractional shares of Common Stock or scrip shall be issued upon conversion of shares of Series B Preferred Stock. In lieu of any fractional share to which the Holder would be entitled but for the provisions of this Section 4(b) based on the number of shares of Series B Preferred Stock held by such Holder, the Company shall issue a number of shares to such Holder rounded up to the nearest whole number of shares of Common Stock. No cash shall be paid to any Holder of Series B Preferred Stock by the Company upon conversion of Series B Preferred Stock by such Holder.

 

(c)  Reservation of Stock . The Company shall at all times when any shares of Series B Preferred Stock shall be outstanding, reserve and keep available out of its authorized but unissued Common Stock, such number of shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding shares of Series B Preferred Stock. If at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all outstanding shares of the Series B Preferred Stock, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purpose.

 

(d)  Issue Taxes . The converting Holder shall pay any and all issue and other non-income taxes that may be payable in respect of any issue or delivery of shares of Common Stock on conversion of shares of Series B Preferred Stock.

 

5. Voting . Except as otherwise expressly provided herein or as required by the law, the Holders of Series B Preferred Stock shall not have voting rights.

 

 

2

 
 

  

IN WITNESS WHEREOF the undersigned has signed this Designation this 12 th day of May, 2017.

 

 

  THC Therapeutics, Inc.
       
By: /s/ Brandon Romanek

 

Name: 

Brandon Romanek  
  Title:  CEO  

 

 

3

 

EXHIBIT 3.7

 

BARBARA K. CEGAVSKE

Secretary of State

202 North Carson Street

Carson City, Nevada 89701-4201

(775) 684-5708

Website: www.nvsos.gov

*150103*

 

 

 

 

 

Amendment to

Certificate of Designation

After Issuance of Class or Series

(PURSUANT TO NRS 78.1955)

 

 

USE BLACK INK ONLY - DO NOT HIGHLIGHT

ABOVE SPACE IS FOR OFFICE USE ONLY

 

Certificate of Amendment to Certificate of Designation
For Nevada Profit Corporations
(Pursuant to NRS 78.1955 - After Issuance of Class or Series)

 

1. Name of corporation:

THC Therapeutics, Inc.

 

 

2. Stockholder approval pursuant to statute has been obtained.

 

3. The class or series of stock being amended:

 

Series B Preferred Stock

 

 

  

4. By a resolution adopted by the board of directors, the certificate of designation is being amended as follows or the new class or series is:

 

Section 1 of the Certificate of Designation is hereby amended to increase the total number of authorized shares of Series B Preferred Stock to 165,000 shares.

 

 

  

5. Effective date of filing: (optional)

 

 

(must not be later than 90 days after the certificate is filed)

 

6. Signature: (required)

 

X /s/ Brandon Romanek                                                                       

Signature of Officer

 

Filing Fee: $175.00

 

IMPORTANT: 
Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

 

This form must be accompanied by appropriate fees.

Reset

Nevada Secretary of State NRS Amend Designation - After

Revised: 1-5-15

  

 

 

EXHIBIT 3.8

 

 

 

 *090204*

  

BARBARA K. CEGAVSKE

Secretary of State

202 North Carson Street

Carson City, Nevada 89701-4201

(775) 684-5708

Website: www.nvsos.gov

           

 

Certificate of Amendment

(PURSUANT TO NRS 78.385 AND 78.390)

 

USE BLACK INK ONLY - DO NOT HIGHLIGHT

ABOVE SPACE IS FOR OFFICE USE ONLY

 

Certificate of Amendment to Articles of Incorporation

For Nevada Profit Corporations

(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)

 

1.  Name of corporation:

Millennium BlockChain Inc.

  

2. The articles have been amended as follows: (provide article numbers, if available)

Article I of the corporation's Articles of Incorporation is hereby amended to change the name of the corporation to "THC Therapeutics, Inc."

 

 

      

3. The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted in favor of the amendment is:

 

92.5%

    

4. Effective date and time of filing:   (optional)      Date:

 Time:

 

 

 

(must not be later than 90 days after the certificate is filed)

    

5. Signature: (required)

 

 

X /s/ Brandon Romanek                                       

Signature of Officer

 

*If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.

 

IMPORTANT: Failure to include any of the above information and submit with the proper fees may cause this filing to be rejected.

 

This form must be accompanied by appropriate fees.

Nevada Secretary of State Amend Profit-After

 

Revised: 1-5-15

 

 

Reset

 

EXHIBIT 10.1

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 
 
 

 

 

 

 

 
 
 

 

 

 
 
 

 

 

 
 

 

EXHIBIT 10.2

 

ASSET PURCHASE AGREEMENT

 

This ASSET PURCHASE AGREEMENT dated June 1, 2017 (this “Agreement”), is by and among: GENESIS FLOAT SPA, LLC, a Nevada limited liability company (the “Purchaser”); THC THERAPEUTICS, INC., a Nevada corporation, the sole member and parent company of the Purchaser (the “Parent”); URBAN OASIS FLOAT CENTER, LLC, a Nevada limited liability company (the “Seller”); and the members of the Seller, AMANDA ESCAMILLA, CARLOS ESCAMILLA, JR., and DANIEL WILLIAM

JONES (each a “ Member ” and all, collectively, the “ Members ”).

 

RECITALS

 

WHEREAS, the Purchaser desires to purchase from the Seller and the Seller desires to sell to the Purchaser all of Seller’s rights, title and interest in and to the Assets (as hereinafter defined), all upon the terms and conditions set forth in this Agreement.

 

NOW, THEREFORE, in consideration of the representations, warranties and covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

ARTICLE I

CERTAIN DEFINITIONS

 

1.1 CERTAIN DEFINITIONS.

 

(a) The following terms, when used in this Agreement, shall have the respective meanings ascribed to them below:

 

“ACTION” means any claim, action, suit, inquiry, hearing, investigation or other proceeding.

 

“AFFILIATE” means, with respect to a Person, any other Person that, directly or indirectly, through one or more intermediaries, Controls, is controlled by or is under common Control with, such Person. For purposes of this definition, “CONTROL” (including, with correlative meanings, the terms “Controlled by” and “under common Control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of stock, as trustee or executor, by Contract or credit arrangement or otherwise.

 

“AGREEMENT” has the meaning set forth in the preamble hereto.

 
 
1
 
 

 

“ANCILLARY AGREEMENTS” means each of: (i) the Secured Promissory Note attached as Exhibit A hereto; (ii) the Certificate of Designation for the Parent’s Series B Preferred Stock attached as Exhibit B hereto; (iii) the Parent Warrants attached as Exhibit C hereto; and (iv) the Bill of Sale attached as Exhibit D hereto.

 

“ASSETS” has the meaning set forth in Section 2.1.

 

“BILL OF SALE” has the meaning set forth in Section 3.2(b).

 

“CLAIM NOTICE” means written notification pursuant to Section 7.2(a) of a Third-Party Claim as to which indemnity under Section 7.1 is sought by an Indemnified Party, enclosing a copy of all papers served, if any, and specifying the nature of and basis for such Third-Party Claim and for the Indemnified Party’s claim against the Indemnifying Party under Section 7.1, together with the amount or, if not then reasonably ascertainable, the estimated amount, determined in good faith, of the Indemnified Party’s Losses in respect of such Third-Party Claim.

 

“CLOSING” has the meaning set forth in Section 3.1. “CLOSING DATE” has the meaning set forth in Section 3.1.

 

“CONTRACT” means any agreement, lease, debenture, note, bond, evidence of Indebtedness, mortgage, indenture, security agreement, option or other contract or commitment (whether written or oral).

 

“DISPUTE NOTICE” means a written notice provided by any party against which indemnification is sought under this Agreement to the effect that such party disputes its indemnification obligation under this Agreement.

 

“DISPUTE PERIOD” means the period ending thirty calendar days following receipt by an Indemnifying Party of either a Claim Notice or an Indemnity Notice.

 

“GAAP” means United States generally accepted accounting principles as in effect from time to time, consistently applied throughout the specified period and all prior comparable periods.

 

“GOVERNMENTAL ENTITY” means any government or political subdivision thereof, whether foreign or domestic, federal, state, provincial, county, local, municipal or regional, or any other governmental entity, any agency, authority, department, division or instrumentality of any such government, political subdivision or other governmental entity, any court, arbitral tribunal or arbitrator, and any nongovernmental regulating body, to the extent that the rules, regulations or orders of such body have the force of Law.

 

 
2
 
 

 

“INDEBTEDNESS” means, as to any Person: (i) all obligations, whether or not contingent, of such Person for borrowed money (including, without limitation, reimbursement and all other obligations with respect to surety bonds, letters of credit and bankers’ acceptances, whether or not matured), (ii) all obligations of such Person evidenced by notes, bonds, debentures, capitalized leases or similar instruments, (iii) all obligations of such Person representing the balance of deferred purchase price of property or services, (iv) all interest rate and currency swaps, caps, collars and similar agreements or hedging devices under which payments are obligated to be made by such Person, whether periodically or upon the happening of a contingency, (v) all indebtedness created or arising under any conditional sale or other title retention Contract with respect to property acquired by such Person (even though the rights and remedies of the seller or lender under such Contract in the event of default are limited to repossession or sale of such property), (vi) all indebtedness secured by any Lien on any property or asset owned or held by such Person regardless of whether the indebtedness secured thereby shall have been assumed by such Person or is non-recourse to the credit of such Person, and (vii) all indebtedness referred to in clauses (i) through (vi) above of any other Person that is guaranteed, directly or indirectly, by such Person.

 

“INDEMNIFIED PARTY” means any Person claiming indemnification under any provision of Article VII.

 

“INDEMNIFYING PARTY” means any Person against whom a claim for indemnification is being asserted under any provision of Article VII.

 

“INDEMNITY NOTICE” means written notification pursuant to Section 7.2(b) of a claim for indemnification under Article VII by an Indemnified Party, specifying the nature of and basis for such claim, together with the amount or, if not then reasonably ascertainable, the estimated amount, determined in good faith, of the Indemnified Party’s Losses in respect of such claim.

 

“INTELLECTUAL PROPERTY” means: all (i) discoveries and inventions (whether patentable or unpatentable and whether or not reduced to practice), all improvements thereto, and all United States, international, and foreign patents, patent applications (either filed or in preparation for filing), patent disclosures and statutory invention registrations, including all reissuances, divisions, continuations, continuations in part, extensions and reexaminations thereof, all rights therein provided by international treaties or conventions, (ii) trademarks, service marks, trade dress, logos, trade names, corporate names, and other source identifiers (whether or not registered) including all common law rights, all registrations and applications for registration (either filed or in preparation for filing) thereof, all rights therein provided by international treaties or conventions, and all renewals of any of the foregoing, (iii) all copyrightable works and copyrights (whether or not registered), all registrations and applications for registration thereof, all rights therein provided by international treaties or conventions, and all data and documentation relating thereto, (iv) confidential and proprietary information, trade secrets, know-how (whether patentable or nonpatentable and whether or not reduced to practice), processes and techniques, research and development information including patent and/or copyright searches conducted by Seller and/or any third party, ideas, technical data, designs, drawings and specifications, (v) software, (vi) coded values, formats, data and historical or current databases, whether or not copyrightable, (vii) domain names, Internet websites or identities used or held for use by the Seller, (viii) other proprietary rights relating to any of the foregoing (including without limitation any and all associated goodwill and remedies against infringements thereof and rights of protection of an interest therein under the laws of all jurisdictions), and (ix) copies and tangible embodiments of any of the foregoing.

 
 
3
 
 

 

“KNOWLEDGE” means the actual or constructive knowledge after due inquiry of any Member or any current officer or manager of the Seller.

 

“LAWS” means all laws, statutes, rules, regulations, ordinances and other pronouncements having the effect of law of the United States, any foreign country or any domestic or foreign state, county, city or other political subdivision or of any Governmental Entity.

 

“LIABILITY” means all Indebtedness, obligations and other Liabilities of a Person, whether absolute, accrued, contingent, fixed or otherwise, and whether due or to become due (including for Taxes).

 

“LIEN” means any mortgage, pledge, assessment, security interest, lease, lien, adverse claim, levy, charge or other encumbrance of any kind, whether voluntary or involuntary (including any conditional sale Contract, title retention Contract or Contract committing to grant any of the foregoing).

 

“LOSS” means any and all damages, fines, fees, penalties, deficiencies, losses and expenses (including, without limitation, all interest, court costs, fees and expenses of attorneys, accountants and other experts or other expenses of litigation or other proceedings or of any claim, default or assessment).

 

“MATERIAL ADVERSE EFFECT” means any material adverse effect on the condition, operations, business, prospects or results of sales of the Seller; PROVIDED, HOWEVER, that any adverse effect arising out of or resulting from the entering into of this Agreement or the consummation of the transactions contemplated hereby, shall be excluded in determining whether a Material Adverse Effect has occurred.

 

“ORDER” means any writ, judgment, decree, injunction or similar order of any Governmental Entity (in each case whether preliminary or final).

 
 
4
 
 

 

“PERSON” means any individual, partnership, limited liability company, corporation, association, joint stock company, trust, estate, joint venture, unincorporated organization, Governmental Entity or any other entity of any kind.

 

“PRIOR SECURED NOTE” means the Promissory Note issued by the Seller on May 13, 2016 to Go Float Yourself, LLC in the original principal amount of $50,000 (the “Secured Note”), a true and correct copy of which is attached hereto as Exhibit E.

 

“PURCHASE PRICE” has the meaning set forth in Section 2.1. “PURCHASER” has the meaning set forth in the preamble hereto.

 

“RESOLUTION PERIOD” means the period ending thirty days following receipt by an Indemnified Party of a Dispute Notice.

 

“SELLER” has the meaning set forth in the preamble hereto.

 

“SOFTWARE” means all computer software, including source code, object code, machine-readable code, HTML or other markup language, program listings, comments, user interfaces, menus, buttons and icons, web applications and all files, data, manuals, design notes, research and development documents, and other items and documentation related thereto or associated therewith.

 

“SOLVENT” means, with respect to the Seller, that (a) the Seller is able to pay its Liabilities, as they mature in the normal course of business, and (b) the fair value of the assets of the Seller is greater than the total amount of Liabilities of the Seller.

 

“TAXES” means all federal, state, local and foreign income, profits, franchise, license, social security, transfer, registration, estimated, gross receipts, environmental, customs duty, capital stock, severance, stamp, payroll, sales, employment, unemployment, disability, use, property, withholding, excise, production, value added, occupancy and other taxes, duties or assessments of any nature whatsoever together with all interest, penalties, fines and additions to tax imposed with respect to such amounts and any interest in respect of such penalties and additions to tax.

 

“THIRD-PARTY CLAIM” has the meaning set forth in Section 7.2(a).

 

 “TRADEMARK ASSIGNMENT” has the meaning set forth in Section 3.2(c).

 

 “TRANSFER TAXES” means all sales, use, value added, excise, registration, documentary, stamps, transfer, real property transfer, recording, gains, stock transfer and other similar Taxes and fees.

 
 
5
 
 

 

(b) For purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires: (i) words using the singular or plural number also include the plural or singular number, respectively, and the use of any gender herein shall be deemed to include the other genders; (ii) references herein to “Articles”, “Sections”, “subsections” and other subdivisions without reference to a document are to the specified Articles, Sections, subsections and other subdivisions of this Agreement; (iii) a reference to a subsection without further reference to a Section is a reference to such subsection as contained in the same Section in which the reference appears, and this rule shall also apply to other subdivisions within a Section or subsection; (iv) the words “herein”, “hereof”, “hereunder”, “hereby” and other words of similar import refer to this Agreement as a whole and not to any particular provision; and (v) the words “include”, “includes” and “including” are deemed to be followed by the phrase “without limitation”. All accounting terms used herein and not expressly defined herein shall have the meanings given to them under GAAP.

 

1.2 MEMBERSHIP PURCHASE AGREEMENT CANCELLED AND REPLACED.

 

The Membership Purchase Agreement previously executed by the Seller, the Members, and the Parent, dated May 12, 2017, is hereby cancelled and rescinded by the agreement of all parties thereto, and shall be deemed to be of no legal effect. In place and instead of the transaction described thereunder, the parties enter into this Asset Purchase Agreement effective as of May 12, 2017. The Secured Promissory Note, shares of Series B Preferred Stock, and Parent Warrants issued by the Parent, and the cash paid by the Parent, under the terms of such prior agreement shall be accepted by the Seller and the Members as payment of the Purchase Price under this Asset Purchase Agreement as described in Section 2.1, below.

 

ARTICLE II

PURCHASE AND SALE OF ASSETS

 

2.1 PURCHASE AND SALE OF ASSETS.

 

(a) At the Closing, as hereinafter defined, Purchaser and the Parent shall pay Seller and the Members for the Assets (the “PURCHASE PRICE”) as follows:

 

i. Payment of Cash in the total amount of $20,000, to be paid to the Members as follows:

 

Amanda Escamilla and Carlos Escamilla, Jr. (jointly) – $10,200 Daniel William Jones – $9,800

 

The Members acknowledge their prior receipt of such cash payments.

 
 
6
 
 

 

ii. Issuance of a Secured Promissory Note in the principal amount of $60,000, to be issued by the Parent and payable jointly to the Members (the “Parent Note”), in the form attached hereto as Exhibit A . The Members acknowledge the Parent’s issuance and their receipt of the Secured Promissory Note on May 12, 2017.

 

iii. Issuance of One hundred twenty thousand (120,000) shares of the Parent’s Series B Preferred Stock, stated value $1.00 per share (the “Parent Preferred Shares”), to be issued as follows:

 

Amanda Escamilla and Carlos Escamilla, Jr. (jointly) – 61,200 shares Daniel William Jones – 58,800 shares

 

The Members acknowledge the Parent’s prior issuance of the Parent Preferred Shares to them on May 12, 2017.

 

The rights, preferences, privileges, qualifications, limitations and restrictions of the Parent Preferred Shares shall be as set forth in the Certificate of Designation included as Exhibit B hereto. The Certificate of Designation has been filed with the Nevada Secretary of State. The Seller and the Members acknowledge and agree that such Certificate of Designation may be later amended by the Board of Directors of the Parent to increase the number of authorized Series B Preferred Shares, with such additional authorized preferred shares to be issued by the Parent in settlement of certain secured debt encumbering the Assets.

 

iv. Issuance of Warrants to purchase twenty-five thousand (25,000) shares of the Parent’s common stock at an exercise price of $2.00 per share, exercisable for a period of three (3) years from the date of issue (the “Parent Warrants”). The Parent Warrants shall be issued to the Members, in the form attached as Exhibit C hereto, as follows:

 

Amanda Escamilla and Carlos Escamilla, Jr. (jointly) – 12,750 warrants Daniel William Jones – 12,250 warrants

 

The Members acknowledge the Parent’s prior issuance of the Parent Warrants to them on May 12, 2017.

 
 
7
 
 

 

(b) In consideration of the payment by the Purchaser and the Parent of the PURCHASE PRICE, the Seller hereby agrees to sell, convey, transfer, assign, grant and deliver to the Purchaser, and the Purchaser hereby agrees to purchase, acquire and accept from the Seller, at the Closing, all of the Seller’s right, title and interest in and to all of the Assets, free and clear of all Liens, with the sole exception of the Prior Secured Note. The term “ASSETS” means the following assets of Seller only: four float pods and related equipment, Seller’s client list, and general intangibles relating to such client list. For clarity, Seller shall retain and is not selling to Purchaser any other assets of Seller related in any way to the ownership and operation of the “Go Float Yourself” floatation therapy center located at 4500 East Sunset Road in Henderson, Nevada (the “Business”), including (a) the inventory on hand, furniture, fixtures, equipment (other than that equipment included in the Assets being sold to Purchaser) and other tangible assets related to the Business; (b) all trade names, common law trademarks, domain names, websites, ecommerce sites, Twitter, Facebook and all other social media sites of any nature relating to the Business;

 

(c) all rights under any contracts to which Seller is bound; and (d) all general intangibles relating or associated with the operation of the Business; and all goodwill generated by, and associated with, the Business (other than general intangibles related to the client list included in the Assets being sold to Purchaser).

 

2.2 ASSUMPTION OF LIABILITIES. For greater certainty, the Purchaser and the Parent assume no Liabilities relating to the Assets, the Members, or the Seller or the Seller’s business (including Tax Liabilities).

 

ARTICLE III

THE CLOSING

 

3.1 CLOSING. The closing of the transactions contemplated hereby (the “CLOSING”) shall take place upon the Parties’ execution of this Agreement, or on such other date as the parties hereto may mutually determine in writing (the “CLOSING DATE”).

 

3.2 DELIVERY OF ITEMS BY THE SELLER. The Seller shall deliver to the Purchaser at the Closing the items listed below:

 

(a) a Bill of Sale and General Assignment for the Assets, duly executed by the Seller, in the form attached hereto as EXHIBIT D (the “BILL OF SALE”); and

 

(b) such other documents and instruments as the Purchaser may reasonably request.

 
 
8
 
 

 

3.3 DELIVERY OF ITEMS BY THE PURCHASER. The Purchaser shall deliver to the Seller at the Closing the items listed below:

 

(a) Cash in the amount of $20,000 to be paid as set forth above, prior payment of which is hereby acknowledged by the Seller and the Members;

 

(b) The Parent Note, the prior issuance and delivery of which is hereby acknowledged by the Seller and the Members;

 

(c) The Parent Preferred Shares, the prior issuance and delivery of which is hereby acknowledged by the Seller and the Members;

 

(d) The Parent Warrants, the prior issuance and delivery of which is hereby acknowledged by the Seller and the Members; and

 

(b) such other documents and instruments as the Seller and the Members may reasonably request.

 

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF THE SELLER AND THE MEMBERS

 

As an inducement to the Purchaser and Parent to enter into this Agreement, the Seller and the Members represent and warrant to the Purchaser and the Parent as follows:

 

4.1 AUTHORIZATION. The Seller has full power and authority to execute and deliver this Agreement and the Ancillary Agreements, as applicable, and to perform its obligations hereunder and thereunder. This Agreement and the Ancillary Agreements have been duly executed and delivered by the Seller and, assuming the due authorization, execution and delivery hereto and thereof by the Purchaser and the Parent, constitute the valid and legally binding obligations of the Seller enforceable in accordance with their respective terms. Seller is a limited liability company organized under the laws of the State of Nevada, in good standing, and has obtained all consents and other approvals necessary under Nevada law, its Articles of Organization, and its Operating Agreement necessary for the execution, delivery and performance of this Agreement and the Ancillary Agreements.

 

4.2 BROKERS’ FEES. No agent, broker, finder, investment banker, financial advisor or other similar Person will be entitled to any fee, commission or other compensation in connection with any of the transactions contemplated by this Agreement on the basis of any act or statement made or alleged to have been made by the Seller, any of its Affiliates, or any investment banker, financial advisor, attorney, accountant or other Person retained by or acting for or on behalf of the Seller or any such Affiliate.

 

4.3 NONCONTRAVENTION.

 

 
9
 
 

 

(a) Neither the execution, delivery or performance of this Agreement or the Ancillary Agreements, as applicable, nor the consummation of the transactions contemplated hereby or thereby will, with or without the giving of notice or the lapse of time or both, (i) violate any Law or Order or other restriction of any Governmental Entity to which the Seller may be subject or (ii) conflict with, result in a breach of, constitute a default under, result in the acceleration of any right or obligation under, create in any party the right to accelerate, terminate, modify, cancel, require any notice under or result in the creation of a Lien on any of the Assets under, any Contract to which the Seller is a party or by which it is bound and to which any of its Assets is subject.

 

(b) The execution and delivery of this Agreement and the Ancillary Agreements, as applicable, by the Seller do not, and the performance of this Agreement and the Ancillary Agreements by the Seller and the consummation of the transactions contemplated hereby and thereby will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Entity.

 

4.4 LITIGATION. There is no pending or, to the Knowledge of the Seller, threatened Action against or affecting the Assets. Neither the Seller nor the Assets are subject to any Order restraining, enjoining or otherwise prohibiting or making illegal any action by the Seller, this Agreement or any of the transactions contemplated hereby.

 

4.5 CONTRACTS. There are no executory Contracts (whether license agreements, development agreements or otherwise), to which any of the Assets are bound or subject (other than this Agreement).

 

4.6 INTELLECTUAL PROPERTY.

 

(a) The Seller is the sole and exclusive owner of, and has good and marketable title to, all of the Intellectual Property in and to the Assets, free and clear of all Liens, with the sole exception of the Prior Secured Note. The Seller has sole and exclusive right to develop, perform, use, create derivative works of, operate, reproduce, market, sell, license, display, distribute, publish and transmit the Intellectual Property in and to the Assets. Upon the Closing, the Purchaser will have sole and exclusive right, title and interest in and to the Intellectual Property in and to the Assets, such that the Purchaser shall thereafter have sole and exclusive rights to perform, reproduce, create derivative works of, develop, use, operate, market, sell, license, display, publish, transmit and distribute the Assets, free of all encumbrances. The Seller has taken reasonable measures to protect the proprietary nature of the Intellectual Property in and to the Assets and to maintain in confidence the trade secrets and confidential information that it owns or uses. With the sole exception of the holder of the Prior Secured Note, no other Person has any rights to any of Intellectual Property in and to the Assets and, to the knowledge of the Seller, no other Person is infringing, violating or misappropriating any of the Intellectual Property in and to the Assets.

 
 
10
 
 

 

(c) With respect to the Seller’s Intellectual Property contributed to the Assets, such Intellectual Property does not infringe upon, violate or constitute a misappropriation of any Intellectual Property or other right of any other Person. In addition, to Seller’s knowledge, none of the activities or business presently conducted by the Seller with respect to the Assets infringes or violates, or constitutes a misappropriation of, any Intellectual Property or other right of any other Person. Neither the Seller nor any Affiliate of the Seller has received any written complaint, claim or notice alleging any such infringement, violation or misappropriation. Further, neither the Seller nor any Affiliate of the Seller has disclosed to any Person, any product formula, or any portion or aspect of any product formula, which is part of the Assets, including the Intellectual Property.

 

4.7 COMPLIANCE WITH LAWS. The Seller is not in violation of, has not violated and, to the Knowledge of the Seller, is not under investigation with respect to any possible violation of, and has not been threatened to be charged with any violation of, any Order of Law applicable to the Assets.

 

4.8 TITLE TO ASSETS. Except as to Intellectual Property (which warranty is contained in Section 4.6): (i) the Seller has good and marketable title to all of the Assets free and clear of all Liens with the sole exception of the Prior Secured Note; (ii) this Agreement and the instruments of transfer to be executed and delivered pursuant hereto will effectively vest in the Purchaser good and marketable title to all of the Assets free and clear of all Liens with the sole exception of the Prior Secured Note; (iii) and no Person other than the Seller has any ownership interest in any of the Assets. Following the Closing, the Purchaser and the Parent shall arrange for satisfaction of the Prior Secured Note on such terms as they deems advisable.

 

4.9 SOLVENCY. The Seller is and, after consummation of the transactions contemplated by this Agreement, will be Solvent.

 

4.10 DISCLOSURE. The representations and warranties on the part of the Seller and the Members contained in this Agreement, and the statements contained in any of the Schedules or in any certificates furnished to the Purchaser or the Parent pursuant to any provisions of this Agreement, including pursuant to Article VI hereof, do not contain any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements herein or therein, in light of the circumstances under which they were made, not misleading.

 

4.11 ACQUISITION ENTIRELY FOR OWN ACCOUNT. The Parent Preferred Shares and the Parent Warrants proposed to be acquired by the Members hereunder will be acquired for investment for their own account, and not with a view to the resale or distribution of any part thereof, and the Members have no present intention of selling or otherwise distributing the Parent Preferred Shares or the Parent Warrants, except in compliance with applicable securities laws.

 
 
11
 
 

 

4.12 AVAILABLE INFORMATION. The Members have such knowledge and experience in financial and business matters that they are capable of evaluating the merits and risks of an investment in the Parent.

 

4.13 NON-REGISTRATION. The Members understand that the Parent Preferred Shares and the Parent Warrants have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) and, if issued in accordance with the provisions of this Agreement, will be issued by reason of a specific exemption from the registration provisions of the Securities Act that depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Members’ representations as expressed herein. The non-registration shall have no prejudice with respect to any rights, interests, benefits and entitlements attached to the Parent Preferred Shares and the Parent Warrants in accordance with the Parent charter documents or the laws of its jurisdiction of incorporation.

 

4.14 RESTRICTED SECURITIES. The Members understand that the Parent Preferred Shares and the Parent Warrants are characterized as “restricted securities” under the Securities Act inasmuch as this Agreement contemplates that, if acquired by the Members pursuant hereto, the Parent Preferred Shares and the Parent Warrants would be acquired in a transaction not involving a public offering. The Members further acknowledge that if the Parent Preferred Shares and the Parent Warrants are issued to the Members in accordance with the provisions of this Agreement, the Parent Preferred Shares and the Parent Warrants may not be resold without registration under the Securities Act or the existence of an exemption therefrom. The Members represent that they are familiar with Rule 144 promulgated under the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act.

 

4.15 LEGENDS. It is understood that the Parent Preferred Shares and the Parent Warrants will bear the following legend or another legend that is similar to the following:

 

THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.

 
 
12
 
 

 

and any legend required by the “blue sky” laws of any state to the extent such laws are applicable to the securities represented by the certificate so legended.

 

4.16 ADDITIONAL REPRESENTATIONS AND WARRANTIES OF THE MEMBERS

 

(a) The Members acknowledge that the acquisition of the Parent Preferred Shares and the Parent Warrants involves a high degree of risk in that the Parent has only recently commenced its current business operations and may require substantial additional funds;

 

(b) The Members recognize that an investment in the Parent is highly speculative and only investors who can afford the loss of their entire investment should consider investing in the Parent, the Parent Preferred Shares, and the Parent Warrants;

 

(c) The Members have such knowledge and experience in finance, securities, investments, including investment in unregistered securities, and other business matters so as to be able to protect their interests in connection with this transaction;

 

(d) The Members acknowledge that the Parent Preferred Shares and the Parent Warrants, and the shares of Parent common stock underlying such securities, are subject to significant restrictions on transfer as imposed by state and federal securities laws, including but not limited to a minimum holding period of at least one (1) year;

 

(e) The Members are not aware of any advertisement of the Parent Preferred Shares and the Parent Warrants or any general solicitation in connection with any offering of the Parent Preferred Shares and the Parent Warrants;

 

(f) The Members acknowledge review of the Parent’s Articles of Incorporation and the bylaws of the Parent, together with the opportunity and the Purchaser’s encouragement to seek the advice and consultation of independent investment, legal and tax counsel; and

 

(g) The Members acknowledge and agree that the Parent has previously made available to the Members the opportunity to ask questions of and to receive answers from representatives of the Parent concerning the Parent, the Parent Preferred Shares and the Parent Warrants, as well as to conduct whatever due diligence the Members, in their discretion, deems advisable. The Members are relying solely upon the information obtained during their due diligence investigation in making a decision to invest in the Parent, the Parent Preferred Shares and the Parent Warrants.

 
 
13
 
 

 

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF THE PURCHASER AND THE PARENT

 

As an inducement to the Seller and the Members to enter into this Agreement, the Purchaser and the Parent represent and warrant to the Seller and the Members as follows:

 

5.1 AUTHORIZATION. The Purchaser and the Parent have full power and authority to execute and deliver this Agreement and the Ancillary Agreements, as applicable, and to perform its obligations hereunder and thereunder. This Agreement and the Ancillary Agreements have been duly executed and delivered by the Purchaser and the Parent and, assuming the due authorization, execution and delivery hereof and thereof by the Seller and the Members, constitute the valid and legally binding obligations of the Purchaser and the Parent enforceable in accordance with their respective terms. Purchaser is a limited liability company organized under the laws of the State of Nevada, in good standing. Parent is a corporation organized under the laws of the State of Nevada, in good standing. Purchaser and Parent have obtained all consents and other approvals necessary under Nevada law and their respective governing documents necessary for the execution, delivery and performance of this Agreement and the Ancillary Agreements.

 

5.2 NONCONTRAVENTION.

 

(a) Neither the execution, delivery or performance of this Agreement or the Ancillary Agreements, as applicable, nor the consummation of the transactions contemplated hereby or thereby will, with or without the giving of notice or the lapse of time or both, (i) violate any Law or Order or other restriction of any Governmental Entity to which the Purchaser or Parent may be subject.

 

(b) The execution and delivery of this Agreement and the Ancillary Agreements, as applicable, by the Purchaser and the Parent does not, and the performance of this Agreement and the Ancillary Agreements by the Purchaser and the Parent and the consummation of the transactions contemplated hereby and thereby will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Entity.

 

5.3 BROKERS’ FEES. No agent, broker, finder, investment banker, financial advisor or other similar Person will be entitled to any fee, commission or other compensation in connection with any of the transactions contemplated by this Agreement on the basis of any act or statement made or alleged to have been made by the Purchaser and the Parent, any of their Affiliates, or any investment banker, financial advisor, attorney, accountant or other Person retained by or acting for or on behalf of the Purchaser or the Parent or any such Affiliate.

 
 
14
 
 

 

5.4 PARENT PREFERRED SHARES AND PARENT WARRANTS. Upon issue, the Parent Preferred Shares will be duly and validly issued, fully paid and non-assessable preferred stock in the capital of the Parent. Upon conversion or exercise in accordance with the terms thereof, the shares of common stock in the Parent to be issued to the Members upon conversion or exercise of the Parent Preferred Shares and the Parent Warrants shall be validly issued, fully paid, and non-assessable common stock in the capital of the Parent.

 

ARTICLE VI

CONDITIONS TO OBLIGATION TO CLOSE

 

6.1 CONDITIONS TO CLOSING BY THE PURCHASER AND THE PARENT. The obligation of the Purchaser and the Parent to effect the transactions contemplated hereby is subject to the satisfaction or waiver by the Purchaser and the Parent of the following conditions:

 

(a) The representations and warranties of the Seller and the Members set forth in this Agreement shall be true and correct in all material respects, with respect to representations and warranties not qualified by materiality, or in all respects, with respect to representations and warranties qualified by materiality, as of the date of this Agreement and as of the Closing Date as though made on and as of the Closing Date.

 

(b) The Seller shall have performed in all material respects the covenants required to be performed by it under this Agreement at or prior to the Closing Date.

 

(c) The Seller shall have executed and delivered each of the Ancillary Agreements, as applicable.

 

(d) There shall be no effective or pending Law or Order that would prohibit the Closing, and the Seller shall have obtained all necessary approvals of any Governmental Entities in connection with the transactions contemplated hereby and by the Ancillary Agreements.

 

(e) The Seller shall have delivered each of the items described in Section 3.2.

 

6.2 CONDITIONS TO CLOSING BY THE SELLER AND THE MEMBERS. The obligation of the Seller and the Members to effect the transactions contemplated hereby is subject to the satisfaction or waiver by the Seller and the Members of the following conditions:

 

(a) The representations and warranties of the Purchaser and the Parent set forth in this Agreement shall be true and correct in all material respects, with respect to representations and warranties not qualified by materiality, and in all respects, with respect to representations and warranties qualified by materiality, in each case as of the date of this Agreement and as of the Closing Date as though made on and as of the Closing Date.

 
 
15
 
 

 

(b) The Purchaser and the Parent shall have performed in all material respects the covenants required to be performed by them under this Agreement at or prior to the Closing Date.

 

(c) The Purchaser and the Parent shall have executed and delivered each of the Ancillary Agreements, as applicable.

 

(d) There shall be no effective or pending Law or Order that would prohibit the Closing, and the Purchaser and the Parent shall have obtained all necessary approvals of any Governmental Entities in connection with the transactions contemplated hereby and by the Ancillary Agreements.

 

(e) The Purchaser and the Parent shall have delivered each of the items described in Section 3.3.

 

ARTICLE VII

INDEMNIFICATION

 

7.1 INDEMNIFICATION OBLIGATIONS.

 

(a) Purchaser and the Parent shall indemnify the Members, and the Seller and its officers, directors, employees, agents and Affiliates (each, an “INDEMNIFIED PARTY”) in respect of, and hold each harmless from and against, any and all Losses suffered, incurred or sustained by it or to which it becomes subject, resulting from, arising out of or relating to (i) any misrepresentation or breach of representation or warranty on the part of the Purchaser or Parent contained in this Agreement, (ii) any nonfulfillment of or failure to perform any covenant or agreement on the part of the Purchaser or Parent contained in this Agreement, and (iii) any Liabilities related to the Assets or the Business and arising from or related to facts, circumstances, or events occurring subsequent to the Closing.

 

(b) Seller and the Members shall indemnify the Purchaser, the Parent and their officers, directors, employees, agents and Affiliates (each, an “INDEMNIFIED PARTY”) in respect of, and hold each harmless from and against, any and all Losses suffered, incurred or sustained by them or to which they becomes subject, resulting from, arising out of or relating to (i) any misrepresentation or breach of representation or warranty on the part of the Seller or the Members contained in this Agreement, (ii) any nonfulfillment of or failure to perform any covenant or agreement on the part of the Seller or the Members contained in this Agreement, and (iii) any Liabilities related to the Assets or the Business and arising from or related to facts, circumstances, or events occurring prior to the Closing.

 
 
16
 
 

 

(c) For purposes of indemnification under this Article VII only, all qualifications as to materiality and/or Material Adverse Effect contained in any representation or warranty shall be disregarded.

 

7.2 METHOD OF ASSERTING CLAIMS. Claims for indemnification by an Indemnified Party under Section 7.1 will be asserted and resolved as follows:

 

(a) THIRD-PARTY CLAIMS. In the event that any claim or demand in respect of which an Indemnified Party might seek indemnification under Section 7.1 in respect of, arising out of or involving a claim or demand made by any Person not a party to this Agreement against an Indemnified Party (a “THIRD-PARTY CLAIM”), the Indemnified Party shall deliver a Claim Notice to the either the Purchaser and Parent or the Seller and the Members, as appropriate, as the “Indemnifying Party” within sixty (60) days after receipt by such Indemnified Party of written notice of the Third Party Claim. If the Indemnified Party fails to provide the Claim Notice within such time period, the Indemnifying Party will not be obligated to indemnify the Indemnified Party with respect to such Third-Party Claim to the extent that the Indemnifying Party’s ability to defend is actually prejudiced by such failure of the Indemnified Party. The Indemnifying Party will notify the Indemnified Party as soon as practicable within the Dispute Period whether the Indemnifying Party accepts or disputes its liability to the Indemnified Party under Section 7.1 and whether the Indemnifying Party desires, at its sole cost and expense, to defend the Indemnified Party against such Third-Party Claim.

 

(i) DEFENSE BY INDEMNIFYING PARTY. If the Indemnifying Party notifies the Indemnified Party within the Dispute Period that the Indemnifying Party desires to defend the Indemnified Party with respect to the Third-Party Claim pursuant to this Section 7.2, then the Indemnifying Party will have the right to defend, with counsel reasonably satisfactory to the Indemnified Party, at the sole cost and expense of the Indemnifying Party, such Third-Party Claim by all appropriate proceedings, which proceedings will be vigorously and diligently prosecuted or defended by the Indemnifying Party to a final conclusion or will be settled at the discretion of the Indemnifying Party (but only with the consent of the Indemnified Party in its sole discretion in the case of any settlement that provides for any relief other than the payment of monetary damages or that provides for the payment of monetary damages as to which the Indemnified Party will not be indemnified in full pursuant to Section 7.1). Subject to the immediately preceding sentence, the Indemnifying Party will have full control of such defense and proceedings, including any compromise or settlement thereof; PROVIDED, HOWEVER, that the Indemnified Party may, at the cost and expense of the Indemnifying Party, at any time prior to the Indemnifying Party’s delivery of notice to assume the defense of such Third Party Claim, file any motion, answer or other pleadings or take any other action that the Indemnified Party reasonably believes to be necessary or appropriate to protect its interests. The Indemnifying Party shall not be liable to the Indemnified Party for legal expenses incurred by the Indemnified Party in connection with the defense of such Third Party Claim after the Indemnifying Party’s delivery of notice to assume the defense. In addition, if requested by the Indemnifying Party, the Indemnified Party will, at the sole cost and expense of the Indemnifying Party, provide reasonable cooperation to the Indemnifying Party in contesting any Third- Party Claim that the Indemnifying Party elects to contest.

 
 
17
 
 

 

(ii) DEFENSE BY INDEMNIFIED PARTY. If the Indemnifying Party fails to notify the Indemnified Party within the Dispute Period that the Indemnifying Party desires to assume the defense of the Third-Party Claim, or if the Indemnifying Party fails to give any notice whatsoever within the Dispute Period, then the Indemnified Party will have the right to defend, at the sole cost and expense of the Indemnifying Party, the Third-Party Claim by all appropriate proceedings, which proceedings will be prosecuted by the Indemnified Party in good faith or will be settled at the discretion of the Indemnified Party. The Indemnified Party will have full control of such defense and proceedings, including any compromise or settlement thereof; PROVIDED, HOWEVER, that if requested by the Indemnified Party, the Indemnifying Party will, at the sole cost and expense of the Indemnifying Party, provide reasonable cooperation to the Indemnified Party and its counsel in contesting any Third-Party Claim which the Indemnified Party is contesting. Notwithstanding the foregoing provisions of this Section 7.2, if the Indemnifying Party has notified the Indemnified Party within the Dispute Period that the Indemnifying Party disputes its liability hereunder to the Indemnified Party with respect to such Third-Party Claim and if such dispute is resolved in all respects in favor of the Indemnifying Party in the manner provided in clause (iii) below, the Indemnifying Party will not be required to bear the costs and expenses of the Indemnified Party’s defense pursuant to this Section 7.2 or of the Indemnifying Party’s participation therein at the Indemnified Party’s request. The Indemnifying Party may participate in, but not control, any defense or settlement controlled by the Indemnified Party pursuant to this Section 7.2, and the Indemnifying Party will bear its own costs and expenses with respect to such participation.

 

(iii) ACCEPTANCE BY INDEMNIFYING PARTY. If the Indemnifying Party notifies the Indemnified Party that it accepts its indemnification liability to the Indemnified Party with respect to the Third-Party Claim under Section 7.1, the Loss identified in the Claim Notice, as finally determined, will be conclusively deemed a liability of the Indemnifying Party under Section 7.1 and the Indemnifying Party shall pay the amount of such Loss to the Indemnified Party on demand. If the Indemnifying Party timely disputes its liability with respect to such Third-Party Claim or fails to notify the Indemnified Party within the Dispute Period whether the Indemnifying Party disputes its liability to the Indemnified Party with respect to such Third-Party Claim, the Indemnifying Party and the Indemnified Party will proceed in good faith to negotiate a resolution of such dispute, and if not resolved through negotiations with the Resolution Period, such dispute shall be resolved by litigation in a court of competent jurisdiction.

 

(b) NON-THIRD PARTY CLAIMS. In the event any Indemnified Party should have a claim under Section 7.1 against any Indemnifying Party that does not involve a Third-Party Claim, the Indemnified Party shall deliver an Indemnity Notice with reasonable promptness to the Indemnifying Party. The failure or delay by any Indemnified Party to give the Indemnity Notice shall not impair such party’s rights hereunder except to the extent that the Indemnifying Party is actually prejudiced by such failure or delay. If the Indemnifying Party notifies the Indemnified Party that it does not dispute the claim described in such Indemnity Notice within the Dispute Period, the Loss indemnified in the Indemnity Notice will be conclusively deemed a Liability of the Indemnified Party under Section 7.1 and the Indemnifying Party shall pay the amount of such Loss to the Indemnified Party on demand. If the Indemnifying Party has timely disputed its liability with respect to such claim or fails to notify the Indemnified Party within the Dispute Period whether the Indemnifying Party disputes the claim described in such Indemnity Notice, the Indemnifying Party and the Indemnified Party will proceed in good faith to negotiate a resolution of such dispute and, if not resolved through negotiations within the Resolution Period, such dispute shall be resolved by litigation in a court of competent jurisdiction.

 
 
18
 
 

 

ARTICLE VIII

POST-CLOSING COVENANTS

 

8.1 TRANSFER TAXES. Notwithstanding anything herein to the contrary, Seller shall be liable for and shall pay any Transfer Taxes or other similar tax imposed in connection with the transfer of the Assets pursuant to this Agreement. The party responsible under applicable Law for remitting any such tax shall pay and remit such tax on a timely basis and, if such party is the Purchaser, the Purchaser shall notify the Seller of the amount of such tax, and the Seller shall promptly pay to the Purchaser the amount of such tax.

 

8.2 FURTHER ACTION. From and after the Closing each of the parties hereto shall execute and deliver such documents and take such further actions as may reasonably be required to carry out the provisions of this Agreement and the Ancillary Agreements and to give effect to the transactions contemplated hereby and thereby, including to give the Purchaser effective ownership and control of the Assets.

 

ARTICLE IX

MISCELLANEOUS

 

9.1 SURVIVAL. Notwithstanding any right of the Purchaser (whether or not exercised) to investigate the affairs of the Seller or any right of any party (whether or not exercised) to investigate the accuracy of the representations and warranties of the other party contained in this Agreement or the waiver of any condition to Closing, each of the parties hereto has the right to rely fully upon the representations, warranties, covenants and agreements of the other contained in this Agreement. The representations, warranties, covenants and agreements of the parties hereto contained in this Agreement and any certificate or other document provided hereunder or thereunder will survive the Closing.

 

9.2 NO THIRD-PARTY BENEFICIARIES. The terms and provisions of this Agreement are intended solely for the benefit of the parties hereto and their respective successors and permitted assigns, and it is not the intention of the parties to confer third-party beneficiary rights, and this Agreement does not confer any such rights, upon any other Person, except for any Person entitled to indemnity under Article VII.

 
 
19
 
 

 

9.3 ENTIRE AGREEMENT. This Agreement (including the Exhibits and the Schedules hereto) constitute the entire agreement between the parties hereto with respect to the subject matter hereof and thereof and supersede any prior understandings, agreements or representations by or between the parties hereto, written or oral, with respect to such subject matter.

 

9.4 SUCCESSION AND ASSIGNMENT. This Agreement shall be binding upon and inure to the benefit of the parties named herein and their respective successors and permitted assigns. No party hereto may assign either this Agreement or any of its rights, interests or obligations hereunder without the prior written approval of the other parties hereto.

 

9.5 DRAFTING. The parties have participated jointly in the negotiation and drafting of this Agreement and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement.

 

9.6 NOTICES. All notices, requests and other communications hereunder must be in writing and will be deemed to have been duly given only if delivered personally against written receipt or by facsimile transmission or mailed (by registered or certified mail, postage prepaid, return receipt requested) or delivered by reputable overnight courier, fee prepaid, to the parties hereto at the following addresses or facsimile numbers:

 

 

IF TO PURCHASER OR

Genesis Float Spa, LLC

 

PARENT, TO:

THC Therapeutics, Inc.

 

 

11700 W Charleston Blvd #73

 

 

Las Vegas, NV 89135

 

 

Attention: Brandon Romanek

 

 

  

 

With a copy to:

Laxague Law, Inc.

Attn: Joe Laxague, Esq.

1 East Liberty, Suite 600

Reno, NV 899501

(775) 996-3283 (fax)

 

   

 

 

IF TO SELLER OR THE

Urban Oasis Float Center, LLC

 

MEMBERS, TO:

Amanda Escamilla and Carlos Escamilla, Jr.

 

 

Daniel William Jones

_______________________

 

_______________________

 

Attention: _______________

 

 
20
 
 

 

Any party hereto may change the address to which notices, requests, demands, claims and other communications hereunder are to be delivered by giving the other parties hereto notice in the manner set forth herein.

 

9.7 GOVERNING LAW. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Nevada, without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the Laws of any jurisdiction other than the State of Nevada.

 

9.8 [omitted].

 

9.9 AMENDMENTS AND WAIVERS. No amendment of any provision of this Agreement shall be valid unless such amendment is in writing and signed by each of the parties hereto. No waiver by any party hereto of any default, misrepresentation or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence. No waiver shall be valid unless such waiver is in writing and signed by the party against whom such waiver is sought to be enforced.

 

9.10 SEVERABILITY. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future Law, and if the rights or obligations of any party hereto under this Agreement will not be materially and adversely affected thereby, (a) such provision will be fully severable, (b) this Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement will remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid or unenforceable provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms of such illegal, invalid or unenforceable provision as may be possible.

 

9.11 EXPENSES. Except as otherwise expressly set forth herein or therein, each of the parties hereto will bear its own costs and expenses (including legal fees and expenses) incurred in connection with this Agreement, the Ancillary Agreements and the transactions contemplated hereby or thereby, whether or not the transactions contemplated hereby or thereby are consummated.

 

9.12 INCORPORATION OF EXHIBITS AND SCHEDULES. The Exhibits, Annexes and Schedules identified in this Agreement are incorporated herein by reference and made a part hereof. Unless otherwise specified, no information contained in any particular numbered Schedule shall be deemed to be contained in any other numbered Schedule unless explicitly included therein (by cross reference or otherwise).

 

9.13 SPECIFIC PERFORMANCE. The parties hereto agree that irreparable damage would occur in the event that any provision of this Agreement was not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof in addition to any other remedy available to them at law or equity.

 

9.14 HEADINGS. The descriptive headings contained in this Agreement are included for convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement.

 

9.15 COUNTERPARTS. This Agreement may be executed in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.

 

Remainder of page intentionally left blank; signature page follows

 

 
21
 
 

 

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the date first written above.

 

The Parent:

 

THC THERAPEUTICS, INC.
 
By: /s/ Brandon Romanek

Name:

Brandon Romanek
Title: President and CEO
 

The Purchaser:

 

GENESIS FLOAT SPA, LLC

 

By:

/s/ Brandon Romanek

Name:

Brandon Romanek

Title:

Manager

 

The Seller:

 

URBAN OAISIS FLOAT CENTER, LLC

   

By:

/s/ Carlos Escamilla, Jr.

 

 

 

Print

Name:

Carlos Escamilla, Jr.

 

Title:

 

The Members:

  

 

 

Amanda Escamilla

  

/s/ Carlos Escamilla, Jr.

 

Carlos Escamilla, Jr.

 

/s/ Daniel William Jones

 

Daniel William Jones

 

 
22
 
 

 

EXHIBIT A

 

Parent Note

 

 

 

 
23
 
 

 

EXHIBIT B

 

Certificate of Designation

 

 

 

 

 

 

 

 

 
24
 
 

 

EXHIBIT C

 

Parent Warrant

 

 

 

 

 

 

 

 
25
 
 

 

EXHIBIT D

 

Bill of Sale

 

 

 

 

 

 

 

 

 

 

 

 

 

 
26
 
 

 

EXHIBIT E

 

Prior Secured Note

 

 

 

 

 

 

 

 

 

 

 

 

27

 

EXHIBIT 10.3

 

THIS INSTRUMENT AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM.

 

BURSTIQ ANALYTICS CORPORATION

 

SAFE

(Simple Agreement for Future Equity)

 

THIS CERTIFIES THAT in exchange for consideration provided by Millennium Blockchain, Inc., a Nevada corporation (the “ Investor ”) equal to or in the amount of $2,500,000 USD (the “ Purchase Amount ”) on or about March 31, 2018 (the “ Execution Date ”), BurstIQ Analytics Corporation, a Colorado corporation (the “ Company ”), hereby issues to the Investor the right (the “ Right ”) to certain shares of the Company’s capital stock, subject to the terms set forth below.

 

1. Events

 

(a) Equity Financing . If there is an Equity Financing before the expiration or termination of this instrument, the Company will automatically issue to the Investor a number of shares of Preferred Stock sold in the Equity Financing equal to the Purchase Amount divided by the Price Per Share of the Preferred Stock.

 

In connection with the issuance of such shares of Preferred Stock to the Investor pursuant to this Section 1(a):

 

(i) The Investor will execute and deliver to the Company all transaction documents related to the Equity Financing; provided, that such documents are the same documents to be entered into with the purchasers of Preferred Stock, and provided further, that such documents have customary exceptions to any drag-along applicable to the Investor, including, without limitation, limited representations and warranties and limited liability and indemnification obligations on the part of the Investor; and

 

(ii) The Investor and the Company will execute a Pro Rata Rights Agreement, unless the Investor is already included in such rights in the transaction documents related to the Equity Financing.

 

(b) Liquidity Event . If there is a Liquidity Event before the expiration or termination of this instrument, the Investor will, at its option, either (i) receive a cash payment equal to the Purchase Amount (subject to the following paragraph) or (ii) automatically receive from the Company a number of shares of Common Stock equal to the Purchase Amount divided by the fair market value of the Common Stock at the time of the Liquidity Event (determined by reference to the purchase price payable in connection with such Liquidity Event) (the “ Liquidity Price ”), if the Investor fails to select the cash option.

 

In connection with Section (b)(i), the Purchase Amount will be due and payable by the Company to the Investor immediately prior to, or concurrent with, the consummation of the Liquidity Event. If there are not enough funds to pay the Investor and holders of other SAFEs (collectively, the “ Cash-Out Investors ”) in full, then all of the Company’s available funds will be distributed with equal priority and pro rata among the Cash-Out Investors in proportion to their Purchase Amounts, and the Cash-Out Investors will automatically receive the number of shares of Common Stock equal to the remaining unpaid Purchase Amount divided by the Liquidity Price. In connection with a Change of Control intended to qualify as a tax-free reorganization, the Company may reduce, pro rata , the Purchase Amounts payable to the Cash-Out Investors by the amount determined by its board of directors in good faith to be advisable for such Change of Control to qualify as a tax-free reorganization for U.S. federal income tax purposes, and in such case, the Cash-Out Investors will automatically receive the number of shares of Common Stock equal to the remaining unpaid Purchase Amount divided by the Liquidity Price.

 

 
1
 
 

 

(c) Dissolution Event . If there is a Dissolution Event before this instrument expires or terminates, the Company will pay an amount equal to the Purchase Amount, due and payable to the Investor immediately prior to, or concurrent with, the consummation of the Dissolution Event. The Purchase Amount will be paid prior and in preference to any Distribution of any of the assets of the Company to holders of outstanding Capital Stock by reason of their ownership thereof. If immediately prior to the consummation of the Dissolution Event, the assets of the Company legally available for distribution to the Investor and all holders of all other SAFEs (the “ Dissolving Investors ”), as determined in good faith by the Company’s board of directors, are insufficient to permit the payment to the Dissolving Investors of their respective Purchase Amounts, then the entire assets of the Company legally available for distribution will be distributed with equal priority and pro rata among the Dissolving Investors in proportion to the Purchase Amounts they would otherwise be entitled to receive pursuant to this Section 1(c).

 

(d) Termination . This instrument will expire and terminate (without relieving the Company of any obligations arising from a prior breach of or non-compliance with this instrument) upon either (i) the issuance of stock to the Investor pursuant to Section 1(a) or Section 1(b)(ii); or (ii) the payment, or setting aside for payment, of amounts due the Investor pursuant to Section 1(b)(i) or Section 1(c).

 

2. Definitions

 

Capital Stock ” means the capital stock of the Company, including, without limitation, the “ Common Stock ” and the “ Preferred Stock .”

 

Change of Control ” means (i) a transaction or series of related transactions in which any “person” or “group” (within the meaning of Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), becomes the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended), directly or indirectly, of more than 50% of the outstanding voting securities of the Company having the right to vote for the election of members of the Company’s board of directors, (ii) any reorganization, merger or consolidation of the Company, other than a transaction or series of related transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding voting securities of the Company or such other surviving or resulting entity or (iii) a sale, lease or other disposition of all or substantially all of the assets of the Company.

 

Distribution ” means the transfer to holders of Capital Stock by reason of their ownership thereof of cash or other property without consideration whether by way of dividend or otherwise, other than dividends on Common Stock payable in Common Stock, or the purchase or redemption of Capital Stock by the Company or its subsidiaries for cash or property other than: (i) repurchases of Common Stock held by employees, officers, directors or consultants of the Company or its subsidiaries pursuant to an agreement providing, as applicable, a right of first refusal or a right to repurchase shares upon termination of such service provider’s employment or services; or (ii) repurchases of Capital Stock in connection with the settlement of disputes with any stockholder.

 

 
2
 
 

 

Dissolution Event ” means (i) a voluntary termination of operations, (ii) a general assignment for the benefit of the Company’s creditors or (iii) any other liquidation, dissolution or winding up of the Company ( excluding a Liquidity Event), whether voluntary or involuntary.

 

Equity Financing ” means a bona fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company issues and sells shares of Preferred Stock at a fixed pre-money valuation with an aggregate sales price of not less than $250,000 (excluding all Subsequent Convertible Securities).

 

Initial Public Offering ” means the closing of the Company’s first firm commitment underwritten initial public offering of Common Stock pursuant to a registration statement filed under the Securities Act.

 

Liquidity Event ” means a Change of Control or an Initial Public Offering.

 

Price Per Share ” means six dollars and fifty cents, represented in US Dollars ($6.50 USD).

 

Pro Rata Rights Agreement means a written agreement between the Company and the Investor (and holders of other SAFEs, as appropriate) giving the Investor a right to purchase its pro rata share of private placements of securities by the Company occurring after the Equity Financing , subject to customary exceptions. Pro rata for purposes of the Pro Rata Rights Agreement will be calculated based on the ratio of (1) the number of shares of Capital Stock owned by the Investor immediately prior to the issuance of the securities to (2) the total number of shares of outstanding Capital Stock on a fully diluted basis, calculated as of immediately prior to the issuance of the securities.

 

SAFE ” means an instrument containing a future right to shares of Capital Stock, similar in form and content to this instrument, purchased by investors for the purpose of funding the Company’s business operations.

 

Subsequent Convertible Securities ” means convertible securities that the Company may issue after the issuance of this instrument with the principal purpose of raising capital, including but not limited to, other SAFEs, convertible debt instruments and other convertible securities. Converting Securities excludes: (i) options issued pursuant to any equity incentive or similar plan of the Company; (ii) convertible securities issued or issuable to (A) banks, equipment lessors, financial institutions or other persons engaged in the business of making loans pursuant to a debt financing or commercial leasing or (B) suppliers or third party service providers in connection with the provision of goods or services pursuant to transactions; and (iii) convertible securities issued or issuable in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships.

 

3. “ MFN Amendment Provision . If the Company issues any Subsequent Convertible Securities prior to termination of this instrument, the Company will promptly provide the Investor with written notice thereof, together with a copy of all documentation relating to such Subsequent Convertible Securities and, upon written request of the Investor, any additional information related to such Subsequent Convertible Securities as may be reasonably requested by the Investor. In the event the Investor determines that the terms of the Subsequent Convertible Securities are preferable to the terms of this instrument, the Investor will notify the Company in writing. Promptly after receipt of such written notice from the Investor, the Company agrees to amend and restate this instrument to be identical to the instrument(s) evidencing the Subsequent Convertible Securities.

 

4. Company Representations

 

(a) The Company is a corporation duly organized, validly existing and in good standing under the laws of the state of its incorporation, and has the power and authority to own, lease and operate its properties and carry on its business as now conducted.

 

 
3
 
 

 

(b) The execution, delivery and performance by the Company of this instrument is within the power of the Company and, other than with respect to the actions to be taken when equity is to be issued to the Investor, has been duly authorized by all necessary actions on the part of the Company. This instrument constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity. To the knowledge of the Company, it is not in violation of (i) its current certificate of incorporation or bylaws, (ii) any material statute, rule or regulation applicable to the Company or (iii) any material indenture or contract to which the Company is a party or by which it is bound, where, in each case, such violation or default, individually, or together with all such violations or defaults, could reasonably be expected to have a material adverse effect on the Company.

 

(c) The performance and consummation of the transactions contemplated by this instrument do not and will not: (i) violate any material judgment, statute, rule or regulation applicable to the Company; (ii) result in the acceleration of any material indenture or contract to which the Company is a party or by which it is bound; or (iii) result in the creation or imposition of any lien upon any property, asset or revenue of the Company or the suspension, forfeiture, or nonrenewal of any material permit, license or authorization applicable to the Company, its business or operations.

 

(d) No consents or approvals are required in connection with the performance of this instrument, other than: (i) the Company’s corporate approvals; (ii) any qualifications or filings under applicable securities laws; and (iii) necessary corporate approvals for the authorization of Capital Stock issuable pursuant to Section 1.

 

(e) To its knowledge, the Company owns or possesses (or can obtain on commercially reasonable terms) sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, processes and other intellectual property rights necessary for its business as now conducted and as currently proposed to be conducted, without any conflict with, or infringement of the rights of, others.

 

 

(1) Company realizes that (i) the purchase of the Investor Securities is a long-term investment; (ii) the holder of the Investor Securities must bear the economic risk of investment for an indefinite period of time because the Investor Securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or under the securities laws of any state; and (iii) the transferability of the Investor Securities are restricted, and a restrictive legend will be placed on any instrument or certificate representing the Investor Securities, substantially to the following effect:

 

 

 

 

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”). THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF A CURRENT AND EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT WITH RESPECT TO SUCH SECURITIES, OR AN OPINION SATISFACTORY TO THE ISSUER AND ITS COUNSEL TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED UNDER THE ACT.

 

 
4
 
 

 

 

(2) The Company represents and warrants that the Company comes within one of the categories of “accredited investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act or that it has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the prospective investment in the Investor Securitiess. The Company agrees to furnish any additional information that the Investor deems necessary in order to verify the Company’s representation hereunder.

 

5. Investor Representations

 

(a) The Investor has full legal capacity, power and authority to execute and deliver this instrument and to perform its obligations hereunder. This instrument constitutes valid and binding obligation of the Investor, enforceable in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity.

 

(b) The Investor has been advised that this instrument and the underlying securities have not been registered under the Securities Act, or any state securities laws and, therefore, cannot be resold unless they are registered under the Securities Act and applicable state securities laws or unless an exemption from such registration requirements is available. The Investor is purchasing this instrument and the securities to be acquired by the Investor hereunder for its own account for investment, not as a nominee or agent, and not with a view to, or for resale in connection with, the distribution thereof, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same. The Investor has such knowledge and experience in financial and business matters that the Investor is capable of evaluating the merits and risks of such investment, is able to incur a complete loss of such investment without impairing the Investor’s financial condition and is able to bear the economic risk of such investment for an indefinite period of time.

 

6. Procedures for Purchase of the Right and Payment of Purchase Amount.

 

(a) Within five (5) business days after the Execution Date, Investor shall pay the Purchase Amount to Company by issuing to Company 2,500,000 shares (“ Investor Securities ”) of Investor’s common stock at a price per share equal to $1.00 USD per Investor Security.

 

(b) Such Investor Securities will be conveyed, assigned, transferred, and delivered to Company free and clear of any mortgage, pledge, lien, encumbrance or other security interest.

 

(c) In the event of a payment by Company to Investor pursuant to Section 1(b)(i) or Section 1(c), the parties agree that Investor Securities may serve as an instrument of payment (in whole or part) thereunder and that Company, in its sole discretion, shall determine whether any such payment shall comprise or include Investor Securities.

 

7. Miscellaneous

 

(a) Any provision of this instrument may be amended, waived or modified only upon the written consent of the Company and the Investor.

 

(b) Any notice required or permitted by this instrument will be deemed sufficient when delivered personally or by overnight courier or sent by email to the relevant address listed on the signature page, or 48 hours after being deposited in the U.S. mail as certified or registered mail with postage prepaid, addressed to the party to be notified at such party’s address listed on the signature page, as subsequently modified by written notice.

 

 
5
 
 

 

(c) The Investor is not entitled, as a holder of this instrument, to vote or receive dividends or be deemed the holder of Capital Stock for any purpose, nor will anything contained herein be construed to confer on the Investor, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action or to receive notice of meetings, or to receive subscription rights or otherwise until shares have been issued upon the terms described herein.

 

(d) Neither this instrument nor the rights contained herein may be assigned, by operation of law or otherwise, by either party without the prior written consent of the other; provided, however , that this instrument and/or the rights contained herein may be assigned without the Company’s consent by the Investor to any other entity who directly or indirectly, controls, is controlled by or is under common control with the Investor, including, without limitation, any general partner, managing member, officer or director of the Investor, or any venture capital fund now or hereafter existing which is controlled by one or more general partners or managing members of, or shares the same management company with, the Investor; and provided, further , that the Company may assign this instrument in whole, without the consent of the Investor, in connection with a reincorporation to change the Company’s domicile.

 

(e) In the event any one or more of the provisions of this instrument is for any reason held to be invalid, illegal or unenforceable, in whole or in part or in any respect, or in the event that any one or more of the provisions of this instrument operate or would prospectively operate to invalidate this instrument, then and in any such event, such provision(s) only will be deemed null and void and will not affect any other provision of this instrument and the remaining provisions of this instrument will remain operative and in full force and effect and will not be affected, prejudiced, or disturbed thereby.

 

(f) All rights and obligations hereunder will be governed by the laws of the State of Colorado, without regard to the conflicts of law provisions of such jurisdiction.

 

(g) Each of the Company and the Investor agree to treat this instrument as a forward contract for U.S. federal, state and local income tax purposes, and will not take any position on any tax return, report, statement or other tax document that is inconsistent with such treatment, unless otherwise required by a change in law occurring after the date hereof, a closing agreement with an applicable tax authority or a final non-appealable judgment of a court of competent jurisdiction.

 

(h) The Investor shall, and shall cause its affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably requested by Company to carry out the provisions of this instrument and give effect to the transactions contemplated by this instrument, including, without limitation, to enable the Company or the transactions contemplated by this instrument to comply with applicable laws.

 

(i) The Company shall not be liable or responsible to the Investor, nor be deemed to have defaulted under or breached this instrument, for any failure or delay in fulfilling or performing any term of this instrument, including without limitation, completing an Equity Financing event, when and to the extent such failure or delay is caused by or results from acts beyond Company’s reasonable control, including, without limitation: (a) acts of God; (b) flood, fire, earthquake or explosion; (c) war, invasion, hostilities (whether war is declared or not), terrorist threats or acts, or other civil unrest; (d) Law; or (e) action by any Governmental Authority.

 

( Signature page follows )

 

 
6
 
 

 

IN WITNESS WHEREOF, the undersigned have caused this instrument to be duly executed and delivered.

 

BURSTIQ ANALYTICS CORPORATION

 

MILLENNIUM BLOCKCHAIN, INC.

 

 

 

 

 

 

 

By:

 

 

By:

 

 

Frank J. Ricotta Jr.

 

 

Brandon Romanek

 

 

Chief Executive Officer

 

 

Chief Executive Officer

 

 

 

 

 

 

 

Address:

5790 Regal View Road

Colorado Springs, CO 80919

 

Address:

11700 W. Charleston Blvd #73

Las Vegas, NV 89135

 

 

 

 

 

 

 

Email:

frank.ricotta@burstiq.com

 

Email:

brandon@mblockchain.io

 

 

 

 

 

 

 

Date:

3/31/2018

 

Date:

3/31/2018

 

 

 

7

 

EXHIBIT 10.4

  

THIS DOCUMENT IS DIRECTED ONLY AT RELEVANT PERSONS AND PERSONS WHO ARE NOT RELEVANT PERSONS SHOULD NOT TAKE ANY ACTION BASED UPON THIS DOCUMENT AND SHOULD NOT RELY ON IT. IT IS A CONDITION OF YOU RECEIVING AND RETAINING THIS DOCUMENT THAT YOU WARRANT TO THE COMPANY, ITS DIRECTORS, AND ITS OFFICERS THAT YOU ARE A RELEVANT PERSON.

 

BIQ , a product of

BURSTIQ ANALYTICS CORPORATION

 

SAFT

(Simple Agreement for Future Tokens)

 

THIS CERTIFIES THAT in exchange for consideration provided by the Millennium Blockchain Inc., a Nevada corporation (the “ Purchaser ”) equal to or in the amount of $2,500,000 USD (the “ Purchase Amount ”) on or about March 31, 2018 (the “ Execution Date ”), BurstIQ Analytics Corporation, a Colorado corporation (the “ Company ”), hereby issues to the Purchaser the right (the “ Right ”) to certain units of BIQ (the “ Token ” or “ BIQ ”), subject to the terms set forth below.

 

1. Events

 

(a) Network Launch . If there is a Network Launch before the expiration or termination of this instrument, the Company will automatically issue to the Purchaser a number of units of the Token equal to the Purchase Amount divided by the Discount Price.

 

In connection with and prior to the issuance of Tokens by the Company to the Purchaser pursuant to this Section 1(a):

 

(i) The Purchaser will execute and deliver to the Company any and all other transaction documents related to this SAFT, including verification of accredited investor status or non-U.S. person status under the applicable securities laws; and

 

(ii) The Purchaser will provide to the Company a network address for which to allocate Purchaser ‘s Tokens upon the Network Launch.

 

(b) Dissolution Event . If there is a Dissolution Event before this instrument expires or terminates, the Company will pay an amount equal to the Purchase Amount, due and payable to the Purchaser immediately prior to, or concurrent with, the consummation of the Dissolution Event, subject to the rights and preferences of the holders of the Company ‘s Preferred Stock, as set forth in the Company ‘s Certificate of Incorporation, as it may be amended from time to time. If immediately prior to the consummation of the Dissolution Event, the assets of the Company that remain legally available for distribution to the Purchaser and all holders of all other SAFTs (the “ Dissolving Purchasers ”), as determined in good faith by the Company ‘s board of directors, are insufficient to permit the payment to the Dissolving Purchasers of their respective Discounted Purchase Amounts, then the remaining assets of the Company legally available for distribution, following all distributions to the holders of the Company ‘s preferred stock, will be distributed with equal priority and pro rata among the Dissolving Purchasers in proportion to the Purchase Amounts they would otherwise be entitled to receive pursuant to this Section 1(b). Any distributed amounts shall be in U.S. Dollars.

 

 
1
 
 

 

 

(c) Termination . This instrument will expire and terminate upon the earlier of (i) the issuance of Tokens to the Purchaser pursuant to Section 1(a); (ii) the payment, or setting aside for payment, of amounts due the Purchaser pursuant to Section 1(b); and (iii) March 31, 2018 (the “ Deadline Date ”), if the Network Launch has not occurred as of such date; provided that, the Company shall have the right to extend the Deadline Date by sixty (60) days, in its sole discretion.

 

2. Definitions

 

“Base Price” means the maximum price per Token sold by the Company to the public during the Network Launch.

 

Discount Price ” means the Base Price minus an amount equal to the Base Price multiplied by the Discount Rate.

 

Discount Rate ” is 35%.

 

Dissolution Event ” means (i) a voluntary termination of operations of the Company, (ii) a general assignment for the benefit of the Company ‘s creditors or (iii) any other liquidation, dissolution or winding up of the Company, whether voluntary or involuntary.

 

Network Launch means a bona fide transaction or series of transactions, pursuant to which the Company will sell the Tokens to the general public in a publicized product launch.

 

SAFT ” means an agreement containing a future right to units of Tokens purchased by Purchasers, similar in form and content to this agreement, which a significant portion of the amount raised under the SAFTs will be used to fund the Company ‘s development of a decentralized blockchain-based computer network (the “ Network ”) that enables individuals to control their health data, data managers to obtain marketplace services and offset platform fees and solution providers to offer platform and marketplace services.

 

4. Company Representations

 

(a) The Company is a corporation duly organized, validly existing and in good standing under the laws of Colorado, and has the power and authority to own, lease and operate its properties and carry on its business as now conducted.

 

(b) The execution, delivery and performance by the Company of this instrument is within the power of the Company and, other than with respect to the actions to be taken when Tokens are to be issued to the Purchaser, has been duly authorized by all necessary actions on the part of the Company. This instrument constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors ‘ rights generally and general principles of equity. To the knowledge of the Company, it is not in violation of (i) its current articles of incorporation or bylaws, (ii) any material statute, rule or regulation applicable to the Company, or (iii) any material indenture or contract to which the Company is a party or by which it is bound, where, in each case, such violation or default, individually, or together with all such violations or defaults, could reasonably be expected to have a material adverse effect on the Company.

 

(c) To the knowledge of the Company, the performance and consummation of the transactions contemplated by this instrument do not and will not: (i) violate any material judgment, statute, rule or regulation applicable to the Company; (ii) result in the acceleration of any material indenture or contract to which the Company is a party or by which it is bound; or (iii) result in the creation or imposition of any lien upon any property, asset or revenue of the Company or the suspension, forfeiture, or nonrenewal of any material permit, license or authorization applicable to the Company, its business or operations.

 

 
2
 
 

 

 

(d) No consents or approvals are required in connection with the performance of this instrument, other than: (i) the Company ‘s corporate approvals; and (ii) any qualifications or filings under applicable securities laws.

 

(e) To its knowledge, the Company owns or possesses (or can obtain on commercially reasonable terms) sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, processes and other intellectual property rights necessary for its business as now conducted and as currently proposed to be conducted, without an infringement of the rights of others.

 

(f) Company Representations Regarding Purchase of Purchaser Securities

 

 

(1) The Company understands that the Purchaser has a history of net losses and that there is a risk that it may not be able to continue as a going concern.

 

 

 

 

(2) The Company understands that the Purchaser is currently focused on investing in blockchain technologies and crypto-assets focused on financial markets, healthcare, crypto-mining and high-technology, but that the Purchaser has historically been focused on developing a sanitizing herb dryer, and has only recently shifted its focus to blockchain technologies; and that even though the Purchaser is currently evaluating a number of potential blockchain technologies and potential crypto-assets, the Purchaser does not currently have any blockchain technologies, crypto-assets or other blockchain operations.

 

 

 

 

(3) The Company has received and had the opportunity to review the Purchaser ‘s material information, including business plan information, risk factors associated with investment in the Purchaser ‘s securities, and financial statements and notes and other information; has been given full and complete access to information regarding the Purchaser and has utilized such access to the Company ‘s satisfaction for the purpose of obtaining such information regarding the Purchaser as the Company has reasonably requested; and the Company has been given reasonable opportunity to ask questions of, and receive answers from, representatives of the Purchaser concerning the Purchaser Securities and to obtain any additional information regarding Purchaser to the extent reasonably available;

 

 

 

 

(4) The Company is acquiring the Purchaser Securities solely for investment for its own account and not with a view to, or for, resale in connection with any distribution within the meaning of any federal securities laws, state securities laws or any other applicable federal or state laws of the United States;

 

 

 

 

(5) The Company recognizes that the Purchaser Securities as an investment involve a very high degree of risk, including, but not limited to, the risk of economic losses from operations of the Purchaser.

 

 
3
 
 

 

 

 

(6) The Company confirms that its purchase of the Purchaser Securities would be suitable and consistent with its investment program; that its financial position enables it to bear the risks of investment in the Purchaser Securities; and that there is no liquid public market for the Purchaser Securities.

 

 

 

 

(7) The Company understands that the Purchaser Securities may not be transferred, encumbered, sold, hypothecated, or otherwise disposed of, if such disposition will violate any federal and/or state securities laws; disposition shall include, but is not limited to acts of selling, assigning, transferring, pledging, encumbering, hypothecating, giving, and any form of conveying, whether voluntary or not.

 

 

 

 

(8) The Company realizes that (i) the purchase of the Purchaser Securities is a long-term investment; (ii) the purchaser of the Purchaser Securities must bear the economic risk of investment for an indefinite period of time because the Purchaser Securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or under the securities laws of any state; and (iii) the transferability of the Purchaser Securities are restricted, and a restrictive legend will be placed on any instrument or certificate representing the Purchaser Securities, substantially to the following effect:

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”). THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF A CURRENT AND EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT WITH RESPECT TO SUCH SECURITIES, OR AN OPINION SATISFACTORY TO THE ISSUER AND ITS COUNSEL TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED UNDER THE ACT.

 

 

(9) The Company represents and warrants that the Company comes within one of the categories of “accredited investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act or that it has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the prospective investment in the Purchaser Securities. The Company agrees to furnish any additional information that the Purchaser deems necessary in order to verify the Company ‘s representation hereunder.

 

5. Purchaser Representations

 

(a) The Purchaser has full legal capacity, power and authority to execute and deliver this instrument and to perform its obligations hereunder. This instrument constitutes valid and binding obligation of the Purchaser, enforceable in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors ‘ rights generally and general principles of equity.

 

(b) The Purchaser has been advised that this instrument is a security and that the offers and sales of this instrument have not been registered under any country ‘s securities laws and, therefore, cannot be resold except in compliance with the applicable country ‘s laws. The Purchaser is purchasing this instrument for its own account for investment, not as a nominee or agent, and not with a view to, or for resale in connection with, the distribution thereof, and the Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same. The Purchaser has such knowledge and experience in financial and business matters that the Purchaser is capable of evaluating the merits and risks of such investment, is able to incur a complete loss of such investment without impairing the Purchaser ‘s financial condition and is able to bear the economic risk of such investment for an indefinite period of time.

 

 
4
 
 

 

 

(c) The Purchaser enters into this SAFT with such knowledge and experience in financial and business matters that the Purchaser is capable of evaluating the merits and risks of such purchase, is able to incur a complete loss of such purchase without impairing the Purchaser ‘s financial condition and is able to bear the economic risk of such purchase for an indefinite period of time.

 

6. Procedures for Purchase of Rights and Payment of Purchase Amount.

 

(a) Within five (5) business days after the Execution Date, Purchaser shall pay the Purchase Amount to Company by issuing to Company 2,500,000 shares (“ Purchaser Shares ”) of Purchaser ‘s common stock at a price per share equal to $1.00 USD per Purchaser Share.

 

(b) Such Purchaser Shares will be conveyed, assigned, transferred, and delivered to Company free and clear of any mortgage, pledge, lien, encumbrance or other security interest.

 

(c) In the event of a payment by Company to Purchaser pursuant to Section 1(b), the parties agree that Purchaser Shares may serve as an instrument of payment (in whole or part) thereunder and that Company, in its sole discretion, shall determine whether any such payment shall comprise or include Purchaser Shares.

 

7. Miscellaneous

 

(a) This instrument sets forth the entire agreement and understanding of the parties relating to the subject matter herein and supersedes all prior or contemporaneous disclosures, discussions, understandings and agreements, whether oral of written, between them. This instrument is one of a series of similar instruments entered into by the Company from time to time. Any provision of this instrument may be amended, waived or modified only upon the written consent of the Company and the holders of a majority, in the aggregate, of the Purchase Amounts paid to the Company with respect to all SAFTs outstanding at the time of such amendment, waiver or modification.

 

(b) Any notice required or permitted by this instrument will be deemed sufficient when sent by email to the relevant address listed on the signature page, as subsequently modified by written notice received by the appropriate party.

 

(c) The Purchaser is not entitled, as a holder of this instrument, to vote or receive dividends or be deemed the holder of capital stock of the Company for any purpose, nor will anything contained herein be construed to confer on the Purchaser, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action or to receive notice of meetings, or to receive subscription rights or otherwise.

 

(d) Neither this instrument nor the rights contained herein may be assigned, by operation of law or otherwise, by either party without the prior written consent of the other; provided, however , that this instrument and/or the rights contained herein may be assigned without the Company ‘s consent by the Purchaser to any other entity who directly or indirectly, controls, is controlled by or is under common control with the Purchaser, including, without limitation, any general partner, managing member, officer or director of the Purchaser, or any venture capital fund now or hereafter existing which is controlled by one or more general partners or managing members of, or shares the same management company with, the Purchaser; and provided, further , that the Company may assign this instrument in whole, without the consent of the Purchaser, in connection with a reincorporation to change the Company ‘s domicile.

 

 
5
 
 

 

 

(e) In the event any one or more of the provisions of this instrument is for any reason held to be invalid, illegal or unenforceable, in whole or in part or in any respect, or in the event that any one or more of the provisions of this instrument operate or would prospectively operate to invalidate this instrument, then and in any such event, such provision(s) only will be deemed null and void and will not affect any other provision of this instrument and the remaining provisions of this instrument will remain operative and in full force and effect and will not be affected, prejudiced, or disturbed thereby.

 

(f) All rights and obligations hereunder will be governed by the laws of Colorado, without regard to the conflicts of law provisions of such jurisdiction.

 

(g) Each of the Company and the Purchaser agree to treat this instrument as a forward contract for U.S. federal, state and local income tax purposes, and will not take any position on any tax return, report, statement or other tax document that is inconsistent with such treatment, unless otherwise required by a change in law occurring after the date hereof, a closing agreement with an applicable tax authority or a final non-appealable judgment of a court of competent jurisdiction.

 

(h) The Purchaser shall, and shall cause its affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably requested by Company to carry out the provisions of this instrument and give effect to the transactions contemplated by this instrument, including, without limitation, to enable the Company or the transactions contemplated by this instrument to comply with applicable laws.

 

(i) The Company shall not be liable or responsible to the Purchaser, nor be deemed to have defaulted under or breached this instrument, for any failure or delay in fulfilling or performing any term of this instrument, including without limitation, launching the Network or consummating the Network Launch, when and to the extent such failure or delay is caused by or results from acts beyond the affected party ‘s reasonable control, including, without limitation: (a) acts of God; (b) flood, fire, earthquake or explosion; (c) war, invasion, hostilities (whether war is declared or not), terrorist threats or acts, or other civil unrest; (d) Law; or (e) action by any Governmental Authority.

 

(j) Each party to this SAFT acknowledges that Cooley LLP (“ Cooley ”), outside general counsel to the Company, has in the past performed and is or may now or in the future represent one or more Purchasers or their affiliates in matters unrelated to the transactions contemplated by this SAFT (the “ Financing ”), including representation of such Purchasers or their affiliates in matters of a similar nature to the Financing. The applicable rules of professional conduct require that Cooley inform the parties hereunder of this representation and obtain their consent. Cooley has served as outside general counsel to the Company and has negotiated the terms of the Financing solely on behalf of the Company. The Company and each Purchaser hereby (a) acknowledge that they have had an opportunity to ask for and have obtained information relevant to such representation, including disclosure of the reasonably foreseeable adverse consequences of such representation; (b) acknowledge that with respect to the Financing, Cooley has represented solely the Company, and not any Purchaser or any stockholder, director or employee of the Company or any Purchaser; and (c) gives its informed consent to Cooley ‘s representation of the Company in the Financing.

 

( Signature page follows )

 

 
6
 
 

 

 

IN WITNESS WHEREOF, the undersigned have caused this instrument to be duly executed and delivered.

 

 

         

BURSTIQ ANALYTICS CORPORATION

 

MILLENNIUM BLOCKCHAIN, INC.

 

 

 

 

 

 

 

By:

  By:  

 

Frank J. Ricotta Jr.     Brandon Romanek  

 

Chief Executive Officer     Chief Executive Officer  

 

 

 

 

 

 

Address:

5790 Regal View Road

 

Address:

11700 W. Charleston Blvd #73

 

 

Colorado Springs, CO 80919

 

 

Las Vegas, NV 89135

 

 

 

 

 

 

 

Email: frank.ricotta@burstiq.com

 

Email: brandon@mblockchain.io

 

 

 

 

 

 

 

Date:

3/31/2018

 

Date:

3/31/2018

 

 

 

 
7
 
 

  

  


 

 

8

 

EXHIBIT 10.5

 

NOTICE TO RESIDENTS OF THE UNITED STATES

 

THE OFFER AND SALE OF THE RIGHTS SET FORTH IN THIS PURCHASE AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THE RIGHTS DESCRIBED IN THIS PURCHASE AGREEMENT MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHIN THE UNITED STATES EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM.

 

NOTICE TO RESIDENTS OF CANADA

 

UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THE RIGHTS UNDER THIS PURCHASE AGREEMENT MUST NOT TRADE THE RIGHTS BEFORE THE DATE THAT THE ISSUER BECOMES A REPORTING ISSUER IN ANY PROVINCE OR TERRITORY.

 

NOTICE TO RESIDENTS OF CHINA AND SOUTH KOREA

 

THE RIGHTS ARE NOT BEING OFFERED OR SOLD AND MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, WITHIN THE PEOPLE’S REPUBLIC OF CHINA (FOR SUCH PURPOSES, NOT INCLUDING THE HONG KONG AND MACAU SPECIAL ADMINISTRATIVE REGIONS OR TAIWAN), SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH OFFER AND SALE IS PROHIBITED BY LAW.

 

 
1
 
 

 

NOTICE TO RESIDENTS OF GERMANY

 

NEITHER THE PURCHASE AGREEMENT, THE RELATED OFFERING MEMORANDUM NOR THE RIGHTS IS A SECURITIES PROSPECTUS (WERTPAPEIERPROSPEKT) WITHIN THE MEANING OF THE GERMAN SECURITIES ACT ( WERTPAPEIERPROSPEKTGESETZ) OR AN INVESTMENT PRODUCT PROSPECTUS ( VERKAUFSPROSPEKT) WITHIN THE MEANING OF THE GERMAN INVESTMENT PRODUCT ACT ( VERMÖGENANLAGENGESETZ). NO SECURITIES PROSPECTUS ( WERTPAPIERPROSPEKT) OR INVESTMENT PRODUCT PROSPECTUS ( VERKAUFSPROSPEKT) HAS BEEN OR WILL BE FILED WITH THE GERMAN FEDERAL FINANCIAL SUPERVISORY AUTHORITY (“BAFIN”) OR OTHERWISE PUBLISHED IN THE FEDERAL REPUBLIC OF GERMANY. NO PUBLIC OFFER, SALE OR DISTRIBUTION OF COPIES OF ANY DOCUMENT RELATED TO THE RIGHTS WILL BE MADE IN THE FEDERAL REPUBLIC OF GERMANY EXCEPT WHERE AN EXPRESS EXEMPTION FROM COMPLIANCE WITH THE PUBLIC OFFER RESTRICTIONS UNDER THE GERMAN SECURITIES PROSPECTUS ACT AND THE INVESTMENT PRODUCT ACT APPLIES.

 

 
2
 
 

 

NOTICE TO RESIDENTS OF THE UNITED KINGDOM

 

IN THE UNITED KINGDOM THIS DOCUMENT IS BEING DISTRIBUTED ONLY TO, AND IS DIRECTED ONLY AT (AND ANY INVESTMENT ACTIVITY TO WHICH IT RELATES WILL BE ENGAGED ONLY WITH): (i) INVESTMENT PROFESSIONALS (WITHIN THE MEANING OF ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 AS AMENDED (THE ‘‘ FPO ’’)); (ii) PERSONS OR ENTITIES OF A KIND DESCRIBED IN ARTICLE 49 OF THE FPO; (iii) CERTIFIED SOPHISTICATED INVESTORS (WITHIN THE MEANING OF ARTICLE 50(1) OF THE FPO); AND (iv) OTHER PERSONS TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS ‘‘RELEVANT PERSONS’’).

 

THIS DOCUMENT HAS NOT BEEN APPROVED BY AN AUTHORIZED PERSON. ANY INVESTMENT TO WHICH THIS DOCUMENT RELATES IS AVAILABLE ONLY TO (AND ANY INVESTMENT ACTIVITY TO WHICH IT RELATES WILL BE ENGAGED ONLY WITH) RELEVANT PERSONS. THIS DOCUMENT IS DIRECTED ONLY AT RELEVANT PERSONS AND PERSONS WHO ARE NOT RELEVANT PERSONS SHOULD NOT TAKE ANY ACTION BASED UPON THIS DOCUMENT AND SHOULD NOT RELY ON IT. IT IS A CONDITION OF YOUR RECEIVING AND RETAINING THIS DOCUMENT THAT YOU WARRANT TO COMPANY, ITS DIRECTORS, AND ITS OFFICERS THAT YOU ARE A RELEVANT PERSON.

 

MPQ TOKENS a product of

IMPACTPPA LIMITED PURCHASE AGREEMENT

 

This Purchase Agreement (the “ Purchase Agreement” ) is entered as of the last date set forth on the signature page hereto between the undersigned (the “ Purchaser ”) and ImpactPPA Limited, a Bahamian company under The Bahamas’ International Business Companies Act of 1990 (“ Company ”) for the purchase of the right by Purchaser from Company (the “ Right ”) to receive certain units of MPQ Tokens (as defined below) and the Warrants (as defined below), subject to the terms set forth in this Purchase Agreement. Company is conducting an offering of rights pursuant to the Offering Documents (as defined below).

 

NOW, THEREFORE, in consideration of the premises and of the representations, warranties, covenants and agreements herein contained, the parties hereto, intending to be legally bound, agree as follows:

 

1.

Definitions . Additional defined terms not defined throughout the Purchase Agreement are:

 

 

 

 

a. Bonus Percentage ” is:

 

 

i. Tier 1: For any Purchaser who buys the Right before the first aggregate $2 million in Purchase Amount is received by ImpactPPA after February 25, 2018 50%, expressed as 0.50 for purposes of any mathematical calculations in this Purchase Agreement.

 

 
3
 
 

 

 

ii. Tier 2: For any Purchaser who buys the Right after the second aggregate $2 million in Purchase Amount is received by ImpactPPA after February 25, 2018 40%, expressed as 0.40 for purposes of any mathematical calculations in this Purchase Agreement.

 

 

 

 

iii. Tier 3: For any Purchaser who buys the Right after the third aggregate $2 million in Purchase Amount is received by ImpactPPA after February 25, 2018 30%, expressed as 0.30 for purposes of any mathematical calculations in this Purchase Agreement.
 

 

b. Dissolution Event ” means: (i) a voluntary termination of operations of Company; (ii) a general assignment for the benefit of Company’s creditors, (iii) any other liquidation, dissolution or winding up of Company, or (iv) the failure of Company to hold a Token Sale within one (1) year of January 1, 2018.

 

 

 

 

c. MPQ Tokens ” are the tentative brand name for the future cryptographic public utility tokens to be sold by Company in its Token Sale as described in Company’s White Paper (as defined below). Purchaser agrees that Company may in its sole discretion approve a different brand name for its cryptographic public utility tokens before the close of its Token Sale and that this Purchase Agreement shall apply to such re- branded MPQ Tokens. All references to “MPQ Tokens” in this Purchase Agreement shall be automatically amended with the re-branded name approved by Company. “MPQ Tokens” shall refer to both “Purchased MPQ Tokens” and “Bonus MPQ Tokens” (each, as defined below).

 

 

 

 

d. Offering Documents ” shall mean the White Paper (as defined below), this Purchase Agreement and any offering placement memorandum previously delivered to Purchaser.

 

 

 

 

e. OFAC Regulations ” means individual-specific sanctions programs or regulations implemented by the U.S. Office of Foreign Asset Control.

 

 

 

 

f. Purchase Amount ” is the total purchase amount in U.S. Dollars set forth on the signature page of this Purchase Agreement and to be paid by Purchaser to Company upon execution of this Purchase Agreement for the Right to buy MPQ Tokens in the Token Sale. The value of the Purchase Amount shall be deemed in U.S. dollars whether Buyer pays in fiat, Bitcoin, Bitcoin Cash, Eth, Litecoin, Zcash or any other crypto currency, valued at the applicable exchange rate at the time, which means the volume-weighted hourly price of the currency across exchanges in the one hour preceding and one hour after receipt of the currency by the Company as reasonably determined by the Company, or whether Buyer pays with Purchaser Securities (as defined hereinafter).

 

 
4
 
 

 

 

g. Token Price ” is the closing price per MPQ Token set by Company for the Token Sale, which is anticipated to be denominated in ETH.

 

 

 

 

h. Token Sale ” is the future cryptographic utility token bona fide sale of MPQ Tokens by Company to the general public in a publicized product launch with definitive terms and conditions to be set forth at that time.

 

 

 

 

i. “Warrants” means the warrants to purchase shares of Tightnod Holdings Limited, a Cyprus company, on the form attached hereto as Exhibit A.

 

 

 

 

j. White Paper ” means the disclosure document previously provided to Purchaser by Company which describes the proposed business of Company, the proposed Token Sale and the proposed MPQ Tokens.

 

2.

  Events .

 

 

 

 

a. Purchaser of Right . In exchange for the Purchase Amount, at closing of the transactions contemplated herein, Company shall issue Purchaser the Right to MPQ Tokens in the Token Sale, and Company’s parent company, Tightnod Holdings Limited, shall issue Purchaser the Warrants. Purchaser agrees and acknowledges that a certificate representing the Right will not be issued by Company and Company will maintain an electronic register of the Rights. Notwithstanding anything to the contrary herein, the Purchase Amount shall be paid by Purchaser in the form of 60,000 restricted shares of Purchaser’s Series A Preferred Stock (the “ Purchaser Securities ”).

 

 

 

 

b. Closing of Token Sale . If there is a closing of the Token Sale before the expiration or termination of this Purchase Agreement, upon such closing:

 

 

i. Purchaser’s Right shall automatically be deemed to be exercised without any further action upon the part of Purchaser and Company will issue to Purchaser a number of units of the MPQ Token equal to:

 

The Purchase Amount multiplied by

( The Bonus Percentage plus 1.00) divided by

The Token Price

 

 

The MPQ Tokens the Purchaser is to receive based on payment of the Purchase Amount are the “ Purchased MPQ Tokens .”

 

 

 

 

The MPQ Tokens the Purchaser is to receive based on application of the Bonus Percentage are the “ Bonus MPQ Tokens .”

 

 

 

 

Company shall issue the Purchased MPQ Tokens to Purchaser as soon as reasonably possible following the closing of the Token Sale but in any case no later than six weeks after the closing of the Token Sale (the “ Delivery Date ”).

 

 
5
 
 

 

 

The Bonus MPQ Tokens shall be subject to a hold-back such that: (A) 50% of the Bonus MPQ Tokens shall be retained by Company and delivered to the Purchaser three (3) months after the Delivery Date; and (B) the remaining 50% of the Bonus MPQ Tokens shall be retained by Company and delivered to Purchaser six (6) months after the Delivery Date.

 

 

 

 

ii. Purchaser’s Right will extinguish upon the automatic exercise described above under Section 2(a)(i) above.

 

 

 

 

 

c.

Dissolution Event .

 

 

 

 

 

 

 

 

i. If there is a Dissolution Event before this Purchase Agreement expires or terminates, Company shall pay Purchaser an amount equal to the Purchase Amount, which shall be due and payable to Purchaser concurrently with, or as soon as reasonably practicable following, the occurrence of the Dissolution Event. The Purchase Amount may be paid in U.S. Dollars, BTC, ETH, another recognized cryptocurrency or any combination of the foregoing in Company’s sole discretion. If immediately prior to the consummation of a Dissolution Event, the assets of Company legally available for distribution to Purchaser and all other holders of Rights (the “ Right Holders ”), as determined in good faith by Company’s board of directors, are insufficient to permit payment to the Right Holders of their respective Purchase Amounts, then the entire assets of Company legally available for distribution will be distributed with equal priority and pro rata among the Right Holders in proportion to the Purchase Amounts they would otherwise be entitled to receive under this Section 2(b).

 

 

 

 

 

 

 

 

ii. Notwithstanding anything to the contrary contained herein, Purchaser acknowledges and agrees that the value of ETH, BTC and other cryptocurrencies may fluctuate following the date of this Purchase Agreement and that if Purchaser pays the Purchase Amount in ETH, BTC or another cryptocurrency Purchaser bears the risk of such fluctuation. In furtherance and not in limitation of the foregoing, in the event of any increase in the value of any cryptocurrency paid by Purchaser as part of the Purchase Amount as compared to another cryptocurrency or U.S. Dollars, in no event will Purchaser be entitled to a greater value of ETH, BTC, another cryptocurrency or fiat in connection with a Dissolution Event than Purchaser paid to Company, whether directly or based on a pro rata amount as compared to other Right Holders in connection with such Dissolution Event; provided, however, that Company will use reasonable efforts to return funds to Purchaser in the same form of currency used by Purchaser to purchase the Right (with any appreciation or depreciation in the value of such currency to be borne by the respective Purchasers).

 

 
6
 
 

 

 

d.

Termination . This Purchase Agreement will expire and terminate (without relieving Company of any obligations arising from a prior breach of or non-compliance with this Purchase Agreement) upon the earlier to occur of the following:

 

 

 

 

 

 

 

 

i. The issuance of MPQ Tokens, including Bonus MPQ Tokens, to Purchaser pursuant to Section 2(a), or

 

 

 

 

 

 

 

 

ii. The payment, or setting aside for payment, of amounts due to Purchaser pursuant to Section 2(b).

  

3.

Company Representations . Company hereby represents and warrants to Purchaser as follows:

 

 

 

 

a. Company is duly formed and validly existing under the laws of the Bahamas, and has the corporate power and authority to own, lease and operate its properties and carry on its business as now conducted.

 

 

 

 

b. The execution, delivery and performance by Company of this Purchase Agreement is within Company’s corporate power and has been duly authorized by all necessary actions of Company. This Purchase Agreement constitutes, and each other transaction document when executed by Purchaser will constitute, a valid, legal and binding obligation of Company, enforceable against it in accordance with its terms, except as limited by bankruptcy, insolvency, or other laws of general application to or affecting the enforcement of creditors’ rights generally and general principles of equity.

 

 

 

 

c. To the knowledge of Company’s officers, Company is not in violation of (i) its current certificate of incorporation and memorandum and articles of association (or similar organizational documents), (ii) any material statute, rule or regulation applicable to it, or (iii) any material indenture or contract to which Company is a party or by which it is bound, where, in each case, such violation or default, individually, or together with all such violations or defaults, could reasonably be expected to have a material adverse effect on Company.

 

 

 

 

d. To the knowledge of Company’s officers, the performance and consummation of the transactions contemplated by this Purchase Agreement do not and will not (i) violate any material judgment, statute, rule or regulation applicable to Company, (ii) result in the acceleration of any material indenture or contract to which Company is a party or by which it is bound, or (iii) result in the creation or imposition of any lien upon any property, asset or revenue of Company or the suspension, forfeiture or nonrenewal of any material permit, license or authorization applicable to Company, its business or operations.

 

 

 

 

e. No consents or approvals are required in connection with the performance of this Purchase Agreement, other than (i) Company’s corporate approvals and (ii) any qualifications or filings under applicable law, including securities law filings, each of which shall be made prior to closing of this Offering.

 

 
7
 
 

 

 

f. To the knowledge of Company’s officers, Company owns or possesses (or can obtain on commercially reasonably terms) sufficient legal rights to all material patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, processes and other intellectual property rights necessary for its business as now conducted and as currently proposed to be conducted, without any conflict with or infringement of the rights of others.

 

 

 

 

g.

Company Representations Regarding Purchase of Purchaser Securities .

 

 

i. The Company understands that the Purchaser has a history of net losses and that there is a risk that it may not be able to continue as a going concern.

 

 

 

 

ii. The Company understands that the Purchaser is currently focused on investing in blockchain technologies and crypto-assets focused on financial markets, healthcare, crypto-mining and high-technology, but that the Purchaser has historically been focused on developing a sanitizing herb dryer, and has only recently shifted its focus to blockchain technologies; and that even though the Purchaser has agreed to purchase other crypto-assets, the Purchaser does not yet have any blockchain technologies or crypto- assets.

 

 

 

 

iii. The Company has received and had the opportunity to review the Purchaser’s material information, including business plan information, risk factors associated with investment in the Purchaser’s securities, and financial statements and notes and other information; has been given full and complete access to information regarding the Purchaser and has utilized such access to the Company’s satisfaction for the purpose of obtaining such information regarding the Purchaser as the Company has reasonably requested; and the Company has been given reasonable opportunity to ask questions of, and receive answers from, representatives of the Purchaser concerning the Purchaser Securities and to obtain any additional information regarding Purchaser to the extent reasonably available;

 

 

 

 

iv. The Company is acquiring the Purchaser Securities solely for investment for its own account and not with a view to, or for, resale in connection with any distribution within the meaning of any federal securities laws, state securities laws or any other applicable federal or state laws of the United States;

 

 

 

 

v. The Company recognizes that the Purchaser Securities as an investment involve a very high degree of risk, including, but not limited to, the risk of economic losses from operations of the Purchaser.

 

 

 

 

vi. The Company confirms that its purchase of the Purchaser Securities would be suitable and consistent with its investment program; that its financial position enables it to bear the risks of investment in the Purchaser Securities; and that there is no liquid public market for the Purchaser Securities.

 

 
8
 
 

 

 

vii. The Company understands that the Purchaser Securities may not be transferred, encumbered, sold, hypothecated, or otherwise disposed of, if such disposition will violate any federal and/or state securities laws; disposition shall include, but is not limited to acts of selling, assigning, transferring, pledging, encumbering, hypothecating, giving, and any form of conveying, whether voluntary or not.

 

 

 

 

viii. The Company realizes that (i) the purchase of the Purchaser Securities is a long-term investment; (ii) the purchaser of the Purchaser Securities must bear the economic risk of investment for an indefinite period of time because the Purchaser Securities have not been registered under the Securities Act or under the securities laws of any state; and (iii) the transferability of the Purchaser Securities are restricted, and a restrictive legend will be placed on any instrument or certificate representing the Purchaser Securities, substantially to the following effect:

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”). THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF A CURRENT AND EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT WITH RESPECT TO SUCH SECURITIES, OR AN OPINION SATISFACTORY TO THE ISSUER AND ITS COUNSEL TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED UNDER THE ACT.

 

 

 

ix. The Company represents and warrants that the Company comes within one of the categories of “accredited investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act or that it has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the prospective investment in the Purchaser Securities.

 

4.

Purchaser Representations, Warranties and Covenants . Purchaser hereby represents, warrants and covenants to Company, and acknowledges and agrees, as follows:

 

 

 

 

a. Purchaser has the full legal capacity, power and authority to execute and deliver this Purchase Agreement and to perform its obligations hereunder. This Purchase Agreement constitutes, and each other transaction document when executed by Purchaser will constitute, a valid and binding obligation of Purchaser, enforceable in accordance with its terms, except as limited by bankruptcy, insolvency, or other laws of general application to or affecting the enforcement of creditors’ rights generally and general principles of equity.

 

 
9
 
 

 

 

b. Purchaser has been advised that the Right and Warrants (the “ Securities ”) issued under this Purchase Agreement may constitute securities under United States securities laws and that the offers and sales of the Securities have not been registered under any country’s securities laws and, therefore, the Securities cannot be resold except in compliance with law. Purchaser further acknowledges and agrees that the regulatory status of the Purchased MPQ Tokens is uncertain and depends on a number of factors, including factors outside of Company’s control; at the time of the Token Sale, the Purchased Tokens may constitute securities and not utility tokens under the applicable laws and regulations of one or more jurisdictions; and if the Purchased MPQ Tokens constitute securities they may be subject to transfer and other restrictions under applicable laws and regulations. Purchaser was not formed for the specific purpose of entering into this Purchase Agreement or purchasing the Securities, and Purchaser is purchasing the Securities for Purchaser’s own account for investment, not as a nominee or agent, and not with a view to, or for resale in connection with, the distribution thereof. Purchaser does not presently intend to, and has not entered into any contract, undertaking, agreement or other arrangement to, sell, grant any participation in or otherwise transfer or distribute the Securities under this Purchase Agreement. Purchaser has such knowledge and experience in technology, financial and business matters that Purchaser is capable of evaluating the merits and risks of such investment, is able to incur a complete loss of such investment without impairing Purchaser’s financial condition and is able to bear the economic risk of such investment for an indefinite period of time.

 

 

 

 

c. If Purchaser is acquiring the Securities pursuant to Regulation D of the Securities Act of 1933, as amended (the “Securities Act”), Purchaser agrees (on Purchaser’s behalf and on behalf of any purchaser account for which Purchaser is are acquiring the Securities and the MPQ Tokens), and each subsequent holder of the Securities and MPQ Tokens by its acceptance thereof will be deemed to agree, that prior to the expiration of the applicable holding period set forth in Rule 144 under the Securities Act (“Rule 144A”), Purchaser will not offer, sell or otherwise transfer the Securities or the MPQ Tokens except (a) to ImpactPPA or any of its subsidiaries, (b) for so long as the Securities and/or MPQ Token are eligible for resale pursuant to Rule 144A, to a person Purchaser reasonably believes is a Qualified Institutional Buyer, as defined in Rule 144A (“QIB”) that purchases for its own account or for the account of a QIB to which notice is given that the transfer is being made in reliance on Rule 144A, (c) pursuant to offers and sales that occur outside the United States in accordance with Regulation S of the Securities Act and in accordance with the applicable laws in the jurisdiction in which such purchase is made, (d) pursuant to a registration statement that has been declared effective under the Securities Act, or (e) pursuant to any other available exemption from the registration requirements of the Securities Act.

 

 
10
 
 

 

 

d. Purchaser has had access, during the course of the transactions and prior to Purchaser’s execution of this Purchase Agreement, to all such information as Purchaser has deemed necessary or appropriate and that Purchaser has had, during the course of the transactions and prior to the execution of this Purchase Agreement, the opportunity to ask questions of, and receive answers from, Company concerning the terms and conditions of the transactions contemplated by this Purchase Agreement and to obtain additional information necessary to verify the accuracy of any information furnished to Purchaser or to which Purchaser had access. Purchaser has had an opportunity to review the proposed functionality and code of the MPQ Token and has read and understood Company’s materials describing Company and the MPQ Token, including the Offering Memorandum. None of Purchaser’s representations, warranties or covenants, including without limitation the foregoing, limit, expand or otherwise modify the representations and warranties of Company in Section 3 of this Purchase Agreement.

 

 

 

 

e. With the assistance of Purchaser’s own professional advisors, to the extent that Purchaser has deemed appropriate, Purchaser has made Purchaser’s own legal, tax, accounting and financial evaluation of the merits and risks of an investment in the Securities and the consequences of this Purchase Agreement. Purchaser has considered the suitability of the Securities as an investment in light of Purchaser’s own circumstances and financial condition and Purchaser is able to bear the risks associated with an investment in the Securities.

 

 

 

 

f. Other than the Offering Documents, Purchaser is not relying on (and will not at any time rely on) Company, any affiliate of Company, any representative of any of the foregoing, or any other person, firm or corporation in making Purchaser’s decision to enter into this Purchase Agreement and to purchase the Securities, it being understood that information and explanations related to the terms and conditions of the Securities and the Offering Memorandum shall not be considered investment advice or a recommendation to purchase the Securities. Company has not (i) given any guarantee or representation as to the potential success, return, effect or benefit (either legal, regulatory, tax, financial, accounting or otherwise) of an investment in the Securities or (ii) made any representation to Purchaser regarding the legality of an investment in the Securities under applicable legal investment or similar laws or regulations. In deciding to enter into this Purchase Agreement and to purchase the Securities, Purchaser is not relying on the advice or recommendations of Company. Purchaser has not relied on any representation, warranty or provision not explicitly stated in this Purchase Agreement or the Offering Memorandum; no oral or written statement has been made to Purchaser that in any way shall waive, expand or otherwise modify any of the terms or conditions of this Purchase Agreement or the disclosures set forth in the Offering Memorandum; and Purchaser expressly waives any reliance on, and any cause of action in connection with, any disclosures or statements not expressly set forth in this Purchase Agreement or the Offering Memorandum.

 

 

 

 

g. Purchaser has complied with all applicable import, re-import, export, re-export control, anti-money laundering laws, regulations guidance and programs, including the Export Administration Regulations, International Traffic in Arms Regulations, the USA Patriot Act of 2001, the Bank Secrecy Act and OFAC Regulations and similar governmental laws and regulations in other countries. Purchaser is solely responsible for compliance with such laws related to its purchase of the Right.

 

 
11
 
 

 

 

h. Purchaser has accurately completed the purchaser questionnaire attached as Schedule 1 to this Purchase Agreement and shall provide Company with any information requested by it in order to confirm Purchaser’s suitability to enter into this Purchase Agreement and purchase the Securities, including but not limited to financial information and residency information and any information required by applicable “know your customer” or “anti-money laundering” laws and regulations, as they may be promulgated from time to time.

 

 

 

 

i. Purchaser is not a citizen or resident of, is not located in and does not have a primary residence or domicile in the People’s Republic of China, South Korea or any country subject to sanctions under OFAC Regulations. Purchaser is not a person subject to sanctions under OFAC Regulations or in any jurisdiction in which access to or use of cryptocurrency or digital tokens is prohibited by law, decree, regulation, treaty or otherwise.

 

 

 

 

j. Purchaser does not intend to hinder, delay or defraud Company or any other holders of Securities or eventual MPQ Tokens or engage in any illegal conduct or unlawful activity, including without limitation in relation to money laundering, receiving the proceeds of drug trafficking or terrorist activities or receiving the proceeds of criminal activities, terrorist activities or trading with such countries as might from time to time be subject to any embargo imposed by the Security Council of the United Nations, the European Union, the United States or in any other place in the world.

 

 

 

 

k. Purchaser may not and shall not assign or transfer this Purchase Agreement (including by operation of law, by merger or otherwise) or sell, delegate or sublicense Purchaser’s Right without the express written consent of Company, which consent may be withheld by Company in its sole discretion. Any such assignment, sale, delegation or sublicense without Purchaser’s prior written consent shall be null and void, shall confer no rights on the purported assignee and may be a violation of applicable securities laws.

 

 

 

 

l. Purchaser will have no right against Company or any other Person except in the event of Company’s breach of this Purchase Agreement or intentional fraud. COMPANY’S AGGREGATE LIABILITY ARISING OUT OF OR RELATED TO THIS PURCHASE AGREEMENT, WHETHER ARISING OUT OF OR RELATED TO BREACH OF CONTRACT, TORT OR OTHERWISE, SHALL NOT EXCEED THE TOTAL OF THE AMOUNTS PAID TO COMPANY PURSUANT TO THIS PURCHASE AGREEMENT CALCULATED, WITH RESPECT TO AMOUNTS PAID IN BTC, ETH OR ANY OTHER CRYPTOCURRENCY, USING THE APPLICABLE EXCHANGE RATE SET FORTH IN THE DEFINTION OF “PURCHASE AMOUNT” AND SUBJECT IN ALL EVENTS TO SECTION 2(b). NEITHER COMPANY NOR ITS REPRESENTATIVES SHALL BE LIABLE FOR CONSEQUENTIAL, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR ENHANCED DAMAGES, LOST PROFITS OR REVENUES OR DIMINUTION IN VALUE, ARISING OUT OF OR RELATING TO ANY BREACH OF THIS PURCHASE AGREEMENT.

 

 
12
 
 

 

 

m. Other than the right to use an MPQ Token as a means to enable usage of and interaction with and within Company’s platform, applications and website, the MPQ Token underlying this Right will not grant Purchaser any:

 

 

i. ownership rights in Company;

 

 

 

 

ii. return on investment from a future issuance of a MPQ Token;

 

 

 

 

iii. profit or passive income from holding a MPQ Token; or

 

 

 

 

iv. any other express or implied rights, including without limitation any intellectual property rights, income, profit, dividend, capital equity, royalties, or any economic, governance, decision-making or voting rights related to Company or any other entity in a corporate capacity.

 

 

n. Company may establish a separate issuing entity for the MPQ Token and all rights and obligations of Company under this Purchase Agreement, including the Right, may be assigned to the issuing entity; provided however, that any such assignee assumes all rights and obligations of Company hereunder, including, without limitation, the obligations set forth in Section 2 (b) (i) hereof.

 

 

 

 

o. Purchaser acknowledges and agrees that if Purchaser is sending the Purchase Amount using cryptocurrency rather than fiat:

 

 

i. Purchaser may not send any portion of the Purchase Amount directly from a wallet public address that is provided by a cryptocurrency exchange service provider;

 

 

 

 

ii. Purchaser’s wallet public address can technically support ERC20 tokens;

 

 

 

 

iii. Purchaser is solely responsible for ensuring that the wallet public address listed on the signature page to receive MPQ Tokens is fit to receive MPQ Tokens and handle any return or refund functions, which are ERC20 tokens;

 

 

 

 

iv. any failure to comply with these requirements may lead to the loss of all or a portion of the Purchase Amount; and

 

 

 

 

v. Purchaser is solely responsible for ensuring such payment in cryptocurrency is successfully delivered to Company’s designated wallet.

 

5. Taxes; Indemnification . Purchaser shall pay all applicable taxes and duties, including without limitation any value-added tax and sales tax that may arise in connection with its purchase of the Rights and the automatic exercise of the Rights for MPQ Tokens (“ Purchaser Taxes ”). Purchaser shall promptly provide Company with any information it reasonably requests to determine whether Company is obligated to collect taxes from Purchaser. Purchaser to the fullest extent permitted by law will indemnify, defend and hold harmless Company, its affiliates and its and their respective officers, directors, employees and other representatives from any claims, damages, losses, liabilities, penalties, fines, costs and expenses (including reasonable attorneys’ fees) arising out of or relating to any third party claim concerning this Purchase Agreement, including without limitation any claims related to Purchaser Taxes.

 

 
13
 
 

 

6.

Security and Data Privacy .

 

 

 

 

a. Purchaser shall provide true and complete information to Company in relation to Purchaser’s identity as well as such other information as Company may reasonable request from time to time. Such information may include personal data as defined under the data protection laws of various jurisdictions. Personal data shall be processed in accordance with this Purchase Agreement and Company’s privacy policy, as amended from time to time and as posted on its website or otherwise made available to Purchaser upon request.

 

 

 

 

b. Purchaser shall implement reasonable measures designed to secure any device connected to the email address associated with Purchaser’s account or private keys required to access any cryptocurrency account or wallet and Purchaser’s username, password, login or other identifying credentials. In the event Purchaser is no longer in possession of a device connected with Purchaser’s account or private keys or Purchaser is not able to provide Purchaser’s login, password or other identifying credentials, Company may, in its sole discretion, and only if it is able, grant access to Purchaser’s account to any person providing additional credentials to Company. Company reserves the right to determine the additional credentials required, which may include a sworn, notarized or apostilled statement of identity. Purchaser shall be responsible for the delivery of, and shall bear all risks associated with the failure to deliver, MPQ Tokens to the correct cryptocurrency account or wallet, provided, that Company delivered the MPQ Tokens to the cryptocurrency account or wallet in accordance with, the details provided to Company by Purchaser and listed on the signature page.

 

 

 

 

c. Purchaser shall promptly provide to Company, upon its request, any information that Company deems necessary to maintain compliance with any applicable laws, regulations or policies of any jurisdiction. Purchaser acknowledges and agrees that failure to provide any such requested information to Company allows Company to refuse to issue the Right or MPQ Tokens to Purchaser until the requested information has been provided and Company has determined it is permissible to issue the Right and/or MPQ Tokens to Purchaser. Purchaser will not be entitled to a refund of its Right and no MPQ Tokens shall be issued to Purchaser if Purchaser refuses to provide information requested pursuant to this Section 6(c) or if the information provided indicates that a refund of its Right may be a violation of law under the laws of any applicable jurisdiction.

 

 

 

 

d. This Purchase Agreement may be terminated by Company in the event that it becomes aware that Purchaser’s crypto-wallet or identify information discloses any risk of crime, fraud, money laundering or other illegal or material matters or that there have been misrepresentations made by Purchaser. Purchaser is aware that applicable law or governmental authorities may not allow Company to return the Purchase Amount to Purchaser in the event of this type of termination of this Purchase Agreement. If Company is prevented from or delayed in returning some or all of the Purchase Amount pursuant to applicable law or by governmental authorities, Company shall not be liable to Purchaser for interest on the Purchase Amount or for any other losses suffered by Purchaser, including without limitation any fluctuations in the value of fiat, ETH, BTC and other cryptocurrencies.

 

 
14
 
 

 

 

e. Company may use aggregate statistical information about Purchaser’s activity on Company’s platform, applications or website for marketing or any other purpose. Company may use Purchaser’s internet protocol address to verify Purchaser’s purchase of the Right and MPQ Tokens. However, Company may not release Purchaser’s personal information to any third party without Purchaser’s consent except as permitted by law or as set forth in this Purchase Agreement or its privacy policy, as amended from time to time and as posted on its website or otherwise made available to Purchase upon request. Company’s privacy policy (as amended from time to time) is hereby incorporated into and made part of this Purchase Agreement.

 

7.

Miscellaneous .

 

 

 

 

a. The representations, warranties, covenants, agreements and other obligations of Purchaser and Company set forth herein shall survive the execution of this Agreement, the automatic exercise of the Right and the closing of the Token Sale.

 

 

 

 

b. If any provision of this Purchase Agreement shall be unlawful, void or for any reason unenforceable, then that provision shall be deemed severable from this Purchase Agreement and shall not affect the validity and enforceability of the remaining provisions of this Purchase Agreement.

 

 

 

 

c. This Agreement shall be interpreted and construed in accordance with the laws of Bahamas. Any and all claims, controversies, and causes of action arising out of or relating to this Agreement, whether sounding in contract, tort or statute, shall be governed by Bahamian law, including its statutes of limitations, without giving effect to any conflict-of-laws or other rule that would result in the application of the laws of a different jurisdiction. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement. Purchaser irrevocably agrees that the courts of the Bahamas shall have exclusive jurisdiction with respect to any and all claims, controversies and causes of action arising out of or relating to this Purchase Agreement, whether sounding in contract, tort or statute, and Purchaser waives any objection to proceedings in such courts on the grounds of venue or on the grounds that proceedings have been brought in an inconvenient forum. Nothing in this clause will limit Company’s right to take proceedings against Purchaser in any other court of competent jurisdiction, nor shall the taking of proceedings in any one of more jurisdictions preclude the taking of proceedings in other jurisdictions, whether concurrently or not, to the extent permitted by the law of such other jurisdiction.

 

 

 

 

d. Each party agrees that such party has not relied on any representation, warranty or provision not explicitly stated in this Purchase Agreement or the Offering Memorandum, and that no oral or written statement has been made to either party that in any way will waive, expand or otherwise modify any of the terms or conditions of this Purchase Agreement or the disclosures set forth in the Offering Memorandum. This Purchase Agreement and the Offering Memorandum contain a complete and exclusive statement of the terms and conditions of this Purchase Agreement and the transactions contemplated hereby. In the event there is a conflict between this Purchase Agreement and any other agreements between Purchaser and Company, this Purchase Agreement shall take precedence unless such additional terms expressly reference variation to this Purchase Agreement.

 

 
15
 
 

 

 

e. Any notice required or permitted by this Purchase Agreement will be deemed sufficient when sent by email to the relevant address listed on the signature page, as subsequently modified by written notice received by the appropriate party.

 

 

 

 

f. Purchaser is not entitled, as a holder of the Right, to vote or receive dividends or be deemed the holder of any equity interest in Company for any purpose, nor will anything contained herein be construed to confer on Purchaser, as such, any of the rights of an equity holder of Company or any right to vote for the election of directors or upon any matter submitted to equity holders at any meeting thereof, or to give or withhold consent to any corporate action or to receive notice of meetings, or to receive subscription rights or otherwise.

 

 

 

 

g. This Purchase Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter herein and supersedes all prior or contemporaneous disclosures, discussions, understandings and agreements, whether oral or written, between them. This Purchase Agreement is one of a series of similar Purchase Agreement s entered into by Company from time to time. Any provision of this Purchase Agreement may be amended, waived or modified only upon the written consent of Company and the holders of a majority, in the aggregate, of the Purchase Amounts paid to Company with respect to all Rights outstanding at the time of such amendment, waiver or modification.

 

 

 

 

h. This Purchase Agreement and any other document or other agreement delivered in connection with this Purchase Agreement or the transactions contemplated hereby may be executed in two or more counterparts (including by PDF or other electronic transmission), all of which shall be considered one and the same agreement, it being understood that Purchaser and Company need not sign the same counterpart.

 

 

 

 

i. When used in this Purchase Agreement, the words “include,” “includes” and “including” will be deemed to be followed by the words “without limitation.” Any terms defined in the singular will have a comparable meaning when used in the plural, and vice-versa. Except where the context otherwise requires, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or).

 

THE NEXT PAGE IS THE SIGNATURE PAGE.

 

 
16
 
 

 

IN WITNESS WHEREOF, the undersigned have caused this Purchase Agreement to be duly executed and delivered.

 

IMPACTPPA LIMITED

     
By:

Dan Bates

 

Chief Executive Officer

 

 

 

PURCHASER:

       
By:

Brandon Romanek

 

 

 

 

 

Name:

Brandon Romanek

 

 

 

 

 

  Title: CEO  

 

 

 

 

  Email: brandon@mblockchain.io  

 

 

 

 

 

Cell:

702-912-3982

 

 

 

 

 

 

Address:

11700 W Charleston #73 Las Vegas,NV 89135

 

 

Signature Page

 

 
 
 
 

 

Schedule 1

 

PURCHASER SUITABILITY QUESTIONNAIRE

 

Full Name of Purchaser:  Millennium BlockChain                                                                                                           

 

The information contained herein is being furnished to ImpactPPA, Limited (“ Company ”), to enable it to determine whether the undersigned is a suitable Purchaser under the Purchase Agreement with Company. Terms not defined in this questionnaire are as defined in the Purchase Agreement. Upon completion of this Questionnaire, Company may request additional information from Purchaser in order to confirm its purchaser suitability, including but not limited to financial information and residency information and any information required by applicable “know your customer” or “anti-money laundering” laws and regulations, as they may be promulgated from time to time.

 

 

1.

Purchaser must be able to verify the accuracy of each of the following statements by checking the box next to each one:

 

 

 

 

 

 

¨ Purchaser is not a citizen or primary resident of, not located in, and does not have a domicile within the People’s Republic of China (for such purposes, not including the Hong Kong and Macau Special Administrative Regions or Taiwan), South Korea or any other jurisdiction where such offer and sale is prohibited by law.

 

 

 

 

 

 

¨ Purchaser is not a citizen or resident of, is not located in, and does not have a primary residence or domicile in a country subject to sanctions under OFAC Regulations.

 

 

 

 

 

 

¨ Purchaser is not a company, an entity or an individual subject to sanctions under OFAC Regulations.

 

 

 

 

 

 

 

For your reference, here are the weblinks to relevant OFAC search sanction lists: http://www.treasury.gov/resource-center/sanctions/SDN-List/Pages/default.aspx http://www.treasury.gov/resource-center/sanctions/Programs/Pages/Programs.aspx http://www.treasury.gov/resource-center/sanctions/SDN- List/Pages/consolidated.aspx

 

 

2.

Purchaser must be able to verify the accuracy of one of the following statements by checking the box next to the one that is applicable:

 

 

 

 

 

 

¨ Purchaser is located within the United States (or was offered the Right within the United States) or is acquiring the Right for the account or benefit of a person within the United States (or who was offered the Right within the United States); Purchaser (and any person for whose account or for whose benefit Purchaser is acquiring the Right) (i) is either an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended (the “ Securities Act ”), or

 

 
 
 
 

 

 

 

(ii) has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the prospective investment.

 

 

 

 

 

 

The definition of “accredited investor” as defined in Rule 501(a) may be found at the following weblink: http://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&r=SECTION&n=17y3.0.1.1.12.0.46.176

 

 

 

 

 

 

¨ Purchaser is not located within the United States (and was not offered the Right within the United States) and is not acquiring the Right for the account or benefit of any person located within the United States (or who was offered the Right within the United States).

 

 

3.  

For Purchasers in the United Kingdom : In addition to checking the applicable box under 2 above, if Purchaser is a resident of, located in or has a primary residence in the United Kingdom, Purchaser must be able to verify the accuracy of the following statement by checking the box next to it:

 

 

 

 

 

 

¨ Purchaser is (i) an investment professional (within the meaning of article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the ‘‘ FPO ’’)); (ii) a person or entity of a kind described in article 49 of the FPO; or (iii) a certified sophisticated investor (within the meaning of article 50(1) of the FPO). A copy of the Financial Services and Markets Act 2000 may be found at the following weblink: http://www.legislation.gov.uk/uksi/2005/1529/contents/made

 

 

 

 

 

4.

For Purchasers in Canada : In addition to checking the applicable box under 2 above, if Purchaser is a resident of, located in or has a primary residence in the Canada, Purchaser must be able to verify the accuracy of the following statement by checking the box next to it:

 

 

 

 

 

 

¨

Purchaser is an “accredited investor” as defined in National Instrument 45-106 Prospect Exemptions.

 

 

 

 

 

 

 

The definition of “accredited investor” as defined in Part 2, Section 2.3 can be found at the following weblink: http://www.osc.gov.on.ca/documents/en/Securities- Category4/ni_20170119_45-106_unofficial-consolidation.pdf

 

Purchaser understands that Company will rely upon the information contained herein and any additional information requested by Company for purposes of determining Purchaser’s suitability to enter into the Purchase Agreement and invest in the Right, and Purchaser will promptly provide Company with any additional information requested by Company in connection with the foregoing.

 

THE NEXT PAGE IS THE SIGNATURE PAGE.

 

 
 
 
 

 

SIGNATURE PAGE

 

SIGNATURE BLOCK FOR INDIVIDUALS

 

SIGNATURE BLOCK FOR ENTITIES

 

 

 

 

 

Millennium BlockChain

Name of Purchaser (print)

 

Name of Purchaser (print)

 

 

 

 

 

By:

Brandon Romanek

Signature of Purchaser

 

 

Authorized Signatory

 

 

 

 

 

 

Brandon Romanek                                               CEO

 

 

(print name and title of Authorized Signatory)

Date Signed: ___________________________________

 

 

 

 

Date Signed: 5/8/2018 10:19:00 AM PDT            

 

Millennium BlockChain is receiving 3 million dollars worth of ImpactPPA tokens(MPQ) with a 50% bonus for a total amount of 4.5 million dollars worth of ImpactPPA tokens (MPQ)

 

 

 

 

 

 

Dan Bates

 

Brandon Romanek

 

 
 
 
 

 

Exhibit A

 

FORM OF WARRANT OF TIGHTNOD HOLDINGS LIMITED

 

 

 

 

 

 

EXHIBIT 10.6

 

EMPLOYMENT AGREEMENT

 

THIS EMPLOYMENT AGREEMENT (“ Agreement ”) is made this 1 day of November, 2017 (the “ Effective Date ”) between THC Therapeutics, Inc., a Nevada corporation (“ Company ”), and Brandon Romanek (“ Executive ”).

 

RECITALS

 

Company wishes to employ Executive and Executive wishes to be employed by Company in accordance with the terms and conditions set forth in this Agreement.

 

TERMS AND CONDITIONS

 

In consideration of the mutual covenants herein contained, and other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, Executive and Company agree as follows:

 

1. Employment

 

As of the Effective Date, Company hereby agrees to employ Executive, and Executive agrees to be employed by Company, as its President and Chief Executive Officer. Executive will report directly to Company’s Board of Directors. Executive’s responsibilities will include all those matters customarily assigned to a Chief Executive Officer and those which may be reasonably assigned by Company. Executive shall follow the reasonable instructions of Executive’s manager and will comply in all material respects with all rules, policies and procedures of Company as modified from time to time to the extent that they are not inconsistent with this Agreement. Executive will perform all of Executive’s responsibilities in compliance with all applicable laws.

 

2. Term of Employment

 

Employment under this Agreement shall be terminable at-will, and, in such case either Executive or Company may terminate Executive’s employment at any time with or without Cause or Good Reason, as defined in this Agreement, and without notice, subject to the requirements set forth in Section 5. Any termination of Executive’s employment by Executive or Company (other than death) shall be communicated by written notice of termination to the other party in accordance with Section 16 of this Agreement.

 

3. Compensation

 

For the duration of Executive’s employment under this Agreement, Executive shall be entitled to compensation computed and paid pursuant to the following subparagraphs and subject to applicable withholdings and deductions:

 

3.1 Salary . Executive shall be paid a gross salary at the rate of $78,000 per year (the “Annual Base Salary”), or $6,500 a month beginning November 1, 2017, with actual amounts paid to be prorated for the actual period of employment, payable in equal installments in accordance with Company’s normal payroll practices. Company may review Executive’s salary from time to time as part of a review of Executive’s performance and other relevant factors and may determine in its sole discretion whether any increase in salary shall be made.

 

 
1
 
 

 

3.2 Bonuses

 

3.2.1. During the term of this Agreement, Company will provide Executive with the opportunity for annual cash bonus awards in accordance with its management incentive plans and the financial performance targets set for Executive thereunder (“ Annual Bonus ”), with a target amount equal to 100% of the Annual Base Salary (the target bonus as a percentage of Annual Base Salary, as in effect from time to time, is hereinafter referred to as the “ Target Bonus ”). If earned, any Annual Bonus payable hereunder shall be paid between January 1st and March 15th of the year immediately following the year to which such Annual Bonus relates (the date of payment being the “Payment Date”). During the portion of the term of this Agreement commencing on the Effective Date and ending on December 31, 2018, Executive’s Target Bonus opportunity under Company’s management incentive plans will be an amount equal to the product of (A) 100% of the Annual Base Salary, multiplied by (B) a fraction (i) the numerator of which is the number of days Executive was employed by Company during 2018 and (ii) the denominator of which is 365.

 

4. Other Benefits

 

4.1 Certain Benefits. Executive may participate in employee benefit programs established by Company for personnel on a basis commensurate with Executive's position and in accordance with Company’s benefit plans and arrangements from time to time, including eligibility requirements. Company shall have the right to amend or terminate any such plans or programs. Notwithstanding the foregoing, Executive acknowledges that its participation in certain benefit programs may be limited if Executive is not viewed or treated as an employee of Company for federal income tax purposes.

 

4.2 Vacation and Holidays. Executive shall be entitled to all public holidays observed by Company. Vacation days shall be in accordance with the applicable provision of Company’s vacation policy, provided, however, that Executive shall be granted not less than 20 vacation days per year. Vacation days that have not been used within a given year may be carried forward into subsequent years in accordance with Company’s policies and procedures as may be in effect from time to time for other similarly situated executives.

 

4.3 Expenses. Company shall reimburse Executive in accordance with Company’s policies and procedures for reasonable expenses necessarily incurred in Executive’s performance of Executive’s duties against appropriate receipts and vouchers indicating the specific business purpose for each such expenditure.

 

5. Termination

 

The following provisions shall apply upon termination of Executive’s employment under applicable circumstances as set forth below. Any amount payable to Executive under this Section 5 shall be subject to all applicable federal, state and local withholdings, or payroll or other taxes. Except as set forth in this Section 5, upon termination of employment, Executive shall not be entitled to further payments, severance or other benefits arising under this Agreement or from Executive’s employment with Company or its termination, except as required by law.

 

5.1 By Company with Cause . If Company terminates Executive’s employment for Cause, Executive shall be paid unpaid wages including all Deferred Compensation and unused vacation earned through the termination date.

 

 
2
 
 

 

5.1.1. “Cause,” as used herein, shall mean Executive’s (i) willful and continued failure to perform his material duties with respect to Company or its affiliates (except where due to a physical or mental incapacity) which continues beyond fifteen (15) business days after a written demand for substantial performance is delivered to Executive by Company, (ii) conviction of or plea nolo contendere to (A) the commission of a felony by Executive, or (B) any misdemeanor that is a crime of moral turpitude, (iii) Executive’s willful and gross misconduct in connection with his employment duties, (iv) breach of the non-competition, non-solicitation or confidentiality covenants to which Executive is subject, (v) any willful and intentional act having the intended effect of injuring the reputation, business or business relationships of Company or its affiliates. No act on Executive’s part shall be deemed “willful” unless done, or omitted to be done, by Executive not in good faith and without reasonable belief that such action was in the best interest of Company. No failure of Executive or Company to achieve performance goals, in and of itself, shall be treated as a basis for termination of Executive’s employment for Cause. Notwithstanding anything herein to the contrary, no termination shall be treated as for “Cause” (and any such termination shall instead be treated as without “Cause”) unless (i) Executive has been given not less than fifteen (15) business days’ written notice by the Chief Executive Officer or the board of its intention to terminate Executive’s employment for Cause, such notice to state in detail the particular act or acts or failure or failures to act that constitute the grounds on which the proposed termination for Cause is based (the “Cause Notice”), (ii) the Cause Notice is delivered not later than sixty (60) days after the Chief Executive or board’s learning of such act or acts or failure or failures to act, and (iii) the Chief Executive or board has thereafter provided Executive with a copy of a resolution duly adopted by the board (after Executive has been given a reasonable opportunity, together with counsel, to be heard before the board) confirming that, in its judgment, grounds for Cause on the basis of the original notice exist, and no cure was timely effected.

 

5.1.2. “Good Reason,” as used herein, shall mean (i) a material reduction in Executive’s base salary or a material reduction in annual incentive compensation opportunity, in each case other than any isolated or inadvertent failure by Company that is not in bad faith and is cured within thirty (30) business days after Executive gives Company notice of such event; (ii) a material diminution in Executive’s title, duties and responsibilities, other than any isolated or inadvertent failure by Company that is not in bad faith and is cured within thirty (30) business days after Executive gives Company notice of such event; (iii) a transfer of Executive’s primary workplace by more than fifty (50) miles from his current workplace, or (iv) the failure of a successor to have assumed this Agreement in connection with any sale of the business, where such assumption does not occur by operation of law, provided that in order for an event described in this Section 5.1.2 to constitute Good Reason, Executive must provide notice to Company (in accordance with Section 16 of this Agreement) within ninety (90) business days of the initial existence of such event.

 

5.1.3. “Change of Control” shall mean the sale, lease, conveyance or other disposition of all or substantially all of the Company’s property, assets or business or the merger or consolidation of the Company with or into any other entity or any other transaction or series of related transactions in which more than fifty percent (50%) of the voting power of the Company, directly or indirectly, is disposed of.

 

 
3
 
 

 

5.2 By Company other than for Cause or Total Disability or by Executive for Good Reason . If Company terminates Executive’s employment other than for Cause or Total Disability or if Executive terminates Executive’s employment for Good Reason in the absence of Cause, Company shall pay to Executive the amounts and benefits, and cause the vesting as set forth in this Section 5.2; provided, however, that Executive’s entitlement to the amounts described in Sections 5.2.2 and 5.2.3 is conditioned upon Executive executing and not revoking a release substantially in the form attached as Exhibit A (the “Release”) within the applicable 28 or 52 day time period provided for therein (the “Applicable Release Period”); provided, however, that in any case where the first and last days of the Applicable Release Period are in two separate taxable years, any payments required to be made to Executive that are treated as deferred compensation for purposes of Code Section 409A shall be made in the later taxable year, promptly following the conclusion of the Applicable Release Period.

 

5.2.1 Unpaid wages and unused accrued vacation earned through the termination date including Deferred Compensation;

 

5.2.2 A severance payment, payable in a lump sum payment not later than fifteen (15) days following Executive’s termination date, an amount equal to the sum of (A) eighteen (18) months of the Annual Base Salary plus (B) one (1) times the Target Bonus for the year in which Executive’s employment terminates;

 

5.2.3 A pro-rated bonus equal to the product of (A) the Target Bonus that would have been earned had Executive remained employed until the end of the year of termination multiplied by (B) a fraction (i) the numerator of which is the number of days Executive was employed during the year in which Executive’s employment terminates and (ii) the denominator of which is 365 (the “Prorated Bonus”), payable in a lump sum at the time such payment would be paid in accordance with Company’s then current bonus plan;

 

5.2.4 Accelerated vesting of unvested previously awarded stock or restricted stock units, options and long-term incentive awards, such stock, options and awards to become fully vested as of the date of Executive’s termination, subject to compliance with all terms and conditions of the relevant plans.

 

5.3 Change of Control . If at any time during Executive’s employment at the Company there is a Change of Control, Executive may at his option terminate his employment and such termination shall be considered to be a Termination by the Company for reasons other than for Cause.

 

5.4 Total Disability . If Company or Executive terminates Executive’s employment due to Executive’s Total Disability, Company shall pay to Executive unpaid wages and unused accrued vacation earned through the termination date (including Deferred Compensation), and the Prorated Bonus. Vesting of Executive’s unvested previously awarded member units, options and long-term incentive awards shall accelerate, subject to compliance with all terms and conditions of the relevant plans, such options and awards to become fully vested as of Executive’s termination date. “Total Disability” as used herein shall have the same meaning as the term “Total Disability” as used in Company’s long-term disability policy in effect at the time of termination, if one exists. If Company does not have a long-term disability policy in effect at such time, the term “Total Disability” shall mean Executive’s inability (with or without such accommodation as may be required by law protecting persons with disabilities) to perform the essential functions of Executive’s duties hereunder for a period aggregating to ninety (90) calendar days in a twelve (12) month period, provided, however, that this period may be extended in the sole discretion of the Chief Executive Officer.

 

5.4 Death . If Executive’s employment terminates due to death, Company shall pay to Executive’s estate the unpaid wages and unused accrued vacation earned through the termination date, and the Prorated Bonus. Vesting of Executive’s unvested previously awarded member units, options and long-term incentive awards shall accelerate, subject to compliance with all terms and conditions of the relevant plans, such options and awards to become fully vested as of Executive’s termination date.

 

 
4
 
 

 

6. Confidential Information

 

6.1 Executive recognizes that the success of Company and its current or future Affiliates (as defined below in this Section 6) and Managed Companies depends upon the protection of information or materials that are designated as confidential and/or proprietary at the time of disclosure or should, based on their nature or the circumstances surrounding such disclosure, reasonably be deemed confidential including, without limitation, information to which Executive has access while employed by Company whether recorded in any medium or merely memorized (all such information being “ Confidential Information ”). Confidential Information includes without limitation, and whether or not such information is specifically designated as confidential or proprietary: all business plans and marketing strategies; information concerning existing and prospective markets, suppliers, and customers; financial information; information concerning the development of new products and services; and technical and non-technical data related to software programs, designs, specifications, compilations, inventions (as defined in Section 8.1), improvements, patent applications, studies, research, methods, devices, prototypes, processes, procedures and techniques. Confidential Information expressly includes information provided to Company by third parties under circumstances that require them to maintain the confidentiality of such information. Notwithstanding the foregoing, Executive shall have no confidentiality obligation with respect to disclosure of any Confidential Information that (a) was, or at any time becomes, available in the public domain other than through a violation of this Agreement or (b) Executive can demonstrate by written evidence was furnished to Executive by a third party in lawful possession thereof and who was not under an obligation of confidentiality to Company or any of its Affiliates or Managed Companies.

 

6.2 Executive agrees that during Executive’s employment and after termination of employment irrespective of cause, Executive will use Confidential Information only for the benefit of Company and will not directly or indirectly use or divulge, or permit others to use or divulge, any Confidential Information for any reason, except as authorized by Company. Notwithstanding the foregoing, Executive may disclose Confidential Information as required pursuant to an order or requirement of a court, administrative agency or other government body, provided Executive has notified Company immediately after receipt of such order or requirement and allowed Company a meaningful opportunity to apply for protective measures, if time permits.

 

6.3 Executive hereby assigns to Company any rights Executive may have or acquire in such Confidential Information and acknowledges that all Confidential Information shall be the sole property of Company or its assigns.

 

6.4 There are no rights granted or any understandings, agreements or representations between the parties hereto, express or implied, regarding Confidential Information that are not specified herein.

 

6.5 Executive’s obligations under this Section 6 are in addition to any obligations that Executive has under state or federal law.

 

6.6 Executive agrees that in the course of Executive’s employment with Company, Executive will not violate in any way the rights that any entity, including former employers, has with regard to trade secrets or proprietary or confidential information.

 

6.7 Executive’s obligations under this Section 6 shall survive the termination of this Agreement for a period of eighteen (18) months thereafter.

 

 
5
 
 

 

7. Return of Company Property

 

Executive acknowledges that all tangible items containing any Confidential Information, including without limitation memoranda, photographs, records, reports, manuals, drawings, blueprints, prototypes, notes, documents, drawings, specifications, software, media and other materials, including any copies thereof (including electronically recorded copies), are the exclusive property of Company, and Executive shall deliver to Company all such material in Executive’s possession or control upon Company’s request and in any event upon the termination of Executive’s employment with Company. Executive shall also return any keys, equipment, identification or credit cards, or other property belonging to Company upon termination or request.

 

8. Inventions

 

8.1 Executive understands and agrees that all Inventions are the exclusive property of Company. As used in this Agreement, “Inventions” shall include without limitation ideas, discoveries, developments, concepts, inventions, original works of authorship, trademarks, mask works, trade secrets, ideas, data, information, know-how, documentation, formulae, results, prototypes, designs, methods, processes, products, formulas and techniques, improvements to any of the foregoing, and all other matters ordinarily intended by the words “intellectual property,” whether or not patentable, copyrightable, or otherwise able to be registered, which are developed, created, conceived of or reduced to practice by Executive, alone or with others, during Executive’s employment with Company or Affiliates, whether or not during working hours or within three (3) months thereafter and related to Company’s then existing or proposed business. In recognition of Company’s ownership of all Inventions, Executive shall make prompt and full disclosure to Company of, will hold in trust for the sole benefit of Company, and (subject to Section 8.2 below) hereby assigns, and agrees to assign in the future, exclusively to Company all of Executive’s right, title, and interest in and to any and all such Inventions.

 

8.2 Executive understands that Executive’s obligation to assign inventions shall not apply to any inventions for which no equipment, supplies, facilities, or trade secret information of Company was used and that was developed entirely on Executive’s own time, unless (a) the invention relates (i) directly to the business of Company, or (ii) to Company’s actual or demonstrably anticipated research or development, or (b) the invention results from any work performed by Executive for Company.

 

8.3 To the extent any works of authorship created by Executive made within the scope of employment may be considered “works made for hire” under United States copyright laws, they are hereby agreed to be works made for hire. To the extent any such works do not qualify as a “work made for hire” under applicable law, and to the extent they include material subject to copyright, Executive hereby irrevocably and exclusively assigns and conveys all rights, title and interests in such works to Company subject to no liens, claims or reserved rights. Executive hereby waives any and all “moral rights” that may be applicable to any of the foregoing, for any and all uses, alterations, and exploitation thereof by Company, or its successors, assignees or licensees. To the extent that any such “moral rights” may not be waived in accordance with law, Executive agrees not to bring any claims, actions or litigation against Company or its successors, assignees or licensees, based on or to enforce such rights. Without limiting the preceding, Executive agrees that Company may in its discretion edit, modify, recast, use, and promote any such works of authorship, and derivatives thereof, without the use of Executive’s name or image, without compensation to Executive other than that expressly set forth herein.

 

 
6
 
 

 

8.4 Executive hereby waives and quitclaims to Company any and all claims of any nature whatsoever that Executive now or hereafter may have for infringement of any patent or patents from any patent applications for any Inventions. Executive agrees to cooperate fully with Company and take all other such acts requested by Company (including signing applications for patents, assignments, and other papers, and such things as Company may require) to enable Company to establish and protect its ownership in any Inventions and to carry out the intent and purpose of this Agreement, during Executive’s employment or thereafter. If Executive fails to execute such documents by reason of death, mental or physical incapacity or any other reason, Executive hereby irrevocably appoints Company and its officers and agents as Executive’s agent and attorney-in-fact to execute such documents on Executive’s behalf.

 

8.5 Executive agrees that there are no Inventions made by Executive prior to Executive’s employment with Company and belonging to Executive that Executive wishes to have excluded from this Section 8 (the “Excluded Inventions”). If during Executive’s employment with Company, Executive uses in the specifications or development of, or otherwise incorporates into a product, process, service, technology, or machine of Company, or otherwise uses any invention, proprietary know-how, or other intellectual property in existence before the Effective Date owned by Executive or in which Executive has any interest (“Existing Know-How”), Company is hereby granted and shall have a non-exclusive, royalty-free, fully paid up, perpetual, irrevocable, worldwide right and license under the Existing Know-How (including any patent or other intellectual property rights therein) to make, have made, use, sell, reproduce, distribute, make derivative works from, publicly perform and display, and import, and to sublicense any and all of the foregoing rights to that Existing Know-How (including the right to grant further sublicenses) without restriction as to the extent of Executive’s ownership or interest, for so long as such Existing Know-How is in existence and is licensable by Executive.

 

9. Nonsolicitation

 

9.1 During Executive’s employment with Company, and for a period expiring eighteen (18) months after the termination of Executive’s employment, regardless of the reason, if any, for such termination, Executive shall not, directly or indirectly:

 

9.1.1 solicit or entice away or in any other manner persuade or attempt to persuade any officer or employee of Company to alter or discontinue his or her relationship with Company;

 

9.1.2 solicit from any person or entity that was a customer of Company during Executive’s employment with Company, any business of a type or nature similar to the business of Company or any of its Affiliates or Managed Companies with such customer;

 

9.1.3 solicit, divert, or in any other manner persuade or attempt to persuade any supplier of Company to discontinue its relationship with Company; 9.1.4 engage in or participate in the development, engineering or sale of smart sprinkler controllers; or

 

9.1.5 solicit, divert, take away any customers of Company.

 

 
7
 
 

 

9.2 Nothing in Section 9.1 limits Executive’s ability to hire an employee of Company or any of its Affiliates or Managed Companies in circumstances under which such employee first contacts Executive regarding employment and Executive does not violate any of Sections 9.1.1, 9.1.2, 9.1.3, 9.1.4 or 9.1.5 herein.

 

9.3 Company and Executive agree that the provisions of this Section 9 do not impose an undue hardship on Executive and are not injurious to the public; that this provision is necessary to protect the business of Company; that the nature of Executive’s responsibilities with Company under this Agreement provide and/or will provide Executive with access to Confidential Information that is valuable and confidential to Company; that Company would not employ Executive if Executive did not agree to the provisions of this Section 9; that this Section 9 is reasonable in terms of length of time and scope; and that adequate consideration supports this Section 9. In the event that a court determines that any provision of this Section 9 is unreasonably broad or extensive, Executive agrees that such Court should narrow such provision to the extent necessary to make it reasonable and enforce the provision as narrowed.

 

10. Remedies

 

Notwithstanding any other provisions of this Agreement regarding dispute resolution, including Section 10, Executive agrees that Executive’s violation of any of Sections 6, 7, 8 or 9 of this Agreement may cause Company irreparable harm which would not be adequately compensated by monetary damages and that an injunction may be granted by any court or courts having jurisdiction, restraining Executive from violation of the terms of this Agreement, upon any breach or threatened breach of Executive of the obligations set forth in any of Sections 6, 7, 8 or 9. The preceding sentence shall not be construed to limit Company from any other relief or damages to which it may be entitled as a result of Executive’s breach of any provision of this Agreement, including Sections 6, 7, 8 or 9.

 

11. Venue

 

Except for proceedings for injunctive relief, the venue of any litigation arising out of Executive’s employment with Company or interpreting or enforcing this Agreement shall lie in a court of appropriate jurisdiction in Clark County, Nevada.

 

12. Fees

 

The prevailing party will be entitled to its reasonable costs and attorneys’ fees incurred in any litigation relating to the interpretation or enforcement of this Agreement.

 

13. Disclosure

 

Executive agrees fully and completely to reveal the terms of Sections 6, 7, 8 or 9 of this Agreement to any future employer or business contacts of Executive and authorizes Company, at their election, to make such disclosure.

 

14. Representation of Executive

 

Executive represents and warrants to Company that Executive is free to enter into this Agreement and has no commitment, arrangement or understanding to or with any party that restrains or is in conflict with Executive’s performance of the covenants, services and duties provided for in this Agreement. Executive shall not in the course of Executive’s employment violate any obligation that Executive may owe any third party, including former employers.

 

 
8
 
 

 

15. Assignability

 

During Executive’s employment, this Agreement may not be assigned by either party without the written consent of the other; provided, however, that Company may assign its rights and obligations under this Agreement without Executive’s consent to any of its Affiliates or to a successor by sale, merger or liquidation, if such successor carries on the business substantially in the form in which it is being conducted at the time of the sale, merger or liquidation and notwithstanding anything in this Agreement, such assignment and Executive’s transfer of employment thereunder shall not be deemed a termination of employment under Section 5.2 of this Agreement. This Agreement is binding upon Executive, Executive’s heirs, personal representatives and permitted assigns and on Company, its successors and assigns.

 

16. Notices

 

All notices, requests, consents, and other communications required or permitted to be given hereunder, shall be in writing and shall be deemed to have been duly give if delivered personally or sent by Fedex, or mailed first class postage prepaid as follows:

 

 

If to Employee:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

If to Company:

 

 

 

 

 

 

 

 

 

 

  

17. Severability

 

If any provision of this Agreement or compliance by any of the parties with any provision of this Agreement constitutes a violation of any law, or is or becomes unenforceable or void, then such provision, to the extent only that it is in violation of law, unenforceable or void, shall be deemed modified to the extent necessary so that it is no longer in violation of law, unenforceable or void, and such provision will be enforced to the fullest extent permitted by law. If such modification is not possible, said provision, to the extent that it is in violation of law, unenforceable or void, shall be deemed severable from the remaining provisions of this Agreement, which provisions will remain binding on the parties.

 

18. Waivers

 

No failure on the part of either party to exercise, and no delay in exercising, any right or remedy hereunder will operate as a waiver thereof; nor will any single or partial waiver of a breach of any provision of this Agreement operate or be construed as a waiver of any subsequent breach; nor will any single or partial exercise of any right or remedy hereunder preclude any other or further exercise thereof or the exercise of any other right or remedy granted hereby or by law.

 

19. Governing Law

 

The validity, construction and performance of this Agreement shall be governed by the laws of the State of Nevada without regard to the conflicts of law provisions of such laws.

 

 
9
 
 

 

20. Survival

 

Notwithstanding anything to the contrary in this Agreement, the obligations of this Agreement shall survive a termination of this Agreement or the termination of Executive’s employment with Company, except for obligations under Sections 1, 2, 3 and 4.

 

21. Entire Agreement

 

This instrument constitutes the entire agreement of Executive and Company with respect to the subject matter herein and supersedes all prior such agreements and understandings, and there are no other such representations or agreements other than as stated in this Agreement related to the terms and conditions of Executive’s employment with Company. This Agreement may be changed only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension or discharge is sought, and any such modification agreed to by Company must, in order to be binding upon Company, be signed by the Chief Executive Officer of Company.

 

22. Executive’s Recognition of Agreement

 

Executive acknowledges that Executive has read and understood this Agreement and agrees that its terms are necessary for the reasonable and proper protection of the business of Company. Executive acknowledges that Executive has been advised by Company that Executive is entitled to have this Agreement reviewed by an attorney of his selection, at Executive’s expense, prior to signing, and that Executive has either done so or elected to forgo that right.

 

23. Delayed Payment Under CBertain Circumstances

 

Notwithstanding anything in this Agreement to the contrary, to the extent required to avoid an excise tax under Internal Revenue Code Section 409A, the payment of any compensation pursuant to Sections 5.2.2, 5.2.3, 5.3 or 5.4, Executive’s separation from service shall be delayed for a period of six (6) months if Executive is a “specified employee” as defined in Code Section 409A(a)(2)(B)(i). In such a circumstance, the payments that would otherwise have been made during such six (6) month period will be paid on the

six-month anniversary of Executive's separation from service.

 

 
10
 
 

 

IN WITNESS WHEREOF , the parties have duly signed and delivered this Agreement as of the day and year first above written.

 

 

 

COMPANY:

 

 

     

THC Therapeutics, Inc.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Name: Brandon Romanek  
 

 

Title: Chief Executive Officer  

 

 

 

 

 

EXECUTIVE:

 

 

 

 

 

 

 

 

 

Brandon Romanek

 

 

 

 

 

 

 

 

 

Individually

 

 

 

 

 
11
 
 

 

EXHIBIT A

 

RELEASE

 

[Company Name] RELEASE

 

This Release (“Release”) is entered into by (“Executive”) with respect to the termination of the employment relationship between Executive and [Company Name] (the “Company”).

 

1. Executive’s last day of employment with the Company was (“Termination Date”). Executive shall not seek future employment or any right to future employment with the Company, its parent or any of its affiliates.

 

2. Executive has been provided all compensation and benefits earned Executive by virtue of employment with Employer, except to the extent that Executive may still be owed salary earned during the last pay period prior to the Termination Date and accrued unused vacation and excluding amounts payable to Executive under the Employment Agreement between Executive and Company dated (“Employment Agreement”).

 

3. As consideration for the obligations undertaken by the Company pursuant to the Employment Agreement, Executive hereby releases Company and its affiliates, and their respective officers, directors, and employees, from any and all claims, causes of action, and liability for damages of whatever kind, known or unknown, arising from or relating to Executive’s employment and separation from employment (“Released Claims”). Released Claims include claims (including claims to attorneys’ fees), damages, causes of action, and disputes of any kind whatsoever, including without limitation all claims for wages, employee benefits, and damages arising out of any: contracts, express or implied; tort; discrimination; wrongful termination; any federal, state, local, or other governmental statute or ordinance, including, without limitation Title VII of the Civil Rights Act of 1964, as amended, the Age Discrimination in Employment Act, as amended (“ADEA”), the Fair Labor Standards Act, the Washington Law Against Discrimination, the Washington Minimum Wage Act and the Employee Retirement Income Security Act of 1974, as amended (“ERISA”); and any other legal limitation on the employment relationship. Notwithstanding the foregoing, “Released Claims” do not include claims for breach or enforcement of this Agreement, claims that arise after the execution of this Agreement, claims to vested benefits under ERISA, workers’ compensation claims, or any other claims that may not be released under this Agreement in accordance with applicable law. This waiver and release shall not apply to claims arising after Executive’s execution of this Release.

 

4. Executive represents and warrants that Executive has not filed any litigation based on any Released Claims. Executive covenants and promises never to file, press, or join in any lawsuit based on any Released Claim and agrees that any such claim, if filed by Executive, shall be dismissed, except that this covenant and promise does not apply to any claim of Executive challenging the validity of this Agreement in connection with claims arising under the ADEA. Executive represents and warrants that Executive is the sole owner of any and all Released Claims that Executive may have; and that Executive has not assigned or otherwise transferred Executive’s right or interest in any Released Claim.

 

5. Executive represents and warrants that Executive has turned over to Employer all property of Employer, including without limitation all files, memoranda, keys, manuals, equipment, data, records, and other documents, including electronically recorded documents and data that Executive received from Employer or its employees or that Executive generated in the course of employment with Employer.

 

 
12
 
 

 

6. Executive specifically agrees as follows:

 

a. Executive is knowingly and voluntarily entering into this Release;

 

b. Executive acknowledges that the Company is providing benefits in the form of payments and compensation, to which Executive would not otherwise be entitled in the absence of Executive’s entry into this Release, as consideration for Executive’s entering into this Release;

 

c. Executive is hereby advised by this Release to consult with an attorney prior to executing this Release;

 

d. Executive understands he has a period of at least twenty-one (21) days from the date a copy of this Release is provided to Executive in which to consider and sign the Release (during which the offer will remain open), and that Executive has an additional seven (7) days after signing this Release within which to revoke acceptance of the Release;

 

e. If during the twenty-one (21) day waiting period Executive should elect not to sign this Release, or during the seven (7) day revocation period Executive should revoke acceptance of the Release, then this Release shall be void and the effective date of this Release shall be the eighth day after Executive signs and delivers this Release, provided he has not revoked acceptance; and

 

f. Executive may accept this Agreement before the expiration of the twenty-one (21) days, in which case Executive shall waive the remainder of the 21-day waiting period.

 

7. Executive hereby acknowledges his obligation to comply with the obligations that survive termination of the Employment Agreement, including without limitation those obligations with respect to confidentiality, inventions and nonsolicitation.

 

8. With regard to the subject matter herein, this Release shall be interpreted pursuant to Nevada law.

 

 

On Behalf of Executive

 

 

 

 

 

 

 

 

Signature

 

 

 

 

 

 

 

 

Name

 

 

 

 

 

 

 

 

Date

 

 

 

13

 

EXHIBIT 10.8

 

MILLENNIUM BLOCKCHAIN INC.

 

COMMON STOCK PURCHASE AGREEMENT

 

THIS COMMON STOCK PURCHASE AGREEMENT (the “ Agreement ”) is made as of July 31, 2018 (the “ Execution Date ”), by and between Millennium Blockchain Inc., a Nevada corporation (the “ Company ”), and Robot Cache, S.L., a Spanish sociedad limitada (the “ Investor ”).

 

RECITALS

 

WHEREAS , pursuant to terms and subject to the conditions set forth in this Agreement, the Company desires to sell to the Investor, and the Investor desires to purchase from the Company, shares of the Company’s common stock, $0.001 par value per share (the “ Common Stock ”), as well as warrants to purchase Common Stock;

 

NOW, THEREFORE , in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

SECTION 1

 

Purchase and Sale of Shares

 

1.1 Sale of Shares . Subject to the terms and conditions hereof, the Company will issue and sell to the Investor, and the Investor will purchase from the Company, at the Closing (as defined below), (i) six million (6,000,000) shares (the “ Shares ”) of Common Stock, and (ii) non-cashless warrants to purchase three million (3,000,000) additional shares of Common Stock on the terms set forth in the Common Stock Purchase Warrants attached hereto as Exhibit C , all in consideration for the right to receive ten million five hundred thirty six thousand three hundred fifteen (10,536,315) cryptographic tokens, known as “IRON,” of the Investor (the “ Tokens ”).

 

1.2 Closing . The purchase and sale of the Shares shall take place remotely via the exchange of documents and signatures (the “ Closing ”) on the first business day following the satisfaction or waiver of the conditions set forth in Section 4 and Section 5 (other than those conditions that by their nature are to be satisfied at or immediately prior to the Closing, but subject to the satisfaction or waiver of those conditions) or at such other date, time and place as the Company and the Investor may agree in writing (the “ Closing Date ”). At the Closing, the Company will deliver or cause to be delivered to the Investor a copy of the irrevocable instructions to the Company’s transfer agent instructing such transfer agent to issue the Shares into book-entry form to the Investor and, concurrently, the Investor and the Company shall enter into the Simple Agreement for Future Token, attached hereto as Exhibit A (the “SAFT” ), which shall grant the Company the right to receive the Tokens on the terms and subject to the conditions set forth in the SAFT.

 

SECTION 2

 

Representations and Warranties of the Company

 

Except as set forth on the Schedule of Exceptions attached hereto as Exhibit B , the Company hereby represents and warrants the following as of the Execution Date:

 

2.1 Organization and Good Standing and Qualifications . The Company is a corporation duly organized, validly existing and in good standing under the State of Nevada and has all requisite power and authority to own, lease, operate and occupy its properties and to carry on its business as now being conducted. Except as set forth on the Schedule of Exceptions, the Company does not own more than fifty percent (50%) of the outstanding capital stock of or control any other business entity. The Company is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction in which the nature of the business conducted or property owned or leased by it makes such qualification necessary, other than those in which the failure so to qualify or be in good standing would not have a Material Adverse Effect. For purposes of this Agreement, “ Material Adverse Effect ” shall mean any event or condition that would reasonably be likely to have a material adverse effect on the business, operations, properties, prospects or financial condition of the Company and its consolidated subsidiaries, taken as a whole, or adversely affect in any material respect the ability of the Company to perform its obligations, or Investor’s rights, under this Agreement.

 
 
1
 
 

 

2.2 Authorization . (i) The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement; (ii) the execution and delivery of this Agreement by the Company, the consummation by the Company of the transactions contemplated hereby and thereby and the issuance, sale and delivery of the Shares have been duly authorized by all necessary corporate action, and no further consent or authorization of the Company, its board of directors or its shareholders is required; and (iii) this Agreement has been duly executed and delivered and constitutes a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, securities, insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies, or indemnification or by other equitable principles of general application.

 

2.3 Valid Issuance of Shares . The issuance of the Shares has been duly authorized by all requisite corporate action. When the Shares are issued, sold and delivered in accordance with the terms of this Agreement for the consideration expressed herein, the Shares will be duly and validly issued and outstanding, fully paid, and nonassessable, and will be free of all liens and restrictions on transfer other than restrictions on transfer under applicable state and federal securities laws and the Investor shall be entitled to all rights accorded to a holder of shares of Common Stock. The Company has reserved a sufficient number of shares of Common Stock for issuance to the Investor in accordance with the Company’s obligations under this Agreement.

 

2.4 No Conflict . The execution, delivery and performance by the Company of this Agreement and the consummation of the transactions contemplated hereby do not and will not (i) contravene or conflict with the Articles of Incorporation of the Company, (ii) contravene or conflict with or violate any federal, state, local or foreign statute, rule, regulation, judgment, order, writ or decree binding upon or applicable to the Company, (iii) contravene or conflict with or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any material contract or other material agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation binding upon or applicable to the Company, or (iv) create or impose a lien, charge or encumbrance on any property of the Company under any agreement or other commitment to which the Company is a party or by which the Company is bound, in the case of each of clauses (iii) and (iv), which would have a Material Adverse Effect.

 

2.5 Consents. Except for the consents that have been obtained on or prior to the Closing or filings required to be made by the Company with federal or state securities commissions or the OTC Markets Group Inc. (“ OTC Market ”), no consent, approval, license, order, authorization, registration, declaration or filing with or of any governmental entity or other person is required to be done or obtained by the Company in connection with (i) the execution and delivery by the Company of this Agreement, (ii) the performance by the Company of its obligations under this Agreement, (iii) the consummation by the Company of any of the transactions contemplated by this Agreement, including the issuance and sale of the Shares in accordance with the terms hereof.

 

2.6 Compliance . The Company is not, and the execution and delivery of this Agreement and the consummation of the transactions contemplated herewith will not cause the Company to be (i) in violation or default of any provision of any instrument, mortgage, deed of trust, loan, contract, or commitment, (ii) in violation of any provision of any judgment, decree, order or obligation to which it is a party or by which it or any of its properties or assets are bound, or (iii) in violation of any federal, state or, to its knowledge, local statute, rule or governmental regulation, in the case of each of clauses (i), (ii) and (iii), which would have a Material Adverse Effect.

 
 
2
 
 

 

2.7 Capitalization . Immediately prior to the Execution Date, a total of 124,035,891 shares of Common Stock are issued and outstanding, 10,000,000 shares of Preferred Stock are authorized, of which 3,000,000 shares are designated Series A Preferred Stock, with 2,060,000 shares of Series A Preferred Stock issued and outstanding, and 165,000 shares of which are designated Series B Preferred Stock, all of which are issued and outstanding. The outstanding shares of capital stock of the Company have been duly and validly issued and are fully paid and nonassessable, were not issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities, and have been issued in compliance with all federal and state securities laws, in each case except as would not reasonably be expected to have a Material Adverse Effect. Except as set forth in the OTC Documents (as defined below), there are no outstanding rights (including, without limitation, preemptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any unissued shares of capital stock or other equity interest in the Company, or any contract, commitment, agreement, understanding or arrangement of any kind to which the Company is a party and relating to the issuance or sale of any capital stock of the Company, any such convertible or exchangeable securities or any such rights, warrants or options. Without limiting the foregoing, no preemptive right, co-sale right, right of first refusal, registration right, or other similar right exists with respect to the Shares or the issuance and sale thereof. There are no shareholder agreements, voting agreements or other similar agreements with respect to the voting of the Shares to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s shareholders.

 

2.8 OTC Documents, Financial Statements . The Common Stock is currently listed or traded on the OTC Market, and the Company has timely filed all reports, schedules, forms, statements and other documents required to be filed by the Company with the OTC Market pursuant to the reporting requirements for listing as a OTC company (all of the foregoing, including filings incorporated by reference therein, being referred to herein as the “ OTC Documents ”). The Company is not in violation of the listing requirements of the OTC Market and has no knowledge of any facts that would reasonably lead to delisting or suspension of its Common Stock from the OTC Market in the foreseeable future. As of its date, each OTC Document filed complied in all material respects with the requirements of the OTC Market and the rules and regulations of the OTC Market promulgated thereunder applicable to such document, and, as of its date, after giving effect to the information disclosed and incorporated by reference therein, no such OTC Document contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements of the Company included in the OTC Documents filed with the OTC Market, compiled as to form and substance in all material respects with applicable accounting requirements and the published rules and regulations of the OTC Market or other applicable rules and regulations with respect thereto. Such financial statements have been prepared in accordance with generally accepted accounting principles (“ GAAP ”) applied on a consistent basis during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary statements), and fairly present in all material respects the financial position of the Company as of the dates thereof and the results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments).

 

2.9 Internal Controls and Procedures. The Company maintains adequate disclosure controls and procedures. Such disclosure controls and procedures are effective as of the latest date of management’s evaluation of such disclosure controls and procedures to ensure that all material information required to be disclosed by the Company in the reports that it files or furnishes to the OTC Market is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the OTC Market. The Company maintains a system of internal controls over financial reporting sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; and (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP.

 

2.10 Material Adverse Change . Except as disclosed in the OTC Documents, since January 31, 2018, no event or series of events has or have occurred that would, individually or in the aggregate, have a Material Adverse Effect.

 

2.11 No Undisclosed Liabilities . To the Company’s knowledge, the Company and its consolidated subsidiaries, taken as a whole, do not have any liabilities, obligations, claims or losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) that would be required to be disclosed on a balance sheet of the Company and its consolidated subsidiaries (including the notes thereto) in conformity with GAAP and are not disclosed in the OTC Documents, other than those incurred in the ordinary course of the Company’s or its subsidiaries’ respective businesses since January 31, 2018.

 

2.12 No Undisclosed Events or Circumstances . Except for the transactions contemplated by this Agreement, event or circumstance has occurred or exists with respect to the Company, its subsidiaries, or their respective businesses, properties, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed and which, individually or in the aggregate, would have a Material Adverse Effect.

 
 
3
 
 

 

2.13 Actions Pending . There is no action, suit, claim, investigation or proceeding pending or, to the knowledge of the Company, threatened against the Company or any subsidiary which questions the validity of this Agreement or the transactions contemplated hereby or any action taken or to be taken pursuant hereto. Except as set forth in the OTC Documents, there is no material action, suit, claim, investigation or proceeding pending or, to the knowledge of the Company, threatened, against or involving the Company, any subsidiary, or any of their respective properties or assets. Except as set forth in the OTC Documents, no material judgment, order, writ, injunction or decree or award has been issued by or, to the knowledge of the Company, requested of any court, arbitrator or governmental agency.

 

2.14 Compliance with Law . The businesses of the Company and its subsidiaries have been and are presently being conducted in material compliance with all applicable federal, state and local governmental laws, rules, regulations and ordinances. The Company and each of its subsidiaries have all material franchises, permits, licenses, consents and other governmental or regulatory authorizations and approvals necessary for the conduct of its business as now being conducted by it, except for such franchises, permits, licenses, consents and other governmental or regulatory authorizations and approvals, the failure to possess which, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect.

 

2.15 Exemption from Registration, Valid Issuance . Subject to, and in reliance on, the representations, warranties and covenants made herein by the Investor, the issuance and sale of the Shares in accordance with the terms and on the bases of the representations and warranties set forth in this Agreement, may be issued and sold without registration under the Securities Act of 1933, as amended (the “ Securities Act ”), pursuant to Section 4(a)(2) thereof. The sale and issuance of the Shares pursuant to, and the Company’s performance of its obligations under, this Agreement will not (i) result in the creation or imposition of any liens, charges, claims or other encumbrances upon the Shares or any of the assets of the Company, or (ii) entitle the holders of any outstanding shares of capital stock of the Company to preemptive or other rights to subscribe to or acquire the Shares or other securities of the Company.

 

2.16 Transfer Taxes . All stock transfer or other taxes (other than income taxes) that are required to be paid in connection with the sale and transfer of the Shares to be sold to Investor hereunder will be, or will have been, fully paid or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with.

 

2.17 Investment Company . The Company is not, and after giving effect to the offering and sale of the Shares will not be, an “investment company” as defined in the Investment Company Act of 1940, as amended.

 

2.18 Brokers . No brokers, finders or financial advisory fees or commissions will be payable by the Company or any of its subsidiaries in respect of the transactions contemplated by this Agreement.

 

SECTION 3

 

Representations and Warranties of the Investor

 

The Investor hereby represents and warrants the following as of the Execution Date:

 

3.1 Experience . The Investor is experienced in evaluating companies such as the Company, has such knowledge and experience in financial and business matters that the Investor is capable of evaluating the merits and risks of the Investor’s perspective investment in the Company, and has the ability to bear the economic risks of the investment.

 

3.2 Investment . The Investor is acquiring the Shares for investment for the Investor’s own account and not with the view to, or for resale in connection with, any distribution thereof. The Investor understands that the Shares have not been and will not be registered under the Securities Act by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent as expressed herein. The Investor further represents that it does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participation to any third person with respect to any of the Shares.

 
 
4
 
 

 

3.3 Rule 144. The Investor is aware of the provisions of Rule 144 promulgated under the Securities Act which permit limited resale of shares purchased in a private placement subject to the satisfaction of certain conditions. In connection therewith, the Investor acknowledges that the Company will make a notation on its stock books regarding the restrictions on transfers set forth in this Section 3 , subject to Section 6.3 , and will transfer the Shares on the books of the Company only to the extent not inconsistent herewith and therewith.

 

3.4 Access to Information . The Investor has received and reviewed information about the Company and has had an opportunity to discuss the Company’s business, management and financial affairs with its management and to review the Company’s facilities. The Investor has had a full opportunity to ask questions of and receive answers from the Company, or any person or persons acting on behalf of the Company, concerning the terms and conditions of an investment in the Shares. The Investor is not relying upon, and has not relied upon, any statement, representation or warranty made by any person, except for the statements, representations and warranties contained in this Agreement.

 

3.5 Authorization . This Agreement when executed and delivered by the Investor will constitute a valid and legally binding obligation of the Investor, enforceable in accordance with its terms, subject to: (i) judicial principles respecting election of remedies or limiting the availability of specific performance, injunctive relief, and other equitable remedies; and (ii) bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in effect generally relating to or affecting creditors’ rights.

 

3.6 Investor Status . The Investor acknowledges that it is an “accredited investor” as defined in Rule 501(a) of Regulation D of the Securities Act, and the Investor shall submit to the Company such further assurances of such status as may be reasonably requested by the Company.

 

3.8 No Conflicts . The execution, delivery and performance by the Investor of this Agreement do not and will not (i) contravene or conflict with the organizational documents of the Investor, (ii) contravene or conflict with or constitute a default under any material provision of any law binding upon or applicable to the Investor or (iii) contravene or conflict with or constitute a default under any material contract or other material agreement, judgment, order, writ, injunction, citation, award or decree binding upon or applicable to the Investor.

 

3.9 Consent . No consent, approval, license, order, authorization, registration, declaration or filing with or of any governmental entity or other person is required to be done or obtained by the Investor in connection with (i) the execution and delivery by the Investor of this Agreement, (ii) the performance by the Investor of its obligations under this Agreement or (iii) the consummation by the Investor of any of the transactions contemplated by this Agreement.

 

SECTION 4

 

Conditions to Investor’s Obligations at Closing

 

The obligations of the Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions, any of which may be waived in writing by the Investor (except to the extent not permitted by law):

 

4.1 No Injunction, etc . No preliminary or permanent injunction or other binding order, decree or ruling issued by a court or governmental agency shall be in effect which shall have the effect of preventing the consummation of the transactions contemplated by this Agreement. No action or claim shall be pending before any court or quasi- judicial or administrative agency of any federal, state, local or foreign jurisdiction or before any arbitrator wherein an unfavorable injunction, judgment, order, decree, ruling or charge would be reasonably likely to (i) prevent consummation of any of the transactions contemplated by this Agreement, (ii) cause any of the transactions contemplated by this Agreement to be rescinded following consummation or (iii) have the effect of making illegal the purchase of, or payment for, any of the Shares by the Investor.

 
 
5
 
 

 

4.2 Representations and Warranties . The representations and warranties of the Company contained in Section 2 shall have been true and correct in all material respects (except for such representations and warranties that are qualified by “materiality” or “Material Adverse Effect” which shall be true and correct in all respects) on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the Closing.

 

4.3 Performance . The Company shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the Closing.

 

4.5 Securities Laws . The offer and sale of the Shares to the Investor pursuant to this Agreement shall be exempt from the registration requirements of the Securities Act and the registration and/or qualification requirements of all applicable state securities laws.

 

4.6 Authorizations . All authorizations, approvals or permits, if any, of any governmental authority or regulatory body that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall have been duly obtained and shall be effective on and as of the Closing.

 

SECTION 5

 

Conditions to the Company’s Obligations at Closing

 

The obligations of the Company to the Investor under this Agreement are subject to the fulfillment on or before the Closing of each of the following conditions by the Investor:

 

5.1 Representations and Warranties . The representations and warranties of the Investor contained in Section 3 shall be true and correct in all material respects (except for such representations and warranties that are qualified by materiality which shall be true and correct in all respects) on and as of the Closing with the same effect as though such representations and warranties had been made on and as of the Closing.

 

5.2 Securities Law Compliance . The offer and sale of the Shares to the Investor pursuant to this Agreement shall be exempt from the registration requirements of the Securities Act and the registration and/or qualification requirements of all applicable state securities laws.

 

5.3 Authorization . All authorizations, approvals or permits, if any, of any governmental authority or regulatory body that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall have been duly obtained and shall be effective on and as of the Closing.

 

SECTION 6

 

Resales; Covenants

 

6.1 Participation Right .

 

(a) The Investor hereby grants the Company the right of first refusal to purchase up to the Company Investment Share (as defined below) of equity securities (the “ Equity Securities ”) issued in the Investor’s next round of Equity Financing (as defined below). However, the Company will have no right to purchase any Equity Securities if the Company cannot demonstrate to the Investor’s reasonable satisfaction that the Company is at the time of the proposed issuance of the Equity Securities an “accredited investor” as such term is defined in Regulation D under the Securities Act.

 
 
6
 
 

 

(b) If the Investor proposes to undertake an issuance of Equity Securities, it shall give notice to the Company of its intention to issue Equity Securities (the “ Notice ”), describing the type of Equity Securities and the price and the general terms upon which the Company proposes to issue the Equity Securities. The Company will have ten (10) days from the date of the Notice to agree in writing to purchase the Company’s share of such Equity Securities for the price and upon the general terms specified in the Notice by giving written notice to the Company and stating therein the quantity of Equity Securities to be purchased (not to exceed the Company Investment Share, unless agree to in writing by the Investor).

 

(c) In connection with any issuance of Equity Securities by the Investor to the Company pursuant to this Section 6.1 , the Company will execute and deliver to the Investor all transaction documents related to the Equity Financing; provided, that these documents are the same or similar to the documents to be entered into with other purchasers of Equity Securities.

 

(c) “ Equity Financing ” means a bona fide transaction or series of transactions pursuant in which the Investor issues and sells capital stock with the principal purpose of raising capital (other than in connection with a sale of tokens or a right to receive tokens).

 

(d) “ Company Investment Share ” means Equity Securities representing three percent (3.00%) of the Investor’s total outstanding shares of capital stock immediately following the Equity Financing.

 

6.2 Rule 144 Reporting . With a view to making available to the Investor the benefits of certain rules and regulations of the Securities and Exchange Commission (the “ Commission ”) that may permit the sale of the Shares to the public without registration and, in each case, for so long as the Investor holds Shares that are not freely transferable without restriction under the Securities Act (including the current public information requirement under Rule 144), the Company agrees to use commercially reasonable efforts to:

 

(a) Make and keep public information available, as those terms are understood and defined in Rule 144 promulgated under the Securities Act;

 

(b) File with the OTC Market in a timely manner all reports and other documents required of the Company by the OTC Market; and

 

(c) Furnish the Investor forthwith upon request (i) a written statement by the Company as to its compliance with the public information requirements of said Rule 144, (ii) a copy of the most recent annual or quarterly report of the Company, and (iii) such other reports and documents as may be reasonably requested in availing the Investor of any rule or regulation of the Commission permitting the sale of any such securities without registration.

 

6.3 Restrictive Legend . The Investor agrees to the imprinting on any stock certificates, so long as is required by this Section 6 , of a restrictive legend in substantially the following form:

 

“THE SECURITIES EVIDENCED OR CONSTITUTED HEREBY HAVE BEEN ISSUED WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) AND MAY NOT BE SOLD, OFFERED FOR SALE, TRANSFERRED, PLEDGED OR HYPOTHECATED WITHOUT REGISTRATION UNDER THE ACT UNLESS EITHER (i) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY, TO THE EFFECT THAT REGISTRATION IS NOT REQUIRED IN CONNECTION WITH SUCH DISPOSITION OR (ii) THE SALE OF SUCH SECURITIES IS MADE PURSUANT TO SECURITIES AND EXCHANGE COMMISSION RULE 144.”

 
 
7
 
 

 

The legend set forth in this Section 6.3 and the related notation in the Company’s register of shareholders shall be removed and the Company shall issue a certificate without such legend or any other legend to the holder of the Shares, if (i) the Shares are registered for resale under the Securities Act, (ii) the Shares are sold or transferred in compliance with to Rule 144 and the Company has received such customary certifications and other information as it shall have reasonably requested to demonstrate compliance of such transfer or sale with Rule 144, or (iii) the Shares are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information required under Rule 144. Following Rule 144 becoming available for the resale of Shares, without the requirement for the Company to be in compliance with the current public information required under Rule 144, the Company shall (at the Company’s expense), upon the written request of Investor, cause its counsel to issue to the Company’s transfer agent a legal opinion authorizing the issuance of a certificate representing the Shares without any restrictive or other legends, if requested by such transfer agent.

 

6.4 Listing . Promptly following the date hereof, the Company shall prepare and submit to the OTC Market a listing application covering the Shares, together with all other documents required by the OTC Market to be submitted in support thereof.

 

6.5 Further Assurances . Each of the Investor and the Company shall execute such further documents and shall take, or shall cause to be taken, such further actions as may be reasonably required to carry out the provisions of this Agreement and give effect to the transactions contemplated hereby.

 

SECTION 7

 

Indemnification

 

7.1 Each party (an “ Indemnifying Party ”) hereby indemnifies and holds harmless the other party, such other party’s respective officers, directors, employees, consultants, representatives and advisers, and any and all Affiliates of the foregoing (each of the foregoing, an “ Indemnified Party ”) from and against all losses, liabilities, costs, damages and expense (including reasonable legal fees and expenses) (collectively, “ Losses ”) suffered or incurred by any such Indemnified Party to the extent arising from, connected with or related to (a) breach of any representation or warranty of such Indemnifying Party in this Agreement; and (b) breach of any covenant or undertaking of any Indemnifying Party in this Agreement. If an event or omission (including, without limitation, any claim asserted or action or proceeding commenced by a third party) occurs which an Indemnified Party asserts to be an indemnifiable event pursuant to this Section 7 , the Indemnified Party will provide written notice to the Indemnifying Party, setting forth the nature of the claim and the basis for indemnification under this Agreement. The Indemnified Party will give such written notice to the Indemnifying Party immediately after it becomes aware of the existence of any such event or occurrence. Such notice will be a condition precedent to any obligation of the Indemnifying Party to act under this Agreement but will not relieve it of its obligations under the indemnity except to the extent that the failure to provide prompt notice as provided in this Agreement prejudices the Indemnifying Party with respect to the transactions contemplated by this Agreement and to the defense of the liability. In case any such action is brought by a third party against any Indemnified Party and it notifies the Indemnifying Party of the commencement thereof, the Indemnifying Party will be entitled to participate therein and, to the extent that it wishes, to assume the defense and settlement thereof with counsel reasonably selected by it and, after notice from the Indemnifying Party to the Indemnified Party of such election so to assume the defense and settlement thereof, the Indemnifying Party will not be liable to the Indemnified Party for any legal expenses of other counsel or any other expenses subsequently incurred by such Indemnified Party in connection with the defense thereof, provided, however, that an Indemnified Party shall have the right to employ separate counsel at the expense of the Indemnifying Party if (i) the employment thereof has been specifically authorized in writing by the Indemnifying Party; or (ii) representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of interests between such parties (which such judgment shall be made by the Indemnified Party in good faith after consultation with counsel). The Indemnified Party agrees to cooperate fully with (and to provide all relevant documents and records and make all relevant personnel available to) the Indemnifying Party and its counsel, as reasonably requested, in the defense of any such asserted claim at no additional cost to the Indemnifying Party. No Indemnifying Party will consent to the entry of any judgment or enter into any settlement with respect to any such asserted claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld or delayed, (A) if such judgment or settlement does not include as an unconditional term thereof the giving by each claimant or plaintiff to each Indemnified Party of a release from all liability in respect to such claim or (B) if, as a result of such consent or settlement, injunctive or other equitable relief would be imposed against the Indemnified Party or such judgment or settlement could materially and adversely affect the business, operations or assets of the Indemnified Party. No Indemnified Party will consent to the entry of any judgment or enter into any settlement with respect to any such asserted claim without the prior written consent of the Indemnifying Party, not to be unreasonably withheld or delayed. If an Indemnifying Party makes a payment with respect to any claim under the representations or warranties set forth herein and the Indemnified Party subsequently receives from a third party or under the terms of any insurance policy a sum in respect of the same claim, the receiving party will repay to the other party such amount that is equal to the sum subsequently received.

 
 
8
 
 

 

7.2 Limitations on Liability . No party hereto shall be liable for any punitive or special damages under this Section 7 (and no claim for indemnification hereunder shall be asserted) as a result of any breach or violation of any covenant or agreement of such party (including under this Section 7 ) in or pursuant to this Agreement.

 

7.3 Exclusive Remedy . The rights of the parties hereto pursuant to (and subject to the conditions of) this Section 7 shall be the sole and exclusive remedy of the parties hereto and their respective Affiliates with respect to any Losses (whether based in contract, tort or otherwise) resulting from or relating to any breach of the representations, warranties covenants and agreements made under this Agreement or any certificate, document or instrument delivered hereunder, and each party hereto hereby waives, to the fullest extent permitted under applicable law, and agrees not to assert after Closing, any other claim or action in respect of any such breach. Notwithstanding the foregoing, claims for common law fraud shall not be waived or limited in any way by this Section 7 .

 

7.4 Affiliates . For all purposes of this Agreement, the term “Affiliate” means, with respect to a specified entity, an entity that directly or indirectly through one or more intermediaries, is controlled by the entity, in each case where the term “control” means possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of an entity, whether through ownership of voting securities, by contract interest or otherwise.

 

SECTION 8

 

Miscellaneous

 

8.1 Governing Law . This Agreement shall be governed in all respects by the laws of California as applied to agreements entered into and performed entirely in the State of California by residents thereof.

 

8.2 Survival . The representations, warranties, covenants and agreements made herein shall survive any investigation made by the Investor and the Closing until the expiration of the applicable statute of limitations.

 

8.3 Successors, Assigns . Except as otherwise provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. This Agreement may not be assigned by either party without the prior written consent of the other; except that either party may assign this Agreement to an Affiliate of such party or to any third party that acquires all or substantially all of such party’s business, whether by merger, sale of assets or otherwise.

 

8.4 Notices . All notices and other communications required or permitted hereunder shall be in writing and shall be sent by electronic mail or mailed by registered or certified mail, postage prepaid, return receipt requested, or otherwise delivered by hand or by messenger, addressed

 

if to the Investor, at the following address:

 

Robot Cache, S.L.

Calle El Pilar No. 5

Edificio Peceno Local 9

38002 Santa Cruz se Tenerife, Spain

Attention: Lee Jacobson, CEO

E-mail: lee@robotcache.com

 
 
9
 
 

 

if to the Company, at the following address:

 

Millennium Blockchain Inc.

11700 W. Charleston Blvd., Suite 73

Las Vegas, Nevada 89135

Attention: Brandon Romanek, CEO

E-mail: brandon@mblockchain.io

 

or at such other address as one party shall have furnished to the other party in writing. All notices and communications under this Agreement shall be deemed to have been duly given (i) when delivered by hand, if personally delivered, (ii) when received by a recipient, if sent by email, or (iii) one business day following sending within the United States by overnight delivery via commercial one-day overnight courier service.

 

8.5 Expenses . Each of the Company and the Investor shall bear its own expenses and legal fees incurred on its behalf with respect to this Agreement and the transactions contemplated hereby.

 

8.6 Finder’s Fees . Each of the Company and the Investor shall indemnify and hold the other harmless from any liability for any commission or compensation in the nature of a finder’s fee, placement fee or underwriter’s discount (including the costs, expenses and legal fees of defending against such liability) for which the Company or the Investor, or any of its respective partners, employees, or representatives, as the case may be, is responsible.

 

8.7 Counterparts . This Agreement may be executed in counterparts, each of which shall be enforceable against the party actually executing the counterpart, and all of which together shall constitute one instrument. Delivery of an executed counterpart of a signature page of this Agreement in Portable Document Format (PDF) or by facsimile transmission shall be effective as delivery of a manually executed original counterpart of this Agreement.

 

8.8 Severability . In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision; provided that no such severability shall be effective if it materially changes the economic benefit of this Agreement to any party.

 

8.9 Entire Agreement . This Agreement, including the exhibits and schedules attached hereto and thereto, constitute the full and entire understanding and agreement among the parties with regard to the subjects hereof and thereof. No party shall be liable or bound to any other party in any manner with regard to the subjects hereof or thereof by any warranties, representations or covenants except as specifically set forth herein or therein.

 

8.10 Waiver . The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition by the other party. None of the terms, covenants and conditions of this Agreement can be waived except by the written consent of the party waiving compliance.

 

[ Signature Page Follows ]

 
 
10
 
 

 

IN WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first set forth above.

 

 

COMPANY

 

MILLENNIUM BLOCKCHAIN INC.

 

 

 

 

 

 

By:

 

 

Name:

Brandon Romanek

 

 

Title:

Chief Executive Officer

 

 

 

 

 

 

INVESTOR

 

ROBOT CACHE, S.L.

 

 

 

 

 

 

By:

 

 

Name:

Lee Jacobson

 

 

Title:

Chief Executive Officer

 

 
 
11
 
 

 

EXHIBIT A

 

SAFT

 

 

 

 

 

 
12
 
 

 

EXHIBIT B

 

SCHEDULE OF EXCEPTIONS

 

 

 

 

 

 
13
 
 

 

EXHIBIT C

 

COMMON STOCK PURCHASE WARRANTS

 

 

 

 

 
 
14

 

EXHIBIT 21

 

Subsidiaries of Registrant

 

Name

 

State of Incorporation or Organization

Genesis Float SPA LLC 

 

Nevada